WO2024081309A1 - Engineered cells and implantable elements for treatment of disease - Google Patents
Engineered cells and implantable elements for treatment of disease Download PDFInfo
- Publication number
- WO2024081309A1 WO2024081309A1 PCT/US2023/034936 US2023034936W WO2024081309A1 WO 2024081309 A1 WO2024081309 A1 WO 2024081309A1 US 2023034936 W US2023034936 W US 2023034936W WO 2024081309 A1 WO2024081309 A1 WO 2024081309A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hla
- function
- level
- implantable element
- cell
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 23
- 201000010099 disease Diseases 0.000 title claims description 17
- 238000011282 treatment Methods 0.000 title description 13
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 189
- 230000009467 reduction Effects 0.000 claims abstract description 139
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 108
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 68
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims abstract description 26
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims description 201
- 239000002773 nucleotide Substances 0.000 claims description 197
- 125000003729 nucleotide group Chemical group 0.000 claims description 197
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 132
- 229920000642 polymer Polymers 0.000 claims description 93
- 125000000623 heterocyclic group Chemical group 0.000 claims description 88
- 101000983747 Homo sapiens MHC class II transactivator Proteins 0.000 claims description 82
- 102000043129 MHC class I family Human genes 0.000 claims description 79
- 108091054437 MHC class I family Proteins 0.000 claims description 79
- 125000003118 aryl group Chemical group 0.000 claims description 73
- 150000001875 compounds Chemical class 0.000 claims description 70
- 125000000217 alkyl group Chemical group 0.000 claims description 67
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 67
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 66
- 125000001072 heteroaryl group Chemical group 0.000 claims description 64
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 61
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 60
- 125000003342 alkenyl group Chemical group 0.000 claims description 60
- 125000000304 alkynyl group Chemical group 0.000 claims description 55
- 229920000615 alginic acid Polymers 0.000 claims description 54
- 235000010443 alginic acid Nutrition 0.000 claims description 52
- 229940072056 alginate Drugs 0.000 claims description 51
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 49
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 49
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 44
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 41
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims description 34
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims description 34
- 102000043131 MHC class II family Human genes 0.000 claims description 32
- 108091054438 MHC class II family Proteins 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- 239000000017 hydrogel Substances 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- 239000002775 capsule Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 22
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 18
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000004043 oxo group Chemical group O=* 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 230000004888 barrier function Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 239000003114 blood coagulation factor Substances 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 210000005260 human cell Anatomy 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 7
- 238000007912 intraperitoneal administration Methods 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- NTEDOEBWPRVVSG-FQUUOJAGSA-N (2s)-1-[(2r)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CO)C(=O)N1CCC[C@H]1C(O)=O NTEDOEBWPRVVSG-FQUUOJAGSA-N 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 108010053299 glycyl-arginyl-glycyl-aspartyl-seryl-proline Proteins 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 5
- 239000000790 retinal pigment Substances 0.000 claims description 5
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 claims description 3
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 3
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 229940014041 hyaluronate Drugs 0.000 claims description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 210000000566 lesser sac Anatomy 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 210000002747 omentum Anatomy 0.000 claims description 2
- 210000003200 peritoneal cavity Anatomy 0.000 claims description 2
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 claims 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 claims 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 abstract description 57
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 abstract description 57
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 abstract description 57
- 238000000034 method Methods 0.000 abstract description 27
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 abstract 1
- 230000006870 function Effects 0.000 description 477
- 230000002829 reductive effect Effects 0.000 description 291
- -1 HLA-DM Proteins 0.000 description 136
- 230000027455 binding Effects 0.000 description 109
- 102100036243 HLA class II histocompatibility antigen, DQ alpha 1 chain Human genes 0.000 description 76
- 102000004196 processed proteins & peptides Human genes 0.000 description 71
- 230000003993 interaction Effects 0.000 description 67
- 230000007423 decrease Effects 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 62
- 229920001184 polypeptide Polymers 0.000 description 58
- 125000005842 heteroatom Chemical group 0.000 description 53
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 51
- 108010075704 HLA-A Antigens Proteins 0.000 description 51
- 108010010378 HLA-DP Antigens Proteins 0.000 description 43
- 102000015789 HLA-DP Antigens Human genes 0.000 description 43
- 125000004432 carbon atom Chemical group C* 0.000 description 42
- 235000001014 amino acid Nutrition 0.000 description 38
- 125000001424 substituent group Chemical group 0.000 description 38
- 210000004901 leucine-rich repeat Anatomy 0.000 description 31
- 102000018638 GTP binding domains Human genes 0.000 description 30
- 108050007795 GTP binding domains Proteins 0.000 description 30
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 30
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 29
- 239000004971 Cross linker Substances 0.000 description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 28
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 27
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 27
- 238000003556 assay Methods 0.000 description 27
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 25
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 description 25
- 108010040960 HLA-DRB4 Chains Proteins 0.000 description 25
- 108010016996 HLA-DRB5 Chains Proteins 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 25
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 23
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 description 23
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 23
- 108010061311 HLA-DRB3 Chains Proteins 0.000 description 23
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 22
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 20
- 108091008874 T cell receptors Proteins 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 229910052717 sulfur Inorganic materials 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- 230000037430 deletion Effects 0.000 description 16
- 238000012217 deletion Methods 0.000 description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 16
- 239000001301 oxygen Chemical group 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 15
- 239000011593 sulfur Chemical group 0.000 description 15
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 14
- 239000011148 porous material Substances 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229920002725 thermoplastic elastomer Polymers 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- 102100026735 Coagulation factor VIII Human genes 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 8
- 108010054218 Factor VIII Proteins 0.000 description 8
- 102000001690 Factor VIII Human genes 0.000 description 8
- 108010000499 Thromboplastin Proteins 0.000 description 8
- 102000002262 Thromboplastin Human genes 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 210000002919 epithelial cell Anatomy 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical group N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 7
- 108010023321 Factor VII Proteins 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000032823 cell division Effects 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 229910052738 indium Inorganic materials 0.000 description 7
- 102100023804 Coagulation factor VII Human genes 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 210000001163 endosome Anatomy 0.000 description 6
- 229960000301 factor viii Drugs 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102100035028 Alpha-L-iduronidase Human genes 0.000 description 5
- 102100022641 Coagulation factor IX Human genes 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108010076282 Factor IX Proteins 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 5
- 239000000854 Human Growth Hormone Substances 0.000 description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 5
- 108010006519 Molecular Chaperones Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 239000000919 ceramic Substances 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 125000004474 heteroalkylene group Chemical group 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 210000003712 lysosome Anatomy 0.000 description 5
- 230000001868 lysosomic effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 230000009258 tissue cross reactivity Effects 0.000 description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- CDEURGJCGCHYFH-UHFFFAOYSA-N 5-ethynyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1C(O)C(CO)OC1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-UHFFFAOYSA-N 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- 102100021044 DNA-binding protein RFXANK Human genes 0.000 description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 4
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 4
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 4
- 108010000521 Human Growth Hormone Proteins 0.000 description 4
- 102000002265 Human Growth Hormone Human genes 0.000 description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 4
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 4
- 102100025587 Leukocyte immunoglobulin-like receptor subfamily A member 1 Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 4
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 4
- 102000004966 Nuclear Receptor Coactivator 1 Human genes 0.000 description 4
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 102100038803 Somatotropin Human genes 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 102100028082 Tapasin Human genes 0.000 description 4
- 108010061174 Thyrotropin Proteins 0.000 description 4
- 102000011923 Thyrotropin Human genes 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000956 alloy Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000008512 biological response Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 229910001092 metal group alloy Inorganic materials 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 239000005060 rubber Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000020347 spindle assembly Effects 0.000 description 4
- 108010059434 tapasin Proteins 0.000 description 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 101800001415 Bri23 peptide Proteins 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 102400000107 C-terminal peptide Human genes 0.000 description 3
- 101800000655 C-terminal peptide Proteins 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 3
- 102100021868 Calnexin Human genes 0.000 description 3
- 108010056891 Calnexin Proteins 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102400000739 Corticotropin Human genes 0.000 description 3
- 102100020986 DNA-binding protein RFX5 Human genes 0.000 description 3
- 101150034979 DRB3 gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102100029095 Exportin-1 Human genes 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 description 3
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 3
- 101001075432 Homo sapiens DNA-binding protein RFX5 Proteins 0.000 description 3
- 101001075464 Homo sapiens DNA-binding protein RFXANK Proteins 0.000 description 3
- 101000984198 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 1 Proteins 0.000 description 3
- 101000984200 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 3 Proteins 0.000 description 3
- 101000784571 Homo sapiens Zinc finger protein ZXDC Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 description 3
- 102100025556 Leukocyte immunoglobulin-like receptor subfamily A member 3 Human genes 0.000 description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- 108010085220 Multiprotein Complexes Proteins 0.000 description 3
- 102000007474 Multiprotein Complexes Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 102100034195 Thrombopoietin Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- 102100020906 Zinc finger protein ZXDC Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000000868 anti-mullerian hormone Substances 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000009838 combustion analysis Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 108700002148 exportin 1 Proteins 0.000 description 3
- 229960004222 factor ix Drugs 0.000 description 3
- 229940012413 factor vii Drugs 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940063557 methacrylate Drugs 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 238000012015 optical character recognition Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000011574 phosphorus Chemical group 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000010703 silicon Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 229960003726 vasopressin Drugs 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 description 2
- SEFVRKXJJPMVHQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]butanedioic acid Chemical compound NC(N)=NCCCC(NC(=O)CN)C(=O)NCC(=O)NC(CC(O)=O)C(O)=O SEFVRKXJJPMVHQ-UHFFFAOYSA-N 0.000 description 2
- UHFFVFAKEGKNAQ-UHFFFAOYSA-N 2-benzyl-2-(dimethylamino)-1-(4-morpholin-4-ylphenyl)butan-1-one Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(=O)C(CC)(N(C)C)CC1=CC=CC=C1 UHFFVFAKEGKNAQ-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- KUDUQBURMYMBIJ-UHFFFAOYSA-N 2-prop-2-enoyloxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC(=O)C=C KUDUQBURMYMBIJ-UHFFFAOYSA-N 0.000 description 2
- 231100000582 ATP assay Toxicity 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 2
- 102100022416 Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 Human genes 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100022794 Bestrophin-1 Human genes 0.000 description 2
- 102100034673 C-C motif chemokine 3-like 1 Human genes 0.000 description 2
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
- 101150011672 CCL9 gene Proteins 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010074864 Factor XI Proteins 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102100035233 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 102400000321 Glucagon Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 101150118346 HLA-A gene Proteins 0.000 description 2
- 101150000578 HLA-B gene Proteins 0.000 description 2
- 108010050568 HLA-DM antigens Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 2
- 101000755762 Homo sapiens Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 Proteins 0.000 description 2
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 2
- 101000946370 Homo sapiens C-C motif chemokine 3-like 1 Proteins 0.000 description 2
- 101000896959 Homo sapiens C-C motif chemokine 4-like Proteins 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 2
- 101001076386 Homo sapiens Interleukin-1 family member 10 Proteins 0.000 description 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 2
- 101000998126 Homo sapiens Interleukin-36 beta Proteins 0.000 description 2
- 101001040964 Homo sapiens Interleukin-36 receptor antagonist protein Proteins 0.000 description 2
- 101000998122 Homo sapiens Interleukin-37 Proteins 0.000 description 2
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 2
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 description 2
- 101001078886 Homo sapiens Retinaldehyde-binding protein 1 Proteins 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 102000002746 Inhibins Human genes 0.000 description 2
- 108010004250 Inhibins Proteins 0.000 description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
- 102100020990 Interferon lambda-1 Human genes 0.000 description 2
- 102100026015 Interleukin-1 family member 10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102100036680 Interleukin-25 Human genes 0.000 description 2
- 108010066979 Interleukin-27 Proteins 0.000 description 2
- 102100033498 Interleukin-36 beta Human genes 0.000 description 2
- 102100033503 Interleukin-36 gamma Human genes 0.000 description 2
- 102100021150 Interleukin-36 receptor antagonist protein Human genes 0.000 description 2
- 102100033502 Interleukin-37 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 2
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 102400000050 Oxytocin Human genes 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 2
- 101710106224 Protein disulfide-isomerase A3 Proteins 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 102100022831 Somatoliberin Human genes 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 101150094313 XPO1 gene Proteins 0.000 description 2
- 229940048053 acrylate Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003570 cell-matrix junction Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000007820 coagulation assay Methods 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 108091016249 marzeptacog alfa (activated) Proteins 0.000 description 2
- 229950006148 marzeptacog alfa (activated) Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229920001179 medium density polyethylene Polymers 0.000 description 2
- 239000004701 medium-density polyethylene Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000000622 polydioxanone Substances 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960000874 thyrotropin Drugs 0.000 description 2
- 230000001748 thyrotropin Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229920001862 ultra low molecular weight polyethylene Polymers 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- QNODIIQQMGDSEF-UHFFFAOYSA-N (1-hydroxycyclohexyl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C1(O)CCCCC1 QNODIIQQMGDSEF-UHFFFAOYSA-N 0.000 description 1
- BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 description 1
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 1
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- UNEATYXSUBPPKP-UHFFFAOYSA-N 1,3-Diisopropylbenzene Chemical compound CC(C)C1=CC=CC(C(C)C)=C1 UNEATYXSUBPPKP-UHFFFAOYSA-N 0.000 description 1
- VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 101710097567 12 kDa protein Proteins 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- AZXGXVQWEUFULR-UHFFFAOYSA-N 2',4',5',7'-tetrabromofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 AZXGXVQWEUFULR-UHFFFAOYSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- OWPUOLBODXJOKH-UHFFFAOYSA-N 2,3-dihydroxypropyl prop-2-enoate Chemical compound OCC(O)COC(=O)C=C OWPUOLBODXJOKH-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- OWDBMKZHFCSOOL-UHFFFAOYSA-N 2-[2-[2-(2-methylprop-2-enoyloxy)propoxy]propoxy]propyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)COC(C)COC(C)COC(=O)C(C)=C OWDBMKZHFCSOOL-UHFFFAOYSA-N 0.000 description 1
- KMNCBSZOIQAUFX-UHFFFAOYSA-N 2-ethoxy-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(OCC)C(=O)C1=CC=CC=C1 KMNCBSZOIQAUFX-UHFFFAOYSA-N 0.000 description 1
- XMLYCEVDHLAQEL-UHFFFAOYSA-N 2-hydroxy-2-methyl-1-phenylpropan-1-one Chemical compound CC(C)(O)C(=O)C1=CC=CC=C1 XMLYCEVDHLAQEL-UHFFFAOYSA-N 0.000 description 1
- ICBJBNAUJWZPBY-UHFFFAOYSA-N 2-hydroxyethyl 3-methylbut-2-enoate Chemical compound CC(=CC(=O)OCCO)C ICBJBNAUJWZPBY-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- BQZJOQXSCSZQPS-UHFFFAOYSA-N 2-methoxy-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(OC)C(=O)C1=CC=CC=C1 BQZJOQXSCSZQPS-UHFFFAOYSA-N 0.000 description 1
- LWRBVKNFOYUCNP-UHFFFAOYSA-N 2-methyl-1-(4-methylsulfanylphenyl)-2-morpholin-4-ylpropan-1-one Chemical compound C1=CC(SC)=CC=C1C(=O)C(C)(C)N1CCOCC1 LWRBVKNFOYUCNP-UHFFFAOYSA-N 0.000 description 1
- RIWRBSMFKVOJMN-UHFFFAOYSA-N 2-methyl-1-phenylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=CC=C1 RIWRBSMFKVOJMN-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
- 229940076442 9,10-anthraquinone Drugs 0.000 description 1
- 102000006267 AMP Deaminase Human genes 0.000 description 1
- 108700016228 AMP deaminases Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical class [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102100040894 Amylo-alpha-1,6-glucosidase Human genes 0.000 description 1
- 101710104691 Amylo-alpha-1,6-glucosidase Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 101150061927 BMP2 gene Proteins 0.000 description 1
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 1
- 101150072730 Bmp6 gene Proteins 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 102100023705 C-C motif chemokine 14 Human genes 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 1
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 1
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 1
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 description 1
- 102100039435 C-X-C motif chemokine 17 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- 101150049756 CCL6 gene Proteins 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 102100035654 Cathepsin S Human genes 0.000 description 1
- 108090000613 Cathepsin S Proteins 0.000 description 1
- 101150075117 Ccl12 gene Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 101150007483 Cklf gene Proteins 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 102100037529 Coagulation factor V Human genes 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 102100030563 Coagulation factor XI Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- 102100030851 Cortistatin Human genes 0.000 description 1
- 229930185483 Cortistatin Natural products 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102100035298 Cytokine SCM-1 beta Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000016814 DNA-binding protein RFX5 Human genes 0.000 description 1
- 108050006520 DNA-binding protein RFX5 Proteins 0.000 description 1
- 101710205322 DNA-binding protein RFXANK Proteins 0.000 description 1
- 101150082328 DRB5 gene Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 101100228739 Danio rerio mstnb gene Proteins 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108091030376 Duplicated family Proteins 0.000 description 1
- 102100037354 Ectodysplasin-A Human genes 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 101150019331 FGF2 gene Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 101150117713 GDF6 gene Proteins 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101100232738 Gallus gallus IFNL3 gene Proteins 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102100031258 HLA class II histocompatibility antigen, DM beta chain Human genes 0.000 description 1
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 description 1
- 101150035071 HLA-C gene Proteins 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 101150105757 HLA-DOA gene Proteins 0.000 description 1
- 101150049125 HLA-DOB gene Proteins 0.000 description 1
- 108010045483 HLA-DPB1 antigen Proteins 0.000 description 1
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 description 1
- 108010055966 HLA-DR53 Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 108090000481 Heparin Cofactor II Proteins 0.000 description 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 1
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 description 1
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 1
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 description 1
- 101000889048 Homo sapiens C-X-C motif chemokine 17 Proteins 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 1
- 101001027836 Homo sapiens Coagulation factor V Proteins 0.000 description 1
- 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 description 1
- 101001054266 Homo sapiens Delta and Notch-like epidermal growth factor-related receptor Proteins 0.000 description 1
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 101001034829 Homo sapiens Interferon alpha-10 Proteins 0.000 description 1
- 101001034828 Homo sapiens Interferon alpha-14 Proteins 0.000 description 1
- 101001034835 Homo sapiens Interferon alpha-16 Proteins 0.000 description 1
- 101001034834 Homo sapiens Interferon alpha-17 Proteins 0.000 description 1
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 1
- 101001034833 Homo sapiens Interferon alpha-21 Proteins 0.000 description 1
- 101000959708 Homo sapiens Interferon alpha-4 Proteins 0.000 description 1
- 101000959704 Homo sapiens Interferon alpha-5 Proteins 0.000 description 1
- 101000959714 Homo sapiens Interferon alpha-6 Proteins 0.000 description 1
- 101000961126 Homo sapiens Interferon alpha-7 Proteins 0.000 description 1
- 101000999391 Homo sapiens Interferon alpha-8 Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001044447 Homo sapiens Interferon kappa Proteins 0.000 description 1
- 101001002469 Homo sapiens Interferon lambda-2 Proteins 0.000 description 1
- 101001002466 Homo sapiens Interferon lambda-3 Proteins 0.000 description 1
- 101000999370 Homo sapiens Interferon omega-1 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101000998181 Homo sapiens Interleukin-17B Proteins 0.000 description 1
- 101000998178 Homo sapiens Interleukin-17C Proteins 0.000 description 1
- 101000998176 Homo sapiens Interleukin-17D Proteins 0.000 description 1
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 description 1
- 101000960946 Homo sapiens Interleukin-19 Proteins 0.000 description 1
- 101001010591 Homo sapiens Interleukin-20 Proteins 0.000 description 1
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 1
- 101000853009 Homo sapiens Interleukin-24 Proteins 0.000 description 1
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 1
- 101000852998 Homo sapiens Interleukin-27 subunit alpha Proteins 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 description 1
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 1
- 101000998132 Homo sapiens Interleukin-34 Proteins 0.000 description 1
- 101000998140 Homo sapiens Interleukin-36 alpha Proteins 0.000 description 1
- 101000998124 Homo sapiens Interleukin-36 gamma Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
- 101000730648 Homo sapiens Phospholipase A-2-activating protein Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108091058536 IL1F9 Proteins 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 101150046085 INHBA gene Proteins 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710192051 Interferon alpha-1/13 Proteins 0.000 description 1
- 102100039734 Interferon alpha-10 Human genes 0.000 description 1
- 102100039733 Interferon alpha-14 Human genes 0.000 description 1
- 102100039728 Interferon alpha-16 Human genes 0.000 description 1
- 102100039730 Interferon alpha-17 Human genes 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 102100039729 Interferon alpha-21 Human genes 0.000 description 1
- 102100039949 Interferon alpha-4 Human genes 0.000 description 1
- 102100039948 Interferon alpha-5 Human genes 0.000 description 1
- 102100040007 Interferon alpha-6 Human genes 0.000 description 1
- 102100039350 Interferon alpha-7 Human genes 0.000 description 1
- 102100036532 Interferon alpha-8 Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100022469 Interferon kappa Human genes 0.000 description 1
- 102100020989 Interferon lambda-2 Human genes 0.000 description 1
- 102100020992 Interferon lambda-3 Human genes 0.000 description 1
- 102100036479 Interferon omega-1 Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 102100033101 Interleukin-17B Human genes 0.000 description 1
- 102100033105 Interleukin-17C Human genes 0.000 description 1
- 102100033096 Interleukin-17D Human genes 0.000 description 1
- 102100033454 Interleukin-17F Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102100039879 Interleukin-19 Human genes 0.000 description 1
- 102100030692 Interleukin-20 Human genes 0.000 description 1
- 102100030704 Interleukin-21 Human genes 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 102100036671 Interleukin-24 Human genes 0.000 description 1
- 102100036679 Interleukin-26 Human genes 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 102100021596 Interleukin-31 Human genes 0.000 description 1
- 102100033501 Interleukin-32 Human genes 0.000 description 1
- 108010067003 Interleukin-33 Proteins 0.000 description 1
- 102000017761 Interleukin-33 Human genes 0.000 description 1
- 102100033499 Interleukin-34 Human genes 0.000 description 1
- 102100033474 Interleukin-36 alpha Human genes 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102100027670 Islet amyloid polypeptide Human genes 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 101710196514 Leukocyte immunoglobulin-like receptor subfamily A member 1 Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108010048179 Lypressin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108700005089 MHC Class I Genes Proteins 0.000 description 1
- 108700005092 MHC Class II Genes Proteins 0.000 description 1
- 108700002010 MHC class II transactivator Proteins 0.000 description 1
- 101150048453 MSTN gene Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 229910001182 Mo alloy Inorganic materials 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101710164418 Movement protein TGB2 Proteins 0.000 description 1
- 101100165554 Mus musculus Bmp5 gene Proteins 0.000 description 1
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 description 1
- 101100494960 Mus musculus Ccl21a gene Proteins 0.000 description 1
- 101100005911 Mus musculus Cer1 gene Proteins 0.000 description 1
- 101100439907 Mus musculus Cmtm2a gene Proteins 0.000 description 1
- 101100439908 Mus musculus Cmtm2b gene Proteins 0.000 description 1
- 101100222387 Mus musculus Cxcl15 gene Proteins 0.000 description 1
- 101100175316 Mus musculus Gdf5 gene Proteins 0.000 description 1
- 101100175325 Mus musculus Gdf7 gene Proteins 0.000 description 1
- 101100448240 Mus musculus Gdf9 gene Proteins 0.000 description 1
- 101100396562 Mus musculus Ifna9 gene Proteins 0.000 description 1
- 101100072416 Mus musculus Il22b gene Proteins 0.000 description 1
- 101100342330 Mus musculus Klf15 gene Proteins 0.000 description 1
- 101100408043 Mus musculus Pglyrp2 gene Proteins 0.000 description 1
- 101100371162 Mus musculus Tslp gene Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 1
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 1
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102100031942 Oncostatin-M Human genes 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 101100117569 Oryza sativa subsp. japonica DRB6 gene Proteins 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- 102100026466 POU domain, class 2, transcription factor 3 Human genes 0.000 description 1
- 101710084413 POU domain, class 2, transcription factor 3 Proteins 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000011025 Phosphoglycerate Mutase Human genes 0.000 description 1
- 102100032572 Phospholipase A-2-activating protein Human genes 0.000 description 1
- 102000004576 Placental Lactogen Human genes 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000003866 Protein Disulfide Reductase (Glutathione) Human genes 0.000 description 1
- 108090000213 Protein Disulfide Reductase (Glutathione) Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 102400000834 Relaxin A chain Human genes 0.000 description 1
- 101800000074 Relaxin A chain Proteins 0.000 description 1
- 102400000610 Relaxin B chain Human genes 0.000 description 1
- 101710109558 Relaxin B chain Proteins 0.000 description 1
- 101150029512 SCG2 gene Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 101150116986 THPO gene Proteins 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 101150085042 Tnfsf4 gene Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 229920010346 Very Low Density Polyethylene (VLDPE) Polymers 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 101150019524 WNT2 gene Proteins 0.000 description 1
- 102000052556 Wnt-2 Human genes 0.000 description 1
- 108700020986 Wnt-2 Proteins 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- 101000929049 Xenopus tropicalis Derriere protein Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- JUDXBRVLWDGRBC-UHFFFAOYSA-N [2-(hydroxymethyl)-3-(2-methylprop-2-enoyloxy)-2-(2-methylprop-2-enoyloxymethyl)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(CO)(COC(=O)C(C)=C)COC(=O)C(C)=C JUDXBRVLWDGRBC-UHFFFAOYSA-N 0.000 description 1
- HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- YJZATOSJMRIRIW-UHFFFAOYSA-N [Ir]=O Chemical class [Ir]=O YJZATOSJMRIRIW-UHFFFAOYSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 229940117913 acrylamide Drugs 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000013466 adhesive and sealant Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 108010042362 beta-Lipotropin Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 101150006966 bmp3 gene Proteins 0.000 description 1
- 101150067309 bmp4 gene Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 229930006711 bornane-2,3-dione Natural products 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 229950008486 carperitide Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- SZMZREIADCOWQA-UHFFFAOYSA-N chromium cobalt nickel Chemical compound [Cr].[Co].[Ni] SZMZREIADCOWQA-UHFFFAOYSA-N 0.000 description 1
- VNTLIPZTSJSULJ-UHFFFAOYSA-N chromium molybdenum Chemical compound [Cr].[Mo] VNTLIPZTSJSULJ-UHFFFAOYSA-N 0.000 description 1
- UOUJSJZBMCDAEU-UHFFFAOYSA-N chromium(3+);oxygen(2-) Chemical class [O-2].[O-2].[O-2].[Cr+3].[Cr+3] UOUJSJZBMCDAEU-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021703 chronic tic disease Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 108010005430 cortistatin Proteins 0.000 description 1
- DDRPLNQJNRBRNY-WYYADCIBSA-N cortistatin-14 Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)[C@H]1NCCC1)C(=O)N[C@@H](CCCCN)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 DDRPLNQJNRBRNY-WYYADCIBSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- RSJLWBUYLGJOBD-UHFFFAOYSA-M diphenyliodanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[I+]C1=CC=CC=C1 RSJLWBUYLGJOBD-UHFFFAOYSA-M 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 108700007283 factor IX Fc fusion Proteins 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- WIHZLLGSGQNAGK-UHFFFAOYSA-N hafnium(4+);oxygen(2-) Chemical class [O-2].[O-2].[Hf+4] WIHZLLGSGQNAGK-UHFFFAOYSA-N 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108060003558 hepcidin Proteins 0.000 description 1
- 102000018511 hepcidin Human genes 0.000 description 1
- 229940066919 hepcidin Drugs 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 229920005669 high impact polystyrene Polymers 0.000 description 1
- 239000004797 high-impact polystyrene Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical group [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 229910000457 iridium oxide Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229960003837 lypressin Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 150000001247 metal acetylides Chemical class 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical class [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108010087851 prorelaxin Proteins 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SONHXMAHPHADTF-UHFFFAOYSA-M sodium;2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O SONHXMAHPHADTF-UHFFFAOYSA-M 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229920000208 temperature-responsive polymer Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- KUUVQVSHGLHAKZ-UHFFFAOYSA-N thionine Chemical compound C=1C=CC=CSC=CC=1 KUUVQVSHGLHAKZ-UHFFFAOYSA-N 0.000 description 1
- 238000013169 thromboelastometry Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 229940113165 trimethylolpropane Drugs 0.000 description 1
- 229940096522 trimethylolpropane triacrylate Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Definitions
- Treating chronic and genetic diseases by implanting cells engineered to produce a therapeutic substance capable of treating such diseases has exciting potential to improve the health of patients with such diseases.
- the implanted cells must be capable of producing therapeutic levels of the desired therapeutic substance for several weeks, months or even longer without overstimulation of the host immune response.
- Described herein are engineered mammalian cells comprising a reduced level or reduced function of a major histocompatibility complex (MHC) class I protein complex, as well as related devices (e.g., implantable elements), compositions, and methods of making and use thereof.
- the engineered mammalian cell comprises a reduced level or reduced function of one or more of a protein selected from human leukocyte antigen (HLA) A, HLA-B, HLA-C, and beta-2-microglobulin (beta-2M).
- HLA human leukocyte antigen
- HLA-B human leukocyte antigen
- HLA-C beta-2-microglobulin
- beta-2M beta-2-microglobulin
- the reduced level or reduced function of the MHC class I protein complex may be due to a mutation in a component of the MHC class I protein complex or may be due to the silencing or knock down of a component of the MHC class I protein complex.
- the present disclosure may also feature engineered mammalian cells further comprising a reduced level or reduced function of a MHC class II protein complex.
- the engineered mammalian cell comprises a reduced level or reduced function of one or more of a protein selected from HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR.
- the reduced level or reduced function of the MHC class II protein complex may be due to a mutation in a component of the MHC class II protein complex or may be due to the silencing or knock down of a component of the MHC class II protein complex.
- the engineered mammalian cells described herein may also comprise a reduced level or reduced function of a class II major histocompatibility complex transactivator (CIITA).
- CIITA major histocompatibility complex transactivator
- the present disclosure features an implantable element comprising an engineered mammalian cell described herein, or a plurality of engineered mammalian cells.
- the engineered mammalian cells may comprise an embryonic stem cell (ESC) or an induced pluripotent stem cell (iPSC).
- the engineered mammalian cell may comprise a retinal pigment epithelial (RPE) cell, a CCD-33Lu cell, a MRC-5 cell, a MRC-9 cell, a MCFlOa cell, or a cell derived therefrom.
- RPE retinal pigment epithelial
- the engineered mammalian cell comprises an engineered retinal pigment epithelial (RPE) cell (e.g., an engineered ARPE-19 cell), or is derived from a retinal pigment epithelial (RPE) cell (e.g., ARPE-19 cell).
- implantable element comprises at least one cell -containing compartment which comprises the engineered mammalian cell or plurality of engineered mammalian cells described herein.
- implantable element comprises one cell-containing compartment comprising the engineered mammalian cell or plurality of engineered mammalian cells described herein, and a second compartment surrounding the cell-containing compartment.
- the implantable element further comprises at least one means for mitigating the foreign body response (FBR) when the implantable element is implanted into the subject (e.g., a compound of Formula (I) as described herein).
- the implantable element comprises a polymer selected from alginate, hyaluronate, and chitosan.
- the implantable element comprises a cell -containing compartment surrounded by a barrier compartment comprising an alginate hydrogel and optionally a compound of Formula (I) (e.g., a compound of Formula (I) described herein) disposed on the outer surface of the barrier compartment.
- the implantable element is formulated for implantation into a subject (e.g., into the intraperitoneal (IP) space, the peritoneal cavity, the omentum, the lesser sac, the subcutaneous fat).
- the implantable element is configured to shield the engineered mammalian cell or plurality of engineered mammalian cells from the recipient’s immune system and mitigate the foreign body response (FBR) (as defined herein) to the implanted device.
- the implantable element is capable of delivering a therapeutic agent (e.g., a protein) for a sustained time period (e.g., one to several months up to one to several years) after implant into a subject.
- the present disclosure features a method of treating a disease or disorder in a subject, the method comprising administering to the subject an implantable element comprising an engineered mammalian cell described herein, or a plurality of engineered mammalian cells described herein, wherein the engineered mammalian cells or the plurality of engineered mammalian cells comprise a reduced level or reduced function of a MHC class I protein complex.
- the engineered mammalian cells or the plurality of engineered mammalian cells further comprises a reduced level or reduced function of a MHC class II protein complex and/or a reduced level or reduced function of a CIITA.
- the disease or disorder is a lysosomal storage disease.
- the disease or disorder is a metabolic disease.
- an implantable element described herein, or a plurality of implantable elements described herein is combined with a pharmaceutically acceptable excipient to prepare an implantable element preparation or a composition which may be administered to a subject (e.g., into the intraperitoneal cavity) in need of treatment with a therapeutic agent produced by the device.
- the subject is a human
- the engineered mammalian cells are derived from a human cell (e.g., an RPE cell, an ARPE-19 cell) and the implantable element preparation or composition is capable of continuously delivering an effective amount of a therapeutic agent to the subject for a sustained time period, e.g., at least any of 3 months, 6 months, one year, two years or longer.
- FIG. 1 is graph showing that Beta-2M protein expression in IDUA-expressing ARPE-19 cells containing beta-2M shRNA was considerably lower (89% lower) compared to that in IDUA-expressing ARPE-19 cells containing the scrambled control shRNA.
- FIG. 2 is a graph showing that beta-2M expression levels were decreased 99% in ARPE- 19 cells using CRISPR and a beta-2M-targeting gRNA, compared to ARPE-19 cells modified using the scrambled gRNA.
- FIGS. 3A-D are a set of graphs showing that reduction of beta-2M protein expression (FIG. 3B) in ARPE-19 cells with reduced beta-2M protein expression (FIG. 3A) results in decreased HLA Class I expression (FIG. 3D), compared to beta-2M expression in wild type ARPE-19 cells (FIG. 3C).
- the present disclosure features mammalian cells (e.g., human RPE cells) engineered to modulate the level or function of a major histocompatibility complex (MHC) class I protein complex or a component thereof (e.g., beta-2-microglobulin (beta-2M)).
- MHC major histocompatibility complex
- beta-2M beta-2-microglobulin
- the mammalian cells are engineered to reduce the expression of the MHC class I protein complex or a component thereof, e.g., beta-2M.
- the mammalian cells may be engineered to produce a lower functioning or non-functional variant of the MHC class I protein complex or a component thereof (e.g., beta-2M), or the expression of a MHC class I protein complex or component thereof (e.g., beta-2M) may be silenced or knocked down or knocked out.
- the present disclosure also features mammalian cells further engineered to modulate the level or function of the MHC class II protein complex or a component thereof, and/or the level or function of a class II major histocompatibility complex transactivator (CIITA).
- CIITA major histocompatibility complex transactivator
- the mammalian cells are engineered to reduce the expression of the MHC class II protein complex or a component thereof, and/or the level or function of CIITA.
- the mammalian cells may be engineered to produce a lower functioning or non-functional variant of the MHC class II protein complex or a component thereof, and/or CIITA, or the expression of the MHC class II protein complex or a component thereof, and/or CIITA may be silenced or knocked down or knocked out.
- “About” or “approximately” when used herein to modify a numerically defined parameter means that the recited numerical value is within an acceptable functional range for the defined parameter as determined by one of ordinary skill in the art, which will depend in part on how the numerical value is measured or determined, e.g., the limitations of the measurement system, including the acceptable error range for that measurement system. For example, “about” can mean a range of 20% above and below the recited numerical value.
- a hydrogel capsule defined as having a diameter of about 1.5 millimeters (mm) and encapsulating about 5 million (M) cells may have a diameter of 1.2 to 1.8 mm and may encapsulate 4 M to 6 M cells.
- a preparation of about 100 devices includes preparations having 80 to 120 devices.
- the term “about” means that the modified parameter may vary by as much as 15%, 10% or 5% above and below the stated numerical value for that parameter.
- “Acquire” or “acquiring” as used herein refers to obtaining possession of a value, e g., a numerical value, or image, or a physical entity (e.g., a sample), by “directly acquiring” or “indirectly acquiring” the value or physical entity.
- “Directly acquiring” means performing a process (e.g., performing an analytical method or protocol) to obtain the value or physical entity.
- “Indirectly acquiring” refers to receiving the value or physical entity from another party or source (e.g., a third-party laboratory that directly acquired the physical entity or value).
- Directly acquiring a value or physical entity includes performing a process that includes a physical change in a physical substance or the use of a machine or device. Examples of directly acquiring a value include obtaining a sample from a human subject.
- Directly acquiring a value includes performing a process that uses a machine or device, e.g., using a fluorescence microscope to acquire fluorescence microscopy
- administering refers to implanting, absorbing, ingesting, injecting, placing, or otherwise introducing into a subject, an entity described herein (e.g., a device or a preparation of devices), or providing such an entity to a subject for administration.
- an entity described herein e.g., a device or a preparation of devices
- Afibrotic means a compound or material that mitigates the foreign body response (FBR).
- FBR foreign body response
- the amount of FBR in a biological tissue that is induced by implant into that tissue of a device is lower than the FBR induced by implantation of an afibrotic-null reference device, i.e., a device that lacks any afibrotic compound, but is of substantially the same composition (e.g., same cell type(s)) and structure (e.g., size, shape, no. of compartments).
- the degree of the FBR is assessed by the immunological response in the tissue containing the implanted device (e.g., hydrogel capsule), which may include, for example, protein adsorption, macrophages, multinucleated foreign body giant cells, fibroblasts, and angiogenesis, using assays known in the art, e.g., as described in WO 2017/075630, or using one or more of the assays / methods described Vegas, A., et al., Nature Biotechnol (supra), (e.g., subcutaneous cathepsin measurement of implanted capsules, Masson’s trichrome (MT), hematoxylin or eosin staining of tissue sections, quantification of collagen density, cellular staining and confocal microscopy for macrophages (CD68 or F4/80), myofibroblasts (alpha-muscle actin, SMA) or general cellular deposition, quantification of 79 RNA sequences of the tissue
- the FBR is assessed by measuring the levels in the tissue containing the implant of one or more biomarkers of immune response, e.g., cathepsin, TNF-a, IL-13, IL-6, G-CSF, GM-CSF, IL-4, CCL2, or CCL4.
- biomarkers of immune response e.g., cathepsin, TNF-a, IL-13, IL-6, G-CSF, GM-CSF, IL-4, CCL2, or CCL4.
- the FBR induced by a device of the invention is at least about 80%, about 85%, about 90%, about 95%, about 99%, or about 100% lower than the FBR induced by an FBR-null reference device, e.g., a device that is substantially identical to the test or claimed device except for lacking the means for mitigating the FBR (e.g., a hydrogel capsule that does not comprise an afibrotic compound but is otherwise substantially identical to the claimed capsule.
- the FBR (e.g., level of a biomarker(s)) is measured after about 30 minutes, about 1 hour, about 6 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 1 week, about 2 weeks, about 1 month, about 2 months, about 3 months, about 6 months, or longer.
- Cell refers to an engineered cell or a cell that is not engineered.
- a cell is an immortalized cell, or an engineered cell derived from an immortalized cell.
- the cell is a live cell, e.g., is viable as measured by any technique described herein or known in the art.
- Cell -binding peptide means a linear or cyclic peptide that comprises an amino acid sequence that is derived from the cell binding domain of a ligand for a cell-adhesion molecule (CAM) (e.g., that mediates cell-matrix junctions or cell-cell junctions).
- CAM cell-adhesion molecule
- the CBP is any of the CBPs described in international patent publication W02020069429.
- the CBP is a linear peptide comprising RGD and is less than 6 amino acids in length.
- the CBP is a linear peptide that consists essentially of RGD or RGDSP.
- CBP-polymer means a polymer comprising at least one cell-binding peptide molecule covalently attached to the polymer via a linker.
- the polymer in a CBP-polymer is a synthetic or naturally-occurring polysaccharide, e.g., an alginate, e.g., a sodium alginate.
- the linker is an amino acid linker (i.e., consists essentially of a single amino acid, or a peptide of several identical or different amino acids), which is joined via a peptide bond to the N-terminus or C-terminus of the CBP.
- the CBP- polymer is any of the CBP-alginates defined in W02020069429.
- Cell -binding substance means any chemical, biological, or other type of substance (e.g., a small organic compound, a peptide, a polypeptide) that is capable of mimicking at least one activity of a ligand for a cell-adhesion molecule (CAM) or other cellsurface molecule that mediates cell-matrix junctions or cell-cell junctions or other receptor- mediated signaling.
- CAM cell-adhesion molecule
- the CBS when present in a polymer composition encapsulating live cells, the CBS is capable of forming a transient or permanent bond or contact with one or more of the cells.
- the CBS facilitates interactions between two or more live cells encapsulated in the polymer composition.
- the presence of a CBS in a polymer composition encapsulating a plurality of cells is correlated with one or both of increased cell productivity (e.g., expression of a therapeutic agent) and increased cell viability when the encapsulated cells are implanted into a test subject, e.g., a mouse.
- the CBS is physically attached to one or more polymer molecules in the polymer composition.
- the CBS is a cell-binding peptide, as defined herein or in W02020069429.
- “Conservatively modified variants” or conservative substitution”, as used herein, refers to a variant of a reference peptide or polypeptide that is identical to the reference molecule, except for having one or more conservative amino acid substitutions in its amino acid sequence.
- a conservatively modified variant consists of an amino acid sequence that is at least 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the reference amino acid sequence.
- a conservative amino acid substitution refers to substitution of an amino acid with an amino acid having similar characteristics (e.g., charge, side-chain size, hydrophobicity /hydrophilicity, backbone conformation and rigidity, etc.) and which has minimal impact on the biological activity of the resulting substituted peptide or polypeptide.
- Conservative substitution tables of functionally similar amino acids are well known in the art, and exemplary substitutions grouped by functional features are set forth in Table 1 below.
- a therapeutic protein agent secreted by an engineered mammalian cell described herein that consists essentially of a recited amino acid sequence may also include one or more amino acids, including substitutions in the recited amino acid sequence, of one or more amino acid residues, which do not materially affect the relevant biological activity of the therapeutic protein agent, respectively.
- “Derived from”, as used herein with respect to a cell or cells, refers to cells obtained from tissue, cell lines, or cells, which optionally are then cultured, passaged, immortalized, differentiated and/or induced, etc. to produce the derived cell(s).
- “Device”, and “implantable element” as used herein, refers to any implantable object (e.g., a particle, a hydrogel capsule, an implant, a medical device), which contains an engineered cell or cells (e.g., live cells) capable of expressing and secreting a therapeutic agent following implant of the device, and has a configuration that supports the viability of the cells by allowing cell nutrients to enter the device.
- the terms “device”, and “implantable element” are used herein interchangeably.
- “Differential volume,” as used herein, refers to a volume of one compartment within a device described herein that excludes the space occupied by another compartment(s).
- the differential volume of the second (e.g., outer) compartment in a 2-compartment device with inner and outer compartments refers to a volume within the second compartment that excludes space occupied by the first (inner) compartment.
- Effective amount refers to an amount of any of the following: engineered cells secreting a protein, a device preparation producing the protein, or a component of a device (e.g., amount of a therapeutic agent co-expressed with another therapeutic agent by cells in the device, number of engineered cells in the device, amount of a CBS and/or afibrotic compound in the device) that is sufficient to elicit a desired biological response.
- the term “effective amount” refers to the amount of a component of the device (e.g., number of cells in the device, the density of an afibrotic compound disposed on the surface and/or in a barrier compartment of the device, the density of a CBS in the cell -containing compartment.
- the desired biological response upon implant of the implantable element into a subject is a lower amount of pericapsular fibrotic overgrowth (PFO) compared with the amount of PFO observed for a control implantable element (e.g., defined as an otherwise identical implantable element except that the cell does not have the reduction in the MHC class I protein complex).
- An effective amount may comprise the amount of therapeutic agent secreted by the engineered mammalian cells described herein.
- An effective amount encompasses therapeutic and prophylactic treatment.
- Effective amount refers to an amount of genetically modified cells (e.g., derived from human cells (e.g., epithelial cells)) producing an exogenous polypeptide or a device preparation producing the polypeptide that is sufficient to elicit a desired biological response.
- the desired biological response is an increase in levels of the exogenous polypeptide within the cells, or for secreted polypeptides, in a tissue sample removed from a subject treated with (e.g., implanted with) the genetically modified cells, a device or a device preparation containing such cells.
- the effective amount may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the exogenous polypeptide, composition or device, the condition being treated, the mode of administration, and the age and health of the subject.
- An effective amount encompasses therapeutic and prophylactic treatment.
- an “endogenous nucleic acid” as used herein, is a nucleic acid that occurs naturally in a subject cell.
- an “endogenous polypeptide,” as used herein, is a polypeptide that occurs naturally in a subject cell.
- Engineerered human cell and “genetically modified human cell”, may be used interchangeably herein, and each term means a human cell (e.g., an epithelial cell) having a non- naturally occurring genetic alteration (e.g., in the cellular genome), and typically comprises an exogenous nucleic acid sequence (e.g., DNA or RNA) not present (or present at a different level than) in an otherwise similar human cell (e.g., epithelial cell) that is not engineered.
- an engineered human cell e.g., engineered RPE cell
- the exogenous nucleic acid sequence is chromosomal (e.g., the exogenous nucleic acid sequence is an exogenous sequence disposed in endogenous chromosomal sequence) or is extra chromosomal (e.g., a non-integrated expression vector).
- the exogenous nucleic acid sequence comprises an RNA sequence, e.g., an mRNA.
- the exogenous nucleic acid sequence comprises a chromosomal or extra-chromosomal exogenous nucleic acid sequence that comprises a sequence which is expressed as RNA, e.g., mRNA or a regulatory RNA.
- the exogenous nucleic acid sequence comprises a first chromosomal or extra-chromosomal exogenous nucleic acid sequence that modulates the conformation or expression of a second nucleic acid sequence the second nucleic acid sequence can be exogenous or endogenous.
- an engineered cell can comprise an exogenous nucleic acid that controls the expression of an endogenous sequence.
- the engineered cell comprises an exogenous nucleic acid sequence which comprises a codon optimized coding sequence for a polypeptide of interest and achieves higher expression of the polypeptide than a naturally-occurring coding sequence.
- the codon optimized coding sequence may be generated using a commercially available algorithm, e.g., GeneOptimizer (ThermoFisher Scientific), OptimumGeneTM (GenScript, Piscataway, NJ USA), GeneGPS® (ATUM, Newark, CA USA), or Java Codon Adaptation Tool (JCat, www.jcat.de, Grote, A. et al., Nucleic Acids Research, Vol 33, Issue suppl 2, pp. W526-W531 (2005).
- an engineered cell e.g., engineered epithelial cell, e.g., engineered RPE cell, e.g., engineered ARPE-19 cell
- the engineered cell is not an islet cell, as defined herein.
- exogenous nucleic acid is a nucleic acid that does not occur naturally in a subject cell.
- exogenous polypeptide is a polypeptide that is encoded by an exogenous nucleic acid in a subject cell.
- Reference to an amino acid position of a specific sequence means the position of said amino acid in a reference amino acid sequence, e.g., sequence of a full-length mature (after signal peptide cleavage) wild-type protein (unless otherwise stated), and does not exclude the presence of variations, e.g., deletions, insertions and/or substitutions at other positions in the reference amino acid sequence.
- Factor VII protein or “FVII protein” as used herein, means a polypeptide that comprises the amino acid sequence of a naturally occurring factor VII protein or variant thereof that has a FVII biological activity, e.g., promoting blood clotting, as determined by an art- recognized assay, unless otherwise specified.
- Naturally occurring FVII exists as a single chain zymogen, a zymogen-like two-chain polypeptide and a fully activated two-chain form (FVIIa).
- reference to FVII includes single-chain and two-chain forms thereof, including zymogen-like and FVIIa.
- FVII proteins that may be produced by a genetically modified cell described herein (e.g., derived from a human epithelial cell line, e.g., the ARPE-19 cell line), include wild-type primate (e.g., human), porcine, canine, and murine proteins, as well as variants of such wild-type proteins, including fragments, mutants, variants with one or more amino acid substitutions and / or deletions.
- a variant FVII protein is capable of being activated to the fully activated two-chain form (Factor Vila) that has at least 50%, 75%, 90% or more (including >100%) of the activity of wild-type Factor Vila.
- FVII and FVIIa are known, e.g., marzeptacog alfa (activated) (MarzAA) and the variants described in European Patent No. 1373493, US Patent No. 7771996, US Patent No. 9476037 and US published application No. US20080058255.
- Factor VII biological activity may be quantified by an art recognized assay, unless otherwise specified.
- FVII biological activity in a sample of a biological fluid may be quantified by (i) measuring the amount of Factor Xa produced in a system comprising tissue factor (TF) embedded in a lipid membrane and Factor X (Persson et al., J. Biol. Chem. 272: 19919-19924, 1997); (ii) measuring Factor X hydrolysis in an aqueous system; (iii) measuring its physical binding to TF using an instrument based on surface plasmon resonance (Persson, FEBS Letts.
- FVII activity is assessed by a commercially available chromogenic assay (BIOPHEN FVII, HYPHEN BioMed Neuville sur Oise, France), in which the biological sample containing FVII is mixed with thromboplastin calcium, Factor X and SXa-11 (a chromogenic substrate specific for Factor Xa.
- Fractor VIII protein or “FVIII protein” as used herein, means a polypeptide that comprises the amino acid sequence of a naturally occurring factor VIII polypeptide or variant thereof that has an FVIII biological activity, e g., coagulation activity, as determined by an art- recognized assay, unless otherwise specified.
- FVIII proteins that may be expressed by a genetically modified cell described herein (e.g., derived from a human epithelial cell line, e.g., the ARPE-19 cell line), include wild-type primate (e.g., human), porcine, canine, and murine proteins, as well as variants of such wild-type proteins, including fragments, mutants, variants with one or more amino acid substitutions and / or deletions, B-domain deletion (BDD) variants, single chain variants and fusions of any of the foregoing wild-type or variants with a half-life extending polypeptide.
- wild-type primate e.g., human
- porcine porcine
- canine canine
- murine proteins as well as variants of such wild-type proteins, including fragments, mutants, variants with one or more amino acid substitutions and / or deletions
- BDD B-domain deletion
- the cells are engineered to encode a precursor factor VIII polypeptide (e.g., with the signal sequence) with a full or partial deletion of the B domain.
- the cells are engineered to encode a single chain factor VIII polypeptide which contains a variant FVIII protein preferably has at least 50%, 75%, 90% or more (including >100%) of the coagulation activity of the corresponding wild-type factor VIII.
- Assays for measuring the coagulation activity of FVIII proteins include the one stage or two stage coagulation assay (Rizza et al., 1982, Coagulation assay of FVIII: C and FIXa in Bloom ed. The Hemophelias.
- FVIII-BDD variants include, e.g., variants with the full or partial B-domain deletions disclosed in any of the following U.S. Patent Nos: 4,868,112 (e.g., col. 2, line 2 to col. 19, line 21 and table 2); 5,112,950 (e.g., col. 2, lines 55-68, FIG. 2, and example 1); 5,171,844 (e.g., col. 4, line 22 to col. 5, line 36); 5,543,502 (e.g., col.
- a FVIII-BDD protein produced by a genetically modified cell described herein has one or more of the following deletions of amino acids in the B-domain: (i) most of the B domain except for amino-terminal B-domain sequences essential for intracellular processing of the primary translation product into two polypeptide chains (WO 91/09122); (ii) a deletion of amino acids 747-1638 (Hoeben R. C., et al. J. Biol. Chem.
- a FVIII-BDD protein retains any of the following B-domain amino acids or amino acid sequences: (i) one or more N-linked glycosylation sites in the B- domain, e.g., residues 757, 784, 828, 900, 963, or optionally 943, first 226 amino acids or first 163 amino acids (Miao, H. Z., et al., Blood 103(a): 3412-3419 (2004), Kasuda, A., et al., J. Thromb. Haemost. 6: 1352-1359 (2008), and Pipe, S. W., et al., J. Thromb. Haemost. 9: 2235- 2242 (2011).
- the FVIII-BDD protein is a single-chain variant generated by substitution or deletion of one or more amino acids in the furin protease recognition sequence LKRHQR that prevents proteolytic cleavage at this site, including any of the substitutions at the R1645 and/or R1648 positions described in U.S. Patent Nos. 10,023,628, 9,394,353 and 9,670,267.
- any of the above FVIII-BDD proteins may further comprise one or more of the following variations: a F309S substitution to improve expression of the FVIII- BDD protein (Miao, H. Z., et al., Blood 103(a): 3412-3419 (2004); albumin fusions (WO 2011/020866); and Fc fusions (WO 04/101740).
- Fractor IX protein or “FIX protein”, as used herein, means a polypeptide that comprises the amino acid sequence of a naturally occurring factor IX protein or variant thereof that has a FIX biological activity, e.g., coagulation activity, as determined by an art-recognized assay, unless otherwise specified.
- FIX is produced as an inactive zymogen, which is converted to an active form by factor Xia excision of the activation peptide to produce a heavy chain and a light chain held together by one or more disulfide bonds.
- wild-type primate e.g., human
- porcine canine
- murine proteins as well as variants of such wild-type proteins, including fragments, mutants, variants with one or more amino acid substitutions and / or deletions and fusions of any of the foregoing wild-type or variant proteins with a half-life extending polypeptide.
- cells are engineered to encode a full-length wild-type human factor IX polypeptide (e.g., with the signal sequence) or a functional variant thereof.
- a variant FIX protein preferably has at least 50%, 75%, 90% or more (including >100%) of the coagulation activity of wild-type factor VIX.
- Assays for measuring the coagulation activity of FIX proteins include the Biophen Factor IX assay (Hyphen BioMed) and the one stage clotting assay (activated partial thromboplastin time (aPTT), e.g., as described in EP 2 032 607, thrombin generation time assay (TGA) and rotational thromboelastometry, e.g., as described in WO 2012/006624.
- a number of functional FIX variants are known and may be expressed by engineered cells encapsulated in a device described herein, including any of the functional FIX variants described in the following international patent publications: WO 02/040544 at page 4, lines 9-30 and page 15, lines 6-31; WO 03/020764 in Tables 2 and 3 at pages 14-24, and at page 12, lines 1-27; WO 2007/149406 at page 4, line 1 to page 19, line 1 1 ; WO 2007/149406 A2 at page 19, line 12 to page 20, line 9; WO 08/118507 at page 5, line 14 to page 6, line 5; WO 09/051717 at page 9, line 11 to page 20, line 2; WO 09/137254 at page 2, paragraph [006] to page 5, paragraph [011] and page 16, paragraph [044] to page 24, paragraph [057]; WO 09/130198 A2 at page 4, line 26 to page 12, line 6; WO 09/140015 at page 11, paragraph [0043] to page 13, paragraph [0053]; WO 2012
- the FIX polypeptide comprises a wild-type or variant sequence fused to a heterologous polypeptide or non-polypeptide moiety extending the half-life of the FIX protein.
- exemplary half-life extending moieties include Fc, albumin, a PAS sequence, transferrin, CTP (28 amino acid C-terminal peptide (CTP) of human chorionic gonadotropin (hCG) with its 4 O-glycans), polyethylene glycol (PEG), hydroxyethyl starch (HES), albumin binding polypeptide, albumin-binding small molecules, or any combination thereof.
- FIX polypeptide is the rFIXFc protein described in WO 2012/006624, which is an FIXFc single chain (FIXFc-sc) and an Fc single chain (Fc-sc) bound together through two disulfide bonds in the hinge region of Fc.
- FIXFc-sc FIXFc single chain
- Fc-sc Fc single chain
- FIX variants also include gain and loss of function variants.
- An example of a gain of function variant is the “Padua” variant of human FIX, which has a L (leucine) at position 338 of the mature protein instead of an R (arginine) and has greater catalytic and coagulant activity compared to wild-type human FIX (Chang et al., J. Biol. Chem., 273: 12089-94 (1998)).
- An example of a loss of function variant is an alanine substituted for lysine in the fifth amino acid position from the beginning of the mature protein, which results in a protein with reduced binding to collagen IV (e.g., loss of function).
- Islet cell means a cell that comprises any naturally occurring or any synthetically created, or modified, cell that is intended to recapitulate, mimic or otherwise express, in part or in whole, the functions, in part or in whole, of the cells of the pancreatic islets of Langerhans.
- the term “islet cell” includes a glucose-responsive, insulin producing cell derived from a stem cell, e.g., from an induced pluripotent stem cell line.
- Polymer composition is a composition (e.g., a solution, mixture) comprising one or more polymers.
- polymers includes homopolymers, heteropolymers, co-polymers, block polymers, block co-polymers and can be both natural and synthetic. Homopolymers contain one type of building block, or monomer, whereas co-polymers contain more than one type of monomer.
- Polypeptide refers to a polymer comprising amino acid residues linked through peptide bonds and having at least two, and in some embodiments, at least 3, 4, 5, 10, 50, 75,100, 150 or 200 amino acid residues.
- Prevention refers to a treatment that comprises administering a composition (or preparation) of devices encapsulating genetically modified cells that express an exogenous polypeptide, prior to the onset of one or more symptoms of a disease or condition that is amenable to treatment with the exogenous polypeptide, to preclude the physical manifestation of the symptom(s).
- prevention require that signs or symptoms of a disease or condition have not yet developed or have not yet been observed.
- RPE cells include ARPE-19-SEAP-2-neo cells, RPE- J cells, and hTERT RPE-1 cells.
- an RPE described herein is engineered, e g., to have a new property, e.g., the cell is genetically modified by inserting at least one exogenous transcription unit into one or more of the OCR locations described herein.
- Sequence identity when used herein to refer to two nucleotide sequences or two amino acid sequences, means the two sequences are the same within a specified region, or have the same nucleotides or amino acids at a specified percentage of nucleotide or amino acid positions within the specified when the two sequences are compared and aligned for maximum correspondence over a comparison window or designated region. Sequence identity may be determined using standard techniques known in the art including, but not limited to, any of the algorithms described in US Patent Application Publication No. 2017/02334455 Al. In an embodiment, the specified percentage of identical nucleotide or amino acid positions is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher.
- Spherical as used herein means a device (e.g., a hydrogel capsule or other particle) having a curved surface that forms a sphere (e.g., a completely round ball) or sphere-like shape, which may have waves and undulations, e.g., on the surface.
- Spheres and sphere-like objects can be mathematically defined by rotation of circles, ellipses, or a combination around each of the three perpendicular axes, a, b, and c. For a sphere, the three axes are the same length.
- a sphere-like shape is an ellipsoid (for its averaged surface) with semi-principal axes within 10%, or 5%, or 2.5% of each other.
- the diameter of a sphere or sphere-like shape is the average diameter, such as the average of the semi-principal axes.
- Spheroid as that term is used herein to refer to a device (e.g., a hydrogel capsule or other particle), means the device has (i) a perfect or classical oblate spheroid or prolate spheroid shape or (ii) has a surface that roughly forms a spheroid, e.g., may have waves and undulations and/or may be an ellipsoid (for its averaged surface) with semi -principal axes within 100% of each other.
- Subject refers to a human or non-human animal.
- the subject is a human (i.e., a male or female) of any age group, e.g., a pediatric human subject (e.g., infant, child, adolescent) or adult human subject (e.g., young adult, middle-aged adult, or senior adult)).
- the subject is a non-human animal, for example, a mammal (e.g., a mouse, a dog, a primate (e.g., a cynomolgus monkey or a rhesus monkey).
- the subject is a commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog) or a bird (e.g., a commercially relevant bird such as a chicken, duck, goose, or turkey).
- the animal is a mammal.
- the animal may be a male or female and at any stage of development.
- a non-human animal may be a transgenic animal.
- Treatment,” “treat,” and “treating” as used herein refers to one or more of reducing, reversing, alleviating, delaying the onset of, or inhibiting the progress of one or more of a symptom, manifestation, or underlying cause, of a disease (e.g., hemophilia A).
- treating comprises reducing, reversing, alleviating, delaying the onset of, or inhibiting the progress of a symptom or condition associated with the disease.
- treating comprises increasing levels of a therapeutic polypeptide in at least one tissue of a subject in need thereof, e.g., in one or more of plasma, liver, kidney and heart.
- treatment require that signs or symptoms associated with the disease or condition have developed or have been observed.
- treatment may be administered in the absence of signs or symptoms of the disease or condition, e.g., in preventive treatment.
- treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., due to a history of symptoms and/or genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.
- treatment comprises prevention and in other embodiments it does not “Wild-type” (wt) refers to the natural form, including sequence, of a polynucleotide, polypeptide or protein in a species. A wild-type form is distinguished from a mutant form of a polynucleotide, polypeptide or protein arising from genetic mutation(s).
- Ci-Ce alkyl is intended to encompass, Ci, C2, C3, C4, C5, Ce, C1-C6, C1-C 5 , C1-C4, C1-C3, C1-C2, C2-C6, C 2 -C 5 , C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4- C5, and C5-C6 alkyl.
- alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 24 carbon atoms (“C1-C24 alkyl”).
- an alkyl group has 1 to 12 carbon atoms (“C1-C12 alkyl”), 1 to 10 carbon atoms (“C1-C12 alkyl”), 1 to 8 carbon atoms (“Ci-Cs alkyl”), 1 to 6 carbon atoms (“Ci-Ce alkyl”), 1 to 5 carbon atoms (“C1-C5 alkyl”), 1 to 4 carbon atoms (“Ci-C 4 alkyl”), 1 to 3 carbon atoms (“C1-C3 alkyl”), 1 to 2 carbon atoms (“C1-C2 alkyl”), or 1 carbon atom (“Ci alkyl”).
- an alkyl group has 2 to 6 carbon atoms (“C2-C6alkyl”).
- Ci-Ce alkyl groups include methyl (Ci), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C 4 ), tert-butyl (C 4 ), sec-butyl (C 4 ), isobutyl (C 4 ), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (Ce).
- alkyl groups include n-heptyl (C7), n-octyl (Cs) and the like.
- Each instance of an alkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents, e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 24 carbon atoms, one or more carbon-carbon double bonds, and no triple bonds (“C2-C24 alkenyl”).
- an alkenyl group has 2 to 10 carbon atoms (“C2-C10 alkenyl”), 2 to 8 carbon atoms (“C2-C8 alkenyl”), 2 to 6 carbon atoms (“C2-C6 alkenyl”), 2 to 5 carbon atoms (“C2-C5 alkenyl”), 2 to 4 carbon atoms (“C2-C 4 alkenyl”), 2 to 3 carbon atoms (“C2-C3 alkenyl”), or 2 carbon atoms (“C2 alkenyl”).
- the one or more carbon- carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
- Examples of C2-C4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1- butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like.
- Examples of C2-C6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (Ce), and the like.
- Each instance of an alkenyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- alkynyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 24 carbon atoms, one or more carbon-carbon triple bonds (“C2-C24 alkenyl”).
- an alkynyl group has 2 to 10 carbon atoms (“C2-C10 alkynyl”), 2 to 8 carbon atoms (“C2-C8 alkynyl”), 2 to 6 carbon atoms (“C2-C6 alkynyl”), 2 to 5 carbon atoms (“C2-C5 alkynyl”), 2 to 4 carbon atoms (“C2-C4 alkynyl”), 2 to 3 carbon atoms (“C2-C3 alkynyl”), or 2 carbon atoms (“C2 alkynyl”).
- the one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl).
- Examples of C2- C4 alkynyl groups include ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2- butynyl (C4), and the like.
- Each instance of an alkynyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- heteroalkyl refers to a non-cyclic stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quatemized.
- the heteroatom(s) O, N, P, S, and Si may be placed at any position of the heteroalkyl group.
- heteroalkyl Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3.
- heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as -CH2O, -NR C R D , or the like, it will be understood that the terms heteroalkyl and -CH2O or -NR C R D are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as -CH2O, -NR C R D , or the like.
- Each instance of a heteroalkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
- alkylene alkenylene, alkynylene, or “heteroalkylene,” alone or as part of another substituent, mean, unless otherwise stated, a divalent radical derived from an alkyl, alkenyl, alkynyl, or heteroalkyl, respectively.
- An alkylene, alkenylene, alkynylene, or heteroalkylene group may be described as, e.g., a Ci-Ce-membered alkylene, Cz-Ce-membered alkenylene, Ci-Ce-membered alkynylene, or Ci-Ce-membered heteroalkylene, wherein the term “membered” refers to the non-hydrogen atoms within the moiety.
- heteroatoms can also occupy either or both chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(0)2R’- may represent both -C(0)2R’- and -R’C(0)2-
- aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 it electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C6-C14 aryl”).
- an aryl group has six ring carbon atoms (“Ce aryl”; e.g., phenyl).
- an aryl group has ten ring carbon atoms (“C10 aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“Cuaryl”; e.g., anthracyl).
- An aryl group may be described as, e.g., a Ce-Cio- membered aryl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety.
- Aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl.
- Each instance of an aryl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents.
- heteroaryl refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 it electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-10 membered heteroaryl”).
- heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits.
- Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings.
- Heteroaryl also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system.
- Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
- the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
- a heteroaryl group may be described as, e.g., a 6-10-membered heteroaryl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety.
- a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”).
- a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”).
- a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”).
- the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
- Each instance of a heteroaryl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents.
- exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl.
- Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
- Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
- Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl.
- Exemplary 6-membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl.
- Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
- Exemplary 6- membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.
- Exemplary 7-membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl.
- Exemplary 5,6- bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotri azolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadi azolyl, indolizinyl, and purinyl.
- Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
- Other exemplary heteroaryl groups include heme and heme derivatives.
- arylene and “heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively.
- cycloalkyl refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C3-C10 cycloalkyl”) and zero heteroatoms in the non-aromatic ring system.
- a cycloalkyl group has 3 to 8 ring carbon atoms (“Cs-Cscycloalkyl”), 3 to 6 ring carbon atoms (“C3-C6 cycloalkyl”), or 5 to 10 ring carbon atoms (“C5-C10 cycloalkyl”).
- a cycloalkyl group may be described as, e.g., a C4-C?-membered cycloalkyl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety.
- Exemplary C3-C6 cycloalkyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (Ce), cyclohexenyl (Ce), cyclohexadienyl (Ce), and the like.
- Exemplary C3-C8 cycloalkyl groups include, without limitation, the aforementioned C3-C6 cycloalkyl groups as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C8), cyclooctenyl (C8), cubanyl (C8), bicyclo[1.1.1]pentanyl (C5), bicyclo[2.2.2]octanyl (C8), bicyclo[2.1.1]hexanyl (C6), bicyclo[3.1.1]heptanyl (C7), and the like.
- Exemplary C 3 -C 10 cycloalkyl groups include, without limitation, the aforementioned C 3 -C 8 cycloalkyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro–1H–indenyl (C9), decahydronaphthalenyl (C10), spiro [4.5] decanyl (C10), and the like.
- the cycloalkyl group is either monocyclic (“monocyclic cycloalkyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic cycloalkyl”) and can be saturated or can be partially unsaturated.
- “Cycloalkyl” also includes ring systems wherein the cycloalkyl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is on the cycloalkyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the cycloalkyl ring system.
- cycloalkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents.
- “Heterocyclyl” as used herein refers to a radical of a 3– to 10–membered non–aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3–10 membered heterocyclyl”).
- heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits.
- a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated.
- Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings.
- Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more cycloalkyl groups wherein the point of attachment is either on the cycloalkyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system.
- a heterocyclyl group may be described as, e.g., a 3-7-membered heterocyclyl, wherein the term “membered” refers to the non- hydrogen ring atoms, i.e., carbon, nitrogen, oxygen, sulfur, boron, phosphorus, and silicon, within the moiety.
- Each instance of heterocyclyl may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents.
- the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl.
- the heterocyclyl group is substituted 3-10 membered heterocyclyl.
- a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5-10 membered heterocyclyl”).
- a heterocyclyl group is a 5-8 membered non- aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”).
- a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”).
- the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
- Exemplary 3-membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl.
- Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl.
- Exemplary 5-membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2, 5-dione.
- Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
- Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
- Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, piperazinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
- Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl or thiomorpholinyl-1,1- dioxide. Exemplary 7–membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8–membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl.
- Exemplary 5–membered heterocyclyl groups fused to a C6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
- Exemplary 6– membered heterocyclyl groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
- amino refers to the radical –NR 70 R 71 , wherein R 70 and R 71 are each independently hydrogen, C1–C8 alkyl, C3–C10 cycloalkyl, C4–C10 heterocyclyl, C6–C10 aryl, and C5–C10 heteroaryl. In some embodiments, amino refers to NH2. As used herein, “cyano” refers to the radical –CN. As used herein, “halo” or “halogen,” independently or as part of another substituent, mean, unless otherwise stated, a fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) atom.
- hydroxy refers to the radical –OH.
- Alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” heteroalkyl, “substituted” or “unsubstituted” cycloalkyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group).
- substituted means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
- a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
- substituted is contemplated to include substitution with all permissible substituents of organic compounds, such as any of the substituents described herein that result in the formation of a stable compound.
- the present disclosure contemplates any and all such combinations to arrive at a stable compound.
- heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
- Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocyclyl groups.
- Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
- the ring-forming substituents are attached to adjacent members of the base structure.
- two ringforming substituents attached to adjacent members of a cyclic base structure create a fused ring structure.
- the ring-forming substituents are attached to a single member of the base structure.
- two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure.
- the ringforming substituents are attached to non-adjacent members of the base structure.
- Compounds of Formula (I) described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers.
- the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
- Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
- HPLC high-pressure liquid chromatography
- a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess).
- an “S” form of the compound is substantially free from the “R” form of the compound and is, thus, in enantiomeric excess of the “R” form.
- enantiomerically pure or “pure enantiomer” denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 99% by weight, more than 99.5% by weight, or more than 99.9% by weight, of the enantiomer.
- the weights are based upon total weight of all enantiomers or stereoisomers of the compound.
- Compounds of Formula (I) described herein may also comprise one or more isotopic substitutions.
- H may be in any isotopic form, including L H, 2 H (D or deuterium), and 3 H (T or tritium); C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 O and 18 O; and the like.
- pharmaceutically acceptable salt is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolyl sulfonic, citric, tartaric, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galacturonic acids and the like (see, e.g., Berge et al, Journal of Pharmaceutical Science 66: 1-19 (1977)).
- Certain specific compounds used in the devices of the present disclosure e.g., a particle, a hydrogel capsule
- These salts may be prepared by methods known to those skilled in the art.
- Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for use in the present disclosure.
- Devices of the present disclosure may contain a compound of Formula (I) in a prodrug form.
- Prodrugs are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds useful for preparing devices in the present disclosure. Additionally, prodrugs can be converted to useful compounds of Formula (I) by chemical or biochemical methods in an ex vivo environment.
- Certain compounds of Formula (I) described herein can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain compounds of Formula (I) described herein may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
- solvate refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding.
- Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like.
- the compounds described herein may be prepared, e.g., in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates.
- hydrate refers to a compound which is associated with water.
- the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R x H2O, wherein R is the compound and wherein x is a number greater than 0.
- tautomer refers to compounds that are interchangeable forms of a compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of it electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
- connection refers to a connection to an entity, e.g., a polymer (e.g., hydrogel -forming polymer such as alginate) or surface of an implantable device, e.g., a particle, a hydrogel capsule.
- entity e.g., a polymer (e.g., hydrogel -forming polymer such as alginate) or surface of an implantable device, e.g., a particle, a hydrogel capsule.
- the connection represented by “ ” may refer to direct attachment to the entity, e.g., a polymer or an implantable element, may refer to linkage to the entity through an attachment group.
- An “attachment group,” as described herein, refers to a moiety for linkage of a compound of Formula (I) to an entity (e.g., a polymer or an implantable element (e.g., a device) as described herein), and may comprise any attachment chemistry known in the art.
- an attachment group comprises an amine, ketone, ester, amide, alkyl. In some embodiments, an attachment group is a cross-linker. In some embodiments, the ⁇ attachment group is -C(O)(Ci-C6 1 , and R 1 is as described herein®. In some embodiments, the attachment group is -C(O)(Ci-C6-alkylene)-, wherein alkylene is substituted with 1-2 alkyl groups (e.g., 1-2 methyl groups). In some embodiments, the attachment group is -C(O)C(CH3)2-.
- the attachment group is -C(O)(methylene)-, wherein alkylene is substituted with 1-2 alkyl groups (e.g., 1-2 methyl groups).
- the attachment group is -C(O)CH(CH3)-.
- the attachment group is - C(O)C(CH 3 )-.
- the present disclosure provides an engineered mammalian cell capable of modulating the level or function of the MHC class I protein complex, and optionally, the MHC class II protein complex and/or CH I A.
- the engineered mammalian cell reduces a level or function of the MHC class I protein complex, and optionally, the MHC class II protein complex and/or CHTA.
- the MHC class I protein complex is a class of molecules present on the surface of nucleated cells that inform the host’s immune system of the status of a particular antigen as being self or non-self.
- the MHC class I molecules display peptide fragments of cytotoxic proteins on the cell surface, which trigger an immune response within the host if the cytotoxic protein is derived from a non-self-source.
- the MHC class I molecules are heterodimeric proteins that consist of two polypeptide chains.
- the alpha chain is polymorphic, and is encoded by a human leukocy te antigen (HLA) comprising one of HL A- A, HLA-B, or HLA-C.
- HLA human leukocy te antigen
- the beta chain comprises the beta-2-microglobulin (beta-2M) domain.
- the alpha and beta chain of each MHC class I molecule are noncovalently linked through the interaction of the beta-2M and one of the three plasma membrane-spanning domains of the alpha chain (alpha-3).
- the alpha chain also comprises two other domains: alpha- 1 and alpha-2.
- the engineered mammalian cell of the present disclosure comprises a reduced level or function in an MHC class I protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M.
- the groove between the alpha-1 and alpha-2 domains is the peptide-binding groove, in which peptides derived from cytosolic proteins are displayed.
- the groove comprises eight p- pleated sheets on the bottom and two a helices making up sides.
- the groove is flanked by tyrosine residues and creates closed ends that limit the size of peptides that can be bound within the groove.
- the peptide in the groove remains substantially bound there for the life of the class I molecule and is typically 8-9 amino acids in length.
- Self or foreign cytosolic proteins are degraded via the proteasome and transported into the lumen of the ER. In the ER, the peptides are loaded onto an MHC class 1 via the aid of a chaperone protein named tapasin.
- the peptide bound MHC class I is then transported to the cell’s plasma membrane, where it presents the peptide to CDS T cell receptors (Becar M et al. (2022) Physiology, MHC Class I. In: StatPearls [Internet], Treasure Island (FL): StatPearls Publishing; 2023 Jan-.)
- TCR T cell receptor
- Beta-2M is a non-glycosylated 12 kDa protein; one of its functions is to stabilize the MHC class I a-chain. Unlike the a-chain, the beta-2M does not span the membrane.
- the human beta-2M locus is on chromosome 15.
- the beta-2M gene consists of 4 exons and 3 introns. Circulating forms of beta-2M are present in the serum, urine, and other body fluids; thus, the non -covalently MHC
- Beta-2M can be exchanged with circulating beta-2M under physiological conditions, Beta-2M associates not only with the alpha chain of MHC class I molecules, but also with class I- like molecules such as CD1 (5 genes in humans), MR1, the neonatal Fc receptor (FcRn), and Qa- 1 (a form of alloantigen).
- CD1 genes in humans
- MR1 the neonatal Fc receptor
- Qa- 1 a form of alloantigen
- the engineered mammalian cell comprises a reduction in a level or function of an MHC class I protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M.
- the engineered mammalian cell comprises a reduction in the alpha and/or beta chain of the MHC class I protein complex or component thereof.
- the engineered mammalian cell comprises a reduction in a level or function of the alpha-1 domain.
- the level or function of the alpha-1 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%).
- the level or function of the alpha- 1 domain is reduced by about 20%.
- the level or function of the alpha- 1 domain is reduced by about 30%.
- the level or function of the alpha-1 domain is reduced by about 40%.
- the level or function of the alpha-1 domain is reduced by about 50%.
- the level or function of the alpha-1 domain is reduced by about 60%.
- the level or function of the alpha- 1 domain is reduced by about 70%.
- the level or function of the alpha-1 domain is reduced by about 80%. In some embodiments, the level or function of the alpha-1 domain is reduced by about 90%. In some embodiments, the level or function of the alpha-1 domain is reduced by about 100%.
- the level or function of the alpha-1 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more).
- the level or function of the alpha- 1 domain is reduced by at least 10%.
- the level or function of the alpha- 1 domain is reduced by at least 20%.
- the level or function of the alpha- 1 domain is reduced by at least 30%.
- the level or function of the alpha-1 domain is reduced by at least 40%s.
- the level or function of the alpha-1 domain is reduced by at least 50%.
- the level or function of the alpha- 1 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 70% In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 80%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 95%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 99.9%. In some embodiments, the level or function of the alpha- 1 domain is reduced by more than 99.9%.
- the engineered mammalian cell comprises a reduction in a level or function of the alpha-2 domain.
- the level or function of the alpha-2 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%,
- the level or function of the alpha-2 domain is reduced by about 20%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 30%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 40%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 50%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 60%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 70%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 80% In some embodiments, the level or function of the alpha-2 domain is reduced by about 90%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 100%.
- the level or function of the alpha-2 domain is reduced by at least
- 5% e.g.. at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more.
- the level or function of the alpha-2 domain is reduced by at least 10%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 20%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 30%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 40%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 50%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 70% In some embodiments, the level or function of the alpha-2 domain is reduced by at least 80%.
- the level or function of the alpha-2 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 95% In some embodiments, the level or function of the alpha-2 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 99 9%. In some embodiments, the level or function of the alpha-2 domain is reduced by more than 99.9%.
- the engineered mammalian cell comprises a reduction in a level or function of the alpha-3 domain.
- the level or function of the alpha-3 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%,
- the level or function of the alpha-3 domain is reduced by about 20%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 30% In some embodiments, the level or function of the alpha-3 domain is reduced by about 40%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 50%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 60%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 70%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 80%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 90%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 100%.
- the level or function of the alpha-3 domain is reduced by at least
- the level or function of the alpha-3 domain is reduced by at least 10%
- the level or function of the alpha-3 domain is reduced by at least 20%.
- the level or function of the alpha-3 domain is reduced by at least 30%.
- the level or function of the alpha-3 domain is reduced by at least 40%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 50%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 70%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 80%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 95% In some embodiments, the level or function of the alpha-3 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 99.9%. In some embodiments, the level or function of the alpha-3 domain is reduced by more than 99.9%.
- the engineered mammalian cell comprises a reduction in a level or function of the beta-2M domain.
- the level or function of the beta-2M domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%,
- the level or function of the beta-2M domain is reduced by about 20%. In some embodiments, the level or function of the beta-2M domain is reduced by about 30%. In some embodiments, the level or function of the beta-2M domain is reduced by about 40%. In some embodiments, the level or function of the beta-2M domain is reduced by about 50%. In some embodiments, the level or function of the beta-2M domain is reduced by about 60%. In some embodiments, the level or function of the beta-2M domain is reduced by about 70%. In some embodiments, the level or function of the beta-2M domain is reduced by about 80%. In some embodiments, the level or function of the beta-2M domain is reduced by about 90%. In some embodiments, the level or function of the beta-2M domain is reduced by about 100%.
- the level or function of the beta-2M domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more)
- the level or function of the beta-2M domain is reduced by at least 10%.
- the level or function of the beta-2M domain is reduced by at least 20%.
- the level or function of the beta-2M domain is reduced by at least 30%.
- the level or function of the beta-2M domain is reduced by at least 40%.
- the level or function of the beta-2M domain is reduced by at least 50%.
- the level or function of the beta-2191 domain is reduced by at least 60%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 70%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 80%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 90%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 95%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 99%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 99.9%. In some embodiments, the level or function of the beta-2M domain is reduced by more than 99.9%.
- the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of beta-2M to a MHC class I protein complex or component thereof or an MHC class I-like molecule or component (e.g., CD1, MR1, FcRn, and Qa-1).
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to an MHC class I protein complex or component thereof.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to the alpha- 1 domain of an MHC class I protein. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to the alpha-2 domain of an MHC class I protein. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to the alpha-3 domain of an MHC class I protein.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to an MHC class I-like molecule or component (e.g., CD1, MR1, FcRn, and Qa-1). In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to CD1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g , binding) of beta- 2M to MR1.
- an MHC class I-like molecule or component e.g., CD1, MR1, FcRn, and Qa-1
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to CD1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g , binding) of beta- 2
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to FcRn. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to Qa-1.
- HLA-A interacts with calnexin, calreticulin, transporter associated with antigen processing (TAP), tapasin, the thiol-disulfide oxidoreductase ERp57 enzyme, and any cytosolic peptide bound within its peptide-binding groove.
- the reducing the level or function of substantially decreases, prevents, or inhibits, e g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-A to calnexin, calreticuiin, TAP, tapasin, an ERp57 enzyme, and/or any cytosolic peptide bound within its peptide-binding groove.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to calnexin.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to calreticuiin. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to TAP. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to TAP-1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to TAP -2.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g , binding) of HLA- A to tapasin. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to ERp57. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e g , binding) of HLA-A to a cytosolic peptide bound within its peptide-binding groove.
- HLA-C interacts with killer cell immunoglobulin-like receptor 2DL.1 (KIR2DL1 ) and the leukocyte immunoglobulin-like receptor family (e.g., leukocyte immunoglobulin-like receptor subfamily A member 1 (LILRA1 ) and LILRA3).
- KIR2DL1 killer cell immunoglobulin-like receptor 2DL.1
- LILRA1 leukocyte immunoglobulin-like receptor subfamily A member 1
- LILRA3 leukocyte immunoglobulin-like receptor subfamily A member 1
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-C to K1R2DL1.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-C to the leukocyte immunoglobulin-like receptor family.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g , binding) of HLA-C to LILRA1 .
- the reducing the level or function of substantially prevents, or inhibits the interaction (e.g., binding) of HLA-C to LILRA3.
- the reducing the level or function of the MHC class [ protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M results in reduced antigen presentation, thereby reducing and/or abrogating the recruitment of immune cells, e.g , T cells and NK cells.
- the HLA-A gene is located on the short arm of chromosome 6 and encodes the larger, alpha-chain, constituent of HLA-A. Variation of the HLA-A alpha-chain is key to HLA function. This variation promotes genetic diversity in the population. Since each HLA has a different affinity for peptides of certain structures, a greater variety of HLAs means that a greater variety of antigens can be presented Lon the cell surface, enhancing the likelihood that a subset of the population will be resistant to a given foreign invader. This decreases the likelihood that a single pathogen has the capability to wipe out the entire human population.
- Each individual can express up to two types of HLA-A, one from each of their parents. Some individuals will inherit the same/ZL4-A from both parents, decreasing their individual HLA diversity; however, the majority of individuals will receive two different copies tyCHLA-A. This same pattern follows for all HLA groups (Fix et al. (1998). HLA Matching, Antibodies, and You. Kidney Transplantation: Past, Present, and Future University of Michigan Medical Center/Stanford University). In other words, every' single person can only express either one or two of the 2432 known HLA-A alleles.
- HLA-B gene is located on the short (p) arm of chromosome 6 at cytoband 21.3 and encodes the larger, alpha-chain, constituent of HLA-B. Similar to HLA-A, variation of HLA-B alpha-chain is key to HLA function.
- HLA-C is a locus on chromosome 6, which encodes for many HLA-C alleles that are Class-I MHC receptors. HLA-C, localized proximal to the HLA-B locus, is located on the distal end of the HLA region. Most HLA-C:B haplotypes are in strong linkage disequilibrium and many are as ancient as the human species itself.
- the reducing the level or function of the MHC class I protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M comprises mutating one or more nucleotides in the nucleotide sequence of one or more genes selected from HLA-A, HLA-B, HLA-C, or beta-2M.
- a nucleotide mutation may comprise a nucleotide deletion, addition, and/or substitution.
- Such a mutation may result in a reduction in expression of the gene, e.g., by reducing, altering, or abrogating the transcription and/or splicing of the nucleotide sequence
- the reducing the level or function of the MHC class I protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of the beta-2M gene.
- the reducing the level or function of the MHC class I protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of the HLA-A gene.
- the reducing the level or function of the MHC class I protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of the HLA-B gene In some embodiments, the reducing the level or function of the MHC class I protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of the HLA-C gene.
- the nucleotide sequence of the HLA-A, HLA-B, HL/ ⁇ -C, and beta-2M genes comprises a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence identity to a nucleotide sequence provided in Table 5
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 65% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 70% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 75% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 80% sequence identity to a nucleotide sequence provided in Table 5 In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 85% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 90% sequence identity to a nucleotide sequence provided in Table 5 In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 95% sequence identity to a nucleotide sequence provided in Table 5 In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 99% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 99.9% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having greater than 99.9% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 65% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 70% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and bet.a-2M genes comprises a sequence having at least 75% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 80% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at. least 85% sequence homology to a nucleotide sequence provided in Table 5
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 90% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 95% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 99% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at. least 99.9% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having greater than 99 9% sequence homology to a nucleotide sequence provided in Table 5.
- the engineered mammalian cell described herein comprises a reduction in the expression of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell described herein comprises a reduction in the expression of a MHC class I component between 1-25%, 5- 25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell described herein comprises a reduction in the expression of a MHC class I component greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell described herein comprises a reduction in the function of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell described herein comprises a reduction in the function of a MHC class I component between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell described herein comprises a reduction in the function of a MHC class I component greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-A by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-A.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-A between 1-25%, 5-25%, 10-25%, 25-50%, 25- 75%, 50-75%, or 75-100%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-A.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-A greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-A.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-B by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-B.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-B between 1-25%, 5-25%, 10-25%, 25-50%, 25- 75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-B.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-B greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-B.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-C by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-C.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-C between 1-25%, 5-25%, 10-25%, 25-50%, 25- 75%, 50-75%, or 75-100%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-C.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-C greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-C.
- the engineered mammalian cell described herein comprises a reduction in the level or function of beta-2M by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of beta- 2M.
- the engineered mammalian cell described herein comprises a reduction in the level or function of beta-2M between 1-25%, 5-25%, 10-25%, 25-50%, 25- 75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of beta-2M.
- the engineered mammalian cell described herein comprises a reduction in the level or function of beta-2M greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of beta-2M.
- the MHC class I protein complex or a component thereof e.g., HLA-A, HLA-B, HLA-C, or beta-2M, is encoded by one or more nucleotide sequences, or fragments thereof, provided in Table 5.
- the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 15 minutes (e.g., 30 minutes, 1 hour, 12 hours, 24 hours, 48 hours, 72 hours, 1 week, 1 month, or 1 year).
- the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 30 minutes.
- the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 1 hour.
- the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 12 hours. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 24 hours. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 48 hours. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 72 hours. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 1 week.
- the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 1 month. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 1 year.
- the MHC class II protein complex is a class of molecules present on the surface of antigen-presenting cells within a subject, such as dendritic cells, mononuclear phagocytes, certain endothelial cells, and B cells.
- antigens presented by the MHC class II protein complexes are derived from extracellular proteins, unlike the cytosolic antigens presented by the MHC class I protein complexes.
- the MHC class II protein complexes are heterodimeric proteins that consist of two polypeptide chains, the alpha-chain and the beta-chain.
- the MHC class II protein complex comprises homogeneous peptides.
- the alpha-peptide comprises the alpha-1 and beta-1 domains, which come together to make a membrane-distal peptide-binding groove, while the beta-peptide comprises the alpha-2 and beta- 2 domains, which form a membrane-proximal immunoglobulin-like domain.
- the peptide- binding groove is made up of two a-helices walls and a P sheet. Because the antigen-binding groove of MHC class II molecules is open at both ends while the corresponding groove on class I molecules is closed at each end, the antigens presented by MHC class II molecules are longer, generally between 15 and 24 amino acid residues long.
- Exemplary MHC class II protein complex components include HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR.
- the engineered mammalian cell e.g., ARPE-19
- the engineered mammalian cell e.g., ARPE-19
- the engineered mammalian cell comprises a reduction in a level or function of the alpha-1 domain.
- the level or function of the alpha- 1 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%).
- the level or function of the alpha- 1 domain is reduced by about 20%.
- the level or function of the alpha-1 domain is reduced by about 30%.
- the level or function of the alpha- 1 domain is reduced by about 40%.
- the level or function of the alpha- 1 domain is reduced by about 50%.
- the level or function of the alpha- 1 domain is reduced by about 60%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 70%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 80%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 90%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 100%.
- the level or function of the alpha-1 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more).
- the level or function of the alpha-1 domain is reduced by at least 10%.
- the level or function of the alpha-1 domain is reduced by at least 20%.
- the level or function of the alpha-1 domain is reduced by at least 30%.
- the level or function of the alpha- 1 domain is reduced by at least 40%.
- the level or function of the alpha- 1 domain is reduced by at least 50%.
- the level or function of the alpha-1 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 70%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 80%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 95%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 99.9%. In some embodiments, the level or function of the alpha-1 domain is reduced by more than 99.9%.
- the engineered mammalian cell comprises a reduction in a level or function of the alpha-2 domain.
- the level or function of the alpha-2 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%).
- the level or function of the alpha-2 domain is reduced by about 20%.
- the level or function of the alpha-2 domain is reduced by about 30%.
- the level or function of the alpha-2 domain is reduced by about 40%.
- the level or function of the alpha-2 domain is reduced by about 50%.
- the level or function of the alpha-2 domain is reduced by about 60%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 70%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 80%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 90%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 100%.
- the level or function of the alpha-2 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more).
- the level or function of the alpha-2 domain is reduced by at least 10%.
- the level or function of the alpha-2 domain is reduced by at least 20%.
- the level or function of the alpha-2 domain is reduced by at least 30%.
- the level or function of the alpha-2 domain is reduced by at least 40%.
- the level or function of the alpha-2 domain is reduced by at least 50%.
- the level or function of the alpha-2 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 70%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 80%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 95%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 99.9%. In some embodiments, the level or function of the alpha-2 domain is reduced by more than 99.9%.
- the engineered mammalian cell comprises a reduction in a level or function of the beta-1 domain.
- the level or function of the beta-1 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%).
- the level or function of the beta-1 domain is reduced by about 20%.
- the level or function of the beta-1 domain is reduced by about 30%.
- the level or function of the beta-1 domain is reduced by about 40%.
- the level or function of the beta-1 domain is reduced by about 50%.
- the level or function of the beta-1 domain is reduced by about 60%.
- the level or function of the beta-1 domain is reduced by about 70%. In some embodiments, the level or function of the beta-1 domain is reduced by about 80%. In some embodiments, the level or function of the beta-1 domain is reduced by about 90%. In some embodiments, the level or function of the beta-1 domain is reduced by about 100%.
- the level or function of the beta-1 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more).
- the level or function of the beta-1 domain is reduced by at least 10%.
- the level or function of the beta-1 domain is reduced by at least 20%.
- the level or function of the beta-1 domain is reduced by at least 30%.
- the level or function of the beta-1 domain is reduced by at least 40%.
- the level or function of the beta-1 domain is reduced by at least 50%.
- the level or function of the beta-1 domain is reduced by at least 60%.
- the level or function of the beta-1 domain is reduced by at least 70%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 80%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 90%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 95%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 99%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 99.9%. In some embodiments, the level or function of the beta-1 domain is reduced by more than 99.9%.
- the engineered mammalian cell comprises a reduction in a level or function of the beta-2 domain.
- the level or function of the beta-2 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%).
- the level or function of the beta-2 domain is reduced by about 20%.
- the level or function of the beta-2 domain is reduced by about 30%.
- the level or function of the beta-2 domain is reduced by about 40%.
- the level or function of the beta-2 domain is reduced by about 50%.
- the level or function of the beta-2 domain is reduced by about 60%.
- the level or function of the beta-2 domain is reduced by about 70%. In some embodiments, the level or function of the beta-2 domain is reduced by about 80%. In some embodiments, the level or function of the beta-2 domain is reduced by about 90%. In some embodiments, the level or function of the beta-2 domain is reduced by about 100%.
- the level or function of the beta-2 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more).
- the level or function of the beta-2 domain is reduced by at least 10%.
- the level or function of the beta-2 domain is reduced by at least 20%.
- the level or function of the beta-2 domain is reduced by at least 30%.
- the level or function of the beta-2 domain is reduced by at least 40%.
- the level or function of the beta-2 domain is reduced by at least 50%.
- the level or function of the beta-2 domain is reduced by at least 60%.
- the level or function of the beta-2 domain is reduced by at least 70%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 80%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 90%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 95%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 99%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 99.9%. In some embodiments, the level or function of the beta-2 domain is reduced by more than 99.9%.
- the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of the alpha-chain of an MHC class II protein complex or component thereof to the beta-chain.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the alpha-1 domain to the alpha-2 or beta-2 domain.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the beta-1 domain to the alpha-2 or beta-2 domain.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the alpha-2 domain to the alpha- 1 or beta-1 domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the beta-2 domain to the alpha- 1 domain or beta-1 domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the alpha- 1 domain to the beta-1 domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the alpha-2 domain to the beta-2 domain.
- HLA-DP is a protein/peptide-antigen receptor and graft-versus-host disease antigen that is composed of 2 subunits, DPa and DPp.
- DPa and DPp are encoded by two loci, HLA- DPA1 and HLA-DPB1, that are found in the MHC Class II (or HLA-D) region in the HLA complex on human chromosome 6.
- HLA-DP is an aP-heterodimer cell-surface receptor.
- Each DP subunit (a-subunit, P-subunit) is composed of a a-helical N-terminal domain, an IgG-like P-sheet, a membrane spanning domain, and a cytoplasmic domain.
- the a-helical domain forms the sides of the peptide binding groove.
- the P-sheet regions form the base of the binding groove and the bulk of the molecule as well as the inter-subunit (non-covalent) binding region.
- Peptide-bound HLA-DP complexes interact with TCRs on CD4+ T-cells.
- the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-DP to a CD4+ T-cell TCR and/or any peptide (e.g., an antigenic peptide) bound within its peptide-binding groove.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e g., binding) of HLA-DP to a CD4+ T-cell TCR.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA- DP to a peptide bound within its peptide-binding groove.
- HLA-DM a non-classical MHC molecule
- HLA-DMA and HLA-DMB the genes for HLA-DM are located in the MHCII region of the human chromosome 6.
- HLA-DM is a molecular chaperone that works in lysosomes and endosomes in cells of the immune system. It works in APCs like macrophages, dendritic cells, and B cells by interacting with MHC class II molecules (Arndt et al (2000). "Functional HLA-DM on the surface of B cells and immature dendritic cells". The EMBO Journal .
- HLA-DM protects the MHC class II molecules from breaking down, and regulates which proteins or peptides bind to them as well. This regulates how and when a peptide acts as an antigen initiating an immune response.
- HLA-DM is required to release CLIP (a fragment resulting from cathepsin S or cathepsin D-mediated cleavage of CD74) from MHC class II molecules, to chaperone empty MHC molecules against denaturation, to facilitate antigen-antigen exchange (e.g., by releasing weakly bound peptides from the peptide-binding groove in order to load peptides with higher-affinity binding), and to control proper loading and release of peptides at the peptide-binding groove.
- CLIP a fragment resulting from cathepsin S or cathepsin D-mediated cleavage of CD74
- HLA-DM To release peptides from the MHC groove, HLA-DM binds to the N terminus of the groove, altering its conformation and breaking hydrogen bonds such that the peptide that was interacting with the MHC groove can no longer bind and is ejected (Yin et al. (2015). "Evaluating the Role of HLA- DM in MHC Class II-Peptide Association Reactions". Journal of Immunology . 195 (2): 706- 16. doi: 10.4049/jimmunol.1403190). HLA-DM assists in catalysis of peptide exchange not only in late endosomes traveling from the ER, but also on cell membranes and in early endosomes.
- HLA-DM can load exogenous peptides onto MHC class II molecules when they are being expressed on cell surfaces. Loading can also occur in early endosomes that are quickly recycled. HLA-DM does not have the capacity to bind peptides due to its lack of a deep peptide-binding groove - instead, it contains a shallow, negatively charged indent with two disulfide bonds.
- HLA-DM also interacts heavily with chaperone protein HLA-DO, another non-classical MHC molecule.
- HLA-DO starts binding to DM in early endosomes, but is expressed less in late endosomes/lysosomes.
- the binding between HLA-DM and HLA-DO is less strong at low pH, but overall much stronger than HLA-DM binding to MHC molecules.
- Both HLA-DM and HLA- DO lack a transport signal N-terminus.
- DO acts as a chaperone of DM to stabilize it against denaturation and direct it into lysosomes. It binds in the same location to HLA-DM as MHC class II molecules bind, thereby preventing HLA-DM from binding to MHC class II molecules.
- HLA-DOA alpha-chain of HLA-DO
- HLA-DOB beta-chain
- the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e g., binding) of HLA-DM to CLIP, HLA-DO, and the beta-chain of MHC class II molecules.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DM to CLIP.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DM to HLA-DO.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DO to HLA-DM. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA- DM to the beta-chain of MHC class II molecules.
- the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-DO to HLA-DM or any peptide bound within its peptide- binding groove. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DO to HLA-DM. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DO to a peptide bound within its peptide-binding groove.
- HLA-DQ is a cell surface receptor protein found on antigen-presenting cells. It is an aP heterodimer of type MHC class II.
- the alpha- and beta- chains are encoded by two loci, HLA-/J(M / and HLA-DQB1, that are adjacent to each other on chromosome band 6p21.3. Both the alpha-chain and the beta-chain comprise a plethora of variants. A person often produces two a-chain and two P-chain variants and thus 4 isoforms of HLA-DQ.
- the HLA-DQ loci are in close genetic linkage to HLA-DR, and less closely linked to HLA-DP, the non- classical MHC class II molecules (HLA-DM and HLA-DO), and the MHC class I molecules.
- HLA-DQ Different isoforms of HLA-DQ can bind to and present different antigens to T-cells.
- T-cells are stimulated to grow and can signal B-cells to produce antibodies.
- HLA- DQ functions in recognizing and presenting foreign antigens (proteins derived from potential pathogens). For example, peptide-bound HLA-DP complexes interact with TCRs on CD4+ T-cells.
- HLA-DQ is also involved in recognizing common self-antigens and presenting those antigens to the immune system in order to develop tolerance from a very young age. When tolerance to self-proteins is lost, HLA-DQ may become involved in autoimmune disease. Two autoimmune diseases in which HLA-DQ is involved are coeliac disease and type 1 diabetes.
- HLA-DQ mediates autoimmunity by skewing the TCR repertoire during thymic selection (Rubio et al. (2021). "HLA class II mediates type 1 diabetes risk by anti-insulin repertoire selection”. bioRxiv. 2021.09.06.458974. doi: 10.1101/2021.09.06.458974). Carriers of risk serotypes such as HLA-DQ8 have a higher proportion of circulating T-cell receptors that may bind insulin, the primary autoantigen in type 1 diabetes.
- the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-DQ to CD4+ T-cell TCRs and/or any peptide bound within its peptide-binding groove.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DQ to a CD4+ T-cell TCR.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DQ to a peptide bound within its peptide-binding groove.
- HLA-DR is an aP heterodimer, cell surface receptor, each subunit of which contains two extracellular domains, a membrane-spanning domain and a cytoplasmic tail. Both a and P chains are anchored in the membrane.
- the N-terminal domain of the mature protein forms an alphahelix that constitutes the exposed part of the binding groove, the C-terminal cytoplasmic region interacts with the other chain forming a beta-sheet under the binding groove spanning to the cell membrane.
- the majority of the peptide contact positions are in the first 80 residues of each chain.
- HLA-DR is encoded by several loci and several genes Q>f different function at each locus.
- the DR a-chain is encoded by the HLA-DRA locus.
- the DR P-chain is encoded by 4 loci, however no more than 3 functional loci are present in a single individual, and no more than two on a single chromosome (Marsh et al (2010). "Nomenclature for factors of the HLA system, 2010". Tissue Antigens. 75 (4): 291-455. doi: 10.1111/j. 1399-0039.2010.01466.x). Sometimes an individual may only possess 2 copies of the same locus, DRB1.
- the HLA-DRB1 locus is ubiquitous and encodes a very large number of functionally variable gene products (HLA- DR1 to HLA-DR17).
- the HLA-DRB3 locus encodes HLA-DR52, is moderately variable, and is variably associated with certain HLA-DRB1 types.
- the HLA-DRB4 locus encodes HLA-DR53, has some variation, and is associated with certain HLA-DRB1 types.
- the HLA-DRB5 locus encodes HLA-DR51, which is typically invariable and is linked to the HLA-DR2 types.
- HLA- DR interacts with CD74, HLA-DM, CD4+ T-cell TCRs, and/or any peptide bound within its peptide-binding groove.
- the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-DR to CD74, HLA-DM, CD4+ T-cell TCRs, and/or any peptide bound within its peptide-binding groove.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DR to CD74.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DR to HLA- DM. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DR to a CD4+ T-cell TCR. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DR to a peptide bound within its peptide-binding groove.
- the reducing the level or function of the MHC class II protein complex or a component thereof results in reduced antigen presentation, thereby reducing and/or abrogating the recruitment of immune cells, e.g., T cells and NK cells.
- the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of one or more genes selected from HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5.
- a nucleotide mutation may comprise a nucleotide deletion, addition, and/or substitution.
- Such a mutation may result in a reduction in expression of the gene, e g., by reducing, altering, or abrogating the transcription and/or splicing of the nucleotide sequence.
- the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DP.
- the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DM.
- the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DOA. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DOB. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DP.
- the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DM. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DOA. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DOB.
- the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DQA1. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DQB1. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRA.
- the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRB1. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRB3. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRB4. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRB5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA- D0B1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 65% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 70% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA- DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 75% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA- DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 80% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 85% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 90% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA- DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 95% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA- DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 99% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DOA1, HLA-DOB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 99.9% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA- DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having greater than 99.9% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP , HLA- DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 65% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, H LA-DOB, HLA-DQA1, HLA-DQB1, HLA- DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 70% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 75% sequence homology to a nucleotide sequence provided in Table 5.
- DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 80% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 85% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA- DOB J, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 90% sequence homology to a nucleotide sequence provided in Table 5.
- DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA- DRB5 genes comprises a sequence having at least 95% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA- DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 99% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA- DRA, HLA-DRL31, HLA-DRB3, HLA-DRJ34, and HLA-DRB5 genes comprises a sequence having at least 99.9% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having greater than 99.9% sequence homology to a nucleotide sequence provided in Table 5.
- the engineered mammalian cell of the present disclosure comprises a reduced level or function in an MHC class II protein complex or a component thereof, e.g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR.
- an MHC class II protein complex e.g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR.
- the engineered mammalian cell described herein comprises a reduction in the expression of a MHC class II component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class II component.
- the engineered mammalian cell described herein comprises a reduction in the expression of a MHC class II component between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50- 75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class II component.
- the engineered mammalian cell described herein comprises a reduction in the expression of a MHC class II component greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class II component.
- the engineered mammalian cell described herein comprises a reduction in the function of a MHC class II component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class II component.
- the engineered mammalian cell described herein comprises a reduction in the function of a MHC class II component between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class II component.
- the engineered mammalian cell described herein comprises a reduction in the function of a MHC class I component greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class II component.
- the MHC class II protein complex or a component thereof e.g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR, is encoded by one or more nucleotide sequences, or fragments thereof, provided in Table 5.
- the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 15 minutes (e.g., 30 minutes, 1 hour, 12 hours, 24 hours, 48 hours, 72 hours, 1 week, 1 month, or 1 year).
- the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 30 minutes.
- the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 1 hour.
- the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 12 hours.
- the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 24 hours. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 48 hours. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 72 hours. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 1 week. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 1 month. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 1 year.
- the class II major histocompatibility complex transactivator is a gene involved in the regulation of expression of MHC class II protein complexes.
- the CIITA gene is located on chromosome 16 that encodes the CIITA protein, which plays a role in enhancing the transcription of MHC class I genes.
- the CIITA protein comprises an acidic transcriptional activation domain, 4 leucine-rich repeats, and a GTP binding domain. The protein uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus, the protein acts as a positive regulator of class II major histocompatibility complex gene transcription, and is often referred to as the "master control factor" for the expression of these genes (Harton et al.
- the engineered mammalian cell of the present disclosure comprises a reduced level or function in of a CIITA protein.
- the engineered mammalian cell e.g., ARPE-19
- the engineered mammalian cell comprises a reduction in a level or function of a domain of a CIITA protein, wherein the domain is selected from the transcriptional activation domain, a leucine-rich repeat domain, and a GTP binding domain.
- the engineered mammalian cell e.g., ARPE-19
- the level or function of the transcriptional activation domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). For example, in some embodiments, the level or function of the transcriptional activation domain is reduced by about 20%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 30%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 40%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 50%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 60%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 70%.
- the level or function of the transcriptional activation domain is reduced by about 80%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 90%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 100%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the transcriptional activation domain is reduced by at least 10%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 20%.
- the level or function of the transcriptional activation domain is reduced by at least 30%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 40%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 50%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 60%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 70%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 80%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 90%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 95%.
- the level or function of the transcriptional activation domain is reduced by at least 99%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 99.9%. In some embodiments, the level or function of the transcriptional activation domain is reduced by more than 99.9%.
- the engineered mammalian cell comprises a reduction in a level or function of a leucine-rich repeat domain.
- the level or function of the leucine-rich repeat domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%).
- the level or function of the leucine-rich repeat domain is reduced by about 20%.
- the level or function of the leucine-rich repeat domain is reduced by about 30%.
- the level or function of the leucine-rich repeat domain is reduced by about 40%.
- the level or function of the leucine-rich repeat domain is reduced by about 50%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 60%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 70%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 80%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 90%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 100%.
- the level or function of the leucine-rich repeat domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more).
- the level or function of the leucine-rich repeat domain is reduced by at least 10%.
- the level or function of the leucine-rich repeat domain is reduced by at least 20%.
- the level or function of the leucine-rich repeat domain is reduced by at least 30%.
- the level or function of the leucine-rich repeat domain is reduced by at least 40%.
- the level or function of the leucine-rich repeat domain is reduced by at least 50%.
- the level or function of the leucine-rich repeat domain is reduced by at least 60%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 70%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 80%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 90%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 95%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 99%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 99.9%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by more than 99.9%.
- the engineered mammalian cell comprises a reduction in a level or function of the GTP binding domain.
- the level or function of the GTP binding domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%).
- the level or function of the GTP binding domain is reduced by about 20%.
- GTP binding domain is reduced by about 30%.
- GTP binding domain is reduced by about 40%.
- GTP binding domain is reduced by about 50%.
- GTP binding domain is reduced by about 60%.
- GTP binding domain is reduced by about 70%.
- GTP binding domain is reduced by about 80%. In some embodiments, the level or function of the GTP binding domain is reduced by about 90%. In some embodiments, the level or function of the GTP binding domain is reduced by about 100%.
- the level or function of the GTP binding domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more).
- the level or function of the GTP binding domain is reduced by at least 10%.
- the level or function of the GTP binding domain is reduced by at least 20%.
- the level or function of the GTP binding domain is reduced by at least 30%.
- the level or function of the GTP binding domain is reduced by at least 40%.
- the level or function of the GTP binding domain is reduced by at least 50%.
- the level or function of the GTP binding domain is reduced by at least 60%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 70%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 80%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 90%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 95%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 99%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 99.9%. In some embodiments, the level or function of the GTP binding domain is reduced by more than 99.9%.
- the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of a CIITA protein domain to another CIITA protein domain.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the transcriptional activation domain to a leucine-rich repeat domain or the GTP binding domain.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of a leucine-rich repeat domain to the transcriptional activation domain, a leucine-rich repeat domain, or the GTP binding domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the GTP binding domain to the transcriptional activation domain or a leucine-rich repeat domain.
- the CIITA protein interacts with Mitogen-activated protein kinase 1 (MAPK1), nuclear receptor coactivator 1 (NCOA1), DNA-binding protein RFX5 (RFX5), DNA-binding protein RFXANK (RFXANK), exportin 1 (XP01), and Zinc finger, X-linked, duplicated family member C (ZXDC).
- MAPK1 Mitogen-activated protein kinase 1
- NCOA1 nuclear receptor coactivator 1
- RFX5 DNA-binding protein RFX5
- RFXANK DNA-binding protein RFXANK
- exportin 1 XP01
- ZXDC Zinc finger, X-linked, duplicated family member C
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to MAPK1.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to NCOA1.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to RFX5.
- the reducing the level or function of substantially prevents, or inhibits the interaction (e.g., binding) of CIITA to RFXANK.
- the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to XPO1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to ZXDC.
- the reducing the level or function of the CIITA protein results in the reduction of the level of expression (e.g., by reducing the level of transcription) of a MHC class II protein complex or a component thereof, e.g., HLA-DP, HLA-DM, HLA-DOA, HLA- DOB, HLA-DQ, and HLA-DR.
- a MHC class II protein complex or a component thereof, e.g., HLA-DP, HLA-DM, HLA-DOA, HLA- DOB, HLA-DQ, and HLA-DR.
- the reducing the level or function of the CIITA protein comprises mutating one or more nucleotides in the nucleotide sequence of the CIITA gene.
- a nucleotide mutation may comprise a nucleotide deletion, addition, and/or substitution. Such a mutation, as described herein, may result in a reduction in expression of the gene, e.g., by reducing, altering, or abrogating the transcription and/or splicing of the nucleotide sequence.
- the nucleotide sequence of the CIITA gene comprises a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the CIITA genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the CIITA genes comprises a sequence having at least 65% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the CIITA genes comprises a sequence having at least 70% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 75% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 80% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 85% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the CIITA genes comprises a sequence having at least 90% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 95% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 99% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 99.9% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having greater than 99.9% sequence identity to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the CIITA genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the CIITA genes comprises a sequence having at least 65% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the CIITA genes comprises a sequence having at least 70% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the CIITA genes comprises a sequence having at least 75% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 80% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 85% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 90% sequence homology to a nucleotide sequence provided in Table 5.
- the nucleotide sequence of the CIITA genes comprises a sequence having at least 95% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 99% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 99.9% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having greater than 99.9% sequence homology to a nucleotide sequence provided in Table 5.
- the engineered mammalian cell described herein comprises a reduction in the expression of CIITA by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of CIITA.
- the engineered mammalian cell described herein comprises a reduction in the expression of CIITA between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of CIITA.
- the engineered mammalian cell described herein comprises a reduction in the expression of CIITA greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of CIITA.
- the engineered mammalian cell described herein comprises a reduction in the function of CIITA by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of CIITA.
- the engineered mammalian cell described herein comprises a reduction in the function of CIITA between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of CIITA.
- the engineered mammalian cell described herein comprises a reduction in the function of CIITA greater than about 50%, 75%, or 90%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of CIITA.
- the CIITA is encoded by a nucleotide sequence, or a fragment thereof, provided in Table 5.
- the reduction in the level or function of CIITA persists for at least 15 minutes (e.g., 30 minutes, 1 hour, 12 hours, 24 hours, 48 hours, 72 hours, 1 week, 1 month, or 1 year). For example, in some embodiments, the reduction in the level or function of CIITA persists for at least 30 minutes. In some embodiments, the reduction in the level or function of CIITA persists for at least 1 hour In some embodiments, the reduction in the level or function of CIITA persists for at least 12 hours. In some embodiments, the reduction in the level or function of CIITA persists for at least 24 hours In some embodiments, the reduction in the level or function of CIITA persists for at least 48 hours.
- the reduction in the level or function of CIITA persists for at least 72 hours. In some embodiments, the reduction in the level or function of CIITA persists for at least 1 week. In some embodiments, the reduction in the level or function of CIITA persists for at least 1 month. In some embodiments, the reduction in the level or function of CIITA persists for at least 1 year.
- the engineered mammalian cell described herein comprises a reduction in the level or function of a MHC class I protein complex and a reduction in the level or function of a MHC class II protein complex and/or CIITA.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-A and a reduction in the level or function of a MHC class II protein complex and/or CIITA.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-B and a reduction in the level or function of a MHC class II protein complex and/or CIITA.
- the engineered mammalian cell described herein comprises a reduction in the level or function of HLA-C and a reduction in the level or function of a MHC class II protein complex and/or CIITA.
- the engineered mammalian cell described herein comprises a reduction in the level or function of beta- 2M and a reduction in the level or function of a MHC class II protein complex and/or CIITA.
- Gene manipulations and modifications to a mammalian cell or an engineered mammalian cell may be carried out using any known method in the art, including gene silencing, gene knock downs, gene knock outs, and gene editing techniques.
- a gene mutant may be generated using a targeted genome editing technique at a desired site(s) in the target OCRs.
- the targeted genome editing technique may be any technique known in the art, e.g., techniques that employ site directed nucleases such as CRISPR-Cas, zinc finger nucleases, transcription activator-like effector nucleases (TALENs), and meganucleases.
- the engineered mammalian cells described herein may be derived from a variety of different mammalian cell types (e.g., human cells), including adipose cells, epidermal cells, epithelial cells, endothelial cells, fibroblast cells, embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, pericytes, keratinocyte cells, subtypes of any of the foregoing and cells derived from any of the foregoing.
- Exemplary cell types include the cell types recited in WO 2017/075631.
- the cells are derived from a cell-line shown in Table 2 below.
- any of the engineered mammalian cells described herein is derived from an RPE cell, e.g., an ARPE-19 cell.
- an engineered RPE cell e.g., an engineered ARPE-19 cell
- Engineered mammalian cells for use in devices, compositions and methods described herein, e.g., as a plurality of engineered cells contained or encapsulated in a hydrogel capsule, may be in various stages of the cell cycle.
- at least one engineered cell in the plurality of engineered cells is undergoing cell division.
- Cell division may be measured using any known method in the art, e.g., as described in DeFazio A et al (1987) J Histochem Cytochem 35:571-577 and Dolbeare F et al (1983) Proc Natl Acad Sci USA 80:5573-5577, each of which is incorporated by reference in its entirety.
- At least 1, 2, 3, 4, 5, 10, or 20% of the cells are undergoing cell division, e.g., as determined by 5-ethynyl-2’deoxyuridine (EdU) assay or 5-bromo-2’-deoxyuridine (BrdU) assay.
- cell proliferation is visualized or quantified by microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation) or flow cytometry.
- none of the engineered cells in the plurality of engineered cells are undergoing cell division and are quiescent.
- less than 1, 2, 3, 4, 5, 10, or 20% of the cells are undergoing cell division, 5-ethynyl- 2’ deoxyuridine (EdU) assay, 5-bromo-2’-deoxyuridine (BrdU) assay, microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation), or flow cytometry.
- EdU deoxyuridine
- BadU 5-bromo-2’-deoxyuridine
- microscopy e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation
- flow cytometry e.g., flow cytometry.
- At least 50%, 60%, 70%, 80%, 90% or more of the engineered cells in the plurality are viable.
- Cell viability may be measured using any known method in the art, e.g., as described in Riss, T. et al (2013) “Cell Viability Assays” in Assay Guidance Manual (Sittapalam, G.S. et al, eds).
- cell viability may be measured or quantified by an ATP assay, 5-ethynyl-2’deoxyuridine (EdU) assay, 5-bromo-2’-deoxyuridine (BrdU) assay.
- cell viability is visualized or quantified by microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation) or flow cytometry.
- microscopy e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation) or flow cytometry.
- at least 80% of the engineered cells in the plurality are viable, e.g., as determined by an ATP assay, a 5-ethynyl-2’deoxyuridine (EdU) assay, a 5-bromo-2’-deoxyuridine (BrdU) assay, microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation), or flow cytometry.
- EdU 5-ethynyl-2’deoxyuridine
- BadU 5-bromo-2’-deoxyuridine
- the exogenous transcription unit encodes a therapeutic polypeptide (e.g., a protein), such as a clotting factor, growth factor, hormone, enzyme, cytokine (e.g., a pro-inflammatory cytokine or an anti-inflammatory cytokine), cytokine receptor, chimeric protein, fusion protein or lipoprotein.
- a therapeutic polypeptide e.g., a protein
- cytokine e.g., a pro-inflammatory cytokine or an anti-inflammatory cytokine
- cytokine receptor e.g., a pro-inflammatory cytokine or an anti-inflammatory cytokine
- chimeric protein fusion protein or lipoprotein
- the polypeptide encoded by the exogenous transcription unit may have a naturally occurring amino acid sequence or may contain a variant of the naturally occurring sequence.
- the variant can be a non-naturally occurring or naturally occurring amino acid substitution, mutation, deletion or addition relative to the reference (e.g., naturally occurring) sequence
- the naturally occurring amino acid sequence can be a human or a nonhuman amino acid sequence.
- the naturally occurring amino acid sequence is a human sequence.
- the therapeutic polypeptide has about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 45, or less than 50 amino acids.
- the polypeptide has an average molecular weight of 5 kD, 10 kD, 25 kD, 50 kD, 100 kD, 150 kD, 200 kD, 250 kD, 500 kD, or more.
- the polypeptide is a hormone.
- hormones include antidiuretic hormone (ADH), oxytocin, growth hormone (GH), prolactin, growth horm one-releasing hormone (GHRH), thyroid stimulating hormone (TSH), thyrotropin-release hormone (TRH), adrenocorticotropic hormone (ACTH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), luteinizing horm one-releasing hormone (LHRH), thyroxine, calcitonin, parathyroid hormone (PTH), aldosterone, cortisol, epinephrine, glucagon, insulin, estrogen, progesterone, and testosterone.
- ADH antidiuretic hormone
- GH growth hormone
- prolactin growth horm one-releasing hormone
- TSH thyroid stimulating hormone
- TRH thyrotropin-release hormone
- ACTH adrenocorticotropic hormone
- FSH
- the polypeptide is insulin (e.g., insulin A-chain, insulin B-chain, or proinsulin).
- the polypeptide is a growth hormone, such as human growth hormone (hGH), recombinant human growth hormone (rhGH), bovine growth hormone, methionine-human growth hormone, des-phenylalanine human growth hormone, and porcine growth hormone.
- the polypeptide is a growth factor, e.g., vascular endothelial growth factor (VEGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor (TGF), and insulin-like growth factor-I and -II (IGF-I and IGF-II).
- VEGF vascular endothelial growth factor
- NEF nerve growth factor
- PDGF platelet-derived growth factor
- FGF fibroblast growth factor
- EGF epidermal growth factor
- TGF transforming growth factor
- IGF-I and IGF-II insulin-like growth factor-I and -II
- the polypeptide is a clotting factor or a coagulation factor, e.g., a blood clotting factor or a blood coagulation factor.
- the polypeptide is involved in coagulation, i.e., the process by which blood is converted from a liquid to solid or gel.
- Exemplary clotting factors and coagulation factors include Factor I (e.g., fibrinogen), Factor II (e.g., prothrombin), Factor III (e.g., tissue factor), Factor V (e.g., proaccelerin, labile factor), Factor VI, Factor VII (e g., stable factor, proconvertin), Factor VIII (e.g., antihemophilic factor A), Factor VIIIC, Factor IX (e.g., antihemophilic factor B), Factor X (e.g., Stuart-Prower factor), Factor XI (e.g., plasma thromboplastin antecedent), Factor XII (e.g., Hagerman factor), Factor XIII (e.g., fibrin-stabilizing factor), von Willebrand factor (vWF), prekallikrein, heparin cofactor II, high molecular weight kininogen (e.g., Fitzgerald factor), antithrombin III, and fibronect
- the polypeptide is an immunoglobulin chain (heavy or light chain) or fragment thereof, comprising at least one immunoglobulin variable domain sequence, and optionally comprising an immunoglobulin Fc region. In an embodiment, the polypeptide a full- length immunoglobulin chain.
- the polypeptide is a cytokine or a cytokine receptor, or a chimeric protein including cytokines or their receptors, including, for example tumor necrosis factor alpha and beta, their receptors and their derivatives, renin; lipoproteins; colchicine; corti cotrophin; vasopressin; somatostatin; lypressin; pancreozymin; leuprolide; alpha- 1 -antitrypsin; atrial natriuretic factor; lung surfactant; a plasminogen activator other than a tissue-type plasminogen activator (t-PA), for example a urokinase; bombesin; thrombin; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1 -alpha); a serum albumin such as human serum albumin; mullerian- inhibiting substance; relaxin A-chain
- CSFs colony stimulating factors
- ILs interleukins
- T-cell receptors surface membrane proteins
- ILs interleukins
- T-cell receptors surface membrane proteins
- decay accelerating factor transport proteins
- homing receptors addressins
- fertility inhibitors such as the prostaglandins
- fertility promoters regulatory proteins
- antibodies including fragments thereof and chimeric proteins, such as immunoadhesins.
- Suitable polypeptides may be native or recombinant and include, e.g., fusion proteins.
- Examples of a polypeptide that may be encoded by the exogenous transcription unit also include CCL1, CCL2 (MCP-1), CCL3 (MIP-la), CCL4 (MIP-ip), CCL5 (RANTES), CCL6, CCL7, CCL8, CCL9 (CCL10), CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1 (KC), CXCL2 (SDFla), CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8 (IL8), CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, CX3CL1, XCL1, XCL2, TNFA
- the polypeptide is a replacement therapy or a replacement protein.
- the replacement therapy or replacement protein is a clotting factor or a coagulation factor, e.g., Factor VII, Factor VIII or Factor IX.
- the replacement therapy or replacement protein is an enzyme, e.g., alpha-galactosidase A (GLA), alpha-L-iduronidase (IDUA), glucocerebrosidase, or N- sulfoglucosamine sulfohydrolase (SGSH).
- GLA alpha-galactosidase A
- IDUA alpha-L-iduronidase
- SGSH N- sulfoglucosamine sulfohydrolase
- the engineered mammalian cell comprises an exogenous nucleic acid encoding the IDUA.
- the engineered mammalian cells are not islet cells, as defined herein.
- the engineered mammalian cells have one or more of the following characteristics: (i) are not capable of producing insulin (e.g., insulin A-chain, insulin B-chain, or proinsulin) in an amount effective to treat diabetes or another disease or condition that may be treated with insulin; (ii) not capable of producing insulin in a glucose-responsive manner; or (iii) not derived from an induced pluripotent stem cell that was engineered or differentiated into insulin-producing pancreatic beta cells.
- insulin e.g., insulin A-chain, insulin B-chain, or proinsulin
- An engineered mammalian cell described herein or a plurality of such cells may be incorporated into an implantable element for use in treating a disease or disorder in a subject, as well as for reducing the level of pericapsular fibrotic overgrowth on the implantable element upon implantation in a subject.
- An implantable element of the present disclosure comprises at least one barrier that prevents immune cells from contacting cells contained inside the device. At least a portion of the barrier needs to be sufficiently porous to allow a therapeutic agent expressed and secreted by the cells to exit the device.
- a variety of device configurations known in the art are suitable.
- the device e.g., particle
- the device can have any configuration and shape appropriate for supporting the viability and productivity of the contained cells after implant into the intended target location.
- device shapes may be cylinders, rectangles, disks, ovoids, stellates, or spherical.
- the device can be comprised of a mesh-like or nested structure.
- a device is capable of preventing materials over a certain size from passing through a pore or opening.
- a device e.g., particle
- a device is capable of preventing materials greater than 50 kD, 75 kD, 100 kD, 125 kD, 150 kD, 175 kD, 200 kD, 250 kD, 300 kD, 400 kD, 500 kD, 750 kD, or 1,000 kD from passing through.
- the device is a macroencapsulation device.
- macrodevices are described in: WO 2019/068059, WO 2019/169089, US Patent Numbers 9,526,880, 9,724,430 and 8,278,106; European Patent No. EP742818B1, and Sang, S. and Roy, S . , Biotechnol. Bioeng. 113 (7) : 1381 - 1402 (2016) .
- the device is a macrodevice having one or more cell-containing compartments.
- a device with two or more cell-containing compartments may be configured to produce two or more proteins, e.g., cells expressing a first therapeutic agent would be placed in one compartment and cells expressing a different protein (e.g., a therapeutic protein) would be placed in a separate compartment.
- WO 2018/232027 describes a device with multiple cellcontaining compartments formed in a micro-fabricated body and covered by a porous membrane.
- the device is configured as a thin, flexible strand as described in US Patent No. 10,493,107.
- This strand comprises a substrate, an inner polymeric coating surrounding the substrate and an outer hydrogel coating surrounding the inner polymeric coating.
- the protein-expressing cells are positioned in the outer coating.
- a device e.g., particle
- LLD largest linear dimension
- mm millimeter
- a device can be as large as 10 mm in diameter or size.
- a device or particle described herein is in a size range of 0.5 mm to 10 mm, 1 mm to 10 mm, 1 mm to 8 mm, 1 mm to 6 mm, 1 mm to 5 mm, 1 mm to 4 mm, 1 mm to 3 mm, 1 mm to 2 mm, 1 mm to 1.5 mm, 1.5 mm to 8 mm, 1.5 mm to 6 mm, 1.5 mm to 5 mm, 1.5 mm to 4 mm, 1.5 mm to 3 mm, 1.5 mm to 2 mm, 2 mm to 8 mm, 2 mm to 7 mm, 2 mm to 6 mm, 2 mm to 5 mm, 2 mm to 4 mm, 2 mm to 3 mm, 2.5 mm to 8 mm, 2.5 mm to 7 mm, 2.5 mm to 6 mm, 2.5 mm to 5 mm, 2.5 mm to 4 mm, 2.5 mm to 3 mm, 3 mm to 8 mm, 3 mm to 7 mm, 2.5 mm to 6
- a device of the disclosure (e.g., particle, capsule) comprises at least one pore or opening, e.g., to allow for the free flow of materials.
- the mean pore size of a device is between about 0.1 pm to about 10 pm.
- the mean pore size may be between 0.1 pm to 10 pm, 0.1 pm to 5 pm, 0.1 pm to 2 pm, 0.15 pm to 10 pm, 0.15 pm to 5 pm, 0.15 pm to 2 pm, 0.2 pm to 10 pm, 0.2 pm to 5 pm, 0.25 pm to 10 pm, 0.25 pm to 5 pm, 0.5 pm to 10 pm, 0.75 pm to 10 pm, 1 pm to 10 pm, 1 pm to 5 pm, 1 pm to 2 pm, 2 pm to 10 pm, 2 pm to 5 pm, or 5 pm to 10 pm.
- the mean pore size of a device is between about 0.1 pm to 10 pm. In some embodiments, the mean pore size of a device is between about 0.1 pm to 5 pm.
- the mean pore size of a device is between about 0.1 pm to 1 pm.
- the device comprises a semi-permeable, biocompatible membrane surrounding the genetically modified cells that are encapsulated in a polymer composition (e.g., an alginate hydrogel).
- the membrane pore size is selected to allow oxygen and other molecules important to cell survival and function to move through the semi-permeable membrane while preventing immune cells from traversing through the pores.
- the semi- permeable membrane has a molecular weight cutoff of less than 1000 kD or between 50-700 kD, 70-300 kD, or between 70-150 kD, or between 70 and 130 kD.
- the device may contain a cell-containing compartment that is surrounded with a barrier compartment formed from a cell-free biocompatible material, such as the core-shell microcapsules described in Ma, M et al., Adv. Healthc Mater. , 2(5):667-672 (2012).
- a barrier compartment formed from a cell-free biocompatible material, such as the core-shell microcapsules described in Ma, M et al., Adv. Healthc Mater. , 2(5):667-672 (2012).
- a barrier compartment could be used with or without the semi-permeable membrane.
- Cells in the cell -containing compartment(s) of a device of the disclosure may be encapsulated in a polymer composition.
- the polymer composition may comprise one or more hydrogel -forming polymers.
- the device e.g., macrodevice, particle, hydrogel capsule
- the device may comprise or be formed from materials such as metals, metallic alloys, ceramics, polymers, fibers, inert materials, and combinations thereof.
- a device may be completely made up of one type of material, or may comprise other materials within the cell-containing compartment and any other compartments.
- the device comprises a metal or a metallic alloy.
- one or more of the compartments in the device comprises a metal or a metallic alloy.
- Exemplary metallic or metallic alloys include comprising titanium and titanium group alloys (e.g., nitinol, nickel titanium alloys, thermo-memory alloy materials), platinum, platinum group alloys, stainless steel, tantalum, palladium, zirconium, niobium, molybdenum, nickel -chrome, chromium molybdenum alloys, or certain cobalt alloys (e.g., cobalt-chromium and cobalt- chromium-nickel alloys, e.g., ELGILOY® and PHYNOX®).
- a metallic material may be stainless steel grade 316 (SS 316L) (comprised ofFe, ⁇ 0.3% C, 16-18.5% Cr, 10-14% Ni, 2-3% Mo, ⁇ 2% Mn, ⁇ 1% Si, ⁇ 0.45% P, and ⁇ 0.03% S).
- the amount of metal e.g., by % weight, actual weight
- the device comprises a ceramic.
- one or more of the compartments in the device comprises a ceramic.
- Exemplary ceramic materials include oxides, carbides, or nitrides of the transition elements, such as titanium oxides, hafnium oxides, iridium oxides, chromium oxides, aluminum oxides, and zirconium oxides. Silicon based materials, such as silica, may also be used.
- the amount of ceramic (e.g., by % weight, actual weight) can be at least 5%, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more, e.g., w/w; less than 20%, e.g., less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1%, or less.
- the device has two hydrogel compartments, in which the inner, cell-containing compartment is completely surrounded by the second, outer (e.g., barrier) compartment.
- the inner boundary of the second compartment forms an interface with the outer boundary of the first compartment.
- the thickness of the second (outer) compartment means the average distance between the outer boundary of the second compartment and the interface between the two compartments, e.g., the average of the distances measured at each of the thinnest and thickest points visually observed in the outer compartment.
- the thinnest and thickest distances for the outer compartment are between 25 and 110 micrometers (pm) and between 270 and 480 pm, respectively.
- the thickness of the outer compartment is greater than about 10 nanometers (nm), preferably 100 nm or greater and can be as large as 1 millimeter (mm).
- the thickness (e.g., average distance) of the outer compartment in a hydrogel capsule device described herein may be 10 nm to 1 mm, 100 nm to 1mm, 500 nm to 1 millimeter, 1 micrometer (pm) to 1 mm, 1 pm to 1 mm, 1 pm to 500 pm, 1 pm to 250 pm, 1 pm to 1 mm, 5 pm to 500 pm, 5 pm to 250 pm, 10 pm to 1 mm, 10 pm to 500 pm, or 10 pm to 250 pm.
- the thickness (e.g., average distance) of the outer compartment is 100 nm to 1 mm, between 1 pm and 1 mm, between 1 pm and 500 pm or between 5 pm and 1 mm. In some embodiments, the thickness (e.g., average distance) of the outer compartment is between about 50 pm and about 100 pm. In some embodiments (e.g., the device is about 1.5 mm in diameter), the thickness of the outer compartment (e.g., average distance) is between about 180 pm and 260 pm or between about 310 pm and 440 pm.
- the mean pore size of the cell-containing inner compartment and the outer compartment is substantially the same.
- the mean pore size of the inner compartment and the second compartment differ by about 1.5%, 2%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more.
- the mean pore size of the device e.g., mean pore size of the first compartment and/or mean pore size of the second compartment
- the polymer composition in the cell-containing compartment(s) comprises a polysaccharide or other hydrogel -forming polymer (e.g., alginate, hyaluronate or chondroitin).
- a polysaccharide or other hydrogel -forming polymer e.g., alginate, hyaluronate or chondroitin.
- the polymer is an alginate, which is a polysaccharide made up of P-D-mannuronic acid (M) and a-L-guluronic acid (G).
- the alginate has a low molecular weight (e.g., approximate molecular weight of ⁇ 75 kD) and G:M ratio > 1.5, (ii) a medium molecular weight alginate, e.g., has approximate molecular weight of 75-150 kDa and G:M ratio > 1 .5, (iii) a high molecular weight alginate, e g., has an approximate MW of 150 kDa - 250 kDa and G:M ratio > 1.5, (iv) or a blend of two or more of these alginates.
- a low molecular weight e.g., approximate molecular weight of ⁇ 75 kD
- G:M ratio > 1.5 e.g., a medium molecular weight alginate, e.g., has approximate molecular weight of 75-150 kDa and G:M ratio > 1 .5
- a high molecular weight alginate e.g., has an approximate
- the cell -containing compartment(s) further comprises at least one cellbinding substance (CBS), e.g., a cell-binding peptide (CBP) or cell-binding polypeptide (CBPP) described in W02020069429.
- CBS cellbinding substance
- CBP cell-binding peptide
- CBPP cell-binding polypeptide
- the cell-containing compartment(s) comprises an alginate covalently modified with a linker-cell-binding peptide moiety, e.g., GRGD or GRGDSP.
- a linker-cell-binding peptide moiety e.g., GRGD or GRGDSP.
- the cell-binding peptide density in the cell-containing compartment(s) (% nitrogen as determined by combustion analysis, e.g., as described in WO2020198695) to be at least 0.05%, 0.1%, 0.2% or 0.3% but less than 4%, 3%, 2% or 1%.
- the total density of the linker-CBP in a cell containing compartment is about 0.1 to about 1.0 micromoles of the CBP per g of CBP-polymer (e.g., a MMW-alginate covalently modified with GRGD or GRGDSP in solution as determined by a quantitative peptide conjugation assay, e.g., an assay described in WO2020198695.
- the linker-CBP is GRGDSP and the alginate has a molecular weight of 75 kDa to 150 kDa and a G:M ratio of greater than or equal to 1.5.
- the cell-containing compartment also comprises an unmodified alginate with a molecular weight of 75 kDa to 150 kDa and a G:M ratio of greater than or equal to 1.5.
- the device may form part of a plurality of substantially the same devices in a preparation (e.g., composition).
- the devices e.g., particles, hydrogel capsules
- the devices in the preparation have a mean diameter or size between about 0.5 mm to about 8 mm.
- the mean diameter or size of devices in the preparation is between about 0.5 mm to about 4 mm or between about 0.5 mm to about 2 mm.
- the devices in the preparation are two-compartment hydrogel capsules and have a mean diameter or size of about 0.7 mm to about 1.3 mm or about 1.2 mm to about 1.8 mm.
- the surface of the device comprises a compound capable of mitigating the FBR upon implant into a subject, an afibrotic compound as described herein below.
- the afibrotic compound may covalently modify a polymer disposed throughout the barrier compartment and optionally throughout the cell -containing compartment.
- one or more compartments in a device comprises an afibrotic polymer, e.g., an afibrotic compound of Formula (I) covalently attached to a polymer.
- an afibrotic polymer e.g., an afibrotic compound of Formula (I) covalently attached to a polymer.
- some or all the monomers in the afibrotic polymer are modified with the same compound of Formula (I).
- some or all the monomers in the afibrotic polymer are modified with different compounds of Formula (I).
- the afibrotic polymer is present only in the outer, barrier compartment.
- One or more compartments in a device may comprise an unmodified polymer that is the same or different than the polymer in any afibrotic polymer that is present in the device.
- the first compartment, second compartment or all compartments in the device comprise the unmodified polymer.
- Each of the modified and unmodified polymers in the device may be a linear, branched, or cross-linked polymer, or a polymer of selected molecular weight ranges, degree of polymerization, viscosity or melt flow rate.
- Branched polymers can include one or more of the following types: star polymers, comb polymers, brush polymers, dendronized polymers, ladders, and dendrimers.
- a polymer may be a thermoresponsive polymer, e.g., gel (e.g., becomes a solid or liquid upon exposure to heat or a certain temperature) or a photocrosslinkable polymer.
- Exemplary polymers include polystyrene, polyethylene, polypropylene, polyacetylene, poly(vinyl chloride) (PVC), polyolefin copolymers, poly(urethane)s, polyacrylates and polymethacrylates, polyacrylamides and polymethacrylamides, poly(methyl methacrylate), poly(2 -hydroxyethyl methacrylate), polyesters, polysiloxanes, polydimethylsiloxane (PDMS), polyethers, poly(orthoester), poly(carbonates), poly(hydroxyalkanoate)s, polyfluorocarbons, PEEK®, Teflon® (polytetrafluoroethylene, PTFE), PEEK, silicones, epoxy resins, Kevlar®, Dacron® (a condensation polymer obtained from ethylene glycol and terephthalic acid), polyethylene glycol, nylon, polyalkenes, phenolic resins, natural and synthetic elastomers, adhesives and seal
- the amount of a polymer (e.g., by % weight of the device, actual weight of the polymer) can be at least 5%, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more, e.g., w/w; less than 20%, e.g., less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1%, or less.
- one or more of the modified and unmodified polymers in the device comprises a polyethylene.
- exemplary polyethylenes include ultra-low-density polyethylene (ULDPE) (e.g., with polymers with densities ranging from 0.890 to 0.905 g/cm 3 , containing comonomer); very-low-density polyethylene (VLDPE) (e.g., with polymers with densities ranging from 0.905 to 0.915 g/cm 3 , containing comonomer); linear low-density polyethylene (LLDPE) (e.g., with polymers with densities ranging from 0.915 to 0.935 g/cm 3 , contains comonomer); low-density polyethylene (LDPE) (e.g., with polymers with densities ranging from about 0.915 to 0.935 g/m 3 ); medium density polyethylene (MDPE) (e.g., with polymers with densities ranging from ULD
- one or more of the modified and unmodified polymers in the device comprises a polypropylene.
- exemplary polypropylenes include homopolymers, random copolymers (homophasic copolymers), and impact copolymers (heterophasic copolymers), e.g., as described in McKeen, Handbook of Polymer Applications in Medicine and Medical Devices, 3- Plastics Used in Medical Devices, (2014):21-53.
- one or more of the modified and unmodified polymers in the device comprises a polypropylene.
- exemplary polystyrenes include general purpose or crystal (PS or GPPS), high impact (HIPS), and syndiotactic (SPS) polystyrene.
- one or more of the modified and unmodified polymers comprises a comprises a thermoplastic elastomer (TPE).
- TPEs include (i) TP A — polyamide TPE, comprising a block copolymer of alternating hard and soft segments with amide chemical linkages in the hard blocks and ether and/or ester linkages in the soft blocks; (ii) TPC — copolyester TPE, consisting of a block copolymer of alternating hard segments and soft segments, the chemical linkages in the main chain being ester and/or ether; (iii) TPO — olefinic TPE, consisting of a blend of a polyolefin and a conventional rubber, the rubber phase in the blend having little or no cross-linking; (iv) TPS — styrenic TPE, consisting of at least a triblock copolymer of styrene and a specific diene, where the two end blocks (hard blocks) are polys
- the unmodified polymer is an unmodified alginate.
- the alginate is a high guluronic acid (G) alginate, and comprises greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more guluronic acid (G).
- the alginate is a high mannuronic acid (M) alginate, and comprises greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more mannuronic acid (M).
- the ratio of M:G is about 1. In some embodiments, the ratio of M:G is less than 1. In some embodiments, the ratio of M:G is greater than 1.
- the unmodified alginate has a molecular weight of 150 kDa - 250 kDa and a G:M ratio of > 1.5.
- the afibrotic polymer comprises an alginate chemically modified with a Compound of Formula (I).
- the alginate in the afibrotic polymer may be the same or different than any unmodified alginate that is present in the device.
- the density of the Compound of Formula (I) in the afibrotic alginate e.g, amount of conjugation
- the amount of Compound 101 produces an increase in % N (as compared with the unmodified alginate) of about 0.5% to 2% 2% to 4% N, about 4% to 6% N, about 6% to 8%, or about 8% to 10% N), where % N is determined by combustion analysis and corresponds to the amount of Compound 101 in the modified alginate.
- the density (e.g., concentration) of the Compound of Formula (I) (e.g. Compound 101) in the afibrotic alginate is defined as the % w/w, e.g., % of weight of amine / weight of afibrotic alginate in solution (e.g., saline) as determined by a suitable quantitative amine conjugation assay (e.g.
- the density of a Compound of Formula (I) is between about 1.0 % w/w and about 3.0 % w/w, between about 1.3 % w/w and about 2.5 % w/w or between about 1.5 % w/w and 2.2 % w/w.
- the amount of modified and unmodified alginates (e.g, by % weight of the device, actual weight of the alginate) can be at least 5%, e.g, at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more, e.g, w/w; less than 20%, e.g, less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1%, or less.
- the alginate in an afibrotic polymer can be chemically modified with a compound of Formula (I) using any suitable method known in the art.
- the alginate carboxylic acid moiety can be activated for coupling to one or more amine-functionalized compounds to achieve an alginate modified with a compound of Formula (I).
- the alginate polymer may be dissolved in water (30 mL/gram polymer) and treated with 2-chloro-4,6-dimethoxy-l,3,5-triazine (0.5 eq) and N-methylmorpholine (1 eq). To this mixture may be added a solution of the compound of Formula (I) in acetonitrile (0.3M).
- the reaction may be warmed to 55 °C for 16h, then cooled to room temperature and gently concentrated via rotary evaporation, then the residue may be dissolved, e.g, in water.
- the mixture may then be filtered, e.g, through a bed of cyanomodified silica gel (Silicycle) and the filter cake washed with water.
- the resulting solution may then be dialyzed (10,000 MWCO membrane) against water for 24 hours, e.g., replacing the water twice.
- the resulting solution can be concentrated, e.g., via lyophilization, to afford the desired chemically modified alginate.
- modified polymers described herein may be covalently bound to a photoactive crosslinker.
- a photoactive crosslinkers is a moiety that is activated upon exposure to light.
- the light may comprise any wavelength of light, from infrared to x-ray energy.
- the light comprises ultraviolet light (e.g., between 360 nm to 400 nm, e.g., 370 nm to 390 nm, e.g., 380 nm to 400 nm, e.g., 390 nm to 400 nm).
- the light comprises visible light (e.g., between 400 nm to 700 nm).
- Photoactive crosslinkers often include at least one unsaturated functional group capable of undergoing free radical polymerization.
- a photoactive crosslinker comprises an alkenyl group (e.g, C2-C12 alkenyl, C2- C8 alkenyl).
- a photoactive crosslinker comprises an alkynyl group (e.g,, C2- C12 alkynyl, C2-C8 alkynyl).
- Moieties that may be activated upon exposure to irradiation include aromatic groups, alkenyl groups, alkynyl groups, and azide groups.
- alkenyl compounds that may act as photoactive crosslinkers include alkenoic acids such as acrylate, methacrylate, acrylamide, and methacrylamide and their corresponding acid chlorides and anhydrides.
- Other exemplary alkenyl compounds include enols (e.g., 2-propen-l-ol), alkenyl halides (such as allyl chloride, and the like), organometallic alkenyl compounds (such as vinyl magnesium bromide), aryl compounds (e.g., styrene).
- photoactive crosslinkers include acrylate, methacrylate, ethylene glycol dimethylacrylate, divinylbenzene, 1,3 -di isopropyl benzene, and N,N’ -methylenebisacrylamide.
- the photoactive crosslinker is a bifunctional crosslinker, i.e., has two reactive functional groups.
- the photoactive covalent crosslinker has both alkenyl and amide functional groups.
- the photoactive crosslinker has both alkenyl and carboxylate functional groups.
- the photoactive crosslinker has both alkenyl and amide functional groups.
- the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV): pharmaceutically acceptable salt or tautomer thereof, wherein X 1 is absent, O, NR 33 , or C(R 34a )(R 34b ); each of R 30a , R 30b , R 31 , R 32 , R 33 , R 34a , and R 34b is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 , -C(O)OR A1 , -C(O)R B1 ,-OC(O)R B1 , -N(R C1 )(R D1 ), -N(R C1 )C(O)R B1 , -C(O)N(R C1 ), SR E1 , cycloalkyl, heterocyclyl, aryl, or heteroaryl; each of R 30
- X 1 is O, each of R 30a , R 30b , R 31 , and R 32 is hydrogen, and R 32 is heteroalkyl (e.g., propylamine, e.g., -CH2CH2CH2NH2).
- R 32 is heteroalkyl (e.g., propylamine, e.g., -CH2CH2CH2NH2).
- X 1 is O, each of R 30a , R3°b, j ⁇ 3i an j j ⁇ 32 j s hydrogen, and R 32 is heteroalkyl (e.g., ethylamine, e.g., -CH2CH2NH2).
- the photoactive crosslinker of Formula (IV) is methacrylate.
- X 1 is absent; R 32 is halo (e.g., chloro); and each of R 30a , R 30b and R 31 is hydrogen.
- the photoactive crosslinker of Formula (IV) is acryloyl chloride.
- X 1 is NR 33 (e.g., NH), and each of R 30a , R 30b , R 31 , and R 32 is hydrogen.
- the photoactive crosslinker of Formula (IV) is acrylamide.
- the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV-a):
- R (IV-a), or a pharmaceutically acceptable salt or tautomer thereof wherein each of R 30a , R 30b , R 31 , R 32 and R 35 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 , -C(O)OR A1 , -C(O)R B1 ,-OC(O)R B1 , - N(R C1 )(R D1 ), -N(R C1 )C(O)R B1 , -C(O)N(R C1 ), SR E1 , cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R A1 , R B1 , R C1 , R D1 , and R E1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycly
- the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV-b): pharmaceutically acceptable salt or tautomer thereof, wherein each of R 30a , R 30b , R 31 , R 32 , R 36a , and R 36b is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 , -C(O)OR A1 , -C(O)R B1 ,-OC(O)R B1 , - N(R C1 )(R D1 ), -N(R C1 )C(O)R B1 , -C(O)N(R C1 ), SR E1 , cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R A1 , R B1 , R C1 , R D1 , and R E1 is independently hydrogen, alkyl,
- the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV-c): pharmaceutically acceptable salt or tautomer thereof, wherein each of R 30a , R 30b , and R 31 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 , -C(O)OR A1 , -C(O)R B1 ,-OC(O)R B1 , -N(R C1 )(R D1 ), - N(R C1 )C(O)R B1 , -C(O)N(R C1 ), SR E1 , cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 32 is alkyl, alkenyl, alkynyl, heteroalkyl, -C(O)OR A1 , -C(O)R B1
- the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV-d): pharmaceutically acceptable salt or tautomer thereof, wherein each of R 30a , R 30b , R 31 , R 32 , R 36a , and R 36b is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 , -C(O)OR A1 , -C(O)R B1 ,-OC(O)R B1 , - N(R C1 )(R D1 ), -N(R C1 )C(O)R B1 , -C(O)N(R C1 ), SR E1 , cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 32 is alkyl, alkenyl, alkynyl, heteroalkyl ,-C(O)OR
- Photoactive crosslinkers may be used alone or, preferably in the presence of a photoinitiator.
- a “photoinitiator,” as used herein, refers to a molecule capable of absorbing radiation e.g., light e.g., photons, and forming a reactive species in an excited state.
- free radical initiators as can readily be identified by those of skill in the art, can be employed in the practice of the present invention.
- a photoinitiator is an ultraviolent (UV) photoinitiator.
- UV photoinitiators include lithium phenyl-2,4,6- trimethylbenzoylphopshinate (LAP), camphorquinone, benzoin methyl ether, J-hydroxy- cyclohexyl-phenyl-ketone (i.e., Irgacure 184), 2-hydroxy-2-methyl-l -phenyl-l-propanone (i.e., Darocur 1173) 2-hydroxy-l-[4-(2-hydroxyethoxy)phenyl]-2-methylpropan-l-one (i.e., Irgacure 2959), 2-benzyl-2-(dimethylamino)-l-(4-morpholin-4-ylphenyl)butan-1-one (i.e., Irgacure 369), 2-methyl-l-(4-methylsulfanylphenyl)-2-morpholm-4-ylpropan-l-one (i.e., Irgacure 907) diphenyl
- a system of dye and cocatalyst may be used.
- exemplary visible light photoinitiators include 2-(2, 4,5,7- tetrabromo-3-hydroxy-6-oxoxanthen-9-yl)benzoic acid (i.e.. Eosin Y), erythrosine, riboflavin, rose Bengal, methylene blue, and thionine
- Eosin Y 2-(2, 4,5,7- tetrabromo-3-hydroxy-6-oxoxanthen-9-yl)benzoic acid
- erythrosine erythrosine
- riboflavin rose Bengal
- methylene blue thionine
- thionine A small amount of a comonomer can optionally be added to the crosslinking reaction to increase the polymerization rates.
- Suitable comonomers include vinyl pyrrolidinone, acrylamide, methacrylamide, acrylic acid, methacrylic adit sodium acrylate, sodium methacrylate, hydroxyethyl acrylate, hydroxy ethyl methacrylate (HEMA), ethylene glycol diacrylate, ethylene glycol dimethacrylate, pentaerythritol triacrylate, pentaerythritol tri methacryl ate, tri methylol propane tri acrylate, trimethylol propane trimethaciylate, tripropylene glycol diaciylate, tripropylene glycol dimethacrylate, glyceryl acrylate, glyceryl methacrylate, and the like.
- the photoiniiiator is a thermally activated photoinitiator.
- a photoactive crosslinker may be used in the presence of a single photoinitiator or a plurality of photoinitiators.
- the plurality of photoinitiators may include 2, 3, 4, 5, 6, 7, 8, or more photoinitiators.
- the covalent crosslinking moiety is present on the polysaccharide polymer at a density of at least 1%, e.g., 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or more, e.g., as determined by LC-UV assay.
- the photoactive crosslinker may be covalently bound to a polysaccharide, e.g., an alginate.
- the modified polysaccharide polymer e.g., modified alginate polymer, may be capable of being crosslinked to another polymer.
- the polysaccharide polymer is modified with more than one type of photoactive crosslinker.
- the modified polysaccharide is a compound of Formula (V):
- each of T and U is independently C(R 40 )(R 41 ), O, or N(R 42 ); each of R 38a , R 38b ; R 39a , R 39b , R 40 , R 41 ,and R 42 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 , -C(O)OR A1 , -C(O)R B1 ,-OC(O)R B1 , - N(R C1 )(R D1 ), N(R C1 )C(O)R B1 , C(O)N(R C1 ), SR E1 , cycloalkyl, heterocyclyl, aryl, or heteroaryl; each of R 32 and R 35 is hydrogen, alkyl, heteroalkyl, halo, cyan
- Formula (V-a) pharmaceutically acceptable salt or tautomer thereof, wherein each of T and U is independently C(R 40 )(R 41 ), O, or N(R 42 ); each of R 30a , R 30b , R 31 , R 32 , R 38a , R 38b , R 39a , R 39b , R 40 , R 41 , and R 42 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 , -C(O)OR A1 , -C(O)R B1 ,-OC(O)R B1 , -
- each R A1 , R B1 , R C1 , R D1 , and R E1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R 7 ; and each R 7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl.
- the modified polymer described herein has the structure of Formula
- each of U and T is independently C(R 40 )(R 41 ), O, or N(R 42 ); each of R 30a , R 30b , R 31 , R 33 , R 38a , R 38b , R 39a , R 39b , R 40 , R 41 , R 42 , R 43a , and R 43b is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 , -C(O)OR A1 , C(O)R B1 , OC(O)R B1 , -N(R C1 )(R D1 ), -N(R C1 )C(O)R B1 , -C(O)N(R C1 ), SR E1 , cycloalkyl, heterocyclyl, aryl, or hetero
- R C1 , R D1 , and R E1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R 7 ; and each R 7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; and n is 1, 2, 3, 4, 5, or 6.
- the modified polymer described herein has the structure of Formula
- the modified polymer described herein comprises the structure of Formula (VI): pharmaceutically acceptable salt or tautomer thereof, wherein each of W, T 1 , T 2 , U 1 , and U 2 is independently C(R 40 )(R 41 ), O, or N(R 42 ); each of R 38a , R 38b , R 38c , R 38d R 39a , R 39b , R 39a , R 39b , R 40 , R 41 , and R 42 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 , -C(O)OR A1 , -C(O)R B1 ,-OC(O)R B1 , -N(R C1 )(R D1 ), -N(R C1 )C(O)R B1 , -C(O)N(R C1 ),
- the device comprises at least one cell-containing compartment, and in some embodiments contains two, three, four or more cell-containing compartments.
- each cell-containing compartment comprises a plurality of cells (e.g., live cells) and the cells in at least one of the compartments are capable of expressing and secreting a mammalian protein when the device is implanted into a subject.
- all the cells in a cell-containing compartment are derived from a single parental cell-type or a mixture of at least two different parental cell types. In an embodiment, all of the cells in a cell -containing compartment are derived from the same parental cell type. In devices with two or more cell-containing compartments, the cells and the protein(s) produced thereby may be the same or different in each cell -containing compartment. In some embodiments, all of the cell-containing compartments are surrounded by a single barrier compartment. In some embodiments, the barrier compartment is substantially cell-free. In an embodiment, cells to be incorporated into a device described herein, e.g., a hydrogel capsule, are prepared in the form of a cell suspension prior to being encapsulated within the device.
- the cells in the suspension may take the form of single cells (e.g., from a monolayer cell culture), or provided in another form, e.g., disposed on a microcarrier (e.g., a bead or matrix) or as a three-dimensional aggregate of cells (e.g., a cell cluster or spheroid).
- the cell suspension can comprise multiple cell clusters (e.g., as spheroids) or microcarriers.
- the implantable element described herein comprises a plurality of engineered mammalian cells (e g., engineered ARPE-19 cells), e.g., at a particular cell density.
- the implantable element may comprise a plurality of engineered mammalian cells at greater than 1 million cells per mL, 2.5 million cells per mb, 5 million cells per mb, 7.5 million cells per mL, 10 million cells per mL, 15 million cells per mL, 20 million cells per mL, 25 million cells per mL, 30 million cells per mL, 40 million cells per mL, 50 million cells per mL, or more.
- the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., a hormone, a blood clotting factor, an antibody, or an enzyme) with a cell density of between 1-5 million cells per mL, 5-10 million cells per mL, or 10-20 million cells per mL.
- a protein e.g., a hormone, a blood clotting factor, an antibody, or an enzyme
- the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., insulin) with a cell density of between 1-5 million cells per mL, 5-10 million cells per mL, or 10-20 million cells per mL.
- the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., IDUA) with a cell density of between 1-5 million cells per mL, 5-10 million cells per mL, or 10-20 million cells per mL.
- the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., insulin) with a cell density of between 1-5 million cells per mL, 5- 10 million cells per mL, or 10-20 million cells per mL.
- the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., insulin) with a cell density of between 1-5 million cells per mL, 5-10 million cells per mL, or 10- 20 million cells per mL.
- a protein e.g., insulin
- a device may comprise one or more exogenous agents that are not expressed by the cells, and may include, e.g., a nucleic acid (e.g., an RNA or DNA molecule), a protein (e.g., a hormone, an enzyme (e.g., glucose oxidase, kinase, phosphatase, oxygenase, hydrogenase, reductase) antibody, antibody fragment, antigen, or epitope)), an active or inactive fragment of a protein or polypeptide, a small molecule, or drug.
- the device is configured to release such an exogenous agent.
- the implantable element described herein results in a lower amount of peri capsular fibrotic overgrowth (PFO) when implanted into a mammalian host than compared with implanting a control implantable element (e.g., defined as an otherwise identical implantable element except that the cell does not have the reduction in the MHC class I complex).
- the implantable element described herein comprises an engineered mammalian cell that remains capable of expressing the therapeutic agent for at least any of two months, three months, four months, or longer following implant of the implantable element into a mammalian subject.
- the implantable element described comprises an engineered mammalian cell expressing a therapeutic agent detectable in the plasma of a mammalian subject for at least any of two months, three months, four months, or longer following implant of the implantable element into the subject.
- the devices described herein comprise at least one compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein:
- A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, - B(OR A )-, or a metal, each of which is optionally linked to an attachment group (e.g., an attachment group described herein) and is optionally substituted by one or more R 1 ; each of L 1 and L 3 is independently a bond, alkyl, or heteroalkyl, wherein each alkyl and heteroalkyl is optionally substituted by one or more R 2 ;
- L 2 is a bond
- M is absent, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted by one or more R 3 ;
- P is absent, cycloalkyl, heterocyclyl, or heteroaryl, each of which is optionally substituted by one or more R 4 ;
- Z is hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, -OR A , -C(O)R A , -C(O)OR A , - C(O)N(R C )(R D ), -N(R C )CFV A , cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted by one or more R 5 ; each R A , R B , R C , R D , R E , R F , and R G is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, azido, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkyny
- L 2 is a bond
- M is absent, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted by one or more R 3 ;
- P is heteroaryl optionally substituted by one or more R 4 ;
- Z is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted by one or more R 5 ; each R A , R B , R C , R D , R E , R F , and R G is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, azido, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R 6 ; or R c and R D , taken together with the nitrogen atom to which they are attached, form a ring (e g., a 5-7 membered ring), optionally substituted with one or more R 6 ; each R 1
- A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, -C(O)O-, -C(O)-, -OC(O) -, -N(R c )C(O)-, - N(R c )C(O)(Ci-C6-alkylene)-, -N(R c )C(O)(Ci-C6-alkenylene)-, or -N(R c )-.
- A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, — C(O)O— , -C(O)-, -OC(O) -, or -N(R c )-.
- A is alkyl, alkenyl, alkynyl, heteroalkyl -O-, -C(O)O-, -C(O)-,-OC(O) -, or -N(R C )-.
- A is alkyl, -O-, -C(O)O- -C(O)-, -OC(O), or -N(R C )-. In some embodiments, A is -N(R c )C(O)-, -N(R c )C(O)(Ci-Ce-alkylene)-, or -N(R c )C(O)(Ci-C6-alkenylene)-. In some embodiments, A is -N(R C )-. In some embodiments, A is -N(R C ) -, and R c an R D is independently hydrogen or alkyl. In some embodiments, A is -NH-.
- A is -N(R c )C(O)(Ci-Ce- alkylene)-, wherein alkylene is substituted with R 1 .
- A is - N(R c )C(O)(Ci-C6-alkylene)-, and R 1 is alkyl (e.g., methyl).
- A is - NHC(O)C(CH3)2-.
- A is -N(R c )C(O)(methylene)-, and R 1 is alkyl (e.g., methyl).
- A is -NHC(0)CH(CH3)-.
- A is - NHC(O)C(CH3)-.
- L 1 is a bond, alkyl, or heteroalkyl. In some embodiments, L 1 is a bond or alkyl. In some embodiments, L 1 is a bond. In some embodiments, L 1 is alkyl. In some embodiments, L 1 is Ci-Ce alkyl. I n some embodiments, L 1 is -CH2-, -CH(CH3)-, -CH2CH2CH2, or -CH2CH2-. In some embodiments, L 1 is -CFfc-or - CH2CH2-.
- L 3 is a bond, alkyl, or heteroalkyl. In some embodiments, L 3 is a bond. In some embodiments, L 3 is alkyl. In some embodiments, L 3 is C1-C12 alkyl. In some embodiments, L 3 is Ci-Ce alkyl. In some embodiments, L 3 is -CH2-. In some embodiments, L 3 is heteroalkyl. In some embodiments, L 3 is C1-C12 heteroalkyl, optionally substituted with one or more R 2 (e.g., oxo).
- R 2 e.g., oxo
- L 3 is Ci-Ce heteroalkyl, optionally substituted with one or more R 2 (e.g., oxo). In some embodiments, L 3 is C(O)OCH 2 , CH 2 (OCH 2 CH 2 )2 , CH 2 (OCH 2 CH 2 )3 , CH2CH2O , or -CH2O-. In some embodiments, L 3 is -CH2O-. In some embodiments, for Formulas (I) and (I-a), M is absent, alkyl, heteroalkyl, aryl, or heteroaryl. In some embodiments, for Formulas (I) and (I-a), M is absent, alkyl, heteroalkyl, aryl, or heteroaryl.
- M is heteroalkyl, aryl, or heteroaryl. In some embodiments, M is absent. In some embodiments, M is alkyl (e.g., Ci-Ce alkyl). In some embodiments, M is -CH2-. In some embodiments, M is heteroalkyl (e.g., Ci-Ce heteroalkyl). In some embodiments, M is (-OCFbCFb-Jz, wherein z is an integer selected from 1 to 10. In some embodiments, z is an integer selected from 1 to 5. In some embodiments, M is -(OCH2) 2-, (-OCH 2 CH 2 -)2, (-OCH 2 CH 2 -)3, (-OCH 2 CH 2 -) 4 , or (-OCH2CH2
- M is -OCH2CH2-, (-OCH 2 CH 2 -)2, (-OCH 2 CH 2 -) 3 , or (-OCH 2 CH 2-)4 .
- M is (-OCH 2 -)3.
- M is aryl.
- M is phenyl.
- M is unsubstituted phenyl.
- M is In some embodiments, M is .
- M is phenyl substituted with 1-4 R 3 (e.g., 1 R 3 ). In some embodiments, R 3 is CF3.
- P is absent, heterocyclyl, or heteroaryl. In some embodiments, for Formulas (I) and (I-a), P is absent, heterocyclyl, or heteroaryl. In some embodiments, P is absent. In some embodiments, for Formulas (I) and (I-a), P is a tricyclic, bicyclic, or monocyclic heteroaryl. In some embodiments, P is a monocyclic heteroaryl. In some embodiments, P is a nitrogen-containing heteroaryl. In some embodiments, P is a monocyclic, nitrogen-containing heteroaryl. In some embodiments, P is a 5-membered heteroaryl.
- P is a 5-membered nitrogen-containing heteroaryl. In some embodiments, P is tetrazolyl, imidazolyl, pyrazolyl, or triazolyl, or pyrrolyl. In some embodiments, P is imidazolyl. In some embodiments, P is 1,2,3-triazolyl. In some
- P is heterocyclyl. In some embodiments, P is heterocyclyl. In some embodiments, P is a 5-membered heterocyclyl. In some embodiments, P is imidazolidinonyl. In some embodiments, P is . In some embodiments, P is thiomorpholinyl- 1,1 -di oxidyl.
- Z is alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, for Formulas (I) and (I-a), Z is alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, Z is heterocyclyl. In some embodiments, Z is monocyclic or bicyclic heterocyclyl, 5-membered heterocyclyl, or 6-membered heterocyclyl. In some embodiments, Z is a 6-membered oxygencontaining heterocyclyl. In some embodiments, Z is tetrahydropyranyl. In some embodiments, Z . In some embodiments, Z is a 4-membered oxygen -containing heterocyclyl. In some embodiments, Z is
- Z is a bicyclic oxygen-containing heterocyclyl. In some embodiments, Z is a bicyclic oxygen-containing heterocyclyl. In some embodiments, Z is phthalic anhy dridyl. In some embodiments, Z is a sulfur-containing heterocyclyl some embodiments, Z is a 6-membered sulfur-containing heterocyclyl In some embodiments, Z is a 6-membered heterocyclyl containing a nitrogen atom and a sulfur atom. In some embodiments, Z is thiomorpholinyl-l,l-dioxidyl. In some embodiments, In some embodiments, Z is a nitrogen-containing heterocyclyl. In some embodiments, Z is a 6- membered nitrogen-containing heterocyclyl. In some embodiments, Z is phthalic anhy dridyl. In some embodiments, Z is a sulfur-containing heterocyclyl some embodiments, Z is a 6-membered sulfur-containing heterocyclyl In some embodiments, Z is a 6-membere
- Z is a bicyclic heterocyclyl. In some embodiments, Z is a bicyclic heterocyclyl In some embodiments, Z is a bicyclic nitrogen-containing heterocyclyl, optionally substituted with one or more R 5 . In some embodiments, Z is 2-oxa-7-azaspiro[3.5]nonanyl
- Z is l-oxa-3,8- diazaspiro[4.5]decan-2-one. In some embodiments,
- Z is aryl. In some embodiments, Z is monocyclic aryl. In some embodiments, Z is phenyl. In some embodiments, Z is monosubstituted phenyl (e.g., with 1 R 3 ). In some embodiments, Z is monosubstituted phenyl, wherein the 1 R 5 is a nitrogen-containing group. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R 5 is NHz. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R 5 is an oxygen-containing group.
- Z is monosubstituted phenyl, wherein the 1 R 5 is an oxygen-containing heteroalkyl. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R 5 is OCH3. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R 3 is in the ortho position. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R 5 is in the meta position. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R 3 is in the para position.
- Z is alkyl. In some embodiments, Z is Ci- C12 alkyl. In some embodiments, Z is C1-C10 alkyl. In some embodiments, Z is Ci-Cs alkyl. In some embodiments, Z is Ci-Cs alkyl substituted with 1-5 R 5 . In some embodiments, Z is Ci-Cs alkyl substituted with 1 R 3 .
- Z is Ci-Cs alkyl substituted with 1 R 3 , wherein R 5 is alkyl, heteroalkyl, halogen, oxo, -OR A1 , -C(O)OR A1 , -C(O)R B1 ,-OC(O)R B1 , or -N(R C1 )(R D1 ).
- Z is Ci-Cs alkyl substituted with 1 R 5 , wherein R 5 is - OR A1 or -C(0)0R A1 .
- Z is Ci-Cs alkyl substituted with 1 R 5 , wherein R 5 is -OR A1 or -C(O)OH.
- Z is -CH3.
- Z is heteroalkyl.
- Z is Ci-C 12 heteroalkyl.
- I n some embodiments, Z is C1-C10 heteroalkyl.
- Z is Ci-Cs heteroalkyl.
- I n some embodiments, Z is Ci-Ce heteroalkyl.
- Z is a nitrogen-containing heteroalkyl optionally substituted with one or more R 5 .
- 1 n some embodiments, Z is a nitrogen and sulfur-containing heteroalkyl substituted with 1-5 R 5 .
- Z is N-methyl-2-(methylsulfonyl)ethan-l-aminyl.
- Z is -OR A or -C(0)0R A .
- Z is -OR A (e.g., -OH or OCH3).
- Z is OCH3.
- Z is -C(O)OR A (e.g., -C(O)OH).
- Z is hydrogen
- L 2 is a bond and P and L 3 are independently absent.
- L 2 is a bond
- P is heteroaryl
- L 3 is a bond
- Z is hydrogen
- P is heteroaryl
- L 3 is heteroalkyl
- Z is alkyl.
- the compound of Formula (I) is a compound of Formula (I-b): or a pharmaceutically acceptable salt thereof, wherein Ring M 1 is cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R 3 ; Ring Z 1 is cycloalkyl, heterocyclyl’ aryl or heteroaryl, optionally substituted with 1 -5 R 5 ; each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halo, cyano, nitro, amino, cycloalkyl, heterocyclyl, aryl, or heteroaryl, or each of R 2a and R 2b or R 2c and R 2d is taken together to form an oxo group; X is absent, N(R 1O )(R U ), O, or S; R c is hydrogen, alkyl, alkeny
- each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally and independently substituted with halogen, oxo, cyano, cycloalkyl, or heterocyclyl.
- the compound of Formula (I-b) is a compound of Formula (I-b-i): or a pharmaceutically acceptable salt thereof, wherein Ring M 2 is aryl or heteroaryl optionally substituted with one or more R 3 ; Ring Z 2 is cycloalkyl, heterocyclyl, aryl’ or heteroaryl; each of R 2a , R 2b , R 2C , and R 2d is independently hydrogen, alkyl, or heteroalkyl, or each of R 2a and R 2b or R 2C and R 2d is taken together to form an oxo group; X is absent, O, or S; each R 3 and R 5 is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 , -C(O)OR A1 , or -C(O)R B1 , wherein each alkyl and heteroalkyl is optionally substituted with halogen; or two R 5 are taken together to form a 5-6 membered
- the compound of Formula (I-b-i) is a compound of Formula (I-b- ii): or a pharmaceutically acceptable salt thereof, wherein Ring Z 2 is cycloalkyl, heterocyclyl, aryl or heteroaryl; each of R 2c and R 2d is independently hydrogen, alkyl, or heteroalkyl, or R 2c and R and taken together to form an oxo group; each R 3 and R 5 is independently alkyl, heteroalkyl, halogen, oxo, -0R A1 , -C(0)0R A1 , or -C(0)R B1 , wherein each alkyl and heteroalkyl is optionally substituted with halogen; each R A1 and R B1 is independently hydrogen, alkyl, or heteroalkyl; each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; and refers to a connection to an attachment group or a polymer described herein.
- Ring Z 2 is cycloalkyl, heterocycly
- the compound of Formula (I) is a compound of Formula (I-c): or a pharmaceutically acceptable salt thereof, wherein Ring Z 2 is cycloalkyl, heterocyclyl’ aryl or heteroaryl; each of R 2c and R 2d is independently hydrogen, alkyl, or heteroalkyl, or R 2c and R 2d is taken together to form an oxo group; each R 3 and R 5 is independently alkyl, heteroalkyl, halogen, oxo, -OR, -C(0)0R, or -C(0)R B1 , wherein each alkyl and heteroalkyl is optionally substituted with halogen; each R A1 and R B1 is independently hydrogen, alkyl, or heteroalkyl; m is 1, 2, 3, 4, 5, or 6; each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; and “ ” refers to a connection to an attachment group or a polymer described herein.
- the compound of Formula (I) is a compound of Formula (I-d): or a pharmaceutically acceptable salt thereof, wherein Ring Z 2 is cycloalkyl, heterocyclyl’ aryl or heteroaryl; X is absent, O, or S; each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, alkyl, or heteroalkyl, or each of R 2a and R 2b or R 2c and R 2d is taken together to form an oxo group; each R 3 is independently alkyl, heteroalkyl, halogen, oxo, -0R A1 , -C(0)0R A1 , or -C(O)R B1 , wherein each alkyl and heteroalkyl is optionally substituted with halogen; each R A1 and R is independently hydrogen, alkyl, or heteroalkyl; each of m and n is independently 1, 2, 3, 4, 5, or
- the compound of Formula (I) is a compound of Formula (I-e): (I-e), or a pharmaceutically acceptable salt thereof, wherein Ring Z 2 is cycloalkyl, heterocyclyl, aryl or heteroaryl; X is absent, O, or S; each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, alkyl, or heteroalkyl, or each of R 2a and R 2b or R 2c and R 2d is taken together to form an oxo group; each R 5 is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 , -C(O)OR A1 , or -C(O)R B1 ; each R A1 and R B1 is independently hydrogen, alkyl, or heteroalkyl;
- the compound of Formula (I) is a compound of Formula (I-f): or a pharmaceutically acceptable salt thereof, wherein M is alkyl optionally substituted with one or more R 3 ; Ring P is heteroaryl optionally substituted with one or more R 4 ; L 3 is alkyl or heteroalkyl optionally substituted with one or more R 2 ; Z is alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R 5 ; each of R 2a and R 2b is independently hydrogen, alkyl, or heteroalkyl, or R 2a and R 2b is taken together to form an oxo group; each R 2 , R 3 , R 4 , and R 5 is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 , -C(O)OR A1 , or -C(O)R B1 ; each R A1 and
- the compound of Formula (I) is a compound of Formula (II): or a pharmaceutically acceptable salt thereof, wherein M is a bond, alkyl or aryl, wherein alkyl and aryl is optionally substituted with one or more R 3 ; L 3 is alkyl or heteroalkyl optionally substituted with one or more R 2 ; Z is hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or -OR, wherein alkyl, , cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R 5 ; R A is hydrogen; each of R 2a and R 2b is independently hydrogen, alkyl, or heteroalkyl, or R 2a and R 2b is taken together to form an oxo group; each R 2 , R 3 , and R 5 is independently alkyl, heteroalkyl, halogen, oxo, -OR A
- the compound of Formula (II) is a compound of Formula (Il-a): or a pharmaceutically acceptable salt thereof, wherein L 3 is alkyl or heteroalkyl, each of which is optionally substituted with one or more R 2 ; Z is hydrogen, alkyl, heteroalkyl' or -OR A , heteroalkyl are optionally substituted with one or more R 5 ; each of R 2a and R 2b is independently hydrogen, alkyl, or heteroalkyl, or each of R 2a and R 2b is taken together to form an oxo group- each R 2 , R 3 , and R 5 is independently heteroalkyl, halogen, oxo, -OR A1 , -C(O)OR A1 ; R A is hydrogen; each R A1 and R B1 is independently hydrogen, alkyl, or heteroalkyl; n is independently 1, 2, 3, 4, 5, or 6; and “ - ⁇ wv” refers to a connection to an attachment group or a polymer
- the compound of Formula (I) is a compound of Formula (III): (III), or a pharmaceutically acceptable salt thereof, wherein Z 1 is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R 5; each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halo, cyano, nitro, amino, cycloalkyl, heterocyclyl, aryl, or heteroaryl; or each of R 2a and R 2b or R 2C and R 2d is taken together to form an oxo group; R c is hydrogen, alkyl, alkenyl, alkynyl, or heteroalkyl, wherein each of alkyl, alkenyl, alkynyl, or heteroalkyl is
- the compound of Formula (III) is a compound of Formula (Ill-a): or a pharmaceutically acceptable salt thereof, wherein Ring Z 2 is cycloalkyl, heterocyclyl, aryl, or heteroaryl; each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, alkyl, heteroalkyl, halo; or R 2a and R 2b or R 2c and R 2d are taken together to form an oxo group; each of R 3 and R 5 is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 , -C(O)OR A1 , or -C(O)R B1 ; each R A1 and R B1 is independently hydrogen, alkyl, or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5, or 6; o and p are each independently 0, 1, 2, 3, 4, or 5; q is an integer from 0 to 25; and refers to a
- the compound of Formula (Ill-a) is a compound of Formula (III- or a pharmaceutically acceptable salt thereof, wherein Ring Z 2 is cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R 5; each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, alkyl, heteroalkyl, halo; or R 2a and R 2b or R 2c and R 2d are taken together to form an oxo group; each of R 3 and R 5 is independently alkyl, heteroalkyl, halogen, oxo, - OR A1 , -C(O)OR A1 , or -C(O)R B1 ; each R A1 and R B1 is independently hydrogen, alkyl, or heteroalkyl; m and n 1, 2, 3, 4, 5, or 6; o and p are each independently 0, 1, 2, 3, 4, or 5; q is an integer from
- the compound of Formula (Ill-a) is a compound of Formula (III- c): or a pharmaceutically acceptable salt thereof, wherein X is C(R’)(R”), N(R’), or S(O) X ; each of R’ and R” is independently hydrogen, alkyl, halogen, or cycloalkyl; each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, alkyl, heteroalkyl, or halo; or R 2a and R 2b or R 2c and R 2d are taken together to form an oxo group; each of R 3 and R 5 is independently alkyl, heteroalkyl, halogen, oxo, -0R A1 , -C(0)0R A1 , or -C(0)R B1 ; each R A1 and R B1 is independently hydrogen, alkyl, or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5, or 6; p is
- the compound of Formula (III-c) is a compound of Formula (III- d): or a pharmaceutically acceptable salt thereof, wherein X is C(R’)(R”), N(R’), or S(O) X ; each of R’ and R” is independently hydrogen, alkyl, halogen, or cycloalkyl; each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, alkyl, heteroalkyl, or halo; or R 2a and R 2b or R 2c and R 2d are taken together to form an oxo group; each of R 3 and R 5 is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 , -C(O)OR A1 , or -C(0)R B1 ; each R A1 and R B1 is independently hydrogen, alkyl, or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5, or 6; p is 0,
- the compound is a compound of Formula (I).
- L 2 is a bond and P and L 3 are independently absent.
- the compound is a compound of Formula (I-a).
- L 2 is a bond, P is heteroaryl, L 3 is a bond, and Z is hydrogen.
- P is heteroaryl, L 3 is heteroalkyl, and Z is alkyl.
- L 2 is a bond and P and L 3 are independently absent.
- L 2 is a bond, P is heteroaryl, L 3 is a bond, and Z is hydrogen.
- P is heteroaryl, L 3 is heteroalkyl, and Z is alkyl.
- the compound is a compound of Formula (I-b).
- P is absent, L 1 is -NHCH2, L 2 is a bond, M is aryl (e.g., phenyl), L 3 is -CH2O, and Z is heterocyclyl (e.g., a nitrogen-containing heterocyclyl, e.g., thiomorpholinyl- 1,1 -di oxide).
- the compound of Formula (I-b) is Compound 116.
- P is absent, L 1 is -NHCH2, L 2 is a bond, M is absent, L 3 is a bond, and Z is heterocyclyl (e.g., an oxygen-containing heterocyclyl, e.g., tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, or oxiranyl).
- the compound of Formula (I-b) is Compound 105.
- the compound is a compound of Formula (I-b-i).
- each of R 2a and R 2b is independently hydrogen or CH3, each of R 2C and R 2d is independently hydrogen, m is 1 or 2, n is 1, X is O, p is 0, M 2 is phenyl optionally substituted with one or more R 3 , R 3 is -CF3, and Z 2 is heterocyclyl (e.g., an oxygen-containing heterocyclyl, e.g., tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, or oxiranyl).
- the compound of Formula (I-b-i) is Compound 100, Compound 106, Compound 107, Compound 108, Compound 109, or Compound 111.
- the compound is a compound of Formula (I-b-ii).
- each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, q is 0, p is 0, m is 1, and Z 2 is heterocyclyl (e.g., an oxygen-containing heterocyclyl, e.g., tetrahydropyranyl).
- the compound of Formula (I-b-ii) is Compound 100.
- the compound is a compound of Formula (I-c).
- each of R 2c and R 2d is independently hydrogen, m is 1, p is 1, q is 0, R 3 is -CH3, and Z is heterocyclyl (e.g., a nitrogen-containing heterocyclyl, e.g., piperazinyl).
- the compound of Formula (I-c) is Compound 113.
- the compound is a compound of Formula (I-d).
- each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, m is 1, n is 3, X is O, p is 0, and Z is heterocyclyl (e.g., an oxygen-containing heterocyclyl, e.g., tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, or oxiranyl).
- the compound of Formula (I-d) is Compound 110 or Compound 114.
- the compound is a compound of Formula (I-f).
- each of R 2a and R 2b is independently hydrogen, n is 1, M is -CH2-, P is a nitrogen-containing heteroaryl (e.g., imidazolyl), L 3 is -C(O)OCH2-, and Z is CH3.
- the compound of Formula (I-f) is Compound 115.
- the compound is a compound of Formula (Il-a).
- each of R 2a and R 2b is independently hydrogen, n is 1, q is 0, L 3 is -CH 2 (OCH 2 CH 2 )2, and Z is -OCH3.
- the compound of Formula (Il-a) is Compound 112.
- each of R 2a and R 2b is independently hydrogen, n is 1, L 3 is a bond or -CH2, and Z is hydrogen or -OH
- the compound of Formula (Il-a) is Compound 103 or Compound 104.
- the compound is a compound of Formula (III).
- each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, m is 1, n is 2, q is 3, p is 0, R c is hydrogen, and Z 1 is heteroalkyl optionally substituted with R 5 (e.g., - N(CH3)(CH2CH2)S(O)2CH3).
- the compound of Formula (III) is Compound 120.
- the compound is a compound of Formula (Ill-b).
- each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, m is 0, n is 2, q is 3, p is 0, and Z 2 is aryl (e.g., phenyl) substituted with 1 R 5 (e.g., -NH2).
- the compound of Formula (Ill-b) is Compound 102.
- the compound is a compound of Formula (Ill-b).
- each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen
- m is 1
- n is 2
- q is 3
- p is 0,
- R c is hydrogen
- Z 2 is heterocyclyl (e.g., a nitrogen-containing heterocyclyl, e g., a nitrogen-containing spiro heterocyclyl, e.g., 2-oxa-7-azaspiro[3.5]nonanyl).
- the compound of Formula (Ill-b) is Compound 121.
- the compound is a compound of Formula (Ill-d).
- each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, m is 1, n is 2, q is 1, 2, 3, or 4, p is 0, and X is S(O)2.
- each of R 2a and R 2b is independently hydrogen, m is 1, n is 2, q is 1, 2, 3, or 4, p is 0, and X is S(O)2.
- the compound of Formula (Ill-d) is Compound 101, Compound 117, Compound 118, or Compound 119.
- the compound is a compound of Formula (I-b), (I-d), or (I-e). In some embodiments, the compound is a compound of Formula (I-b), (I-d), or (II). In some embodiments, the compound is a compound of Formula (I-b), (I-d), or (I-f). In some embodiments, the compound is a compound of Formula (I-b), (I-d), or (III).
- the compound of Formula (I) is not a compound disclosed in WO2012/112982, WO2012/167223, WO2014/153126, W02016/019391, WO 2017/075630, US2012-0213708, US 2016-0030359 or US 2016-0030360.
- the compound of Formula (I) comprises a compound shown in Table 4, or a pharmaceutically acceptable salt thereof.
- the exterior surface and / or one or more compartments within a device described herein comprises a small molecule compound shown in Table 4, or a pharmaceutically acceptable salt thereof.
- Conjugation of any of the compounds in Table 4 to a polymer may be performed as described in Example 2 of WO 2019/195055 or any other suitable chemical reaction.
- the compound is a compound of Formula (I) (e.g., Formulas (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (II), (Il-a), (III), (Ill-a), (Ill-b), (III-c), or (III-d)), or a pharmaceutically acceptable salt thereof and is selected from:
- the device described herein comprises the compound of pharmaceutically acceptable salt of either compound.
- a compound of Formula (I) (e.g., Compound 101 in Table 4) is covalently attached to an alginate (e.g., an alginate with approximate MW ⁇ 75 kDa, G:M ratio > 1.5) at a conjugation density of at least 2.0 % and less than 9.0 %, or 3.0 % to 8.0 %, 4.0-7.0, 5.0 to 7.0, or 6.0 to 7.0 or about 6.8 as determined by combustion analysis for percent nitrogen as described in WO 2020/069429.
- an alginate e.g., an alginate with approximate MW ⁇ 75 kDa, G:M ratio > 1.5
- the conjugation density of Compound 101 in the modified alginate is determined by quantitative free amine analysis, e.g., as described in WO2020198695, wherein the determined conjugation density is 1.0 % w/w to 3.0 % w/w, 1.3 % w/w to 2.8 % w/w, 1.3 % w/w to 2.6 % w/w, 1.5 % w/w to 2.4 % w/w, 1.5 % w/w to 2.2 % w/w, or 1.7 % w/w to 2.2 % w/w.
- a device, device preparation or device composition may be configured for implantation, or is implanted or disposed, into or onto any site or part of the body.
- the implantable device or device preparation is configured for implantation into the peritoneal cavity (e.g., the lesser sac, also known as the omental bursa or bursalis omentum).
- a device, device preparation or device composition may be implanted in the peritoneal cavity (e.g., the omentum, e.g., the lesser sac) or disposed on a surface within the peritoneal cavity (e.g., omentum, e.g., lesser sac) via injection or catheter. Additional considerations for implantation or disposition of a device, device preparation or device composition into the omentum (e.g., the lesser sac) are provided in M. Pellicciaro et al. (2017) CellR4 5(3):e2410.
- Engineered mammalian cell (e.g., an engineered ARPE-19 cell)s for use in manufacturing a device, e.g., an implantable element, described herein may be generated and cultured using methods known in the art.
- stably-transfected ARPE-19 cells may be cultured in vitro substantially as described in WO2020198695.
- Compounds of Formula (I) and alginates modified with such compounds may be obtained using procedures known in the art, e.g., substantially as those described in WO2020198695.
- Alginate solutions for making two-compartment hydrogel capsules may be obtained using procedures known in the art, e.g., substantially as described in W02020198695.
- Two-compartment hydrogel capsules encapsulating engineered mammalian cells described herein may be generated using procedure known in the art, e.g., substantially as described in W02020198696.
- an engineered mammalian cell e.g., an engineered ARPE-19 cell
- the engineered mammalian cell comprises (i) a reduction in the level or function of a MHC class I protein complex, and optionally, a MHC class II protein complex and/or CIITA, and (ii) an exogenous nucleic acid encoding a therapeutic agent that, e.g., treats the disease, disorder or condition.
- the engineered mammalian cell comprises a reduction in antigenicity or immunogenicity, e.g., as compared to an to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of a MHC class I protein complex, and optionally, a MHC class II protein complex and/or CIITA.
- the reduction in antigenicity or immunogenicity comprises a reduction in the (a) release of particles or components of an engineered mammalian cell described herein into the subject’s bloodstream, and/or (b) antigen presentation on the subject’s cells comprising particles or components of engineered mammalian cells described herein, e.g., as compared to an to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of a MHC class I protein complex, and optionally, a MHC class II protein complex and/or CIITA.
- Such reductions can be characterized by standard methods known in the art, e.g., by obtaining a blood sample from a subject and quantifying, e.g., protein expression and/or RNA expression.
- the cells may be administered by implanting into the subject an implantable element containing the cells as described herein, or a preparation of such devices.
- the implantable element or preparation of implantable elements is implanted (e.g., via laparoscopy) into the intraperitoneal space, e.g., the greater sac of the peritoneal cavity.
- the engineered mammalian cells are engineered RPE cells
- the method comprises administering (e.g., implanting) an effective amount of a composition of two-compartment alginate hydrogel capsules which comprise the engineered RPE cells and a cell-binding polymer described herein in the inner compartment and comprise a Compound of Formula (I), e.g., Compound 101, on the outer capsule surface.
- the method of treatment directly or indirectly reduces or alleviates at least one symptom of the disease, disorder, or condition and / or the method prevents or slows the onset of the disease, disorder, or condition.
- the subject is a human.
- the disease, disorder, or condition affects a system of the body, e.g., the nervous system (e.g., peripheral nervous system (PNS) or central nervous system (CNS)), vascular system, skeletal system, respiratory system, endocrine system, lymph system, reproductive system, or gastrointestinal tract.
- the disease, disorder, or condition affects a part of the body, e.g., blood, eye, brain, skin, lung, stomach, mouth, ear, leg, foot, hand, liver, heart, kidney, bone, pancreas, spleen, large intestine, small intestine, spinal cord, muscle, ovary, uterus, vagina, or penis.
- the disease, disorder or condition is a neurodegenerative disease, diabetes, a heart disease, an autoimmune disease, a cancer, a liver disease, a lysosomal storage disease, a blood clotting disorder or a coagulation disorder, an orthopedic condition, an amino acid metabolism disorder.
- the disease, disorder or condition is a neurodegenerative disease.
- neurodegenerative diseases include Alzheimer’s disease, Huntington’s disease, Parkinson’s disease (PD) amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and cerebral palsy (CP), dentatorubro-pallidoluysian atrophy (DRPLA), neuronal intranuclear hyaline inclusion disease (NIHID), dementia with Lewy bodies, Down’s syndrome, Hallervorden-Spatz disease, prion diseases, argyrophilic grain dementia, cortocobasal degeneration, dementia pugilistica, diffuse neurofibrillary tangles, Gerstmann-Straussler- Scheinker disease, Jakob-Creutzfeldt disease, Niemann-Pick disease type 3, progressive supranuclear palsy, subacute sclerosing pan encephalitis, spinocerebellar ataxias, Pick’s disease, and dentatoru
- the disease is a liver disease, e.g., hepatitis B, hepatitis C, cirrhosis, NASH.
- the disease, disorder, or condition is cancer.
- cancers include leukemia, lymphoma, melanoma, lung cancer, brain cancer (e.g., glioblastoma), sarcoma, pancreatic cancer, renal cancer, liver cancer, testicular cancer, prostate cancer, or uterine cancer.
- the disease, disorder, or condition is an orthopedic condition.
- orthopedic conditions include osteoporosis, osteonecrosis, Paget’s disease, or a fracture.
- the disease, disorder or condition is a lysosomal storage disease.
- exemplary lysosomal storage diseases include Gaucher disease (e.g., Type I, Type II, Type III), Tay-Sachs disease, Fabry disease, Farber disease, Mucopolysaccharidosis type I (MPS I) (also known as Hurler syndrome), Hunter syndrome, lysosomal acid lipase deficiency, Niemann-Pick disease, Salla disease, Sanfilippo syndrome (also known as mucopolysaccharidosis type IIIA (MPS3A)), multiple sulfatase deficiency, Maroteaux-Lamy syndrome, metachromatic leukodystrophy, Krabbe disease, Scheie syndrome, Hurler-Scheie syndrome, Sly syndrome, hyaluronidase deficiency, Pompe disease, Danon disease, gangliosidosis, or Morquio syndrome.
- Gaucher disease e.g., Type I, Type II, Type III
- the disease, disorder, or condition is a blood clotting disorder or a coagulation disorder.
- blood clotting disorders or coagulation disorders include hemophilia (e.g., hemophilia A or hemophilia B), Von Willebrand disease, thrombocytopenia, uremia, Bernard-Soulier syndrome, Factor XII deficiency, vitamin K deficiency, or congenital afibrinogenimia.
- the disease, disorder, or condition is an amino acid metabolism disorder, e.g., phenylketonuria, tyrosinemia (e.g., Type 1 or Type 2), alkaptonuria, homocystinuria, hyperhomocysteinemia, maple syrup urine disease.
- amino acid metabolism disorder e.g., phenylketonuria, tyrosinemia (e.g., Type 1 or Type 2), alkaptonuria, homocystinuria, hyperhomocysteinemia, maple syrup urine disease.
- the disease, disorder, or condition is a fatty acid metabolism disorder, e.g., hyperlipidemia, hypercholesterolemia, galactosemia.
- the disease, disorder, or condition is a purine or pyrimidine metabolism disorder, e.g., Lesch-Nyhan syndrome.
- the disease, disorder, or condition is diabetes (e.g., Type I or Type II diabetes).
- the disease, disorder or condition is not diabetes.
- the disease, disorder or condition is not Type I diabetes.
- the disease, disorder or condition is not Type II diabetes.
- An implantable element comprising an engineered mammalian cell, wherein:
- the engineered mammalian cell comprises a reduction in the level or function of a major histocompatibility complex (MHC) class I protein complex
- the engineered mammalian cell comprises an exogenous nucleic acid encoding a therapeutic agent.
- beta-2-microglobulin (beta-2M).
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of the MHC class I component HLA-A by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of the MHC class I component HLA-A.
- the engineered mammalian cell comprises a reduction in the level of the MHC class I component HLA-B by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of the MHC class I component HLA-B.
- the engineered mammalian cell comprises a reduction in the level of the MHC class I component HLA-C by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of the MHC class I component HLA-C.
- the engineered mammalian cell comprises a reduction in the level of the MHC class I component beta-2M by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of the MHC class I component beta-2M.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, or 50-75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 1-25%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 5-25%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 10- 25%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 25- 50%, , e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 25- 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 50- 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component of greater than 50%, greater than 75%, or greater than 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component of greater than 50%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component of greater than 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the level of a MHC class I component of greater than 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the function of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the function of HLA-A by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of HLA-A.
- the engineered mammalian cell comprises a reduction in the function of HLA-B by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of HLA-B.
- the engineered mammalian cell comprises a reduction in the function of HLA-C by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of HLA-C.
- the engineered mammalian cell comprises a reduction in the function of beta-2M by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of beta-2M.
- the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 1- 25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 1- 25%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 5- 25%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 10- 25%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 25- 50%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 25- 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 50- 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 75- 100%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- engineered mammalian cell of any one of the preceding embodiments wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component of greater than 50%, greater than 75% or greater than 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- engineered mammalian cell of any one of the preceding embodiments wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component of greater than 50%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- engineered mammalian cell of any one of the preceding embodiments wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component of greater than 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- engineered mammalian cell of any one of the preceding embodiments wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component of greater than 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
- CIITA major histocompatibility complex transactivator
- the engineered mammalian cell comprises an embryonic stem cell (ESC) or an induced pluripotent stem cell (iPSC).
- ESC embryonic stem cell
- iPSC induced pluripotent stem cell
- the engineered mammalian cell comprises a retinal pigment epithelial (RPE) cell, a CCD-33Lu cell, a MRC-5 cell, a MRC-9 cell, a MCFlOa cell, or a cell derived therefrom.
- the engineered mammalian cell comprises an engineered RPE cell (e.g., an engineered ARPE-19 cell).
- the implantable element of any one of the preceding embodiments comprising at least one cell-containing compartment which comprises the engineered mammalian cell of any one of the preceding embodiments.
- the implantable element of any one of the preceding embodiments further comprising at least one means for mitigating the foreign body response (FBR) when the implantable element is implanted into the subject.
- FBR foreign body response
- the polymer composition comprises a polymer selected from alginate, hyaluronate, and chitosan.
- implantable element of embodiment 74, wherein the peptide comprises, consists essentially of, or consists of GRGDSP, GGRGDSP, or GGGRGDSP.
- the polymer composition comprises an alginate covalently modified with a peptide, wherein the peptide consists essentially of or consists of GRGDSP, and wherein the barrier compartment comprises an alginate chemically modified with pharmaceutically acceptable salt thereof.
- the polymer composition comprises an alginate covalently modified with a peptide, wherein the peptide consists essentially of or consists of GGRGDSP, and wherein the barrier compartment comprises an alginate chemically modified with pharmaceutically acceptable salt thereof.
- implantable element of any one of the preceding embodiments wherein the implantable element is spherical with a diameter of about 0.75 mm to about 2 mm.
- the therapeutic agent is a protein, e.g., a hormone, a blood clotting factor, an antibody, or an enzyme.
- an engineered ARPE cell capable of reducing the expression of beta- 2M capable of reducing the expression of beta- 2M
- a polymer composition comprising an alginate covalently modified with one or more of:
- the implantable element of any one of the preceding embodiments formulated for implantation into a subject (e.g., into the intraperitoneal (IP) space, the peritoneal cavity, the omentum, the lesser sac, the subcutaneous fat).
- IP intraperitoneal
- the implantable element of any one of the preceding embodiments formulated for implantation into a subject (e.g., into the intraperitoneal (IP) space).
- the implantable element of any one of the preceding embodiments formulated for implantation into a subject (e.g., into the peritoneal cavity).
- the implantable element of any one of the preceding embodiments formulated for implantation into a subject (e.g., into the omentum).
- the implantable element of any one of the preceding embodiments formulated for implantation into a subject (e.g., into the lesser sac).
- the implantable element of any one of the preceding embodiments formulated for implantation into a subject (e.g., into the subcutaneous fat).
- the implantable element of any one of the preceding embodiments formulated for implantation into the IP space of a subject.
- each implantable element in the preparation is an implantable element of any one of embodiments 1-106.
- a method of treating a disease or disorder in a subject comprising administering to the subject an implantable element of any one of embodiments 1-106 or the preparation of embodiment 107, thereby treating the disease or disorder in the subject.
- Example 1 Culturing Exemplary Engineered ARPE-19 Cells for Encapsulation
- Exemplary engineered ARPE-19 cells comprising one or more genetic modifications as a stably integrated exogenous transcription unit as described herein may be cultured to produce a composition of cells suitable for encapsulation in two compartment hydrogel capsules.
- Cells are grown in complete growth medium (DMEM:F12 with 10% FBS) in 150 cm 2 cell culture flasks or CellSTACK® Culture Chambers (Corning Inc., Corning, NY).
- DMEM complete growth medium
- FBS CellSTACK® Culture Chambers
- the medium in the culture flask is aspirated, and the cell layer is briefly rinsed with phosphate buffered saline (pH 7.4, 137 mM NaCl, 2.7 mM KC1, 8 mM Na 2 HPO 4 , and 2 mM KH 2 PO 4 , Gibco).
- TrypsinEDTA trypsin/ 0.53 mM EDTA solution
- the flasks are placed at 37°C to facilitate dispersal.
- 10 mL complete growth medium is added and the cells are aspirated by gentle pipetting.
- the cell suspension is transferred to a centrifuge tube and spun down at approximately 125 x g for 5-10 minutes to remove TrypsinEDTA. The supernatant is discarded, and the cells are resuspended in fresh growth medium. Appropriate aliquots of cell suspension are added to new culture vessels, which are incubated at 37 °C. The medium is renewed weekly.
- Example 2 Reduced Beta-2M protein expression by a Beta-2M-targeting shRNA in IDUA- expressing ARPE-19 cells
- ARPE-19 cells that had been genetically modified to stably express human IDUA were transduced with shRNA-containing lentiviral particles at a MOI of 100.
- the shRNA contained either a beta-2M targeting sequence or a scrambled sequence as a negative control.
- the beta-2M shRNA sequence consisted of AAGTGGAGCATTCAGACTTGTCTTTCAGC.
- Beta-2M protein expression in the IDUA-expressing ARPE- 19 cells containing the beta-2M shRNA was 89% lower than in the IDUA-expressing ARPE-19 cells containing the scrambled control shRNA.
- Example 3 Reduced Beta-2M protein expression by CRISPR and a Beta-2M-targeting guide RNA in ARPE-19 cells.
- Unmodified ARPE-19 cells were transduced with lentiviral particles containing a beta- 2M-targeting gRNA or a control gRNA with a scrambled sequence and a mCherry fluorescent marker. Following selection with hygromycin, the cells were expanded, and underwent a further transfection with a Cas9/GFP expressing plasmid. Cas9-GFP expressing cells were sorted using flow cytometry to remove the untransfected population. The resulting cells were expanded and characterized by protein-specific ELISA. As shown in FIG. 2, beta-2M expression levels were decreased 99% in the ARPE-19 cells modified with the beta-2M-targeting gRNA compared to ARPE-19 cells modified using the scrambled gRNA.
- Wild-type ARPE-19 cells and the ARPE19 cells with reduced beta-2M protein expression from previous examples were characterized using flow cytometry.
- Cells were stained with a fluorescently labelled antibody that recognizes HLA Class 1 ABC.
- mCherry fluorescence (representative of beta-2M gRNA)
- HLA- ABC antibody fluorescence were recorded.
- 97% of the cells transduced with the B2M-targeting gRNA expressed mCherry (FIG. 3B) compared to 1.4% of the wild type (WT) ARPE-19 cells (FIG. 3A).
- 99% of the WT cells were stained with the HLA-ABC antibody (FIG. 3C) compared to 7.4% of the cells targeted with beta-2M- targeting gRNA (FIG. 3D).
- a polymeric material may be chemically modified with a compound of Formula (I) (or pharmaceutically acceptable salt thereof) prior to formation of a device described herein (e.g., a hydrogel capsule).
- a device described herein e.g., a hydrogel capsule.
- the alginate carboxylic acid is activated for coupling to one or more amine-functionalized compounds to achieve an alginate modified with an afibrotic compound, e.g., a compound of Formula (I).
- the alginate polymer is dissolved in water (30 mL/gram polymer) and treated with 2-chloro-4,6-dimethoxy-l,3,5-triazine (0.5 eq) and N-methylmorpholine (1 eq).
- a solution of the compound of interest e.g., Compound 101 shown in Table 4
- acetonitrile 0.3M
- the amounts of the compound and coupling reagent added depends on the desired concentration of the compound bound to the alginate, e.g., conjugation density.
- a medium conjugation density of Compound 101 typically ranges from 2% to 5% N, while a high conjugation density of Compound 101 typically ranges from 5.1% to 8% N.
- CM-LMW-Alg-101-Medium polymer To prepare a solution of low molecular weight alginate, chemically modified with a medium conjugation density of Compound 101 (CM-LMW-Alg-101-Medium polymer), the dissolved unmodified low molecular weight alginate (approximate MW ⁇ 75 kDa, G:M ratio > 1.5) is treated with 2- chloro-4,6-dimethoxy-l,3,5-triazine (5.1 mmol/g alginate) and N-methylmorpholine (10.2 mmol/ g alginate) and Compound 101 (5.4 mmol/ g alginate).
- 2- chloro-4,6-dimethoxy-l,3,5-triazine 5.1 mmol/g alginate
- N-methylmorpholine (10.2 mmol/ g alginate
- Compound 101 5.4 mmol/ g alginate
- CM- LMW-Alg-101-High polymer a solution of low molecular weight alginate, chemically modified with a high conjugation density of Compound 101 (CM- LMW-Alg-101-High polymer)
- the dissolved unmodified low-molecular weight alginate (approximate MW ⁇ 75 kDa, G:M ratio > 1 5) is treated with 2-chloro-4,6-dimethoxy-l,3,5- triazine (5.1 mmol/g alginate) and N-methylmorpholine (10.2 mmol/ g alginate) and Compound 101 (10.5 mmol/ g alginate).
- the reaction is warmed to 55°C for 16h, then cooled to room temperature and gently concentrated via rotary evaporation, then the residue is dissolved in water.
- the mixture is filtered through a bed of cyano-modified silica gel (Silicycle) and the filter cake is washed with water.
- the resulting solution is then extensively dialyzed (10,000 MWCO membrane) and the alginate solution is concentrated via lyophilization to provide the desired chemically-modified alginate as a solid or is concentrated using any technique suitable to produce a chemically modified alginate solution with a viscosity of 25 cP to 35 cP.
- the conjugation density of a chemically modified alginate is measured by combustion analysis for percent nitrogen.
- the sample is prepared by dialyzing a solution of the chemically modified alginate against water (10,000 MWCO membrane) for 24 hours, replacing the water twice followed by lyophilization to a constant weight.
- a polymeric material may be covalently modified with a cell-binding peptide prior to formation of a device described herein (e.g., a hydrogel capsule described herein) using methods known in the art, see, e.g., Jeon O, et al ., Tissue Eng Part A . 16:2915- 2925 (2010) and Rowley, J.A. et al., Biomaterials 20:45-53 (1999).
- an alginate solution (1%, w/v) is prepared with 50mM of 2-(N-morpholino)-ethanesulfonic acid hydrate buffer solution containing 0.5M NaCl at pH 6.5, and sequentially mixed with N-hydroxysuccinimide and l-ethyl-3 -[3- (dimethylamino)propyl] carbodiimide (EDC).
- EDC N-hydroxysuccinimide
- the molar ratio of N-hydroxysuccinimide to EDC is 0.5 : EO.
- the peptide of interest is added to the alginate solution.
- the amounts of peptide and coupling reagent added depends on the desired concentration of the peptide bound to the alginate, e.g., peptide conjugation density. By increasing the amount of peptide and coupling reagent, higher conjugation density can be obtained. After reacting for 24 h, the reaction is purified by dialysis against ultrapure deionized water (diH2O) (MWCO 3500) for 3 days, treated with activated charcoal for 30 min, filtered (0.22 mm filter), and concentrated to the desired viscosity.
- diH2O ultrapure deionized water
- the conjugation density of a peptide-modified alginate is measured by combustion analysis for percent nitrogen.
- the sample is prepared by dialyzing a solution of the chemically modified alginate against water (10,000 MWCO membrane) for 24 hours, replacing the water twice followed by lyophilization to a constant weight.
- Example 5 Preparation of exemplary alginate solutions for making hydrogel capsules
- a low molecular weight alginate (PRONOVATM VLVG alginate, NovaMatrix, Sandvika, Norway, cat. #4200506, approximate molecular weight ⁇ 75 kDa; G:M ratio > 1.5) is chemically modified with Compound 101 to produce chemically modified low molecular weight alginate (CM-LMW-Alg- 101) solution with a viscosity of 25 cp to 35 cP and a conjugation density of 5.1% to 8% N, as determined by combustion analysis for percent nitrogen.
- CM-LMW-Alg- 101 chemically modified low molecular weight alginate
- a solution of high molecular weight unmodified alginate (U-HMW-Alg) is prepared by dissolving unmodified alginate (PRONOVATM SLG100, NovaMatrix, Sandvika, Norway, cat. #4202106, approximate molecular weight of 150 kDa - 250 kDa) at 3% weight to volume in 0.9% saline.
- the CM- LMW-Alg solution is blended with the U-HMW-Alg solution at a volume ratio of 70% CM- LMW-Alg to 30% U-HMW-Alg (referred to herein as a 70:30 CM-Alg:UM-Alg solution).
- Unmodified alginate solution An unmodified medium molecular weight alginate (SLG20, NovaMatrix, Sandvika, Norway, cat. #4202006, approximate molecular weight of 75- 150 kDa), is dissolved at 1.4% weight to volume in 0.9% saline to prepare a U-MMW-Alg solution. Unmodi fied alginate solution. An unmodified medium molecular weight alginate (SLG20, NovaMatrix, Sandvika, Norway, cat. #4202006, approximate molecular weight of 75- 150 kDa), is dissolved at 1.4% weight to volume in 0.9% saline to prepare a U-MMW-Alg solution.
- Alginate Solution Comprising Cell Binding Sites.
- a solution of SLG20 alginate is modified with a peptide consisting of GRGDSP as described above and concentrated to a viscosity of about lOOcP.
- the amount of the peptide and coupling reagent used are selected to achieve a target peptide conjugation density of about 0.2 to 0.3, as measured by combustion analysis.
- Example 6 Formation of exemplary two-compartment hydrogel capsules
- a desired volume of a composition comprising the cells are centrifuged at 1,400 r.p.m. for 1 min and washed with calcium-free Krebs-Henseleit (KH) Buffer (4.7 mM KC1, 25 mM HEPES, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 x 7H 2 O, 135 mM NaCl, pH « 7.4, -290 mOsm).
- KH Krebs-Henseleit
- the cells are centrifuged again and all of the supernatant is aspirated.
- the cell pellet is resuspended in the GRGDSP-modified alginate solution described in Example 3 at a desired cell density (e.g., about 50 to 150 million suspended single cells per ml alginate solution).
- buffers and alginate solutions Prior to fabricating hydrogel capsules, buffers and alginate solutions are sterilized by filtration through a 0.2-pm filter using aseptic processes.
- an electrostatic droplet generator is set up as follows: an ES series 0-100-kV, 20-watt high-voltage power generator (EQ series, Matsusada, NC, USA) is connected to the top and bottom of a coaxial needle (inner lumen of 22G, outer lumen of 18G, Rame-Hart Instrument Co., Succasunna, NJ, USA).
- the inner lumen is attached to a first 5-ml Luer-lock syringe (BD, NJ, USA), which is connected to a syringe pump (Pump 11 Pico Plus, Harvard Apparatus, Holliston, MA, USA) that is oriented vertically.
- the outer lumen is connected via a luer coupling to a second 5-ml Luer-lock syringe which is connected to a second syringe pump (Pump 11 Pico Plus) that is oriented horizontally.
- a first alginate solution containing the genetically modified cells (as single cells) suspended in a GRGDSP -modified alginate solution is placed in the first syringe and a cell-free alginate solution comprising a mixture of a chemically-modified alginate and unmodified alginate is placed in the second syringe.
- the two syringe pumps move the first and second alginate solutions from the syringes through both lumens of the coaxial needle and single droplets containing both alginate solutions are extruded from the needle into a glass dish containing a cross-linking solution.
- the settings of each Pico Plus syringe pump are 12.06 mm diameter and the flow rates of each pump are adjusted to achieve a flow rate ratio of 1: 1 for the two alginate solutions.
- the flow rate for each alginate solution is about 5 mL/h.
- Control (empty) capsules are prepared in the same manner except that the alginate solution used for the inner compartment is a cell-free solution.
- the alginate droplets are crosslinked for five minutes in a cross-linking solution which contain 25mM HEPES buffer, 20 mM BaCb, 0.2M mannitol and 0.01% of poloxamer 188.
- a cross-linking solution which contain 25mM HEPES buffer, 20 mM BaCb, 0.2M mannitol and 0.01% of poloxamer 188.
- Capsules that fall to the bottom of the crosslinking vessel are collected by pipetting into a conical tube. After the capsules settle in the tube, the crosslinking buffer is removed, and capsules are washed four times in HEPES buffer, two times in 0.9% saline, and two times in culture media and stored in an incubator at 37°C.
Abstract
Described herein are engineered mammalian cells comprising a reduction in the level or function of a major histocompatibility complex (MHC) class I protein complex component, and, optionally, a MHC class II protein complex component and/or CIIT A, as well as and methods of making and using the same.
Description
ENGINEERED CELLS AND IMPLANTABLE ELEMENTS EOR TREATMENT OF DISEASE
CLAIM OF PRIORITY
The present application claims priority to U.S. Provisional Patent Application No. 63/415271, filed Oct 11, 2022.
BACKGROUND
Treating chronic and genetic diseases by implanting cells engineered to produce a therapeutic substance capable of treating such diseases has exciting potential to improve the health of patients with such diseases. To fully achieve the potential of such therapies, the implanted cells must be capable of producing therapeutic levels of the desired therapeutic substance for several weeks, months or even longer without overstimulation of the host immune response.
SUMMARY
Described herein are engineered mammalian cells comprising a reduced level or reduced function of a major histocompatibility complex (MHC) class I protein complex, as well as related devices (e.g., implantable elements), compositions, and methods of making and use thereof. In an embodiment, the engineered mammalian cell comprises a reduced level or reduced function of one or more of a protein selected from human leukocyte antigen (HLA) A, HLA-B, HLA-C, and beta-2-microglobulin (beta-2M). The reduced level or reduced function of the MHC class I protein complex may be due to a mutation in a component of the MHC class I protein complex or may be due to the silencing or knock down of a component of the MHC class I protein complex.
In one aspect, the present disclosure may also feature engineered mammalian cells further comprising a reduced level or reduced function of a MHC class II protein complex. In an embodiment, the engineered mammalian cell comprises a reduced level or reduced function of one or more of a protein selected from HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR. The reduced level or reduced function of the MHC class II protein complex may be due to a mutation in a component of the MHC class II protein complex or may be due to the silencing or knock down of a component of the MHC class II protein complex. In another
aspect, the engineered mammalian cells described herein may also comprise a reduced level or reduced function of a class II major histocompatibility complex transactivator (CIITA).
In another aspect, the present disclosure features an implantable element comprising an engineered mammalian cell described herein, or a plurality of engineered mammalian cells. The engineered mammalian cells may comprise an embryonic stem cell (ESC) or an induced pluripotent stem cell (iPSC). The engineered mammalian cell may comprise a retinal pigment epithelial (RPE) cell, a CCD-33Lu cell, a MRC-5 cell, a MRC-9 cell, a MCFlOa cell, or a cell derived therefrom. In an embodiment, the engineered mammalian cell comprises an engineered retinal pigment epithelial (RPE) cell (e.g., an engineered ARPE-19 cell), or is derived from a retinal pigment epithelial (RPE) cell (e.g., ARPE-19 cell). In an embodiment, implantable element comprises at least one cell -containing compartment which comprises the engineered mammalian cell or plurality of engineered mammalian cells described herein. In an embodiment, implantable element comprises one cell-containing compartment comprising the engineered mammalian cell or plurality of engineered mammalian cells described herein, and a second compartment surrounding the cell-containing compartment. In an embodiment, the implantable element further comprises at least one means for mitigating the foreign body response (FBR) when the implantable element is implanted into the subject (e.g., a compound of Formula (I) as described herein). In an embodiment, the implantable element comprises a polymer selected from alginate, hyaluronate, and chitosan. In an embodiment, the implantable element comprises a cell -containing compartment surrounded by a barrier compartment comprising an alginate hydrogel and optionally a compound of Formula (I) (e.g., a compound of Formula (I) described herein) disposed on the outer surface of the barrier compartment. In an embodiment, the implantable element is formulated for implantation into a subject (e.g., into the intraperitoneal (IP) space, the peritoneal cavity, the omentum, the lesser sac, the subcutaneous fat). In an embodiment, the implantable element is configured to shield the engineered mammalian cell or plurality of engineered mammalian cells from the recipient’s immune system and mitigate the foreign body response (FBR) (as defined herein) to the implanted device. In an embodiment, the implantable element is capable of delivering a therapeutic agent (e.g., a protein) for a sustained time period (e.g., one to several months up to one to several years) after implant into a subject.
In another aspect, the present disclosure features a method of treating a disease or disorder in a subject, the method comprising administering to the subject an implantable element
comprising an engineered mammalian cell described herein, or a plurality of engineered mammalian cells described herein, wherein the engineered mammalian cells or the plurality of engineered mammalian cells comprise a reduced level or reduced function of a MHC class I protein complex. In an embodiment, the engineered mammalian cells or the plurality of engineered mammalian cells further comprises a reduced level or reduced function of a MHC class II protein complex and/or a reduced level or reduced function of a CIITA. In an embodiment, the disease or disorder is a lysosomal storage disease. In an embodiment, the disease or disorder is a metabolic disease.
In an embodiment, an implantable element described herein, or a plurality of implantable elements described herein, is combined with a pharmaceutically acceptable excipient to prepare an implantable element preparation or a composition which may be administered to a subject (e.g., into the intraperitoneal cavity) in need of treatment with a therapeutic agent produced by the device. In an embodiment, the subject is a human, the engineered mammalian cells are derived from a human cell (e.g., an RPE cell, an ARPE-19 cell) and the implantable element preparation or composition is capable of continuously delivering an effective amount of a therapeutic agent to the subject for a sustained time period, e.g., at least any of 3 months, 6 months, one year, two years or longer.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is graph showing that Beta-2M protein expression in IDUA-expressing ARPE-19 cells containing beta-2M shRNA was considerably lower (89% lower) compared to that in IDUA-expressing ARPE-19 cells containing the scrambled control shRNA.
FIG. 2 is a graph showing that beta-2M expression levels were decreased 99% in ARPE- 19 cells using CRISPR and a beta-2M-targeting gRNA, compared to ARPE-19 cells modified using the scrambled gRNA.
FIGS. 3A-D are a set of graphs showing that reduction of beta-2M protein expression (FIG. 3B) in ARPE-19 cells with reduced beta-2M protein expression (FIG. 3A) results in decreased HLA Class I expression (FIG. 3D), compared to beta-2M expression in wild type ARPE-19 cells (FIG. 3C).
DETAILED DESCRIPTION
The present disclosure features mammalian cells (e.g., human RPE cells) engineered to modulate the level or function of a major histocompatibility complex (MHC) class I protein complex or a component thereof (e.g., beta-2-microglobulin (beta-2M)). In an embodiment, the mammalian cells are engineered to reduce the expression of the MHC class I protein complex or a component thereof, e.g., beta-2M. The mammalian cells may be engineered to produce a lower functioning or non-functional variant of the MHC class I protein complex or a component thereof (e.g., beta-2M), or the expression of a MHC class I protein complex or component thereof (e.g., beta-2M) may be silenced or knocked down or knocked out. The present disclosure also features mammalian cells further engineered to modulate the level or function of the MHC class II protein complex or a component thereof, and/or the level or function of a class II major histocompatibility complex transactivator (CIITA). In an embodiment, the mammalian cells are engineered to reduce the expression of the MHC class II protein complex or a component thereof, and/or the level or function of CIITA. The mammalian cells may be engineered to produce a lower functioning or non-functional variant of the MHC class II protein complex or a component thereof, and/or CIITA, or the expression of the MHC class II protein complex or a component thereof, and/or CIITA may be silenced or knocked down or knocked out.
Abbreviations and Definitions
Throughout the detailed description and examples of the disclosure the following abbreviations will be used.
CM-Alg chemically modified alginate
CM-LMW-Alg chemically modified, low molecular weight alginate
CM-LMW-Alg-101 low molecular weight alginate, chemically modified with Compound 101 shown in Table 4
CM-HMW-Alg chemically modified, high molecular weight alginate
CM-HMW-Alg-101 high molecular weight alginate, chemically modified with Compound 101 shown in Table 4
CM-MMW-Alg chemically modified, medium molecular weight alginate
CM-MMW-Alg-101 medium molecular weight alginate, chemically modified with Compound 101 shown in Table 4
HMW-Alg high molecular weight alginate
MMW-Alg medium molecular weight alginate
U-Alg unmodified alginate
U-HMW-Alg unmodified high molecular weight alginate
U-LMW-Alg unmodified low molecular weight alginate
U-MMW-Alg unmodified medium molecular weight alginate
70:30 CM-Alg:U-Alg 70:30 mixture (V:V) of a chemically modified alginate and an unmodified alginate, e.g., as described in W02020069429.
So that the disclosure may be more readily understood, certain technical and scientific terms used herein are specifically defined below. Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this disclosure belongs.
As used herein, including the appended claims, the singular forms of words such as "a," "an," and "the," include their corresponding plural references unless the context clearly dictates otherwise.
“About" or “approximately” when used herein to modify a numerically defined parameter (e.g., amount of a therapeutic agent secreted by an engineered cell, a physical description of a device (e.g., hydrogel capsule) such as diameter, sphericity, number of cells encapsulated therein, the number of devices in a preparation), means that the recited numerical value is within an acceptable functional range for the defined parameter as determined by one of ordinary skill in the art, which will depend in part on how the numerical value is measured or determined, e.g., the limitations of the measurement system, including the acceptable error range for that measurement system. For example, “about” can mean a range of 20% above and below the recited numerical value. As a non-limiting example, a hydrogel capsule defined as having a diameter of about 1.5 millimeters (mm) and encapsulating about 5 million (M) cells may have a diameter of 1.2 to 1.8 mm and may encapsulate 4 M to 6 M cells. As another non-limiting example, a preparation of about 100 devices (e.g., hydrogel capsules) includes preparations having 80 to 120 devices. In some embodiments, the term “about” means that the modified parameter may vary by as much as 15%, 10% or 5% above and below the stated numerical value for that parameter.
“Acquire” or “acquiring” as used herein, refers to obtaining possession of a value, e g., a numerical value, or image, or a physical entity (e.g., a sample), by “directly acquiring” or “indirectly acquiring” the value or physical entity. “Directly acquiring” means performing a
process (e.g., performing an analytical method or protocol) to obtain the value or physical entity. “Indirectly acquiring” refers to receiving the value or physical entity from another party or source (e.g., a third-party laboratory that directly acquired the physical entity or value). Directly acquiring a value or physical entity includes performing a process that includes a physical change in a physical substance or the use of a machine or device. Examples of directly acquiring a value include obtaining a sample from a human subject. Directly acquiring a value includes performing a process that uses a machine or device, e.g., using a fluorescence microscope to acquire fluorescence microscopy data.
“Administer,” “administering,” or “administration,” as used herein, refer to implanting, absorbing, ingesting, injecting, placing, or otherwise introducing into a subject, an entity described herein (e.g., a device or a preparation of devices), or providing such an entity to a subject for administration.
“Afibrotic”, as used herein, means a compound or material that mitigates the foreign body response (FBR). For example, the amount of FBR in a biological tissue that is induced by implant into that tissue of a device (e.g., hydrogel capsule) comprising an afibrotic compound (e g., a hydrogel capsule comprising a polymer covalently modified with a compound listed in Table 4) is lower than the FBR induced by implantation of an afibrotic-null reference device, i.e., a device that lacks any afibrotic compound, but is of substantially the same composition (e.g., same cell type(s)) and structure (e.g., size, shape, no. of compartments). In an embodiment, the degree of the FBR is assessed by the immunological response in the tissue containing the implanted device (e.g., hydrogel capsule), which may include, for example, protein adsorption, macrophages, multinucleated foreign body giant cells, fibroblasts, and angiogenesis, using assays known in the art, e.g., as described in WO 2017/075630, or using one or more of the assays / methods described Vegas, A., et al., Nature Biotechnol (supra), (e.g., subcutaneous cathepsin measurement of implanted capsules, Masson’s trichrome (MT), hematoxylin or eosin staining of tissue sections, quantification of collagen density, cellular staining and confocal microscopy for macrophages (CD68 or F4/80), myofibroblasts (alpha-muscle actin, SMA) or general cellular deposition, quantification of 79 RNA sequences of known inflammation factors and immune cell markers, or FACS analysis for macrophage and neutrophil cells on retrieved devices (e.g., capsules) after 14 days in the intraperitoneal space of a suitable test subject, e.g., an immunocompetent mouse. In an embodiment, the FBR is assessed by measuring the levels in
the tissue containing the implant of one or more biomarkers of immune response, e.g., cathepsin, TNF-a, IL-13, IL-6, G-CSF, GM-CSF, IL-4, CCL2, or CCL4. In some embodiments, the FBR induced by a device of the invention (e.g., a hydrogel capsule comprising an afibrotic compound disposed on its outer surface), is at least about 80%, about 85%, about 90%, about 95%, about 99%, or about 100% lower than the FBR induced by an FBR-null reference device, e.g., a device that is substantially identical to the test or claimed device except for lacking the means for mitigating the FBR (e.g., a hydrogel capsule that does not comprise an afibrotic compound but is otherwise substantially identical to the claimed capsule. In some embodiments, the FBR (e.g., level of a biomarker(s)) is measured after about 30 minutes, about 1 hour, about 6 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 1 week, about 2 weeks, about 1 month, about 2 months, about 3 months, about 6 months, or longer.
“Cell,” as used herein, refers to an engineered cell or a cell that is not engineered. In an embodiment, a cell is an immortalized cell, or an engineered cell derived from an immortalized cell. In an embodiment, the cell is a live cell, e.g., is viable as measured by any technique described herein or known in the art.
“Cell -binding peptide (CBP)”, as used herein, means a linear or cyclic peptide that comprises an amino acid sequence that is derived from the cell binding domain of a ligand for a cell-adhesion molecule (CAM) (e.g., that mediates cell-matrix junctions or cell-cell junctions). In an embodiment, the CBP is any of the CBPs described in international patent publication W02020069429. In an embodiment, the CBP is a linear peptide comprising RGD and is less than 6 amino acids in length. In an embodiment, the CBP is a linear peptide that consists essentially of RGD or RGDSP.
“CBP-polymer”, as used herein, means a polymer comprising at least one cell-binding peptide molecule covalently attached to the polymer via a linker. In an embodiment, the polymer in a CBP-polymer is a synthetic or naturally-occurring polysaccharide, e.g., an alginate, e.g., a sodium alginate. In an embodiment, the linker is an amino acid linker (i.e., consists essentially of a single amino acid, or a peptide of several identical or different amino acids), which is joined via a peptide bond to the N-terminus or C-terminus of the CBP. In an embodiment, the CBP- polymer is any of the CBP-alginates defined in W02020069429.
“Cell -binding substance (CBS)”, as used herein, means any chemical, biological, or other type of substance (e.g., a small organic compound, a peptide, a polypeptide) that is capable of
mimicking at least one activity of a ligand for a cell-adhesion molecule (CAM) or other cellsurface molecule that mediates cell-matrix junctions or cell-cell junctions or other receptor- mediated signaling. In an embodiment, when present in a polymer composition encapsulating live cells, the CBS is capable of forming a transient or permanent bond or contact with one or more of the cells. In an embodiment, the CBS facilitates interactions between two or more live cells encapsulated in the polymer composition. In an embodiment, the presence of a CBS in a polymer composition encapsulating a plurality of cells (e.g., live cells) is correlated with one or both of increased cell productivity (e.g., expression of a therapeutic agent) and increased cell viability when the encapsulated cells are implanted into a test subject, e.g., a mouse. In an embodiment, the CBS is physically attached to one or more polymer molecules in the polymer composition. In an embodiment, the CBS is a cell-binding peptide, as defined herein or in W02020069429.
“Conservatively modified variants” or conservative substitution”, as used herein, refers to a variant of a reference peptide or polypeptide that is identical to the reference molecule, except for having one or more conservative amino acid substitutions in its amino acid sequence. In an embodiment, a conservatively modified variant consists of an amino acid sequence that is at least 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the reference amino acid sequence. A conservative amino acid substitution refers to substitution of an amino acid with an amino acid having similar characteristics (e.g., charge, side-chain size, hydrophobicity /hydrophilicity, backbone conformation and rigidity, etc.) and which has minimal impact on the biological activity of the resulting substituted peptide or polypeptide. Conservative substitution tables of functionally similar amino acids are well known in the art, and exemplary substitutions grouped by functional features are set forth in Table 1 below.
“Consists essentially of’, and variations such as “consist essentially of’ or “consisting essentially of’ as used throughout the specification and claims, indicate the inclusion of any recited elements or group of elements, and the optional inclusion of other elements, of similar or different nature than the recited elements, that do not materially change the basic or novel properties of the specified molecule, composition, device, or method. As a non-limiting example, a therapeutic protein agent secreted by an engineered mammalian cell described herein that consists essentially of a recited amino acid sequence may also include one or more amino acids, including substitutions in the recited amino acid sequence, of one or more amino acid residues, which do not materially affect the relevant biological activity of the therapeutic protein agent, respectively.
“Derived from”, as used herein with respect to a cell or cells, refers to cells obtained from tissue, cell lines, or cells, which optionally are then cultured, passaged, immortalized, differentiated and/or induced, etc. to produce the derived cell(s).
“Device”, and “implantable element” as used herein, refers to any implantable object (e.g., a particle, a hydrogel capsule, an implant, a medical device), which contains an engineered cell or cells (e.g., live cells) capable of expressing and secreting a therapeutic agent following implant of the device, and has a configuration that supports the viability of the cells by allowing cell nutrients to enter the device. The terms “device”, and “implantable element” are used herein interchangeably.
“Differential volume,” as used herein, refers to a volume of one compartment within a device described herein that excludes the space occupied by another compartment(s). For example, the differential volume of the second (e.g., outer) compartment in a 2-compartment device with inner and outer compartments, refers to a volume within the second compartment that excludes space occupied by the first (inner) compartment.
“Effective amount” as used herein refers to an amount of any of the following: engineered cells secreting a protein, a device preparation producing the protein, or a component of a device (e.g., amount of a therapeutic agent co-expressed with another therapeutic agent by cells in the device, number of engineered cells in the device, amount of a CBS and/or afibrotic compound in the device) that is sufficient to elicit a desired biological response. In some embodiments, the term “effective amount” refers to the amount of a component of the device (e.g., number of cells in the device, the density of an afibrotic compound disposed on the surface and/or in a barrier compartment of the device, the density of a CBS in the cell -containing compartment.
In an embodiment, the desired biological response upon implant of the implantable element into a subject is a lower amount of pericapsular fibrotic overgrowth (PFO) compared with the amount of PFO observed for a control implantable element (e.g., defined as an otherwise identical implantable element except that the cell does not have the reduction in the MHC class I protein complex). An effective amount may comprise the amount of therapeutic agent secreted by the engineered mammalian cells described herein. An effective amount encompasses therapeutic and prophylactic treatment.
“Effective amount”, as used herein, refers to an amount of genetically modified cells (e.g., derived from human cells (e.g., epithelial cells)) producing an exogenous polypeptide or a device preparation producing the polypeptide that is sufficient to elicit a desired biological response. In an embodiment, the desired biological response is an increase in levels of the
exogenous polypeptide within the cells, or for secreted polypeptides, in a tissue sample removed from a subject treated with (e.g., implanted with) the genetically modified cells, a device or a device preparation containing such cells. As will be appreciated by those of ordinary skill in this art, the effective amount may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the exogenous polypeptide, composition or device, the condition being treated, the mode of administration, and the age and health of the subject. An effective amount encompasses therapeutic and prophylactic treatment.
An “endogenous nucleic acid” as used herein, is a nucleic acid that occurs naturally in a subject cell.
An “endogenous polypeptide,” as used herein, is a polypeptide that occurs naturally in a subject cell.
“Engineered human cell” and “genetically modified human cell”, may be used interchangeably herein, and each term means a human cell (e.g., an epithelial cell) having a non- naturally occurring genetic alteration (e.g., in the cellular genome), and typically comprises an exogenous nucleic acid sequence (e.g., DNA or RNA) not present (or present at a different level than) in an otherwise similar human cell (e.g., epithelial cell) that is not engineered. In an embodiment, an engineered human cell (e.g., engineered RPE cell) comprises an exogenous nucleic acid encoding a polypeptide, e.g., a therapeutic protein. In an embodiment, the exogenous nucleic acid sequence is chromosomal (e.g., the exogenous nucleic acid sequence is an exogenous sequence disposed in endogenous chromosomal sequence) or is extra chromosomal (e.g., a non-integrated expression vector). In an embodiment, the exogenous nucleic acid sequence comprises an RNA sequence, e.g., an mRNA. In an embodiment, the exogenous nucleic acid sequence comprises a chromosomal or extra-chromosomal exogenous nucleic acid sequence that comprises a sequence which is expressed as RNA, e.g., mRNA or a regulatory RNA. In an embodiment, the exogenous nucleic acid sequence comprises a first chromosomal or extra-chromosomal exogenous nucleic acid sequence that modulates the conformation or expression of a second nucleic acid sequence the second nucleic acid sequence can be exogenous or endogenous. For example, an engineered cell can comprise an exogenous nucleic acid that controls the expression of an endogenous sequence. In an embodiment, the engineered cell comprises an exogenous nucleic acid sequence which comprises a codon optimized coding sequence for a polypeptide of interest and achieves higher expression of the
polypeptide than a naturally-occurring coding sequence. The codon optimized coding sequence may be generated using a commercially available algorithm, e.g., GeneOptimizer (ThermoFisher Scientific), OptimumGene™ (GenScript, Piscataway, NJ USA), GeneGPS® (ATUM, Newark, CA USA), or Java Codon Adaptation Tool (JCat, www.jcat.de, Grote, A. et al., Nucleic Acids Research, Vol 33, Issue suppl 2, pp. W526-W531 (2005). In an embodiment, an engineered cell (e.g., engineered epithelial cell, e.g., engineered RPE cell, e.g., engineered ARPE-19 cell) is cultured from a monoclonal cell line. In some embodiments, the engineered cell is not an islet cell, as defined herein.
An “exogenous nucleic acid,” as used herein, is a nucleic acid that does not occur naturally in a subject cell.
An “exogenous polypeptide,” as used herein, is a polypeptide that is encoded by an exogenous nucleic acid in a subject cell. Reference to an amino acid position of a specific sequence means the position of said amino acid in a reference amino acid sequence, e.g., sequence of a full-length mature (after signal peptide cleavage) wild-type protein (unless otherwise stated), and does not exclude the presence of variations, e.g., deletions, insertions and/or substitutions at other positions in the reference amino acid sequence.
“Factor VII protein” or “FVII protein” as used herein, means a polypeptide that comprises the amino acid sequence of a naturally occurring factor VII protein or variant thereof that has a FVII biological activity, e.g., promoting blood clotting, as determined by an art- recognized assay, unless otherwise specified. Naturally occurring FVII exists as a single chain zymogen, a zymogen-like two-chain polypeptide and a fully activated two-chain form (FVIIa). In some embodiments, reference to FVII includes single-chain and two-chain forms thereof, including zymogen-like and FVIIa. FVII proteins that may be produced by a genetically modified cell described herein (e.g., derived from a human epithelial cell line, e.g., the ARPE-19 cell line), include wild-type primate (e.g., human), porcine, canine, and murine proteins, as well as variants of such wild-type proteins, including fragments, mutants, variants with one or more amino acid substitutions and / or deletions. In some embodiments, a variant FVII protein is capable of being activated to the fully activated two-chain form (Factor Vila) that has at least 50%, 75%, 90% or more (including >100%) of the activity of wild-type Factor Vila. Variants of FVII and FVIIa are known, e.g., marzeptacog alfa (activated) (MarzAA) and the variants described in European Patent No. 1373493, US Patent No. 7771996, US Patent No. 9476037 and
US published application No. US20080058255.
Factor VII biological activity may be quantified by an art recognized assay, unless otherwise specified. For example, FVII biological activity in a sample of a biological fluid, e.g., plasma, may be quantified by (i) measuring the amount of Factor Xa produced in a system comprising tissue factor (TF) embedded in a lipid membrane and Factor X (Persson et al., J. Biol. Chem. 272: 19919-19924, 1997); (ii) measuring Factor X hydrolysis in an aqueous system; (iii) measuring its physical binding to TF using an instrument based on surface plasmon resonance (Persson, FEBS Letts. 413:359-363, 1997); or (iv) measuring hydrolysis of a synthetic substrate; and/or (v) measuring generation of thrombin in a TF -independent in vitro system. In an embodiment, FVII activity is assessed by a commercially available chromogenic assay (BIOPHEN FVII, HYPHEN BioMed Neuville sur Oise, France), in which the biological sample containing FVII is mixed with thromboplastin calcium, Factor X and SXa-11 (a chromogenic substrate specific for Factor Xa.
“Factor VIII protein” or “FVIII protein” as used herein, means a polypeptide that comprises the amino acid sequence of a naturally occurring factor VIII polypeptide or variant thereof that has an FVIII biological activity, e g., coagulation activity, as determined by an art- recognized assay, unless otherwise specified. FVIII proteins that may be expressed by a genetically modified cell described herein (e.g., derived from a human epithelial cell line, e.g., the ARPE-19 cell line), include wild-type primate (e.g., human), porcine, canine, and murine proteins, as well as variants of such wild-type proteins, including fragments, mutants, variants with one or more amino acid substitutions and / or deletions, B-domain deletion (BDD) variants, single chain variants and fusions of any of the foregoing wild-type or variants with a half-life extending polypeptide. In an embodiment, the cells are engineered to encode a precursor factor VIII polypeptide (e.g., with the signal sequence) with a full or partial deletion of the B domain. In an embodiment, the cells are engineered to encode a single chain factor VIII polypeptide which contains a variant FVIII protein preferably has at least 50%, 75%, 90% or more (including >100%) of the coagulation activity of the corresponding wild-type factor VIII. Assays for measuring the coagulation activity of FVIII proteins include the one stage or two stage coagulation assay (Rizza et al., 1982, Coagulation assay of FVIII: C and FIXa in Bloom ed. The Hemophelias. NY Churchill Livingston 1992) or the chromogenic substrate FVIILC assay (Rosen, S. 1984. Scand J Haematol 33: 139-145, suppl.).
A number of FVIII-BDD variants are known, and include, e.g., variants with the full or partial B-domain deletions disclosed in any of the following U.S. Patent Nos: 4,868,112 (e.g., col. 2, line 2 to col. 19, line 21 and table 2); 5,112,950 (e.g., col. 2, lines 55-68, FIG. 2, and example 1); 5,171,844 (e.g., col. 4, line 22 to col. 5, line 36); 5,543,502 (e.g., col. 2, lines 17-46); 5,595,886; 5,610,278; 5,789,203 (e.g., col. 2, lines 26-51 and examples 5-8); 5,972,885 (e.g., col. 1, lines 25 to col. 2, line 40); 6,048,720 (e.g., col. 6, lines 1-22 and example 1); 6,060,447; 6,228,620; 6,316,226 (e.g., col. 4, line 4 to col. 5, line 28 and examples 1-5); 6,346,513; 6,458,563 (e.g., col. 4, lines 25-53) and 7,041,635 (e.g., col. 2, line 1 to col. 3, line 19, col. 3, line 40 to col. 4, line 67, col. 7, line 43 to col. 8, line 26, and col. 11, line 5 to col. 13, line 39).
In some embodiments, a FVIII-BDD protein produced by a genetically modified cell described herein (e.g., derived from a human epithelial cell line, e.g., the ARPE-19 cell line) has one or more of the following deletions of amino acids in the B-domain: (i) most of the B domain except for amino-terminal B-domain sequences essential for intracellular processing of the primary translation product into two polypeptide chains (WO 91/09122); (ii) a deletion of amino acids 747-1638 (Hoeben R. C., et al. J. Biol. Chem. 265 (13): 7318-7323 (1990)); amino acids 771-1666 or amino acids 868-1562 (Meulien P., et al. Protein Eng. 2(4):301-6 (1988); amino acids 982-1562 or 760-1639 (Toole et al., Proc. Natl. Acad. Sci. U.S.A. 83:5939-5942 (1986)); amino acids 797-1562 (Eaton et al., Biochemistry 25:8343-8347 (1986)); 741-1646 (Kaufman, WO 87/04187)), 747-1560 (Sarver et al., DNA 6:553-564 (1987)); amino acids 741-1648 (Pasek, WO 88/00831)), amino acids 816-1598 or 741-1689 (Lagner (Behring Inst. Mitt. (1988) No 82: 16-25, EP 295597); a deletion that includes one or more residues in a furin protease recognition sequence, including any of the specific deletions recited in US Patent No. 9,956,269 at col. 10, line 65 to col. 11, line 36.
In other embodiments, a FVIII-BDD protein retains any of the following B-domain amino acids or amino acid sequences: (i) one or more N-linked glycosylation sites in the B- domain, e.g., residues 757, 784, 828, 900, 963, or optionally 943, first 226 amino acids or first 163 amino acids (Miao, H. Z., et al., Blood 103(a): 3412-3419 (2004), Kasuda, A., et al., J. Thromb. Haemost. 6: 1352-1359 (2008), and Pipe, S. W., et al., J. Thromb. Haemost. 9: 2235- 2242 (2011).
In some embodiments, the FVIII-BDD protein is a single-chain variant generated by substitution or deletion of one or more amino acids in the furin protease recognition sequence
LKRHQR that prevents proteolytic cleavage at this site, including any of the substitutions at the R1645 and/or R1648 positions described in U.S. Patent Nos. 10,023,628, 9,394,353 and 9,670,267.
In some embodiments, any of the above FVIII-BDD proteins may further comprise one or more of the following variations: a F309S substitution to improve expression of the FVIII- BDD protein (Miao, H. Z., et al., Blood 103(a): 3412-3419 (2004); albumin fusions (WO 2011/020866); and Fc fusions (WO 04/101740).
All FVIII-BDD amino acid positions referenced herein refer to the positions in full-length human FVIII, unless otherwise specified.
“Factor IX protein” or “FIX protein”, as used herein, means a polypeptide that comprises the amino acid sequence of a naturally occurring factor IX protein or variant thereof that has a FIX biological activity, e.g., coagulation activity, as determined by an art-recognized assay, unless otherwise specified. FIX is produced as an inactive zymogen, which is converted to an active form by factor Xia excision of the activation peptide to produce a heavy chain and a light chain held together by one or more disulfide bonds. FIX proteins that may be produced by a genetically modified described herein (e g., derived from an RPE cell line, e.g., the ARPE-19 cell line), include wild-type primate (e.g., human), porcine, canine, and murine proteins, as well as variants of such wild-type proteins, including fragments, mutants, variants with one or more amino acid substitutions and / or deletions and fusions of any of the foregoing wild-type or variant proteins with a half-life extending polypeptide. In an embodiment, cells are engineered to encode a full-length wild-type human factor IX polypeptide (e.g., with the signal sequence) or a functional variant thereof. A variant FIX protein preferably has at least 50%, 75%, 90% or more (including >100%) of the coagulation activity of wild-type factor VIX. Assays for measuring the coagulation activity of FIX proteins include the Biophen Factor IX assay (Hyphen BioMed) and the one stage clotting assay (activated partial thromboplastin time (aPTT), e.g., as described in EP 2 032 607, thrombin generation time assay (TGA) and rotational thromboelastometry, e.g., as described in WO 2012/006624.
A number of functional FIX variants are known and may be expressed by engineered cells encapsulated in a device described herein, including any of the functional FIX variants described in the following international patent publications: WO 02/040544 at page 4, lines 9-30 and page 15, lines 6-31; WO 03/020764 in Tables 2 and 3 at pages 14-24, and at page 12, lines
1-27; WO 2007/149406 at page 4, line 1 to page 19, line 1 1 ; WO 2007/149406 A2 at page 19, line 12 to page 20, line 9; WO 08/118507 at page 5, line 14 to page 6, line 5; WO 09/051717 at page 9, line 11 to page 20, line 2; WO 09/137254 at page 2, paragraph [006] to page 5, paragraph [011] and page 16, paragraph [044] to page 24, paragraph [057]; WO 09/130198 A2 at page 4, line 26 to page 12, line 6; WO 09/140015 at page 11, paragraph [0043] to page 13, paragraph [0053]; WO 2012/006624; WO 2015/086406.
In certain embodiments, the FIX polypeptide comprises a wild-type or variant sequence fused to a heterologous polypeptide or non-polypeptide moiety extending the half-life of the FIX protein. Exemplary half-life extending moieties include Fc, albumin, a PAS sequence, transferrin, CTP (28 amino acid C-terminal peptide (CTP) of human chorionic gonadotropin (hCG) with its 4 O-glycans), polyethylene glycol (PEG), hydroxyethyl starch (HES), albumin binding polypeptide, albumin-binding small molecules, or any combination thereof. An exemplary FIX polypeptide is the rFIXFc protein described in WO 2012/006624, which is an FIXFc single chain (FIXFc-sc) and an Fc single chain (Fc-sc) bound together through two disulfide bonds in the hinge region of Fc.
FIX variants also include gain and loss of function variants. An example of a gain of function variant is the “Padua” variant of human FIX, which has a L (leucine) at position 338 of the mature protein instead of an R (arginine) and has greater catalytic and coagulant activity compared to wild-type human FIX (Chang et al., J. Biol. Chem., 273: 12089-94 (1998)). An example of a loss of function variant is an alanine substituted for lysine in the fifth amino acid position from the beginning of the mature protein, which results in a protein with reduced binding to collagen IV (e.g., loss of function).
“Islet cell”, as used herein, means a cell that comprises any naturally occurring or any synthetically created, or modified, cell that is intended to recapitulate, mimic or otherwise express, in part or in whole, the functions, in part or in whole, of the cells of the pancreatic islets of Langerhans. The term “islet cell” includes a glucose-responsive, insulin producing cell derived from a stem cell, e.g., from an induced pluripotent stem cell line.
“Polymer composition”, as used herein, is a composition (e.g., a solution, mixture) comprising one or more polymers. As a class, “polymers’ includes homopolymers, heteropolymers, co-polymers, block polymers, block co-polymers and can be both natural and synthetic. Homopolymers contain one type of building block, or monomer, whereas co-polymers
contain more than one type of monomer.
“Polypeptide”, as used herein, refers to a polymer comprising amino acid residues linked through peptide bonds and having at least two, and in some embodiments, at least 3, 4, 5, 10, 50, 75,100, 150 or 200 amino acid residues.
“Prevention,” “prevent,” and “preventing” as used herein refers to a treatment that comprises administering a composition (or preparation) of devices encapsulating genetically modified cells that express an exogenous polypeptide, prior to the onset of one or more symptoms of a disease or condition that is amenable to treatment with the exogenous polypeptide, to preclude the physical manifestation of the symptom(s). In some embodiments, “prevention,” “prevent,” and “preventing” require that signs or symptoms of a disease or condition have not yet developed or have not yet been observed.
“RPE cell” as used herein refers to a cell having one or more of the following characteristics: a) it comprises a retinal pigment epithelial cell (RPE) (e.g., cultured using an RPE cell line, e.g., the ARPE-19 cell line (ATCC® CRL-2302™)) or a cell derived or engineered therefrom, e.g., by stably transfecting cells cultured from the ARPE-19 cell line with an exogenous sequence that encodes a polypeptide of interest or inserting the exogenous sequence into one of the specific OCR insertion sites described herein, a cell derived from a primary cell culture of RPE cells, a cell isolated directly (without long term culturing, e.g., less than 5 or 10 passages or rounds of cell division since isolation) from naturally occurring RPE cells, e.g., from a human or other mammal, a cell derived from a transformed, an immortalized, or a long term (e.g., more than 5 or 10 passages or rounds of cell division) RPE cell culture; b) a cell that has been obtained from a less differentiated cell, e.g., a cell developed, programmed, or reprogramed (e.g., in vitro) into an RPE cell or a cell that is, except for any genetic engineering, substantially similar to one or more of a naturally occurring RPE cell or a cell from a primary or long term culture of RPE cells (e.g., the cell can be derived from an IPS cell); or c) a cell that has one or more of the following properties: i) it expresses one or more of the biomarkers CRALBP, RPE- 65, RLBP, BEST1, or aB-cry stallin; ii) it does not express one or more of the biomarkers CRALBP, RPE-65, RLBP, BEST1, or aB-crystallin; iii) it is naturally found in the retina and forms a monolayer above the choroidal blood vessels in the Bruch’s membrane; or iv) it is responsible for epithelial transport, light absorption, secretion, and immune modulation in the retina; or v) it has been created synthetically, or modified from a naturally occurring cell, to have
the same or substantially the same genetic content, and optionally the same or substantially the same epigenetic content, as an immortalized RPE cell line (e.g., the ARPE-19 cell line (ATCC® CRL-2302™)). Other exemplary strains of RPE cells include ARPE-19-SEAP-2-neo cells, RPE- J cells, and hTERT RPE-1 cells. In an embodiment, an RPE described herein is engineered, e g., to have a new property, e.g., the cell is genetically modified by inserting at least one exogenous transcription unit into one or more of the OCR locations described herein.
“Sequence identity” or “percent identical”, when used herein to refer to two nucleotide sequences or two amino acid sequences, means the two sequences are the same within a specified region, or have the same nucleotides or amino acids at a specified percentage of nucleotide or amino acid positions within the specified when the two sequences are compared and aligned for maximum correspondence over a comparison window or designated region. Sequence identity may be determined using standard techniques known in the art including, but not limited to, any of the algorithms described in US Patent Application Publication No. 2017/02334455 Al. In an embodiment, the specified percentage of identical nucleotide or amino acid positions is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher.
“Spherical” as used herein means a device (e.g., a hydrogel capsule or other particle) having a curved surface that forms a sphere (e.g., a completely round ball) or sphere-like shape, which may have waves and undulations, e.g., on the surface. Spheres and sphere-like objects can be mathematically defined by rotation of circles, ellipses, or a combination around each of the three perpendicular axes, a, b, and c. For a sphere, the three axes are the same length. Generally, a sphere-like shape is an ellipsoid (for its averaged surface) with semi-principal axes within 10%, or 5%, or 2.5% of each other. The diameter of a sphere or sphere-like shape is the average diameter, such as the average of the semi-principal axes.
“Spheroid”, as that term is used herein to refer to a device (e.g., a hydrogel capsule or other particle), means the device has (i) a perfect or classical oblate spheroid or prolate spheroid shape or (ii) has a surface that roughly forms a spheroid, e.g., may have waves and undulations and/or may be an ellipsoid (for its averaged surface) with semi -principal axes within 100% of each other.
“Subject” as used herein refers to a human or non-human animal. In an embodiment, the subject is a human (i.e., a male or female) of any age group, e.g., a pediatric human subject (e.g.,
infant, child, adolescent) or adult human subject (e.g., young adult, middle-aged adult, or senior adult)). In an embodiment, the subject is a non-human animal, for example, a mammal (e.g., a mouse, a dog, a primate (e.g., a cynomolgus monkey or a rhesus monkey). In an embodiment, the subject is a commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog) or a bird (e.g., a commercially relevant bird such as a chicken, duck, goose, or turkey). In certain embodiments, the animal is a mammal. The animal may be a male or female and at any stage of development. A non-human animal may be a transgenic animal.
“Treatment,” “treat,” and “treating” as used herein refers to one or more of reducing, reversing, alleviating, delaying the onset of, or inhibiting the progress of one or more of a symptom, manifestation, or underlying cause, of a disease (e.g., hemophilia A). In an embodiment, treating comprises reducing, reversing, alleviating, delaying the onset of, or inhibiting the progress of a symptom or condition associated with the disease. In an embodiment, treating comprises increasing levels of a therapeutic polypeptide in at least one tissue of a subject in need thereof, e.g., in one or more of plasma, liver, kidney and heart. In some embodiments, “treatment,” “treat,” and “treating” require that signs or symptoms associated with the disease or condition have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease or condition, e.g., in preventive treatment. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., due to a history of symptoms and/or genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence. In some embodiments, treatment comprises prevention and in other embodiments it does not “Wild-type" (wt) refers to the natural form, including sequence, of a polynucleotide, polypeptide or protein in a species. A wild-type form is distinguished from a mutant form of a polynucleotide, polypeptide or protein arising from genetic mutation(s).
Selected Chemical Definitions
Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moi eties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March,
March ’s Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001 ; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.
The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.
When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, “Ci-Ce alkyl” is intended to encompass, Ci, C2, C3, C4, C5, Ce, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4- C5, and C5-C6 alkyl.
As used herein, “alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 24 carbon atoms (“C1-C24 alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C1-C12 alkyl”), 1 to 10 carbon atoms (“C1-C12 alkyl”), 1 to 8 carbon atoms (“Ci-Cs alkyl”), 1 to 6 carbon atoms (“Ci-Ce alkyl”), 1 to 5 carbon atoms (“C1-C5 alkyl”), 1 to 4 carbon atoms (“Ci-C4alkyl”), 1 to 3 carbon atoms (“C1-C3 alkyl”), 1 to 2 carbon atoms (“C1-C2 alkyl”), or 1 carbon atom (“Ci alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-C6alkyl”). Examples of Ci-Ce alkyl groups include methyl (Ci), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (Ce). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (Cs) and the like. Each instance of an alkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents, e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
As used herein, “alkenyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 24 carbon atoms, one or more carbon-carbon double bonds, and no triple bonds (“C2-C24 alkenyl”). In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C2-C10 alkenyl”), 2 to 8 carbon atoms (“C2-C8 alkenyl”), 2 to 6 carbon atoms (“C2-C6 alkenyl”), 2 to 5 carbon atoms (“C2-C5 alkenyl”), 2 to 4 carbon atoms (“C2-C4 alkenyl”), 2 to 3 carbon atoms (“C2-C3 alkenyl”), or 2 carbon atoms (“C2 alkenyl”). The one or more carbon-
carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-C4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1- butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-C6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (Ce), and the like. Each instance of an alkenyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
As used herein, the term “alkynyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 24 carbon atoms, one or more carbon-carbon triple bonds (“C2-C24 alkenyl”). In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C2-C10 alkynyl”), 2 to 8 carbon atoms (“C2-C8 alkynyl”), 2 to 6 carbon atoms (“C2-C6 alkynyl”), 2 to 5 carbon atoms (“C2-C5 alkynyl”), 2 to 4 carbon atoms (“C2-C4 alkynyl”), 2 to 3 carbon atoms (“C2-C3 alkynyl”), or 2 carbon atoms (“C2 alkynyl”). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C2- C4 alkynyl groups include ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2- butynyl (C4), and the like. Each instance of an alkynyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
As used herein, the term "heteroalkyl," refers to a non-cyclic stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quatemized. The heteroatom(s) O, N, P, S, and Si may be placed at any position of the heteroalkyl group. Exemplary heteroalkyl groups include, but are not limited to: -CH2-CH2-O-CH3, -CH2-CH2-NH- CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2, -S(O)-CH3, -CH2-CH2-S(O)2-CH3, - CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -0-CH3, and -O-CH2- CH3. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. Where "heteroalkyl" is recited, followed by recitations of specific heteroalkyl groups, such as -CH2O, -NRCRD, or the like, it will be understood that the terms
heteroalkyl and -CH2O or -NRCRD are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term "heteroalkyl" should not be interpreted herein as excluding specific heteroalkyl groups, such as -CH2O, -NRCRD, or the like. Each instance of a heteroalkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
The terms "alkylene," “alkenylene,” “alkynylene,” or “heteroalkylene,” alone or as part of another substituent, mean, unless otherwise stated, a divalent radical derived from an alkyl, alkenyl, alkynyl, or heteroalkyl, respectively. An alkylene, alkenylene, alkynylene, or heteroalkylene group may be described as, e.g., a Ci-Ce-membered alkylene, Cz-Ce-membered alkenylene, Ci-Ce-membered alkynylene, or Ci-Ce-membered heteroalkylene, wherein the term “membered” refers to the non-hydrogen atoms within the moiety. In the case of heteroalkylene groups, heteroatoms can also occupy either or both chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(0)2R’- may represent both -C(0)2R’- and -R’C(0)2-
As used herein, “aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 it electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C6-C14 aryl”). In some embodiments, an aryl group has six ring carbon atoms (“Ce aryl”; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms (“C10 aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“Cuaryl”; e.g., anthracyl). An aryl group may be described as, e.g., a Ce-Cio- membered aryl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety. Aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Each instance of an aryl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents.
As used herein, “heteroaryl” refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 it electrons shared in a cyclic array)
having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-10 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system. Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). A heteroaryl group may be described as, e.g., a 6-10-membered heteroaryl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety.
In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Each instance of a heteroaryl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents.
Exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6- membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6- bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotri azolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadi azolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Other exemplary heteroaryl groups include heme and heme derivatives.
As used herein, the terms "arylene" and "heteroarylene," alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively.
As used herein, “cycloalkyl” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C3-C10 cycloalkyl”) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“Cs-Cscycloalkyl”), 3 to 6 ring carbon atoms (“C3-C6 cycloalkyl”), or 5 to 10 ring carbon atoms (“C5-C10 cycloalkyl”). A cycloalkyl group may be described as, e.g., a C4-C?-membered cycloalkyl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety. Exemplary C3-C6 cycloalkyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (Ce), cyclohexenyl (Ce), cyclohexadienyl (Ce), and the like. Exemplary C3-C8 cycloalkyl groups include, without limitation, the aforementioned C3-C6 cycloalkyl groups as
well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), cubanyl (C8), bicyclo[1.1.1]pentanyl (C5), bicyclo[2.2.2]octanyl (C8), bicyclo[2.1.1]hexanyl (C6), bicyclo[3.1.1]heptanyl (C7), and the like. Exemplary C3-C10 cycloalkyl groups include, without limitation, the aforementioned C3-C8 cycloalkyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro–1H–indenyl (C9), decahydronaphthalenyl (C10), spiro [4.5] decanyl (C10), and the like. As the foregoing examples illustrate, in certain embodiments, the cycloalkyl group is either monocyclic (“monocyclic cycloalkyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic cycloalkyl”) and can be saturated or can be partially unsaturated. “Cycloalkyl” also includes ring systems wherein the cycloalkyl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is on the cycloalkyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the cycloalkyl ring system. Each instance of a cycloalkyl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. “Heterocyclyl” as used herein refers to a radical of a 3– to 10–membered non–aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3–10 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated. Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more cycloalkyl groups wherein the point of attachment is either on the cycloalkyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. A heterocyclyl group may be described as, e.g., a 3-7-membered heterocyclyl, wherein the term “membered” refers to the non- hydrogen ring atoms, i.e., carbon, nitrogen, oxygen, sulfur, boron, phosphorus, and silicon,
within the moiety. Each instance of heterocyclyl may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In certain embodiments, the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3-10 membered heterocyclyl.
In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5-10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-8 membered non- aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
Exemplary 3-membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2, 5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, piperazinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered heterocyclyl groups
containing two heteroatoms include, without limitation, triazinanyl or thiomorpholinyl-1,1- dioxide. Exemplary 7–membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8–membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary 5–membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as a 5,6–bicyclic heterocyclic ring) include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. Exemplary 6– membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6–bicyclic heterocyclic ring) include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like. “Amino” as used herein refers to the radical –NR70R71, wherein R70 and R71 are each independently hydrogen, C1–C8 alkyl, C3–C10 cycloalkyl, C4–C10 heterocyclyl, C6–C10 aryl, and C5–C10 heteroaryl. In some embodiments, amino refers to NH2. As used herein, “cyano” refers to the radical –CN. As used herein, “halo” or “halogen,” independently or as part of another substituent, mean, unless otherwise stated, a fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) atom. As used herein, “hydroxy” refers to the radical –OH. Alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” heteroalkyl, “substituted” or “unsubstituted” cycloalkyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group). In general, the term “substituted”, whether preceded by the term “optionally” or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term “substituted” is contemplated to include substitution with all permissible substituents of organic compounds,
such as any of the substituents described herein that result in the formation of a stable compound. The present disclosure contemplates any and all such combinations to arrive at a stable compound. For purposes of this disclosure, heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocyclyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ringforming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ringforming substituents are attached to non-adjacent members of the base structure.
Compounds of Formula (I) described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ, of Notre Dame Press, Notre Dame, IN 1972). The disclosure additionally encompasses compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.
As used herein, a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, an “S” form of the compound is substantially free from the “R” form of the compound and is, thus,
in enantiomeric excess of the “R” form. The term “enantiomerically pure” or “pure enantiomer” denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 99% by weight, more than 99.5% by weight, or more than 99.9% by weight, of the enantiomer. In certain embodiments, the weights are based upon total weight of all enantiomers or stereoisomers of the compound.
Compounds of Formula (I) described herein may also comprise one or more isotopic substitutions. For example, H may be in any isotopic form, including LH, 2H (D or deuterium), and 3H (T or tritium); C may be in any isotopic form, including 12C, 13C, and 14C; O may be in any isotopic form, including 16O and 18O; and the like.
The term "pharmaceutically acceptable salt" is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of Formula (I) used to prepare devices of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds used in the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolyl sulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galacturonic acids and the like (see, e.g., Berge et al, Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds used in the devices of the
present disclosure (e.g., a particle, a hydrogel capsule) contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. These salts may be prepared by methods known to those skilled in the art. Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for use in the present disclosure.
Devices of the present disclosure may contain a compound of Formula (I) in a prodrug form. Prodrugs are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds useful for preparing devices in the present disclosure. Additionally, prodrugs can be converted to useful compounds of Formula (I) by chemical or biochemical methods in an ex vivo environment.
Certain compounds of Formula (I) described herein can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain compounds of Formula (I) described herein may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
The term “solvate” refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compounds described herein may be prepared, e.g., in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates.
The term “hydrate” refers to a compound which is associated with water. Typically, the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R x H2O, wherein R is the compound and wherein x is a number greater than 0.
The term “tautomer” as used herein refers to compounds that are interchangeable forms of a compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of it electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly
interconverted by treatment with either acid or base. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
The symbol “ as used herein refers to a connection to an entity, e.g., a polymer (e.g., hydrogel -forming polymer such as alginate) or surface of an implantable device, e.g., a particle, a hydrogel capsule. The connection represented by “ ” may refer to direct attachment to the entity, e.g., a polymer or an implantable element, may refer to linkage to the entity through an attachment group. An “attachment group,” as described herein, refers to a moiety for linkage of a compound of Formula (I) to an entity (e.g., a polymer or an implantable element (e.g., a device) as described herein), and may comprise any attachment chemistry known in the art. A listing of exemplary attachment groups is outlined in Bioconjugate Techniques (3rd ed, Greg T. Hermanson, Waltham, MA: Elsevier, Inc, 2013), which is incorporated herein by reference in its entirety. In some embodiments, an attachment group comprises alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)-, -OC(O)-, -N(RC)-, - N(Rc)C(O)-, -C(O)N(Rc)-, -N(RC)N(RD)-, -NCN-, -C(=N(Rc)(RD))O-, -S-, -S(O)X-, - OS(O)x-, -N(RC)S(O)X-, -S(O)xN(Rc)-, -P(RF )y- -Si(ORA) 2 -, -Si(RG)(ORA)-, -B(ORA)-, or a metal, wherein each of RA, Rc, RD, RF, RG, x and y is independently as described herein. In some embodiments, an attachment group comprises an amine, ketone, ester, amide, alkyl. In some embodiments, an attachment group is a cross-linker. In some embodiments, the ^attachment group is -C(O)(Ci-C61, and R1 is as described herein®. In some embodiments, the attachment group is -C(O)(Ci-C6-alkylene)-, wherein alkylene is substituted with 1-2 alkyl groups (e.g., 1-2 methyl groups). In some embodiments, the attachment group is -C(O)C(CH3)2-. In some embodiments, the attachment group is -C(O)(methylene)-, wherein alkylene is substituted with 1-2 alkyl groups (e.g., 1-2 methyl groups). In some embodiments, the attachment group is -C(O)CH(CH3)-. In some embodiments, the attachment group is - C(O)C(CH3)-.
Engineered Mammalian Cells
The present disclosure provides an engineered mammalian cell capable of modulating the level or function of the MHC class I protein complex, and optionally, the MHC class II protein complex and/or CH I A. In an embodiment, the engineered mammalian cell reduces a level or function of the MHC class I protein complex, and optionally, the MHC class II protein complex and/or CHTA.
The MHC class I protein complex is a class of molecules present on the surface of nucleated cells that inform the host’s immune system of the status of a particular antigen as being self or non-self. The MHC class I molecules display peptide fragments of cytotoxic proteins on the cell surface, which trigger an immune response within the host if the cytotoxic protein is derived from a non-self-source. In general, the MHC class I molecules are heterodimeric proteins that consist of two polypeptide chains. The alpha chain is polymorphic, and is encoded by a human leukocy te antigen (HLA) comprising one of HL A- A, HLA-B, or HLA-C. The beta chain comprises the beta-2-microglobulin (beta-2M) domain. The alpha and beta chain of each MHC class I molecule are noncovalently linked through the interaction of the beta-2M and one of the three plasma membrane-spanning domains of the alpha chain (alpha-3). The alpha chain also comprises two other domains: alpha- 1 and alpha-2. In an embodiment, the engineered mammalian cell of the present disclosure comprises a reduced level or function in an MHC class I protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M.
The groove between the alpha-1 and alpha-2 domains is the peptide-binding groove, in which peptides derived from cytosolic proteins are displayed. The groove comprises eight p- pleated sheets on the bottom and two a helices making up sides. The groove is flanked by tyrosine residues and creates closed ends that limit the size of peptides that can be bound within the groove. The peptide in the groove remains substantially bound there for the life of the class I molecule and is typically 8-9 amino acids in length. Self or foreign cytosolic proteins are degraded via the proteasome and transported into the lumen of the ER. In the ER, the peptides are loaded onto an MHC class 1 via the aid of a chaperone protein named tapasin. The peptide bound MHC class I is then transported to the cell’s plasma membrane, where it presents the peptide to CDS T cell receptors (Becar M et al. (2022) Physiology, MHC Class I. In: StatPearls [Internet], Treasure Island (FL): StatPearls Publishing; 2023 Jan-.)
In addition to its interaction with beta-2M, the plasma membrane-spanning alpha-3 domain interacts with the T cell receptor (TCR) co-receptor CI)8, facilitating antigen-specific activation. Although binding of MHC class I to CD8 is about 100-fold weaker than binding of TCR to MHC class I, alpha-3-CD8 binding enhances the affinity of TCR binding (Wooldridge et al. (2010) MHC Class I Molecules with Superenhanced CD8 Bitiding Properties Bypass the Requirement for Cognate TCR Recognition and Nonspecifically Activate CTLs, J. Immunol. 184:3357-3366).
Beta-2M is a non-glycosylated 12 kDa protein; one of its functions is to stabilize the MHC class I a-chain. Unlike the a-chain, the beta-2M does not span the membrane. The human beta-2M locus is on chromosome 15. The beta-2M gene consists of 4 exons and 3 introns. Circulating forms of beta-2M are present in the serum, urine, and other body fluids; thus, the non -covalently MHC
I-associated beta-2M can be exchanged with circulating beta-2M under physiological conditions, Beta-2M associates not only with the alpha chain of MHC class I molecules, but also with class I- like molecules such as CD1 (5 genes in humans), MR1, the neonatal Fc receptor (FcRn), and Qa- 1 (a form of alloantigen).
In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of an MHC class I protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M. In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in the alpha and/or beta chain of the MHC class I protein complex or component thereof. For example, in some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the alpha-1 domain. In some embodiments, the level or function of the alpha-1 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). For example, in some embodiments, the level or function of the alpha- 1 domain is reduced by about 20%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 30%. In some embodiments, the level or function of the alpha-1 domain is reduced by about 40%. In some embodiments, the level or function of the alpha-1 domain is reduced by about 50%. In some embodiments, the level or function of the alpha-1 domain is reduced by about 60%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 70%. In some embodiments, the level or function of the alpha-1 domain is reduced by about 80%. In some embodiments, the level or function of the alpha-1 domain is reduced by about 90%. In some embodiments, the level or function of the alpha-1 domain is reduced by about 100%.
In some embodiments, the level or function of the alpha-1 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the alpha- 1 domain is reduced by at least 10%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 20%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 30%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 40%s. In
some embodiments, the level or function of the alpha-1 domain is reduced by at least 50%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 70% In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 80%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 95%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 99.9%. In some embodiments, the level or function of the alpha- 1 domain is reduced by more than 99.9%.
In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the alpha-2 domain. In some embodiments, the level or function of the alpha-2 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, or 100%). For example, in some embodiments, the level or function of the alpha-2 domain is reduced by about 20%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 30%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 40%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 50%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 60%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 70%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 80% In some embodiments, the level or function of the alpha-2 domain is reduced by about 90%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 100%.
In some embodiments, the level or function of the alpha-2 domain is reduced by at least
5% (e.g.. at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more).
For example, in some embodiments, the level or function of the alpha-2 domain is reduced by at least 10%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 20%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 30%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 40%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 50%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 70% In some
embodiments, the level or function of the alpha-2 domain is reduced by at least 80%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 95% In some embodiments, the level or function of the alpha-2 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 99 9%. In some embodiments, the level or function of the alpha-2 domain is reduced by more than 99.9%.
In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the alpha-3 domain. In some embodiments, the level or function of the alpha-3 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, or 100%). For example, in some embodiments, the level or function of the alpha-3 domain is reduced by about 20%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 30% In some embodiments, the level or function of the alpha-3 domain is reduced by about 40%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 50%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 60%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 70%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 80%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 90%. In some embodiments, the level or function of the alpha-3 domain is reduced by about 100%.
In some embodiments, the level or function of the alpha-3 domain is reduced by at least
5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the alpha-3 domain is reduced by at least 10% In some embodiments, the level or function of the alpha-3 domain is reduced by at least 20%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 30%.
In some embodiments, the level or function of the alpha-3 domain is reduced by at least 40%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 50%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 70%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 80%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 95% In some
embodiments, the level or function of the alpha-3 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha-3 domain is reduced by at least 99.9%. In some embodiments, the level or function of the alpha-3 domain is reduced by more than 99.9%.
In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the beta-2M domain. In some embodiments, the level or function of the beta-2M domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, or 100%). For example, in some embodiments, the level or function of the beta-2M domain is reduced by about 20%. In some embodiments, the level or function of the beta-2M domain is reduced by about 30%. In some embodiments, the level or function of the beta-2M domain is reduced by about 40%. In some embodiments, the level or function of the beta-2M domain is reduced by about 50%. In some embodiments, the level or function of the beta-2M domain is reduced by about 60%. In some embodiments, the level or function of the beta-2M domain is reduced by about 70%. In some embodiments, the level or function of the beta-2M domain is reduced by about 80%. In some embodiments, the level or function of the beta-2M domain is reduced by about 90%. In some embodiments, the level or function of the beta-2M domain is reduced by about 100%.
In some embodiments, the level or function of the beta-2M domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more) For example, in some embodim ents, the level or function of the beta-2M domain is reduced by at least 10%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 20%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 30%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 40%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 50%. In some embodiments, the level or function of the beta-2191 domain is reduced by at least 60%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 70%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 80%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 90%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 95%. In some embodiments, the level or function of the beta-2M domain is reduced by at least 99%. In some embodiments, the level or function of the beta-2M domain is reduced by at
least 99.9%. In some embodiments, the level or function of the beta-2M domain is reduced by more than 99.9%.
In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of beta-2M to a MHC class I protein complex or component thereof or an MHC class I-like molecule or component (e.g., CD1, MR1, FcRn, and Qa-1). For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to an MHC class I protein complex or component thereof. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to the alpha- 1 domain of an MHC class I protein. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to the alpha-2 domain of an MHC class I protein. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to the alpha-3 domain of an MHC class I protein. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to an MHC class I-like molecule or component (e.g., CD1, MR1, FcRn, and Qa-1). In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to CD1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g , binding) of beta- 2M to MR1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to FcRn. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of beta-2M to Qa-1.
In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%>, 90%, 95%, or more, the interaction (e.g., binding) of the alpha-3 domain to the TCR co-receptor CD8.
HLA-A interacts with calnexin, calreticulin, transporter associated with antigen processing (TAP), tapasin, the thiol-disulfide oxidoreductase ERp57 enzyme, and any cytosolic peptide bound within its peptide-binding groove. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e g., by 10%, 20%, 30%, 40%, 50%,
75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-A to calnexin, calreticuiin, TAP, tapasin, an ERp57 enzyme, and/or any cytosolic peptide bound within its peptide-binding groove. For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to calnexin. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to calreticuiin. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to TAP. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to TAP-1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to TAP -2. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g , binding) of HLA- A to tapasin. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-A to ERp57. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e g , binding) of HLA-A to a cytosolic peptide bound within its peptide-binding groove.
HLA-C interacts with killer cell immunoglobulin-like receptor 2DL.1 (KIR2DL1 ) and the leukocyte immunoglobulin-like receptor family (e.g., leukocyte immunoglobulin-like receptor subfamily A member 1 (LILRA1 ) and LILRA3). In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-C to KIR2DLl and the leukocyte immunoglobulin-like receptor family (e.g., LILRA1 and LILRA3). For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-C to K1R2DL1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-C to the leukocyte immunoglobulin-like receptor family. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g , binding) of HLA-C to LILRA1 . In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-C to LILRA3.
In some embodiments, the reducing the level or function of the MHC class [ protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M, results in reduced antigen presentation, thereby reducing and/or abrogating the recruitment of immune cells, e.g , T cells and NK cells.
The HLA-A gene is located on the short arm of chromosome 6 and encodes the larger, alpha-chain, constituent of HLA-A. Variation of the HLA-A alpha-chain is key to HLA function. This variation promotes genetic diversity in the population. Since each HLA has a different affinity for peptides of certain structures, a greater variety of HLAs means that a greater variety of antigens can be presented Lon the cell surface, enhancing the likelihood that a subset of the population will be resistant to a given foreign invader. This decreases the likelihood that a single pathogen has the capability to wipe out the entire human population.
Each individual can express up to two types of HLA-A, one from each of their parents. Some individuals will inherit the same/ZL4-A from both parents, decreasing their individual HLA diversity; however, the majority of individuals will receive two different copies tyCHLA-A. This same pattern follows for all HLA groups (Fix et al. (1998). HLA Matching, Antibodies, and You. Kidney Transplantation: Past, Present, and Future University of Michigan Medical Center/Stanford University). In other words, every' single person can only express either one or two of the 2432 known HLA-A alleles.
The HLA-B gene is located on the short (p) arm of chromosome 6 at cytoband 21.3 and encodes the larger, alpha-chain, constituent of HLA-B. Similar to HLA-A, variation of HLA-B alpha-chain is key to HLA function. HLA-C is a locus on chromosome 6, which encodes for many HLA-C alleles that are Class-I MHC receptors. HLA-C, localized proximal to the HLA-B locus, is located on the distal end of the HLA region. Most HLA-C:B haplotypes are in strong linkage disequilibrium and many are as ancient as the human species itself.
In some embodiments, the reducing the level or function of the MHC class I protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M, comprises mutating one or more nucleotides in the nucleotide sequence of one or more genes selected from HLA-A, HLA-B, HLA-C, or beta-2M. A nucleotide mutation may comprise a nucleotide deletion, addition, and/or substitution. Such a mutation, as described herein, may result in a reduction in expression of the gene, e.g., by reducing, altering, or abrogating the transcription and/or splicing of the nucleotide sequence For example, in some embodiments, the reducing the level or
function of the MHC class I protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of the beta-2M gene. In some embodiments, the reducing the level or function of the MHC class I protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of the HLA-A gene. In some embodiments, the reducing the level or function of the MHC class I protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of the HLA-B gene In some embodiments, the reducing the level or function of the MHC class I protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of the HLA-C gene.
In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HL/\-C, and beta-2M genes comprises a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence identity to a nucleotide sequence provided in Table 5 For example, in some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 65% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 70% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 75% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 80% sequence identity to a nucleotide sequence provided in Table 5 In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 85% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 90% sequence identity to a nucleotide sequence provided in Table 5 In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 95% sequence identity to a nucleotide sequence provided in Table 5 In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 99% sequence identity
to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 99.9% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having greater than 99.9% sequence identity to a nucleotide sequence provided in Table 5.
In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence homology to a nucleotide sequence provided in Table 5. For example, in some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 65% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 70% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and bet.a-2M genes comprises a sequence having at least 75% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 80% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at. least 85% sequence homology to a nucleotide sequence provided in Table 5 In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 90% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 95% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at least 99% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having at. least 99.9% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-A, HLA-B, HLA-C, and beta-2M genes comprises a sequence having greater than 99 9% sequence homology to a nucleotide sequence provided in Table 5.
In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the expression of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE- 19), comprises a reduction in the expression of a MHC class I component between 1-25%, 5- 25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the expression of a MHC class I component greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the function of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component. In an embodiment, the engineered mammalian cell described herein (e g., ARPE- 19), comprises a reduction in the function of a MHC class I component between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the function of a MHC class I component greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered
mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-A by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-A. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-A between 1-25%, 5-25%, 10-25%, 25-50%, 25- 75%, 50-75%, or 75-100%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-A. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-A greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-A.
In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-B by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-B. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-B between 1-25%, 5-25%, 10-25%, 25-50%, 25- 75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-B. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-B greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian
cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-B.
In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-C by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-C. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-C between 1-25%, 5-25%, 10-25%, 25-50%, 25- 75%, 50-75%, or 75-100%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-C. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-C greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of HLA-C.
In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of beta-2M by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of beta- 2M. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of beta-2M between 1-25%, 5-25%, 10-25%, 25-50%, 25- 75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of beta-2M. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of beta-2M greater than about 50%, 75%, or 90%, e.g., as compared to an engineered
mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of beta-2M.
In some embodiments, the MHC class I protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M, is encoded by one or more nucleotide sequences, or fragments thereof, provided in Table 5.
In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof, e.g., HLA-A, HLA-B, HLA-C, or beta-2M persists for at least 15 minutes (e.g., 30 minutes, 1 hour, 12 hours, 24 hours, 48 hours, 72 hours, 1 week, 1 month, or 1 year). For example, in some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 30 minutes. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 1 hour. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 12 hours. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 24 hours. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 48 hours. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 72 hours. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 1 week. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 1 month. In some embodiments, the reduction in the level or function of the MHC class I protein complex or a component thereof persists for at least 1 year.
The MHC class II protein complex is a class of molecules present on the surface of antigen-presenting cells within a subject, such as dendritic cells, mononuclear phagocytes, certain endothelial cells, and B cells. One key distinguishing feature between the MHC class II protein complex and the MHC class I protein complex is that the antigens presented by the MHC class II protein complexes are derived from extracellular proteins, unlike the cytosolic antigens presented by the MHC class I protein complexes. Like the MHC class I protein complexes, the MHC class II protein complexes are heterodimeric proteins that consist of two polypeptide chains, the alpha-chain and the beta-chain. Unlike the MHC class I protein complexes, the MHC
class II protein complex’s alpha-chain and beta-chain comprises homogeneous peptides. The alpha-peptide comprises the alpha-1 and beta-1 domains, which come together to make a membrane-distal peptide-binding groove, while the beta-peptide comprises the alpha-2 and beta- 2 domains, which form a membrane-proximal immunoglobulin-like domain. The peptide- binding groove is made up of two a-helices walls and a P sheet. Because the antigen-binding groove of MHC class II molecules is open at both ends while the corresponding groove on class I molecules is closed at each end, the antigens presented by MHC class II molecules are longer, generally between 15 and 24 amino acid residues long.
Exemplary MHC class II protein complex components include HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, and HLA-DR. In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of an MHC class II protein complex or a component thereof, e g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR. In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in the alpha and/or beta chain of the MHC class II protein complex or component thereof. For example, in some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the alpha-1 domain. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). For example, in some embodiments, the level or function of the alpha- 1 domain is reduced by about 20%. In some embodiments, the level or function of the alpha-1 domain is reduced by about 30%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 40%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 50%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 60%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 70%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 80%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 90%. In some embodiments, the level or function of the alpha- 1 domain is reduced by about 100%.
In some embodiments, the level or function of the alpha-1 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the alpha-1 domain is reduced by at least 10%. In some embodiments, the level or function of the alpha-1 domain is
reduced by at least 20%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 30%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 40%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 50%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 70%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 80%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 95%. In some embodiments, the level or function of the alpha-1 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha- 1 domain is reduced by at least 99.9%. In some embodiments, the level or function of the alpha-1 domain is reduced by more than 99.9%.
In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the alpha-2 domain. In some embodiments, the level or function of the alpha-2 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). For example, in some embodiments, the level or function of the alpha-2 domain is reduced by about 20%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 30%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 40%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 50%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 60%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 70%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 80%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 90%. In some embodiments, the level or function of the alpha-2 domain is reduced by about 100%.
In some embodiments, the level or function of the alpha-2 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the alpha-2 domain is reduced by at least 10%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 20%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 30%. In some embodiments, the level or function of the alpha-2 domain is
reduced by at least 40%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 50%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 60%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 70%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 80%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 90%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 95%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 99%. In some embodiments, the level or function of the alpha-2 domain is reduced by at least 99.9%. In some embodiments, the level or function of the alpha-2 domain is reduced by more than 99.9%.
In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the beta-1 domain. In some embodiments, the level or function of the beta-1 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). For example, in some embodiments, the level or function of the beta-1 domain is reduced by about 20%. In some embodiments, the level or function of the beta-1 domain is reduced by about 30%. In some embodiments, the level or function of the beta-1 domain is reduced by about 40%. In some embodiments, the level or function of the beta-1 domain is reduced by about 50%. In some embodiments, the level or function of the beta-1 domain is reduced by about 60%. In some embodiments, the level or function of the beta-1 domain is reduced by about 70%. In some embodiments, the level or function of the beta-1 domain is reduced by about 80%. In some embodiments, the level or function of the beta-1 domain is reduced by about 90%. In some embodiments, the level or function of the beta-1 domain is reduced by about 100%.
In some embodiments, the level or function of the beta-1 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the beta-1 domain is reduced by at least 10%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 20%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 30%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 40%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 50%. In some embodiments, the level or function of the beta-1 domain is reduced by at
least 60%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 70%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 80%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 90%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 95%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 99%. In some embodiments, the level or function of the beta-1 domain is reduced by at least 99.9%. In some embodiments, the level or function of the beta-1 domain is reduced by more than 99.9%.
In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the beta-2 domain. In some embodiments, the level or function of the beta-2 domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). For example, in some embodiments, the level or function of the beta-2 domain is reduced by about 20%. In some embodiments, the level or function of the beta-2 domain is reduced by about 30%. In some embodiments, the level or function of the beta-2 domain is reduced by about 40%. In some embodiments, the level or function of the beta-2 domain is reduced by about 50%. In some embodiments, the level or function of the beta-2 domain is reduced by about 60%. In some embodiments, the level or function of the beta-2 domain is reduced by about 70%. In some embodiments, the level or function of the beta-2 domain is reduced by about 80%. In some embodiments, the level or function of the beta-2 domain is reduced by about 90%. In some embodiments, the level or function of the beta-2 domain is reduced by about 100%.
In some embodiments, the level or function of the beta-2 domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the beta-2 domain is reduced by at least 10%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 20%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 30%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 40%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 50%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 60%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 70%. In some embodiments, the level or function of the beta-2 domain is reduced by at
least 80%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 90%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 95%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 99%. In some embodiments, the level or function of the beta-2 domain is reduced by at least 99.9%. In some embodiments, the level or function of the beta-2 domain is reduced by more than 99.9%.
In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of the alpha-chain of an MHC class II protein complex or component thereof to the beta-chain. For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the alpha-1 domain to the alpha-2 or beta-2 domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the beta-1 domain to the alpha-2 or beta-2 domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the alpha-2 domain to the alpha- 1 or beta-1 domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the beta-2 domain to the alpha- 1 domain or beta-1 domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the alpha- 1 domain to the beta-1 domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the alpha-2 domain to the beta-2 domain.
HLA-DP is a protein/peptide-antigen receptor and graft-versus-host disease antigen that is composed of 2 subunits, DPa and DPp. DPa and DPp are encoded by two loci, HLA- DPA1 and HLA-DPB1, that are found in the MHC Class II (or HLA-D) region in the HLA complex on human chromosome 6. HLA-DP is an aP-heterodimer cell-surface receptor. Each DP subunit (a-subunit, P-subunit) is composed of a a-helical N-terminal domain, an IgG-like P-sheet, a membrane spanning domain, and a cytoplasmic domain. The a-helical domain forms the sides of the peptide binding groove. The P-sheet regions form the base of the binding groove and the bulk of the molecule as well as the inter-subunit (non-covalent) binding region. Peptide-bound HLA-DP complexes interact with TCRs on CD4+ T-cells.
In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-DP to a CD4+ T-cell TCR and/or any peptide (e.g., an antigenic peptide) bound within its peptide-binding groove. For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e g., binding) of HLA-DP to a CD4+ T-cell TCR. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA- DP to a peptide bound within its peptide-binding groove.
HLA-DM, a non-classical MHC molecule, is an intracellular protein involved in the mechanism of antigen presentation and is encoded by the genes HLA-DMA and HLA-DMB. Like HLA-DP, the genes for HLA-DM are located in the MHCII region of the human chromosome 6. HLA-DM is a molecular chaperone that works in lysosomes and endosomes in cells of the immune system. It works in APCs like macrophages, dendritic cells, and B cells by interacting with MHC class II molecules (Arndt et al (2000). "Functional HLA-DM on the surface of B cells and immature dendritic cells". The EMBO Journal . 19 (6): 1241— 51. doi: 10.1093/emboj/19.6.1241; Pashine et al (2003). "Interaction ofHLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides". Immunity. 19 (2): 183-92. doi: 10.1016/S1074-7613(03)00200-0). HLA-DM protects the MHC class II molecules from breaking down, and regulates which proteins or peptides bind to them as well. This regulates how and when a peptide acts as an antigen initiating an immune response. HLA-DM is required to release CLIP (a fragment resulting from cathepsin S or cathepsin D-mediated cleavage of CD74) from MHC class II molecules, to chaperone empty MHC molecules against denaturation, to facilitate antigen-antigen exchange (e.g., by releasing weakly bound peptides from the peptide-binding groove in order to load peptides with higher-affinity binding), and to control proper loading and release of peptides at the peptide-binding groove. To release peptides from the MHC groove, HLA-DM binds to the N terminus of the groove, altering its conformation and breaking hydrogen bonds such that the peptide that was interacting with the MHC groove can no longer bind and is ejected (Yin et al. (2015). "Evaluating the Role of HLA- DM in MHC Class II-Peptide Association Reactions". Journal of Immunology . 195 (2): 706- 16. doi: 10.4049/jimmunol.1403190). HLA-DM assists in catalysis of peptide exchange not only in late endosomes traveling from the ER, but also on cell membranes and in early endosomes.
Much of this pathway is still being researched, but it is known that HLA-DM can load exogenous peptides onto MHC class II molecules when they are being expressed on cell surfaces. Loading can also occur in early endosomes that are quickly recycled. HLA-DM does not have the capacity to bind peptides due to its lack of a deep peptide-binding groove - instead, it contains a shallow, negatively charged indent with two disulfide bonds.
HLA-DM also interacts heavily with chaperone protein HLA-DO, another non-classical MHC molecule. HLA-DO starts binding to DM in early endosomes, but is expressed less in late endosomes/lysosomes. The binding between HLA-DM and HLA-DO is less strong at low pH, but overall much stronger than HLA-DM binding to MHC molecules. Both HLA-DM and HLA- DO lack a transport signal N-terminus. Before encountering an antigen, DO acts as a chaperone of DM to stabilize it against denaturation and direct it into lysosomes. It binds in the same location to HLA-DM as MHC class II molecules bind, thereby preventing HLA-DM from binding to MHC class II molecules. This inhibits peptide exchange catalysis and keeps CLIP in the MHC groove until antigen-containing lysosome fuses with DM/DO/MHC containing lysosomes, prompting the degradation of HLA-DO molecules. The alpha-chain of HLA-DO (HLA-DOA) is encoded by the HLA-DOA gene and the beta-chain (HLA-DOB) is encoded by the HLA-DOB gene.
In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e g., binding) of HLA-DM to CLIP, HLA-DO, and the beta-chain of MHC class II molecules. For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DM to CLIP. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DM to HLA-DO. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DO to HLA-DM. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA- DM to the beta-chain of MHC class II molecules.
In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-DO to HLA-DM or any peptide bound within its peptide-
binding groove. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DO to HLA-DM. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DO to a peptide bound within its peptide-binding groove.
HLA-DQ is a cell surface receptor protein found on antigen-presenting cells. It is an aP heterodimer of type MHC class II. The alpha- and beta- chains are encoded by two loci, HLA-/J(M / and HLA-DQB1, that are adjacent to each other on chromosome band 6p21.3. Both the alpha-chain and the beta-chain comprise a plethora of variants. A person often produces two a-chain and two P-chain variants and thus 4 isoforms of HLA-DQ. The HLA-DQ loci are in close genetic linkage to HLA-DR, and less closely linked to HLA-DP, the non- classical MHC class II molecules (HLA-DM and HLA-DO), and the MHC class I molecules.
Different isoforms of HLA-DQ can bind to and present different antigens to T-cells. In this process T-cells are stimulated to grow and can signal B-cells to produce antibodies. HLA- DQ functions in recognizing and presenting foreign antigens (proteins derived from potential pathogens). For example, peptide-bound HLA-DP complexes interact with TCRs on CD4+ T-cells. HLA-DQ is also involved in recognizing common self-antigens and presenting those antigens to the immune system in order to develop tolerance from a very young age. When tolerance to self-proteins is lost, HLA-DQ may become involved in autoimmune disease. Two autoimmune diseases in which HLA-DQ is involved are coeliac disease and type 1 diabetes. HLA-DQ mediates autoimmunity by skewing the TCR repertoire during thymic selection (Rubio et al. (2021). "HLA class II mediates type 1 diabetes risk by anti-insulin repertoire selection". bioRxiv. 2021.09.06.458974. doi: 10.1101/2021.09.06.458974). Carriers of risk serotypes such as HLA-DQ8 have a higher proportion of circulating T-cell receptors that may bind insulin, the primary autoantigen in type 1 diabetes.
In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-DQ to CD4+ T-cell TCRs and/or any peptide bound within its peptide-binding groove. For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DQ to a CD4+ T-cell TCR. In some embodiments, the reducing the level or function of substantially
decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DQ to a peptide bound within its peptide-binding groove.
HLA-DR is an aP heterodimer, cell surface receptor, each subunit of which contains two extracellular domains, a membrane-spanning domain and a cytoplasmic tail. Both a and P chains are anchored in the membrane. The N-terminal domain of the mature protein forms an alphahelix that constitutes the exposed part of the binding groove, the C-terminal cytoplasmic region interacts with the other chain forming a beta-sheet under the binding groove spanning to the cell membrane. The majority of the peptide contact positions are in the first 80 residues of each chain. HLA-DR is encoded by several loci and several genes Q>f different function at each locus. The DR a-chain is encoded by the HLA-DRA locus. Unlike the other DR loci, functional variation in mature DRA gene products is absent. The DR P-chain is encoded by 4 loci, however no more than 3 functional loci are present in a single individual, and no more than two on a single chromosome (Marsh et al (2010). "Nomenclature for factors of the HLA system, 2010". Tissue Antigens. 75 (4): 291-455. doi: 10.1111/j. 1399-0039.2010.01466.x). Sometimes an individual may only possess 2 copies of the same locus, DRB1. The HLA-DRB1 locus is ubiquitous and encodes a very large number of functionally variable gene products (HLA- DR1 to HLA-DR17). The HLA-DRB3 locus encodes HLA-DR52, is moderately variable, and is variably associated with certain HLA-DRB1 types. The HLA-DRB4 locus encodes HLA-DR53, has some variation, and is associated with certain HLA-DRB1 types. The HLA-DRB5 locus encodes HLA-DR51, which is typically invariable and is linked to the HLA-DR2 types. HLA- DR interacts with CD74, HLA-DM, CD4+ T-cell TCRs, and/or any peptide bound within its peptide-binding groove.
In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of HLA-DR to CD74, HLA-DM, CD4+ T-cell TCRs, and/or any peptide bound within its peptide-binding groove. For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DR to CD74. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DR to HLA- DM. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DR to a CD4+ T-cell TCR. In some
embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of HLA-DR to a peptide bound within its peptide-binding groove.
In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof, e g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR, results in reduced antigen presentation, thereby reducing and/or abrogating the recruitment of immune cells, e.g., T cells and NK cells.
In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof, e g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR, comprises mutating one or more nucleotides in the nucleotide sequence of one or more genes selected from HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5. A nucleotide mutation may comprise a nucleotide deletion, addition, and/or substitution. Such a mutation, as described herein, may result in a reduction in expression of the gene, e g., by reducing, altering, or abrogating the transcription and/or splicing of the nucleotide sequence. For example, in some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DP. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DM. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DOA. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DOB. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DP. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DM. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DOA. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide
sequence of HLA-DOB. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DQA1. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DQB1. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRA. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRB1. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRB3. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRB4. In some embodiments, the reducing the level or function of the MHC class II protein complex or a component thereof comprises mutating one or more nucleotides in the nucleotide sequence of HLA-DRB5.
In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA- D0B1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence identity to a nucleotide sequence provided in Table 5. For example, in some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 65% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 70% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-
DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 75% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA- DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 80% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 85% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 90% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA- DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 95% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA- DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 99% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DOA1, HLA-DOB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 99.9% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA- DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having greater than 99.9% sequence identity to a nucleotide sequence provided in Table 5.
In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence homology to a nucleotide sequence provided in Table 5. For example, in some embodiments, the nucleotide sequence of the HLA-DP , HLA- DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3,
HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 65% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, H LA-DOB, HLA-DQA1, HLA-DQB1, HLA- DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 70% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 75% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-
DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 80% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 85% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA- DOB J, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 90% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-
DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA- DRB5 genes comprises a sequence having at least 95% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA- DRB3, HLA-DRB4, and HLA-DRB5 genes comprises a sequence having at least 99% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA- DRA, HLA-DRL31, HLA-DRB3, HLA-DRJ34, and HLA-DRB5 genes comprises a sequence having at least 99.9% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA- DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes
comprises a sequence having greater than 99.9% sequence homology to a nucleotide sequence provided in Table 5.
In an embodiment, the engineered mammalian cell of the present disclosure comprises a reduced level or function in an MHC class II protein complex or a component thereof, e.g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the expression of a MHC class II component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class II component. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the expression of a MHC class II component between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50- 75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class II component. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the expression of a MHC class II component greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class II component.
In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the function of a MHC class II component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class II component. In an embodiment, the engineered mammalian cell described herein (e g., ARPE- 19), comprises a reduction in the function of a MHC class II component between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it
does not comprise a reduction in the function of an MHC class II component. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the function of a MHC class I component greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class II component.
In some embodiments, the MHC class II protein complex or a component thereof, e.g., HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, or HLA-DR, is encoded by one or more nucleotide sequences, or fragments thereof, provided in Table 5.
In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 15 minutes (e.g., 30 minutes, 1 hour, 12 hours, 24 hours, 48 hours, 72 hours, 1 week, 1 month, or 1 year). For example, in some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 30 minutes. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 1 hour. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 12 hours. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 24 hours. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 48 hours. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 72 hours. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 1 week. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 1 month. In some embodiments, the reduction in the level or function of the MHC class II protein complex or a component thereof persists for at least 1 year.
The class II major histocompatibility complex transactivator (CIITA) is a gene involved in the regulation of expression of MHC class II protein complexes. The CIITA gene is located on chromosome 16 that encodes the CIITA protein, which plays a role in enhancing the transcription of MHC class I genes. The CIITA protein comprises an acidic transcriptional
activation domain, 4 leucine-rich repeats, and a GTP binding domain. The protein uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus, the protein acts as a positive regulator of class II major histocompatibility complex gene transcription, and is often referred to as the "master control factor" for the expression of these genes (Harton et al.
(2000). "Class II transactivator: mastering the art of major histocompatibility complex expression" . Molecular and Cellular Biology . 20 (17): 6185-94. doi: 10.1128/MCB.20.17.6185- 6194.2000; LeibundGut-Landmann et al. (2004). "Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes". European Journal of Immunology. 34 (6): 1513-25. doi: 10.1002/eji.200424964). CIITA expression is induced by interferon gamma (Heuberger et al. (2021). "Why do intestinal epithelial cells express MHC class W." . Immunology. 162 (4): 357-367. doi : 10.1111/imm. l 3270).
In an embodiment, the engineered mammalian cell of the present disclosure comprises a reduced level or function in of a CIITA protein. In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of a domain of a CIITA protein, wherein the domain is selected from the transcriptional activation domain, a leucine-rich repeat domain, and a GTP binding domain. For example, in some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the transcriptional activation domain. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). For example, in some embodiments, the level or function of the transcriptional activation domain is reduced by about 20%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 30%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 40%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 50%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 60%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 70%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 80%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 90%. In some embodiments, the level or function of the transcriptional activation domain is reduced by about 100%.
In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the transcriptional activation domain is reduced by at least 10%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 20%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 30%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 40%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 50%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 60%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 70%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 80%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 90%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 95%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 99%. In some embodiments, the level or function of the transcriptional activation domain is reduced by at least 99.9%. In some embodiments, the level or function of the transcriptional activation domain is reduced by more than 99.9%.
In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of a leucine-rich repeat domain. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). For example, in some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 20%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 30%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 40%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 50%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 60%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 70%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 80%. In some embodiments, the level or function of the leucine-rich repeat
domain is reduced by about 90%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by about 100%.
In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 10%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 20%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 30%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 40%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 50%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 60%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 70%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 80%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 90%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 95%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 99%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by at least 99.9%. In some embodiments, the level or function of the leucine-rich repeat domain is reduced by more than 99.9%.
In some embodiments, the engineered mammalian cell (e.g., ARPE-19) comprises a reduction in a level or function of the GTP binding domain. In some embodiments, the level or function of the GTP binding domain is reduced by about 10% (e.g., about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). For example, in some embodiments, the level or function of the GTP binding domain is reduced by about 20%. In some embodiments, the level or function of the
GTP binding domain is reduced by about 30%. In some embodiments, the level or function of the
GTP binding domain is reduced by about 40%. In some embodiments, the level or function of the
GTP binding domain is reduced by about 50%. In some embodiments, the level or function of the
GTP binding domain is reduced by about 60%. In some embodiments, the level or function of the
GTP binding domain is reduced by about 70%. In some embodiments, the level or function of the
GTP binding domain is reduced by about 80%. In some embodiments, the level or function of the
GTP binding domain is reduced by about 90%. In some embodiments, the level or function of the GTP binding domain is reduced by about 100%.
In some embodiments, the level or function of the GTP binding domain is reduced by at least 5% (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9% or more). For example, in some embodiments, the level or function of the GTP binding domain is reduced by at least 10%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 20%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 30%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 40%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 50%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 60%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 70%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 80%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 90%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 95%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 99%. In some embodiments, the level or function of the GTP binding domain is reduced by at least 99.9%. In some embodiments, the level or function of the GTP binding domain is reduced by more than 99.9%.
In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of a CIITA protein domain to another CIITA protein domain. For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the transcriptional activation domain to a leucine-rich repeat domain or the GTP binding domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of a leucine-rich repeat domain to the transcriptional activation domain, a leucine-rich repeat domain, or the GTP binding domain. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of the GTP binding domain to the transcriptional activation domain or a leucine-rich repeat domain.
The CIITA protein interacts with Mitogen-activated protein kinase 1 (MAPK1), nuclear receptor coactivator 1 (NCOA1), DNA-binding protein RFX5 (RFX5), DNA-binding protein
RFXANK (RFXANK), exportin 1 (XP01), and Zinc finger, X-linked, duplicated family member C (ZXDC). In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits, e.g., by 10%, 20%, 30%, 40%, 50%, 75%, 90%, 95%, or more, the interaction (e.g., binding) of CIITA to MAPK1, NCOA1, RFX5, RFXANK, XPO1, and/or ZXDC. For example, in some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to MAPK1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to NCOA1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to RFX5. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to RFXANK. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to XPO1. In some embodiments, the reducing the level or function of substantially decreases, prevents, or inhibits the interaction (e.g., binding) of CIITA to ZXDC.
In some embodiments, the reducing the level or function of the CIITA protein results in the reduction of the level of expression (e.g., by reducing the level of transcription) of a MHC class II protein complex or a component thereof, e.g., HLA-DP, HLA-DM, HLA-DOA, HLA- DOB, HLA-DQ, and HLA-DR.
In some embodiments, the reducing the level or function of the CIITA protein comprises mutating one or more nucleotides in the nucleotide sequence of the CIITA gene. A nucleotide mutation may comprise a nucleotide deletion, addition, and/or substitution. Such a mutation, as described herein, may result in a reduction in expression of the gene, e.g., by reducing, altering, or abrogating the transcription and/or splicing of the nucleotide sequence.
In some embodiments, the nucleotide sequence of the CIITA gene comprises a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence identity to a nucleotide sequence provided in Table 5. For example, in some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 65% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at
least 70% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 75% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 80% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 85% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 90% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 95% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 99% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 99.9% sequence identity to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having greater than 99.9% sequence identity to a nucleotide sequence provided in Table 5.
In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 60% (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9%, or greater) sequence homology to a nucleotide sequence provided in Table 5. For example, in some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 65% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 70% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 75% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 80% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 85% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 90% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a
sequence having at least 95% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 99% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having at least 99.9% sequence homology to a nucleotide sequence provided in Table 5. In some embodiments, the nucleotide sequence of the CIITA genes comprises a sequence having greater than 99.9% sequence homology to a nucleotide sequence provided in Table 5.
In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the expression of CIITA by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of CIITA. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the expression of CIITA between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of CIITA. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the expression of CIITA greater than about 50%, 75%, or 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of CIITA.
In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the function of CIITA by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of CIITA. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the function of CIITA between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of
CIITA. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the function of CIITA greater than about 50%, 75%, or 90%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of CIITA.
In some embodiments, the CIITA is encoded by a nucleotide sequence, or a fragment thereof, provided in Table 5.
In some embodiments, the reduction in the level or function of CIITA persists for at least 15 minutes (e.g., 30 minutes, 1 hour, 12 hours, 24 hours, 48 hours, 72 hours, 1 week, 1 month, or 1 year). For example, in some embodiments, the reduction in the level or function of CIITA persists for at least 30 minutes. In some embodiments, the reduction in the level or function of CIITA persists for at least 1 hour In some embodiments, the reduction in the level or function of CIITA persists for at least 12 hours. In some embodiments, the reduction in the level or function of CIITA persists for at least 24 hours In some embodiments, the reduction in the level or function of CIITA persists for at least 48 hours. In some embodiments, the reduction in the level or function of CIITA persists for at least 72 hours. In some embodiments, the reduction in the level or function of CIITA persists for at least 1 week. In some embodiments, the reduction in the level or function of CIITA persists for at least 1 month. In some embodiments, the reduction in the level or function of CIITA persists for at least 1 year.
In an embodiment, the engineered mammalian cell described herein (e g., ARPE-19), comprises a reduction in the level or function of a MHC class I protein complex and a reduction in the level or function of a MHC class II protein complex and/or CIITA. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-A and a reduction in the level or function of a MHC class II protein complex and/or CIITA. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE- 19), comprises a reduction in the level or function of HLA-B and a reduction in the level or function of a MHC class II protein complex and/or CIITA. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19), comprises a reduction in the level or function of HLA-C and a reduction in the level or function of a MHC class II protein complex and/or CIITA. In an embodiment, the engineered mammalian cell described herein (e.g., ARPE-19),
comprises a reduction in the level or function of beta- 2M and a reduction in the level or function of a MHC class II protein complex and/or CIITA.
Gene manipulations and modifications to a mammalian cell or an engineered mammalian cell may be carried out using any known method in the art, including gene silencing, gene knock downs, gene knock outs, and gene editing techniques. For example, a gene mutant may be generated using a targeted genome editing technique at a desired site(s) in the target OCRs. The targeted genome editing technique may be any technique known in the art, e.g., techniques that employ site directed nucleases such as CRISPR-Cas, zinc finger nucleases, transcription activator-like effector nucleases (TALENs), and meganucleases.
The engineered mammalian cells described herein may be derived from a variety of different mammalian cell types (e.g., human cells), including adipose cells, epidermal cells, epithelial cells, endothelial cells, fibroblast cells, embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, pericytes, keratinocyte cells, subtypes of any of the foregoing and cells derived from any of the foregoing. Exemplary cell types include the cell types recited in WO 2017/075631. In some embodiments, the cells are derived from a cell-line shown in Table 2 below.
In an embodiment, any of the engineered mammalian cells described herein is derived from an RPE cell, e.g., an ARPE-19 cell. In an embodiment, an engineered RPE cell (e.g., an engineered ARPE-19 cell) comprises any of the expression cassettes, transposons and polynucleotides described herein.
Engineered mammalian cells for use in devices, compositions and methods described herein, e.g., as a plurality of engineered cells contained or encapsulated in a hydrogel capsule, may be in various stages of the cell cycle. In some embodiments, at least one engineered cell in the plurality of engineered cells is undergoing cell division. Cell division may be measured using any known method in the art, e.g., as described in DeFazio A et al (1987) J Histochem Cytochem 35:571-577 and Dolbeare F et al (1983) Proc Natl Acad Sci USA 80:5573-5577, each of which is incorporated by reference in its entirety. In an embodiment at least 1, 2, 3, 4, 5, 10, or 20% of the cells are undergoing cell division, e.g., as determined by 5-ethynyl-2’deoxyuridine (EdU) assay or 5-bromo-2’-deoxyuridine (BrdU) assay. In some embodiments, cell proliferation is visualized or quantified by microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation) or flow cytometry. In some embodiments, none of the engineered cells in the plurality of engineered cells are undergoing cell division and are quiescent. In an embodiment, less than 1, 2, 3, 4, 5, 10, or 20% of the cells are undergoing cell division, 5-ethynyl- 2’ deoxyuridine (EdU) assay, 5-bromo-2’-deoxyuridine (BrdU) assay, microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation), or flow cytometry.
In an embodiment, at least 50%, 60%, 70%, 80%, 90% or more of the engineered cells in the plurality are viable. Cell viability may be measured using any known method in the art, e.g., as described in Riss, T. et al (2013) “Cell Viability Assays” in Assay Guidance Manual (Sittapalam, G.S. et al, eds). For example, cell viability may be measured or quantified by an
ATP assay, 5-ethynyl-2’deoxyuridine (EdU) assay, 5-bromo-2’-deoxyuridine (BrdU) assay. In some embodiments, cell viability is visualized or quantified by microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation) or flow cytometry. In an embodiment, at least 80% of the engineered cells in the plurality are viable, e.g., as determined by an ATP assay, a 5-ethynyl-2’deoxyuridine (EdU) assay, a 5-bromo-2’-deoxyuridine (BrdU) assay, microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation), or flow cytometry.
Any of the parameters described herein may be assessed using standard techniques known to one of skill in the art, such as histology, microscopy, and various functional assays.
In some embodiments, the exogenous transcription unit encodes a therapeutic polypeptide (e.g., a protein), such as a clotting factor, growth factor, hormone, enzyme, cytokine (e.g., a pro-inflammatory cytokine or an anti-inflammatory cytokine), cytokine receptor, chimeric protein, fusion protein or lipoprotein. The polypeptide encoded by the exogenous transcription unit may have a naturally occurring amino acid sequence or may contain a variant of the naturally occurring sequence. The variant can be a non-naturally occurring or naturally occurring amino acid substitution, mutation, deletion or addition relative to the reference (e.g., naturally occurring) sequence. The naturally occurring amino acid sequence may be a polymorphic variant. The naturally occurring amino acid sequence can be a human or a nonhuman amino acid sequence. In some embodiments, the naturally occurring amino acid sequence is a human sequence. In some embodiments, the therapeutic polypeptide has about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 45, or less than 50 amino acids. In some embodiments, the polypeptide has an average molecular weight of 5 kD, 10 kD, 25 kD, 50 kD, 100 kD, 150 kD, 200 kD, 250 kD, 500 kD, or more.
In some embodiments, the polypeptide is a hormone. Exemplary hormones include antidiuretic hormone (ADH), oxytocin, growth hormone (GH), prolactin, growth horm one-releasing hormone (GHRH), thyroid stimulating hormone (TSH), thyrotropin-release hormone (TRH), adrenocorticotropic hormone (ACTH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), luteinizing horm one-releasing hormone (LHRH), thyroxine, calcitonin, parathyroid hormone (PTH), aldosterone, cortisol, epinephrine, glucagon, insulin, estrogen, progesterone, and testosterone. In some embodiments, the polypeptide is insulin (e.g., insulin A-chain, insulin B-chain, or proinsulin). In some embodiments, the polypeptide is a growth hormone, such as
human growth hormone (hGH), recombinant human growth hormone (rhGH), bovine growth hormone, methionine-human growth hormone, des-phenylalanine human growth hormone, and porcine growth hormone.
In some embodiments, the polypeptide is a growth factor, e.g., vascular endothelial growth factor (VEGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor (TGF), and insulin-like growth factor-I and -II (IGF-I and IGF-II).
In some embodiments, the polypeptide is a clotting factor or a coagulation factor, e.g., a blood clotting factor or a blood coagulation factor. In some embodiments, the polypeptide is involved in coagulation, i.e., the process by which blood is converted from a liquid to solid or gel. Exemplary clotting factors and coagulation factors include Factor I (e.g., fibrinogen), Factor II (e.g., prothrombin), Factor III (e.g., tissue factor), Factor V (e.g., proaccelerin, labile factor), Factor VI, Factor VII (e g., stable factor, proconvertin), Factor VIII (e.g., antihemophilic factor A), Factor VIIIC, Factor IX (e.g., antihemophilic factor B), Factor X (e.g., Stuart-Prower factor), Factor XI (e.g., plasma thromboplastin antecedent), Factor XII (e.g., Hagerman factor), Factor XIII (e.g., fibrin-stabilizing factor), von Willebrand factor (vWF), prekallikrein, heparin cofactor II, high molecular weight kininogen (e.g., Fitzgerald factor), antithrombin III, and fibronectin. In some embodiments, the polypeptide is an anti-clotting factor, such as Protein C.
In some embodiments, the polypeptide is an immunoglobulin chain (heavy or light chain) or fragment thereof, comprising at least one immunoglobulin variable domain sequence, and optionally comprising an immunoglobulin Fc region. In an embodiment, the polypeptide a full- length immunoglobulin chain.
In some embodiments, the polypeptide is a cytokine or a cytokine receptor, or a chimeric protein including cytokines or their receptors, including, for example tumor necrosis factor alpha and beta, their receptors and their derivatives, renin; lipoproteins; colchicine; corti cotrophin; vasopressin; somatostatin; lypressin; pancreozymin; leuprolide; alpha- 1 -antitrypsin; atrial natriuretic factor; lung surfactant; a plasminogen activator other than a tissue-type plasminogen activator (t-PA), for example a urokinase; bombesin; thrombin; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1 -alpha); a serum albumin such as human serum albumin; mullerian- inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-
associated peptide; chorionic gonadotropin; a microbial protein, such as beta-lactamase; DNase; inhibin; activin; receptors for hormones or growth factors; integrin; protein A or D; rheumatoid factors; platelet-derived growth factor (PDGF); epidermal growth factor (EGF); transforming growth factor (TGF) such as TGF-a and TGF-P, including TGF-pi, TGF-P2, TGF-P3, TGF-P4, or TGF-P5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(l-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins; CD proteins such as CD-3, CD-4, CD-8, and CD- 19; erythropoietin; osteoinductive factors; immunotoxins; an interferon such as interferon-alpha (e.g., interferon. alpha.2A), -beta, -gamma, -lambda and consensus interferon; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1, IL-2 to IL-10; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; transport proteins; homing receptors; addressins; fertility inhibitors such as the prostaglandins; fertility promoters; regulatory proteins; antibodies (including fragments thereof) and chimeric proteins, such as immunoadhesins. Suitable polypeptides may be native or recombinant and include, e.g., fusion proteins.
Examples of a polypeptide that may be encoded by the exogenous transcription unit also include CCL1, CCL2 (MCP-1), CCL3 (MIP-la), CCL4 (MIP-ip), CCL5 (RANTES), CCL6, CCL7, CCL8, CCL9 (CCL10), CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1 (KC), CXCL2 (SDFla), CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8 (IL8), CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, CX3CL1, XCL1, XCL2, TNFA, TNFB (LTA), TNFC (LTB), TNFSF4, TNFSF5 (CD40LG), TNFSF6, TNFSF7, TNFSF8, TNFSF9, TNFSF10, TNFSF11, TNFSF13B, EDA, IL2, IL15, IL4, IL13, IL7, IL9, IL21, IL3, IL5, IL6, IL11, IL27, IL30, IL31, OSM, LIF, CNTF, CTF1, IL12a, IL12b, IL23, IL27, IL35, IL14, IL16, IL32, IL34, IL10, IL22, IL19, IL20, IL24, IL26, IL29, IFNL1, IFNL2, IFNL3, IL28, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21, IFNB1, IFNK, IFNW1, IFNG, ILIA (IL1F1), IL1B (IL1F2), ILIRa (IL1F3), IL1F5 (IL36RN), IL1F6 (IL36A), IL1F7 (IL37), IL1F8 (IL36B), IL1F9 (IL36G), IL1F10 (IL38), IL33 (IL1F11), IL18 (IL1G), IL17, KITLG, IL25 (IL17E), CSF1 (M-CSF), CSF2 (GM-CSF), CSF3 (G-CSF), SPP1, TGFB1, TGFB2, TGFB3, CCL3L1, CCL3L2, CCL3L3, CCL4L1, CCL4L2, IL17B, IL17C, IL17D, IL17F, AIMP1 (SCYE1), MIF, Areg, BC096441, Bmpl, BmplO, Bmpl5, Bmp2, Bmp3, Bmp4, Bmp5,
Bmp6, Bmp7, Bmp8a, Bmp8b, Cl qtnf4, Ccl21a, Ccl27a, Cd70, Cerl , Cklf, Clcfl, Cmtm2a, Cmtm2b, Cmtm3, Cmtm4, Cmtm5, Cmtm6, Cmtm7, Cmtm8, Crlfl, Ctf2, Ebi3, Ednl, Fam3b, Fasl, Fgf2, Flt31, GdflO, Gdfl l, Gdfl5, Gdf2, Gdf3, Gdf5, Gdf6, Gdf7, Gdf9, Gml2597, Gml3271, Gml3275, Gml3276, Gml3280, Gml3283, Gm2564, Gpil, Greml, Grem2, Gm, Hmgbl, Ifnal l, Ifnal2, Ifna9, Ifnab, Ifne, 1117a, 1123a, 1125, 1131, Iltifb, Inhba, Leftyl, Lefty2, Mstn, Nampt, Ndp, Nodal, Pf4, Pglyrpl, Prl7dl, Scg2, Scgb3al, Slurpl, Sppl, Thpo, TnfsflO, Tnfsfl l, Tnfsfl2, Tnfsfl3, Tnfsfl3b, Tnfsfl4, Tnfsfl5, Tnfsfl8, Tnfsf4, Tnfsf8, TnfsfP, Tslp, Vegfa, Wntl, Wnt2, Wnt5a, Wnt7a, Xcll, epinephrine, melatonin, triiodothyronine, a prostaglandin, a leukotriene, prostacyclin, thromboxane, islet amyloid polypeptide, mullerian inhibiting factor or hormone, adiponectin, corticotropin, angiotensin, vasopressin, arginine vasopressin, atriopeptin, brain natriuretic peptide, calcitonin, cholecystokinin, cortistatin, enkephalin, endothelin, erythropoietin, follicle-stimulating hormone, galanin, gastric inhibitory polypeptide, gastrin, ghrelin, glucagon, glucagon-like peptide-1, gonadotropin-releasing hormone, hepcidin, human chorionic gonadotropin, human placental lactogen, inhibin, somatomedin, leptin, lipotropin, melanocyte stimulating hormone, motilin, orexin, oxytocin, pancreatic polypeptide, pituitary adenylate cyclase-activating peptide, relaxin, renin, secretin, somatostatin, thrombopoietin, thyrotropin, thyrotropin-releasing hormone, vasoactive intestinal peptide, androgen, alpha-glucosidase (also known as acid maltase), glycogen phosphorylase, glycogen debrancher enzyme, phosphofructokinase, phosphoglycerate kinase, phosphoglycerate mutase, lactate dehydrogenase, carnitine palymityl transferase, carnitine, and myoadenylate deaminase.
In some embodiments, the polypeptide is a replacement therapy or a replacement protein. In some embodiments, the replacement therapy or replacement protein is a clotting factor or a coagulation factor, e.g., Factor VII, Factor VIII or Factor IX.
In some embodiments, the replacement therapy or replacement protein is an enzyme, e.g., alpha-galactosidase A (GLA), alpha-L-iduronidase (IDUA), glucocerebrosidase, or N- sulfoglucosamine sulfohydrolase (SGSH). In an embodiment, the engineered mammalian cell comprises an exogenous nucleic acid encoding the IDUA.
In an embodiment, the engineered mammalian cells are not islet cells, as defined herein. In an embodiment, the engineered mammalian cells have one or more of the following characteristics: (i) are not capable of producing insulin (e.g., insulin A-chain, insulin B-chain, or
proinsulin) in an amount effective to treat diabetes or another disease or condition that may be treated with insulin; (ii) not capable of producing insulin in a glucose-responsive manner; or (iii) not derived from an induced pluripotent stem cell that was engineered or differentiated into insulin-producing pancreatic beta cells.
Features of Implantable Elements
An engineered mammalian cell described herein or a plurality of such cells may be incorporated into an implantable element for use in treating a disease or disorder in a subject, as well as for reducing the level of pericapsular fibrotic overgrowth on the implantable element upon implantation in a subject.
An implantable element of the present disclosure comprises at least one barrier that prevents immune cells from contacting cells contained inside the device. At least a portion of the barrier needs to be sufficiently porous to allow a therapeutic agent expressed and secreted by the cells to exit the device. A variety of device configurations known in the art are suitable.
The device (e.g., particle) can have any configuration and shape appropriate for supporting the viability and productivity of the contained cells after implant into the intended target location. As non-limiting examples, device shapes may be cylinders, rectangles, disks, ovoids, stellates, or spherical. The device can be comprised of a mesh-like or nested structure. In some embodiments, a device is capable of preventing materials over a certain size from passing through a pore or opening. In some embodiments, a device (e.g., particle) is capable of preventing materials greater than 50 kD, 75 kD, 100 kD, 125 kD, 150 kD, 175 kD, 200 kD, 250 kD, 300 kD, 400 kD, 500 kD, 750 kD, or 1,000 kD from passing through.
In an embodiment, the device is a macroencapsulation device. Nonlimiting examples of macrodevices are described in: WO 2019/068059, WO 2019/169089, US Patent Numbers 9,526,880, 9,724,430 and 8,278,106; European Patent No. EP742818B1, and Sang, S. and Roy, S . , Biotechnol. Bioeng. 113 (7) : 1381 - 1402 (2016) .
In an embodiment, the device is a macrodevice having one or more cell-containing compartments. A device with two or more cell-containing compartments may be configured to produce two or more proteins, e.g., cells expressing a first therapeutic agent would be placed in one compartment and cells expressing a different protein (e.g., a therapeutic protein) would be
placed in a separate compartment. WO 2018/232027 describes a device with multiple cellcontaining compartments formed in a micro-fabricated body and covered by a porous membrane.
In an embodiment, the device is configured as a thin, flexible strand as described in US Patent No. 10,493,107. This strand comprises a substrate, an inner polymeric coating surrounding the substrate and an outer hydrogel coating surrounding the inner polymeric coating. The protein-expressing cells are positioned in the outer coating.
In some embodiments, a device (e.g., particle) has a largest linear dimension (LLD), e.g., mean diameter, or size that is at least about 0.5 millimeter (mm), preferably about 1.0 mm, about 1.5 mm or greater. In some embodiments, a device can be as large as 10 mm in diameter or size. For example, a device or particle described herein is in a size range of 0.5 mm to 10 mm, 1 mm to 10 mm, 1 mm to 8 mm, 1 mm to 6 mm, 1 mm to 5 mm, 1 mm to 4 mm, 1 mm to 3 mm, 1 mm to 2 mm, 1 mm to 1.5 mm, 1.5 mm to 8 mm, 1.5 mm to 6 mm, 1.5 mm to 5 mm, 1.5 mm to 4 mm, 1.5 mm to 3 mm, 1.5 mm to 2 mm, 2 mm to 8 mm, 2 mm to 7 mm, 2 mm to 6 mm, 2 mm to 5 mm, 2 mm to 4 mm, 2 mm to 3 mm, 2.5 mm to 8 mm, 2.5 mm to 7 mm, 2.5 mm to 6 mm, 2.5 mm to 5 mm, 2.5 mm to 4 mm, 2.5 mm to 3 mm, 3 mm to 8 mm, 3 mm to 7 mm, 3 mm to 6 mm, 3 mm to 5 mm, 3 mm to 4 mm, 3.5 mm to 8 mm, 3.5 mm to 7 mm, 3.5 mm to 6 mm, 3.5 mm to 5 mm, 3.5 mm to 4 mm, 4 mm to 8 mm, 4 mm to 7 mm, 4 mm to 6 mm, 4 mm to 5 mm, 4.5 mm to 8 mm, 4.5 mm to 7 mm, 4.5 mm to 6 mm, 4.5 mm to 5 mm, 5 mm to 8 mm, 5 mm to 7 mm, 5 mm to 6 mm, 5.5 mm to 8 mm, 5.5 mm to 7 mm, 5.5 mm to 6 mm, 6 mm to 8 mm, 6 mm to 7 mm, 6.5 mm to 8 mm, 6.5 mm to 7 mm, 7 mm to 8 mm, or 7.5 mm to 8 mm.
In some embodiments, a device of the disclosure (e.g., particle, capsule) comprises at least one pore or opening, e.g., to allow for the free flow of materials. In some embodiments, the mean pore size of a device is between about 0.1 pm to about 10 pm. For example, the mean pore size may be between 0.1 pm to 10 pm, 0.1 pm to 5 pm, 0.1 pm to 2 pm, 0.15 pm to 10 pm, 0.15 pm to 5 pm, 0.15 pm to 2 pm, 0.2 pm to 10 pm, 0.2 pm to 5 pm, 0.25 pm to 10 pm, 0.25 pm to 5 pm, 0.5 pm to 10 pm, 0.75 pm to 10 pm, 1 pm to 10 pm, 1 pm to 5 pm, 1 pm to 2 pm, 2 pm to 10 pm, 2 pm to 5 pm, or 5 pm to 10 pm. In some embodiments, the mean pore size of a device is between about 0.1 pm to 10 pm. In some embodiments, the mean pore size of a device is between about 0.1 pm to 5 pm. In some embodiments, the mean pore size of a device is between about 0.1 pm to 1 pm.
In some embodiments, the device comprises a semi-permeable, biocompatible membrane surrounding the genetically modified cells that are encapsulated in a polymer composition (e.g., an alginate hydrogel). The membrane pore size is selected to allow oxygen and other molecules important to cell survival and function to move through the semi-permeable membrane while preventing immune cells from traversing through the pores. In an embodiment, the semi- permeable membrane has a molecular weight cutoff of less than 1000 kD or between 50-700 kD, 70-300 kD, or between 70-150 kD, or between 70 and 130 kD.
In an embodiment, the device may contain a cell-containing compartment that is surrounded with a barrier compartment formed from a cell-free biocompatible material, such as the core-shell microcapsules described in Ma, M et al., Adv. Healthc Mater. , 2(5):667-672 (2012). Such a barrier compartment could be used with or without the semi-permeable membrane.
Cells in the cell -containing compartment(s) of a device of the disclosure may be encapsulated in a polymer composition. The polymer composition may comprise one or more hydrogel -forming polymers. In addition to the polymer composition in the cell -containing compartment(s), the device (e.g., macrodevice, particle, hydrogel capsule) may comprise or be formed from materials such as metals, metallic alloys, ceramics, polymers, fibers, inert materials, and combinations thereof. A device may be completely made up of one type of material, or may comprise other materials within the cell-containing compartment and any other compartments.
In some embodiments, the device comprises a metal or a metallic alloy. In an embodiment, one or more of the compartments in the device (e.g., the first compartment, the second compartment, or all compartments) comprises a metal or a metallic alloy. Exemplary metallic or metallic alloys include comprising titanium and titanium group alloys (e.g., nitinol, nickel titanium alloys, thermo-memory alloy materials), platinum, platinum group alloys, stainless steel, tantalum, palladium, zirconium, niobium, molybdenum, nickel -chrome, chromium molybdenum alloys, or certain cobalt alloys (e.g., cobalt-chromium and cobalt- chromium-nickel alloys, e.g., ELGILOY® and PHYNOX®). For example, a metallic material may be stainless steel grade 316 (SS 316L) (comprised ofFe, <0.3% C, 16-18.5% Cr, 10-14% Ni, 2-3% Mo, <2% Mn, <1% Si, <0.45% P, and <0.03% S). In metal-containing devices, the amount of metal (e.g., by % weight, actual weight) can be at least 5%, e.g., at least 5%, 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more, e.g., w/w; less than 20%, e.g., less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1%, or less.
In some embodiments, the device comprises a ceramic. In an embodiment, one or more of the compartments in the device (e.g., the first compartment, the second compartment, or all compartments) comprises a ceramic. Exemplary ceramic materials include oxides, carbides, or nitrides of the transition elements, such as titanium oxides, hafnium oxides, iridium oxides, chromium oxides, aluminum oxides, and zirconium oxides. Silicon based materials, such as silica, may also be used. In ceramic-containing devices, the amount of ceramic (e.g., by % weight, actual weight) can be at least 5%, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more, e.g., w/w; less than 20%, e.g., less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1%, or less.
In some embodiments, the device has two hydrogel compartments, in which the inner, cell-containing compartment is completely surrounded by the second, outer (e.g., barrier) compartment. In an embodiment, the inner boundary of the second compartment forms an interface with the outer boundary of the first compartment. In such embodiments, the thickness of the second (outer) compartment means the average distance between the outer boundary of the second compartment and the interface between the two compartments, e.g., the average of the distances measured at each of the thinnest and thickest points visually observed in the outer compartment. In some embodiments (e.g., the device is about 1.5 mm in diameter), the thinnest and thickest distances for the outer compartment are between 25 and 110 micrometers (pm) and between 270 and 480 pm, respectively. In some embodiments, the thickness of the outer compartment is greater than about 10 nanometers (nm), preferably 100 nm or greater and can be as large as 1 millimeter (mm). For example, the thickness (e.g., average distance) of the outer compartment in a hydrogel capsule device described herein may be 10 nm to 1 mm, 100 nm to 1mm, 500 nm to 1 millimeter, 1 micrometer (pm) to 1 mm, 1 pm to 1 mm, 1 pm to 500 pm, 1 pm to 250 pm, 1 pm to 1 mm, 5 pm to 500 pm, 5 pm to 250 pm, 10 pm to 1 mm, 10 pm to 500 pm, or 10 pm to 250 pm. In some embodiments, the thickness (e.g., average distance) of the outer compartment is 100 nm to 1 mm, between 1 pm and 1 mm, between 1 pm and 500 pm or between 5 pm and 1 mm. In some embodiments, the thickness (e.g., average distance) of the outer compartment is between about 50 pm and about 100 pm. In some embodiments (e.g., the
device is about 1.5 mm in diameter), the thickness of the outer compartment (e.g., average distance) is between about 180 pm and 260 pm or between about 310 pm and 440 pm.
In some embodiments of a two-compartment hydrogel capsule device, the mean pore size of the cell-containing inner compartment and the outer compartment is substantially the same. In some embodiments, the mean pore size of the inner compartment and the second compartment differ by about 1.5%, 2%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more. In some embodiments, the mean pore size of the device (e.g., mean pore size of the first compartment and/or mean pore size of the second compartment) is dependent on a number of factors, such as the material(s) within each compartment and the presence and density of a compound of Formula (I).
In some embodiments, the polymer composition in the cell-containing compartment(s) comprises a polysaccharide or other hydrogel -forming polymer (e.g., alginate, hyaluronate or chondroitin). In some embodiments, the polymer is an alginate, which is a polysaccharide made up of P-D-mannuronic acid (M) and a-L-guluronic acid (G). In some embodiments, the alginate has a low molecular weight (e.g., approximate molecular weight of < 75 kD) and G:M ratio > 1.5, (ii) a medium molecular weight alginate, e.g., has approximate molecular weight of 75-150 kDa and G:M ratio > 1 .5, (iii) a high molecular weight alginate, e g., has an approximate MW of 150 kDa - 250 kDa and G:M ratio > 1.5, (iv) or a blend of two or more of these alginates. In some embodiments, the cell -containing compartment(s) further comprises at least one cellbinding substance (CBS), e.g., a cell-binding peptide (CBP) or cell-binding polypeptide (CBPP) described in W02020069429.
In some embodiments, the cell-containing compartment(s) comprises an alginate covalently modified with a linker-cell-binding peptide moiety, e.g., GRGD or GRGDSP. In an embodiment, the cell-binding peptide density in the cell-containing compartment(s) (% nitrogen as determined by combustion analysis, e.g., as described in WO2020198695) to be at least 0.05%, 0.1%, 0.2% or 0.3% but less than 4%, 3%, 2% or 1%. In an embodiment, the total density of the linker-CBP in a cell containing compartment is about 0.1 to about 1.0 micromoles of the CBP per g of CBP-polymer (e.g., a MMW-alginate covalently modified with GRGD or GRGDSP in solution as determined by a quantitative peptide conjugation assay, e.g., an assay described in WO2020198695. In an embodiment, the linker-CBP is GRGDSP and the alginate has a molecular weight of 75 kDa to 150 kDa and a G:M ratio of greater than or equal to 1.5. In
an embodiment, the cell-containing compartment also comprises an unmodified alginate with a molecular weight of 75 kDa to 150 kDa and a G:M ratio of greater than or equal to 1.5.
The device may form part of a plurality of substantially the same devices in a preparation (e.g., composition). In some embodiments, the devices (e.g., particles, hydrogel capsules) in the preparation have a mean diameter or size between about 0.5 mm to about 8 mm. In some embodiments, the mean diameter or size of devices in the preparation is between about 0.5 mm to about 4 mm or between about 0.5 mm to about 2 mm. In some embodiments, the devices in the preparation are two-compartment hydrogel capsules and have a mean diameter or size of about 0.7 mm to about 1.3 mm or about 1.2 mm to about 1.8 mm.
In some embodiments, the surface of the device comprises a compound capable of mitigating the FBR upon implant into a subject, an afibrotic compound as described herein below. For devices comprising a barrier compartment surrounding the cell-containing compartment, the afibrotic compound may covalently modify a polymer disposed throughout the barrier compartment and optionally throughout the cell -containing compartment.
In some embodiments, one or more compartments in a device comprises an afibrotic polymer, e.g., an afibrotic compound of Formula (I) covalently attached to a polymer. In an embodiment, some or all the monomers in the afibrotic polymer are modified with the same compound of Formula (I). In some embodiments, some or all the monomers in the afibrotic polymer are modified with different compounds of Formula (I). In some embodiments in which the device is a 2-compartment hydrogel capsule, the afibrotic polymer is present only in the outer, barrier compartment.
One or more compartments in a device may comprise an unmodified polymer that is the same or different than the polymer in any afibrotic polymer that is present in the device. In an embodiment, the first compartment, second compartment or all compartments in the device comprise the unmodified polymer.
Each of the modified and unmodified polymers in the device may be a linear, branched, or cross-linked polymer, or a polymer of selected molecular weight ranges, degree of polymerization, viscosity or melt flow rate. Branched polymers can include one or more of the following types: star polymers, comb polymers, brush polymers, dendronized polymers, ladders, and dendrimers. A polymer may be a thermoresponsive polymer, e.g., gel (e.g., becomes a solid or liquid upon exposure to heat or a certain temperature) or a photocrosslinkable polymer.
Exemplary polymers include polystyrene, polyethylene, polypropylene, polyacetylene, poly(vinyl chloride) (PVC), polyolefin copolymers, poly(urethane)s, polyacrylates and polymethacrylates, polyacrylamides and polymethacrylamides, poly(methyl methacrylate), poly(2 -hydroxyethyl methacrylate), polyesters, polysiloxanes, polydimethylsiloxane (PDMS), polyethers, poly(orthoester), poly(carbonates), poly(hydroxyalkanoate)s, polyfluorocarbons, PEEK®, Teflon® (polytetrafluoroethylene, PTFE), PEEK, silicones, epoxy resins, Kevlar®, Dacron® (a condensation polymer obtained from ethylene glycol and terephthalic acid), polyethylene glycol, nylon, polyalkenes, phenolic resins, natural and synthetic elastomers, adhesives and sealants, polyolefins, polysulfones, polyacrylonitrile, biopolymers such as polysaccharides and natural latex, collagen, cellulosic polymers (e.g., alkyl celluloses, etc.), polyethylene glycol and 2-hydroxyethyl methacrylate (HEMA), polysaccharides, poly(glycolic acid), poly(L-lactic acid) (PLLA), poly(lactic glycolic acid) (PLGA), a polydioxanone (PDA), or racemic poly(lactic acid), polycarbonates, (e.g., polyamides (e.g., nylon)), fluoroplastics, carbon fiber, agarose, alginate, chitosan, and blends or copolymers thereof. In polymer-containing devices, the amount of a polymer (e.g., by % weight of the device, actual weight of the polymer) can be at least 5%, e.g., at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more, e.g., w/w; less than 20%, e.g., less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1%, or less.
In some embodiments, one or more of the modified and unmodified polymers in the device comprises a polyethylene. Exemplary polyethylenes include ultra-low-density polyethylene (ULDPE) (e.g., with polymers with densities ranging from 0.890 to 0.905 g/cm3, containing comonomer); very-low-density polyethylene (VLDPE) (e.g., with polymers with densities ranging from 0.905 to 0.915 g/cm3, containing comonomer); linear low-density polyethylene (LLDPE) (e.g., with polymers with densities ranging from 0.915 to 0.935 g/cm3, contains comonomer); low-density polyethylene (LDPE) (e.g., with polymers with densities ranging from about 0.915 to 0.935 g/m3); medium density polyethylene (MDPE) (e.g., with polymers with densities ranging from 0.926 to 0.940 g/cnk, may or may not contain comonomer); high-density polyethylene (HDPE) (e.g., with polymers with densities ranging from 0.940 to 0.970 g/cm3, may or may not contain comonomer) and polyethylene glycol.
In some embodiments, one or more of the modified and unmodified polymers in the device comprises a polypropylene. Exemplary polypropylenes include homopolymers, random
copolymers (homophasic copolymers), and impact copolymers (heterophasic copolymers), e.g., as described in McKeen, Handbook of Polymer Applications in Medicine and Medical Devices, 3- Plastics Used in Medical Devices, (2014):21-53.
In some embodiments, one or more of the modified and unmodified polymers in the device comprises a polypropylene. Exemplary polystyrenes include general purpose or crystal (PS or GPPS), high impact (HIPS), and syndiotactic (SPS) polystyrene.
In some embodiments, one or more of the modified and unmodified polymers comprises a comprises a thermoplastic elastomer (TPE). Exemplary TPEs include (i) TP A — polyamide TPE, comprising a block copolymer of alternating hard and soft segments with amide chemical linkages in the hard blocks and ether and/or ester linkages in the soft blocks; (ii) TPC — copolyester TPE, consisting of a block copolymer of alternating hard segments and soft segments, the chemical linkages in the main chain being ester and/or ether; (iii) TPO — olefinic TPE, consisting of a blend of a polyolefin and a conventional rubber, the rubber phase in the blend having little or no cross-linking; (iv) TPS — styrenic TPE, consisting of at least a triblock copolymer of styrene and a specific diene, where the two end blocks (hard blocks) are polystyrene and the internal block (soft block or blocks) is a polydiene or hydrogenated poly diene; (v) TPU — urethane TPE, consisting of a block copolymer of alternating hard and soft segments with urethane chemical linkages in the hard blocks and ether, ester or carbonate linkages or mixtures of them in the soft blocks; (vi) TPV — thermoplastic rubber vulcanizate consisting of a blend of a thermoplastic material and a conventional rubber in which the rubber has been cross-linked by the process of dynamic vulcanization during the blending and mixing step; and (vii) TPZ — unclassified TPE comprising any composition or structure other than those grouped in TP A, TPC, TPO, TPS, TPU, and TPV.
In some embodiments, the unmodified polymer is an unmodified alginate. In some embodiments, the alginate is a high guluronic acid (G) alginate, and comprises greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more guluronic acid (G). In some embodiments, the alginate is a high mannuronic acid (M) alginate, and comprises greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more mannuronic acid (M). In some embodiments, the ratio of M:G is about 1. In some embodiments, the ratio of M:G is less than 1. In some embodiments, the ratio of M:G is greater than 1. In an embodiment, the unmodified alginate has a molecular weight of 150 kDa - 250 kDa and a G:M ratio of > 1.5.
In some embodiments, the afibrotic polymer comprises an alginate chemically modified with a Compound of Formula (I). The alginate in the afibrotic polymer may be the same or different than any unmodified alginate that is present in the device. In an embodiment, the density of the Compound of Formula (I) in the afibrotic alginate (e.g, amount of conjugation) is between about 4.0% and about 8.0%, between about 5.0% and about 7.0 %, or between about 6.0% and about 7.0 % nitrogen (e.g., as determined by combustion analysis for percent nitrogen). In an embodiment, the amount of Compound 101 produces an increase in % N (as compared with the unmodified alginate) of about 0.5% to 2% 2% to 4% N, about 4% to 6% N, about 6% to 8%, or about 8% to 10% N), where % N is determined by combustion analysis and corresponds to the amount of Compound 101 in the modified alginate.
In other embodiments, the density (e.g., concentration) of the Compound of Formula (I) (e.g. Compound 101) in the afibrotic alginate is defined as the % w/w, e.g., % of weight of amine / weight of afibrotic alginate in solution (e.g., saline) as determined by a suitable quantitative amine conjugation assay (e.g. by an assay described in W02020069429), and in certain embodiments, the density of a Compound of Formula (I) (e.g., Compound 101) is between about 1.0 % w/w and about 3.0 % w/w, between about 1.3 % w/w and about 2.5 % w/w or between about 1.5 % w/w and 2.2 % w/w.
In alginate-containing devices, the amount of modified and unmodified alginates (e.g, by % weight of the device, actual weight of the alginate) can be at least 5%, e.g, at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more, e.g, w/w; less than 20%, e.g, less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1%, or less.
The alginate in an afibrotic polymer can be chemically modified with a compound of Formula (I) using any suitable method known in the art. For example, the alginate carboxylic acid moiety can be activated for coupling to one or more amine-functionalized compounds to achieve an alginate modified with a compound of Formula (I). The alginate polymer may be dissolved in water (30 mL/gram polymer) and treated with 2-chloro-4,6-dimethoxy-l,3,5-triazine (0.5 eq) and N-methylmorpholine (1 eq). To this mixture may be added a solution of the compound of Formula (I) in acetonitrile (0.3M). The reaction may be warmed to 55 °C for 16h, then cooled to room temperature and gently concentrated via rotary evaporation, then the residue may be dissolved, e.g, in water. The mixture may then be filtered, e.g, through a bed of cyanomodified silica gel (Silicycle) and the filter cake washed with water. The resulting solution may
then be dialyzed (10,000 MWCO membrane) against water for 24 hours, e.g., replacing the water twice. The resulting solution can be concentrated, e.g., via lyophilization, to afford the desired chemically modified alginate.
In an embodiment, modified polymers described herein may be covalently bound to a photoactive crosslinker. A photoactive crosslinkers is a moiety that is activated upon exposure to light. The light may comprise any wavelength of light, from infrared to x-ray energy. In some embodiments, the light comprises ultraviolet light (e.g., between 360 nm to 400 nm, e.g., 370 nm to 390 nm, e.g., 380 nm to 400 nm, e.g., 390 nm to 400 nm). In some embodiments, the light comprises visible light (e.g., between 400 nm to 700 nm). Photoactive crosslinkers often include at least one unsaturated functional group capable of undergoing free radical polymerization. In an embodiment, a photoactive crosslinker comprises an alkenyl group (e.g, C2-C12 alkenyl, C2- C8 alkenyl). In an embodiment, a photoactive crosslinker comprises an alkynyl group (e.g,, C2- C12 alkynyl, C2-C8 alkynyl). Moieties that may be activated upon exposure to irradiation include aromatic groups, alkenyl groups, alkynyl groups, and azide groups. Exemplary alkenyl compounds that may act as photoactive crosslinkers include alkenoic acids such as acrylate, methacrylate, acrylamide, and methacrylamide and their corresponding acid chlorides and anhydrides. Other exemplary alkenyl compounds include enols (e.g., 2-propen-l-ol), alkenyl halides (such as allyl chloride, and the like), organometallic alkenyl compounds (such as vinyl magnesium bromide), aryl compounds (e.g., styrene). Exemplary photoactive crosslinkers include acrylate, methacrylate, ethylene glycol dimethylacrylate, divinylbenzene, 1,3 -di isopropyl benzene, and N,N’ -methylenebisacrylamide. In an embodiment, the photoactive crosslinker is a bifunctional crosslinker, i.e., has two reactive functional groups. In an embodiment, the photoactive covalent crosslinker has both alkenyl and amide functional groups. In an embodiment, the photoactive crosslinker has both alkenyl and carboxylate functional groups. In an embodiment, the photoactive crosslinker has both alkenyl and amide functional groups.
In an embodiment, the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV):
pharmaceutically acceptable salt or tautomer thereof, wherein X1 is absent, O, NR33, or C(R34a)(R34b); each of R30a, R30b, R31, R32, R33, R34a , and R34b is
independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, -N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; and each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl.
In an embodiment, X1 is O, each of R30a, R30b, R31, and R32 is hydrogen, and R32 is heteroalkyl (e.g., propylamine, e.g., -CH2CH2CH2NH2). In an embodiment, X1 is O, each of R30a, R3°b, j^3i anj j^32 js hydrogen, and R32 is heteroalkyl (e.g., ethylamine, e.g., -CH2CH2NH2). In an embodiment, the photoactive crosslinker of Formula (IV) is methacrylate. In an embodiment X1 is absent; R32 is halo (e.g., chloro); and each of R30a, R30b and R31 is hydrogen. In an embodiment, the photoactive crosslinker of Formula (IV) is acryloyl chloride.
In an embodiment, X1 is NR33 (e.g., NH), and each of R30a, R30b, R31, and R32 is hydrogen. In an embodiment, the photoactive crosslinker of Formula (IV) is acrylamide.
In an embodiment, the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV-a):
R30a 0 k U /R32
R30b N
R31 135
R (IV-a), or a pharmaceutically acceptable salt or tautomer thereof, wherein each of R30a, R30b, R31, R32 and R35 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, - N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; and each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl.
In an embodiment, the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV-b):
pharmaceutically acceptable salt or tautomer thereof, wherein each of R30a, R30b, R31, R32, R36a, and R36b is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, - N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; R35 is hydrogen, alkyl, heteroalkyl, halo, cyano, nitro, amino, cycloalkyl, heterocyclyl, aryl, or heteroaryl; and n is 1, 2, 3, 4, 5, or 6.
In an embodiment, the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV-c):
pharmaceutically acceptable salt or tautomer thereof, wherein each of R30a, R30b, and R31 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, -N(RC1)(RD1), - N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R32 is alkyl, alkenyl, alkynyl, heteroalkyl, -C(O)ORA1, -C(O)RB1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; and each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl.
In an embodiment, the modified polymers described herein comprise a photoactive crosslinker having the structure of Formula (IV-d):
pharmaceutically acceptable salt or tautomer thereof, wherein each of R30a, R30b, R31, R32, R36a, and R36b is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, - N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R32 is alkyl, alkenyl, alkynyl, heteroalkyl ,-C(O)ORA1, -C(O)RB1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; and n is 1, 2, 3, 4, 5, or 6.
Photoactive crosslinkers may be used alone or, preferably in the presence of a photoinitiator. A “photoinitiator,” as used herein, refers to a molecule capable of absorbing radiation e.g., light e.g., photons, and forming a reactive species in an excited state. A variety of free radical initiators, as can readily be identified by those of skill in the art, can be employed in the practice of the present invention. In an embodiment, a photoinitiator is an ultraviolent (UV) photoinitiator. Exemplary UV photoinitiators include lithium phenyl-2,4,6- trimethylbenzoylphopshinate (LAP), camphorquinone, benzoin methyl ether, J-hydroxy- cyclohexyl-phenyl-ketone (i.e., Irgacure 184), 2-hydroxy-2-methyl-l -phenyl-l-propanone (i.e., Darocur 1173) 2-hydroxy-l-[4-(2-hydroxyethoxy)phenyl]-2-methylpropan-l-one (i.e., Irgacure 2959), 2-benzyl-2-(dimethylamino)-l-(4-morpholin-4-ylphenyl)butan-1-one (i.e., Irgacure 369), 2-methyl-l-(4-methylsulfanylphenyl)-2-morpholm-4-ylpropan-l-one (i.e., Irgacure 907) dipheny1(2,4,6-triraethylbenzoyl)phosphine oxide (e.g., Darocur TPO), benzoin ethyl ether, benzophenone, 9,10-anthraquinone, ethyl-4-N,N-dimethylaminobenzoate, diphenyliodonium chloride, and water soluble derivatives thereof. For visible light polymerization, a system of dye and cocatalyst may be used. Exemplary visible light photoinitiators include 2-(2, 4,5,7- tetrabromo-3-hydroxy-6-oxoxanthen-9-yl)benzoic acid (i.e.. Eosin Y), erythrosine, riboflavin, rose Bengal, methylene blue, and thionine A small amount of a comonomer can optionally be added to the crosslinking reaction to increase the polymerization rates. Examples of suitable comonomers include vinyl pyrrolidinone, acrylamide, methacrylamide, acrylic acid, methacrylic
adit sodium acrylate, sodium methacrylate, hydroxyethyl acrylate, hydroxy ethyl methacrylate (HEMA), ethylene glycol diacrylate, ethylene glycol dimethacrylate, pentaerythritol triacrylate, pentaerythritol tri methacryl ate, tri methylol propane tri acrylate, trimethylol propane trimethaciylate, tripropylene glycol diaciylate, tripropylene glycol dimethacrylate, glyceryl acrylate, glyceryl methacrylate, and the like. In some embodiments, the photoiniiiator is a thermally activated photoinitiator.
A photoactive crosslinker may be used in the presence of a single photoinitiator or a plurality of photoinitiators. The plurality of photoinitiators may include 2, 3, 4, 5, 6, 7, 8, or more photoinitiators. In an embodiment, the covalent crosslinking moiety is present on the polysaccharide polymer at a density of at least 1%, e.g., 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, or more, e.g., as determined by LC-UV assay.
The photoactive crosslinker may be covalently bound to a polysaccharide, e.g., an alginate. The modified polysaccharide polymer, e.g., modified alginate polymer, may be capable of being crosslinked to another polymer. In an embodiment, the polysaccharide polymer is modified with more than one type of photoactive crosslinker.
In an embodiment, the modified polysaccharide is a compound of Formula (V):
0 (V), or a pharmaceutically acceptable salt or tautomer thereof, wherein each of T and U is independently C(R40)(R41), O, or N(R42); each of R38a, R38b ; R39a, R39b, R40, R41,and R42 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, - N(RC1)(RD1), N(RC1)C(O)RB1, C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each of R32 and R35 is hydrogen, alkyl, heteroalkyl, halo, cyano, nitro, amino, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; and the photoactive crosslinker has the structure of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d).
In an embodiment, the photoactive crosslinker of Formula (V) has the structure of
Formula (V-a):
pharmaceutically acceptable salt or tautomer thereof, wherein each of T and U is independently C(R40)(R41), O, or N(R42); each of R30a, R30b, R31, R32, R38a, R38b, R39a, R39b, R40, R41, and R42 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, -
N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; and each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl.
In an embodiment, the modified polymer described herein has the structure of Formula
(V-b):
pharmaceutically acceptable salt or tautomer thereof, wherein each of U and T is independently C(R40)(R41), O, or N(R42); each of R30a, R30b, R31, R33, R38a, R38b, R39a, R39b, R40, R41, R42, R43a, and R43b is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, C(O)RB1, OC(O)RB1, -N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; and n is 1, 2, 3, 4, 5, or 6.
In an embodiment, the modified polymer described herein has the structure of Formula
(V-c):
pharmaceutically acceptable salt or tautomer thereof, wherein U is C(R40)(R41), 0, or N(R42); each of R30a, R30b, R31, R35, R38a, R38b, R39a, R39b, R40, R41, R42, R43a, R43b and R44 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, -N(RC1)(RD1), - N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1,
RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; and each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; and n is 1, 2, 3, 4, 5, or 6.
In an embodiment, the modified polymer described herein has the structure of Formula
(V-d):
pharmaceutically acceptable salt or tautomer thereof, wherein U is C(R40)(R41), O, or N(R42); each of R30a, R30b, R31, R38a, R38b, R39a, R39b, R40, R41, R42, R43a, and R43b is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, -N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; and n is 1, 2, 3,
4, 5, or 6.
In an embodiment, the modified polymer described herein comprises the structure of Formula (VI):
pharmaceutically acceptable salt or tautomer thereof, wherein each of W, T1, T2, U1, and U2 is independently C(R40)(R41), O, or N(R42); each of R38a, R38b, R38c, R38d R39a, R39b, R39a, R39b, R40, R41, and R42 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, -N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; and each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; p is an integer from 1- 100; the afibromer has the structure of Formula (I) or a subgenera of Formula (I) as described herein.
In an embodiment, the device comprises at least one cell-containing compartment, and in some embodiments contains two, three, four or more cell-containing compartments. In an embodiment, each cell-containing compartment comprises a plurality of cells (e.g., live cells) and the cells in at least one of the compartments are capable of expressing and secreting a mammalian protein when the device is implanted into a subject.
In an embodiment, all the cells in a cell-containing compartment are derived from a single parental cell-type or a mixture of at least two different parental cell types. In an embodiment, all of the cells in a cell -containing compartment are derived from the same parental cell type. In devices with two or more cell-containing compartments, the cells and the protein(s) produced thereby may be the same or different in each cell -containing compartment. In some embodiments, all of the cell-containing compartments are surrounded by a single barrier compartment. In some embodiments, the barrier compartment is substantially cell-free.
In an embodiment, cells to be incorporated into a device described herein, e.g., a hydrogel capsule, are prepared in the form of a cell suspension prior to being encapsulated within the device. The cells in the suspension may take the form of single cells (e.g., from a monolayer cell culture), or provided in another form, e.g., disposed on a microcarrier (e.g., a bead or matrix) or as a three-dimensional aggregate of cells (e.g., a cell cluster or spheroid). The cell suspension can comprise multiple cell clusters (e.g., as spheroids) or microcarriers.
In an embodiment, the implantable element described herein comprises a plurality of engineered mammalian cells (e g., engineered ARPE-19 cells), e.g., at a particular cell density. For example, the implantable element may comprise a plurality of engineered mammalian cells at greater than 1 million cells per mL, 2.5 million cells per mb, 5 million cells per mb, 7.5 million cells per mL, 10 million cells per mL, 15 million cells per mL, 20 million cells per mL, 25 million cells per mL, 30 million cells per mL, 40 million cells per mL, 50 million cells per mL, or more. In an embodiment, the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., a hormone, a blood clotting factor, an antibody, or an enzyme) with a cell density of between 1-5 million cells per mL, 5-10 million cells per mL, or 10-20 million cells per mL. In an embodiment, the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., insulin) with a cell density of between 1-5 million cells per mL, 5-10 million cells per mL, or 10-20 million cells per mL. In an embodiment, the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., IDUA) with a cell density of between 1-5 million cells per mL, 5-10 million cells per mL, or 10-20 million cells per mL. In an embodiment, the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., insulin) with a cell density of between 1-5 million cells per mL, 5- 10 million cells per mL, or 10-20 million cells per mL. In an embodiment, the implantable element comprises a plurality of engineered ARPE-19 cells capable of expressing a protein (e.g., insulin) with a cell density of between 1-5 million cells per mL, 5-10 million cells per mL, or 10- 20 million cells per mL.
A device (e.g., capsule, particle) may comprise one or more exogenous agents that are not expressed by the cells, and may include, e.g., a nucleic acid (e.g., an RNA or DNA molecule), a protein (e.g., a hormone, an enzyme (e.g., glucose oxidase, kinase, phosphatase, oxygenase, hydrogenase, reductase) antibody, antibody fragment, antigen, or epitope)), an active or inactive
fragment of a protein or polypeptide, a small molecule, or drug. In an embodiment, the device is configured to release such an exogenous agent.
In an embodiment, the implantable element described herein results in a lower amount of peri capsular fibrotic overgrowth (PFO) when implanted into a mammalian host than compared with implanting a control implantable element (e.g., defined as an otherwise identical implantable element except that the cell does not have the reduction in the MHC class I complex). In an embodiment, the implantable element described herein comprises an engineered mammalian cell that remains capable of expressing the therapeutic agent for at least any of two months, three months, four months, or longer following implant of the implantable element into a mammalian subject. In an embodiment, the implantable element described comprises an engineered mammalian cell expressing a therapeutic agent detectable in the plasma of a mammalian subject for at least any of two months, three months, four months, or longer following implant of the implantable element into the subject.
Afibrotic (e.g., FBR-mitigating) Compounds
In some embodiments, the devices described herein comprise at least one compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, -
B(ORA)-, or a metal, each of which is optionally linked to an attachment group (e.g., an attachment group described herein) and is optionally substituted by one or more R1; each of L1 and L3 is independently a bond, alkyl, or heteroalkyl, wherein each alkyl and heteroalkyl is optionally substituted by one or more R2;
L2 is a bond;
M is absent, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted by one or more R3;
P is absent, cycloalkyl, heterocyclyl, or heteroaryl, each of which is optionally substituted by one or more R4;
Z is hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, -ORA, -C(O)RA, -C(O)ORA, - C(O)N(RC)(RD), -N(RC)CFVA, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted by one or more R5; each RA, RB, RC, RD, RE, RF, and RG is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, azido, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; or Rc and RD, taken together with the nitrogen atom to which they are attached, form a ring (e.g., a 5-7 membered ring), optionally substituted with one or more R6; each R1, R2, R3, R4, R5, and R6 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, -N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, S(O)xRE1, -OS(O)xRE1, -N(RC1)S(O)XRE1, - S(O)XN(RC1)(RD1), -P(RF1)y, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted by one or more R7; each RA1, RB1, RC1, RD1, RE1, and RF1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted by one or more R7; each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; x is 1 or 2; and y is 2, 3, or 4.
In some embodiments, the compound of Formula (I) is a compound of Formula (I-a):
or a pharmaceutically acceptable salt thereof, wherein:
A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, - C(O)O- -C(O)-, -OC(O)-, -N(RC)-, -N(Rc)C(O)-, -C(O)N(Rc)-, -N(RC)N(RD)-, N(RC)C(O)(CI-C6- alkylene)-, -N(Rc)C(O)(Ci-C6-alkenylene)-, -NCN-, -C(=N(Rc)(RD))O- - S-, -S(O)X-, -OS(O)X- -N(Rc)S(O)x- -S(O)xN(Rc)-, -P(RF)y-, -Si(ORA)2 -Si(RG)(ORA)-, -B(ORA)-, or a metal, each of which is optionally linked to an attachment group (e.g., an attachment group described herein) and optionally substituted by one or more R1; each of L1 and L3 is independently a bond, alkyl, or heteroalkyl, wherein each alkyl and heteroalkyl is optionally substituted by one or more R2;
L2 is a bond;
M is absent, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted by one or more R3;
P is heteroaryl optionally substituted by one or more R4;
Z is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted by one or more R5; each RA, RB, RC, RD, RE, RF, and RG is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, azido, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; or Rc and RD, taken together with the nitrogen atom to which they are attached, form a ring (e g., a 5-7 membered ring), optionally substituted with one or more R6; each R1, R2, R3, R4, R5, and R6 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, -N(RC1)(RD1), - N(Rcl)C(O)RB1, -C(O)N(RC1), SRE1, S(O)XRE1, -OS(O)xRE1, -N(RC1)S(O)XRE1, - S(O)XN(RC1)(RD1), - P(RF1)y, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted by one or more R7; each RA1, RB1, RC1, RD1, RE1, and RF1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted by one or more R7; each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl;
x is 1 or 2; and y is 2, 3, or 4.
In some embodiments, for Formulas (I) and (I-a), A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, -C(O)O-, -C(O)-, -OC(O) -, -N(Rc)C(O)-, - N(Rc)C(O)(Ci-C6-alkylene)-, -N(Rc)C(O)(Ci-C6-alkenylene)-, or -N(Rc)-. In some embodiments, A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, — C(O)O— , -C(O)-, -OC(O) -, or -N(Rc)-. In some embodiments, A is alkyl, alkenyl, alkynyl, heteroalkyl -O-, -C(O)O-, -C(O)-,-OC(O) -, or -N(RC)-. In some embodiments, A is alkyl, -O-, -C(O)O- -C(O)-, -OC(O), or -N(RC)-. In some embodiments, A is -N(Rc)C(O)-, -N(Rc)C(O)(Ci-Ce-alkylene)-, or -N(Rc)C(O)(Ci-C6-alkenylene)-. In some embodiments, A is -N(RC)-. In some embodiments, A is -N(RC) -, and Rc an RD is independently hydrogen or alkyl. In some embodiments, A is -NH-. In some embodiments, A is -N(Rc)C(O)(Ci-Ce- alkylene)-, wherein alkylene is substituted with R1. In some embodiments, A is - N(Rc)C(O)(Ci-C6-alkylene)-, and R1 is alkyl (e.g., methyl). In some embodiments, A is - NHC(O)C(CH3)2-. In some embodiments, A is -N(Rc)C(O)(methylene)-, and R1 is alkyl (e.g., methyl). In some embodiments, A is -NHC(0)CH(CH3)-. In some embodiments, A is - NHC(O)C(CH3)-.
In some embodiments, for Formulas (I) and (I-a), L1 is a bond, alkyl, or heteroalkyl. In some embodiments, L1 is a bond or alkyl. In some embodiments, L1 is a bond. In some embodiments, L1 is alkyl. In some embodiments, L1 is Ci-Ce alkyl. I n some embodiments, L1 is -CH2-, -CH(CH3)-, -CH2CH2CH2, or -CH2CH2-. In some embodiments, L1 is -CFfc-or - CH2CH2-.
In some embodiments, for Formulas (I) and (I-a), L3 is a bond, alkyl, or heteroalkyl. In some embodiments, L3 is a bond. In some embodiments, L3 is alkyl. In some embodiments, L3 is C1-C12 alkyl. In some embodiments, L3 is Ci-Ce alkyl. In some embodiments, L3 is -CH2-. In some embodiments, L3 is heteroalkyl. In some embodiments, L3 is C1-C12 heteroalkyl, optionally substituted with one or more R2 (e.g., oxo). In some embodiments, L3 is Ci-Ce heteroalkyl, optionally substituted with one or more R2 (e.g., oxo). In some embodiments, L3 is C(O)OCH2 , CH2(OCH2CH2)2 , CH2(OCH2CH2)3 , CH2CH2O , or -CH2O-. In some embodiments, L3 is -CH2O-.
In some embodiments, for Formulas (I) and (I-a), M is absent, alkyl, heteroalkyl, aryl, or heteroaryl. In some embodiments, for Formulas (I) and (I-a), M is absent, alkyl, heteroalkyl, aryl, or heteroaryl. In some embodiments, M is heteroalkyl, aryl, or heteroaryl. In some embodiments, M is absent. In some embodiments, M is alkyl (e.g., Ci-Ce alkyl). In some embodiments, M is -CH2-. In some embodiments, M is heteroalkyl (e.g., Ci-Ce heteroalkyl). In some embodiments, M is (-OCFbCFb-Jz, wherein z is an integer selected from 1 to 10. In some embodiments, z is an integer selected from 1 to 5. In some embodiments, M is -(OCH2) 2-, (-OCH2CH2-)2, (-OCH2CH2-)3, (-OCH2CH2-)4, or (-OCH2CH2
5. In some embodiments, M is -OCH2CH2-, (-OCH2CH2-)2, (-OCH2CH2-)3, or (-OCH2CH2-)4. In some embodiments, M is (-OCH2-)3. In some embodiments, M is aryl. In some embodiments, M is phenyl. In some embodiments, M is unsubstituted phenyl. In some embodiments, M is
In some embodiments, M is
. In some embodiments, M is phenyl substituted with 1-4 R3 (e.g., 1 R3). In some embodiments, R3 is CF3.
In some embodiments, for Formulas (I) and (I-a), P is absent, heterocyclyl, or heteroaryl. In some embodiments, for Formulas (I) and (I-a), P is absent, heterocyclyl, or heteroaryl. In some embodiments, P is absent. In some embodiments, for Formulas (I) and (I-a), P is a tricyclic, bicyclic, or monocyclic heteroaryl. In some embodiments, P is a monocyclic heteroaryl. In some embodiments, P is a nitrogen-containing heteroaryl. In some embodiments, P is a monocyclic, nitrogen-containing heteroaryl. In some embodiments, P is a 5-membered heteroaryl. In some embodiments, P is a 5-membered nitrogen-containing heteroaryl. In some embodiments, P is tetrazolyl, imidazolyl, pyrazolyl, or triazolyl, or pyrrolyl. In some embodiments, P is imidazolyl. In some embodiments, P is 1,2,3-triazolyl. In some
In some embodiments, P is heterocyclyl. In some embodiments, P is heterocyclyl. In some embodiments, P is a 5-membered heterocyclyl. In some embodiments, P is imidazolidinonyl. In
some embodiments, P is
. In some embodiments, P is thiomorpholinyl- 1,1 -di oxidyl.
In some embodiments, for Formulas (I) and (I-a), Z is alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, for Formulas (I) and (I-a), Z is alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, Z is heterocyclyl. In some embodiments, Z is monocyclic or bicyclic heterocyclyl, 5-membered heterocyclyl, or 6-membered heterocyclyl. In some embodiments, Z is a 6-membered oxygencontaining heterocyclyl. In some embodiments, Z is tetrahydropyranyl. In some embodiments, Z
. In some embodiments, Z is a 4-membered oxygen -containing heterocyclyl. In some embodiments, Z is
In some embodiments, Z is a bicyclic oxygen-containing heterocyclyl. In some embodiments, Z is a bicyclic oxygen-containing heterocyclyl. In some embodiments, Z is phthalic anhy dridyl. In some embodiments, Z is a sulfur-containing heterocyclyl
some embodiments, Z is a 6-membered sulfur-containing heterocyclyl In some embodiments, Z is a 6-membered heterocyclyl containing a nitrogen atom and a sulfur atom. In some embodiments, Z is thiomorpholinyl-l,l-dioxidyl. In some embodiments,
In some embodiments, Z is a nitrogen-containing heterocyclyl. In some embodiments, Z is a 6- membered nitrogen-containing heterocyclyl. In some embodiments, Z is
In some embodiments, Z is a bicyclic heterocyclyl. In some embodiments, Z is a bicyclic heterocyclyl In some embodiments, Z is a bicyclic nitrogen-containing heterocyclyl, optionally substituted with one or more R5. In some embodiments, Z is 2-oxa-7-azaspiro[3.5]nonanyl
In some embodiments,
. In some embodiments, Z is l-oxa-3,8- diazaspiro[4.5]decan-2-one. In some embodiments,
In some embodiments, for Formulas (I) and (I-a), Z is aryl. In some embodiments, Z is monocyclic aryl. In some embodiments, Z is phenyl. In some embodiments, Z is monosubstituted phenyl (e.g., with 1 R3). In some embodiments, Z is monosubstituted phenyl, wherein the 1 R5 is a nitrogen-containing group. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R5 is NHz. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R5 is an oxygen-containing group. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R5 is an oxygen-containing heteroalkyl. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R5 is OCH3. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R3 is in the ortho position. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R5 is in the meta position. In some embodiments, Z is monosubstituted phenyl, wherein the 1 R3 is in the para position.
In some embodiments, for Formulas (I) and (I-a), Z is alkyl. In some embodiments, Z is Ci- C12 alkyl. In some embodiments, Z is C1-C10 alkyl. In some embodiments, Z is Ci-Cs alkyl. In some embodiments, Z is Ci-Cs alkyl substituted with 1-5 R5. In some embodiments, Z is Ci-Cs alkyl substituted with 1 R3. In some embodiments, Z is Ci-Cs alkyl substituted with 1 R3, wherein R5 is alkyl, heteroalkyl, halogen, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, or -N(RC1)(RD1). In some embodiments, Z is Ci-Cs alkyl substituted with 1 R5, wherein R5 is -
ORA1 or -C(0)0RA1. In some embodiments, Z is Ci-Cs alkyl substituted with 1 R5, wherein R5 is -ORA1 or -C(O)OH. In some embodiments, Z is -CH3.
In some embodiments, for Formulas (I) and (I-a), Z is heteroalkyl. In some embodiments, Z is Ci-C 12 heteroalkyl. I n some embodiments, Z is C1-C10 heteroalkyl. In some embodiments, Z is Ci-Cs heteroalkyl. I n some embodiments, Z is Ci-Ce heteroalkyl. In some embodiments, Z is a nitrogen-containing heteroalkyl optionally substituted with one or more R5. 1 n some embodiments, Z is a nitrogen and sulfur-containing heteroalkyl substituted with 1-5 R5. In some embodiments, Z is N-methyl-2-(methylsulfonyl)ethan-l-aminyl.
In some embodiments, Z is -ORA or -C(0)0RA. In some embodiments, Z is -ORA (e.g., -OH or OCH3). In some embodiments, Z is OCH3. In some embodiments, Z is -C(O)ORA (e.g., -C(O)OH).
In some embodiments, Z is hydrogen.
In some embodiments, L2 is a bond and P and L3 are independently absent. In some embodiments, L2 is a bond, P is heteroaryl, L3 is a bond, and Z is hydrogen. In some embodiments, P is heteroaryl, L3 is heteroalkyl, and Z is alkyl.
In some embodiments, the compound of Formula (I) is a compound of Formula (I-b):
or a pharmaceutically acceptable salt thereof, wherein Ring M1 is cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R3; Ring Z1 is cycloalkyl, heterocyclyl’ aryl or heteroaryl, optionally substituted with 1 -5 R5; each of R2a, R2b, R2c, and R2d is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halo, cyano, nitro, amino, cycloalkyl, heterocyclyl, aryl, or heteroaryl, or each of R2a and R2b or R2c and R2d is taken together to form an oxo group; X is absent, N(R1O)(RU), O, or S; Rc is hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with 1- 6 R6; each R3, R5 and R6 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -0RA1, -C(0)0RA1, -C(0)RB1,-0C(0)RB1, -N(RC1)(RD1), -N(RC1)C(0)RB1, - C(O)N(RC1), SRE1, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each of R10 and R11 is
independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, -C(O)ORA1, -C(O)RB1,- OC(O)RB1, -C(O)N(RC1), cycloalkyl, heterocyclyl or heteroaryl; each RA1, RB1, RC1, RD1, and RE1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R7; each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; each m and n is independently 1, 2, 3, 4, 5, or 6; and “ -~wv” refers to a connection to an attachment group or a polymer described herein. In some embodiments, for each R3 and R5, each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally and independently substituted with halogen, oxo, cyano, cycloalkyl, or heterocyclyl.
In some embodiments, the compound of Formula (I-b) is a compound of Formula (I-b-i):
or a pharmaceutically acceptable salt thereof, wherein Ring M2 is aryl or heteroaryl optionally substituted with one or more R3; Ring Z2 is cycloalkyl, heterocyclyl, aryl’ or heteroaryl; each of R2a, R2b, R2C, and R2d is independently hydrogen, alkyl, or heteroalkyl, or each of R2a and R2b or R2C and R2d is taken together to form an oxo group; X is absent, O, or S; each R3 and R5 is independently alkyl, heteroalkyl, halogen, oxo, -ORA1, -C(O)ORA1, or -C(O)RB1, wherein each alkyl and heteroalkyl is optionally substituted with halogen; or two R5 are taken together to form a 5-6 membered ring fused to Ring Z2; each RA1 and RB1is independently hydrogen, alkyl, or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5, or 6; p is 0, 1, 2, 3, 4, 5, or 6; and ” refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (I-b-i) is a compound of Formula (I-b- ii):
or a pharmaceutically acceptable salt thereof, wherein Ring Z2 is cycloalkyl, heterocyclyl, aryl or heteroaryl; each of R2c and R2d is independently hydrogen, alkyl, or heteroalkyl, or R2c and R and taken together to form an oxo group; each R3 and R5 is independently alkyl, heteroalkyl, halogen, oxo, -0RA1, -C(0)0RA1, or -C(0)RB1, wherein each alkyl and heteroalkyl is optionally substituted with halogen; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; and
refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (I) is a compound of Formula (I-c):
or a pharmaceutically acceptable salt thereof, wherein Ring Z2 is cycloalkyl, heterocyclyl’ aryl or heteroaryl; each of R2c and R2d is independently hydrogen, alkyl, or heteroalkyl, or R2c and R2d is taken together to form an oxo group; each R3 and R5 is independently alkyl, heteroalkyl, halogen, oxo, -OR, -C(0)0R, or -C(0)RB1, wherein each alkyl and heteroalkyl is optionally substituted with halogen; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; m is 1, 2, 3, 4, 5, or 6; each of p and q is independently 0, 1, 2, 3, 4, 5, or 6; and “ ” refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (I) is a compound of Formula (I-d):
or a pharmaceutically acceptable salt thereof, wherein Ring Z2 is cycloalkyl, heterocyclyl’ aryl or heteroaryl; X is absent, O, or S; each of R2a, R2b, R2c, and R2d is independently hydrogen, alkyl, or heteroalkyl, or each of R2a and R2b or R2c and R2d is taken together to form an oxo group; each R3 is independently alkyl, heteroalkyl, halogen, oxo, -0RA1, -C(0)0RA1, or -C(O)RB1, wherein each alkyl and heteroalkyl is optionally substituted with halogen; each RA1 and R is independently hydrogen, alkyl, or heteroalkyl; each of m and n is independently 1, 2, 3, 4, 5, or
6; p is 0, 1, 2, 3, 4, 5, or 6; and “ -~vw” refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (I) is a compound of Formula (I-e):
(I-e), or a pharmaceutically acceptable salt thereof, wherein Ring Z2 is cycloalkyl, heterocyclyl, aryl or heteroaryl; X is absent, O, or S; each of R2a, R2b, R2c, and R2d is independently hydrogen, alkyl, or heteroalkyl, or each of R2aand R2b or R2c and R2d is taken together to form an oxo group; each R5 is independently alkyl, heteroalkyl, halogen, oxo, -ORA1, -C(O)ORA1, or -C(O)RB1; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; each of m and n is independently 1, 2, 3, 4, 5, or 6; p is 0, 1, 2, 3, 4, 5, or 6; and “ ” refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (I) is a compound of Formula (I-f):
or a pharmaceutically acceptable salt thereof, wherein M is alkyl optionally substituted with one or more R3; Ring P is heteroaryl optionally substituted with one or more R4; L3 is alkyl or heteroalkyl optionally substituted with one or more R2; Z is alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R5; each of R2a and R2b is independently hydrogen, alkyl, or heteroalkyl, or R2a and R2b is taken together to form an oxo group; each R2, R3, R4, and R5 is independently alkyl, heteroalkyl, halogen, oxo, -ORA1, -C(O)ORA1, or -C(O)RB1; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; n is independently 1, 2, 3, 4, 5, or 6; and refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (I) is a compound of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein M is a bond, alkyl or aryl, wherein alkyl and aryl is optionally substituted with one or more R3; L3 is alkyl or heteroalkyl optionally substituted with one or more R2; Z is hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or -OR, wherein alkyl, , cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R5; RA is hydrogen; each of R2a and R2b is independently hydrogen, alkyl, or heteroalkyl, or R2aand R2b is taken together to form an oxo group; each R2, R3, and R5 is independently alkyl, heteroalkyl, halogen, oxo, -ORA1, or -C(O)RB1; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; n is independently 1, 2, 3, 4, 5, or 6; and refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (II) is a compound of Formula (Il-a):
or a pharmaceutically acceptable salt thereof, wherein L3 is alkyl or heteroalkyl, each of which is optionally substituted with one or more R2; Z is hydrogen, alkyl, heteroalkyl' or -ORA, heteroalkyl are optionally substituted with one or more R5; each of R2a and R2b is independently hydrogen, alkyl, or heteroalkyl, or each of R2aand R2b is taken together to form an oxo group- each R2, R3, and R5 is independently heteroalkyl, halogen, oxo, -ORA1, -C(O)ORA1; RA is hydrogen; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; n is independently 1, 2, 3, 4, 5, or 6; and “ -~wv” refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (I) is a compound of Formula (III):
(III), or a pharmaceutically acceptable salt thereof, wherein Z1 is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R5; each of R2a, R2b, R2c, and R2d is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halo, cyano, nitro, amino, cycloalkyl, heterocyclyl, aryl, or heteroaryl; or each of R2a and R2b or
R2C and R2d is taken together to form an oxo group; Rc is hydrogen, alkyl, alkenyl, alkynyl, or heteroalkyl, wherein each of alkyl, alkenyl, alkynyl, or heteroalkyl is optionally substituted with 1-6 R6; each of R3, R5, and R6 is independently alkyl, heteroalkyl, halogen, oxo, -ORA1, - C(O)ORA1, or -C(O)RB1; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5, or 6; q is an integer from 0 to 25; and “ ” refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (III) is a compound of Formula (Ill-a):
or a pharmaceutically acceptable salt thereof, wherein Ring Z2 is cycloalkyl, heterocyclyl, aryl, or heteroaryl; each of R2a, R2b, R2c, and R2d is independently hydrogen, alkyl, heteroalkyl, halo; or R2a and R2b or R2c and R2d are taken together to form an oxo group; each of R3 and R5 is independently alkyl, heteroalkyl, halogen, oxo, -ORA1, -C(O)ORA1, or -C(O)RB1; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5, or 6; o and p are each independently 0, 1, 2, 3, 4, or 5; q is an integer from 0 to 25; and refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (Ill-a) is a compound of Formula (III-
or a pharmaceutically acceptable salt thereof, wherein Ring Z2 is cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-5 R5; each of R2a , R2b, R2c, and R2d is independently hydrogen, alkyl, heteroalkyl, halo; or R2a and R2b or R2c and R2d are taken together to form an oxo group; each of R3 and R5 is independently alkyl, heteroalkyl, halogen, oxo, - ORA1, -C(O)ORA1, or -C(O)RB1; each RA1 and RB1 is independently hydrogen, alkyl, or
heteroalkyl; m and n 1, 2, 3, 4, 5, or 6; o and p are each independently 0, 1, 2, 3, 4, or 5; q is an integer from 0 to 25; and “ refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (Ill-a) is a compound of Formula (III- c):
or a pharmaceutically acceptable salt thereof, wherein X is C(R’)(R”), N(R’), or S(O)X; each of R’ and R” is independently hydrogen, alkyl, halogen, or cycloalkyl; each of R2a , R2b, R2c, and R2d is independently hydrogen, alkyl, heteroalkyl, or halo; or R2a and R2b or R2c and R2d are taken together to form an oxo group; each of R3 and R5 is independently alkyl, heteroalkyl, halogen, oxo, -0RA1, -C(0)0RA1, or -C(0)RB1; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5, or 6; p is 0, 1, 2, 3, 4; q is an integer from 0 to 25; x is 0, 1, or 2; and “ -ww” refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound of Formula (III-c) is a compound of Formula (III- d):
or a pharmaceutically acceptable salt thereof, wherein X is C(R’)(R”), N(R’), or S(O)X; each of R’ and R” is independently hydrogen, alkyl, halogen, or cycloalkyl; each of R2a , R2b, R2c, and R2d is independently hydrogen, alkyl, heteroalkyl, or halo; or R2a and R2b or R2c and R2d are taken together to form an oxo group; each of R3 and R5 is independently alkyl, heteroalkyl, halogen, oxo, -ORA1, -C(O)ORA1, or -C(0)RB1; each RA1 and RB1 is independently hydrogen, alkyl, or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5, or 6; p is 0, 1, 2, 3, 4; q is an integer
from 0 to 25; x is 0, 1, or 2; and “ •~vw” refers to a connection to an attachment group or a polymer described herein.
In some embodiments, the compound is a compound of Formula (I). In some embodiments, L2 is a bond and P and L3 are independently absent.
In some embodiments, the compound is a compound of Formula (I-a). In some embodiments of Formula (Il-a), L2 is a bond, P is heteroaryl, L3 is a bond, and Z is hydrogen. In some embodiments, P is heteroaryl, L3 is heteroalkyl, and Z is alkyl. In some embodiments, L2 is a bond and P and L3 are independently absent. In some embodiments, L2 is a bond, P is heteroaryl, L3 is a bond, and Z is hydrogen. In some embodiments, P is heteroaryl, L3 is heteroalkyl, and Z is alkyl.
In some embodiments, the compound is a compound of Formula (I-b). In some embodiments, P is absent, L1 is -NHCH2, L2 is a bond, M is aryl (e.g., phenyl), L3 is -CH2O, and Z is heterocyclyl (e.g., a nitrogen-containing heterocyclyl, e.g., thiomorpholinyl- 1,1 -di oxide). In some embodiments, the compound of Formula (I-b) is Compound 116.
In some embodiments of Formula (I-b), P is absent, L1 is -NHCH2, L2 is a bond, M is absent, L3 is a bond, and Z is heterocyclyl (e.g., an oxygen-containing heterocyclyl, e.g., tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, or oxiranyl). In some embodiments, the compound of Formula (I-b) is Compound 105.
In some embodiments, the compound is a compound of Formula (I-b-i). In some embodiments of Formula (I-b-i), each of R2a and R2b is independently hydrogen or CH3, each of R2C and R2d is independently hydrogen, m is 1 or 2, n is 1, X is O, p is 0, M2 is phenyl optionally substituted with one or more R3, R3 is -CF3, and Z2 is heterocyclyl (e.g., an oxygen-containing heterocyclyl, e.g., tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, or oxiranyl). In some embodiments, the compound of Formula (I-b-i) is Compound 100, Compound 106, Compound 107, Compound 108, Compound 109, or Compound 111.
In some embodiments, the compound is a compound of Formula (I-b-ii). In some embodiments of Formula (I-b-ii), each of R2a, R2b, R2c, and R2d is independently hydrogen, q is 0, p is 0, m is 1, and Z2 is heterocyclyl (e.g., an oxygen-containing heterocyclyl, e.g., tetrahydropyranyl). In some embodiments, the compound of Formula (I-b-ii) is Compound 100.
In some embodiments, the compound is a compound of Formula (I-c). In some embodiments of Formula (I-c), each of R2c and R2d is independently hydrogen, m is 1, p is 1, q is
0, R3 is -CH3, and Z is heterocyclyl (e.g., a nitrogen-containing heterocyclyl, e.g., piperazinyl). In some embodiments, the compound of Formula (I-c) is Compound 113.
In some embodiments, the compound is a compound of Formula (I-d). In some embodiments of Formula (I-d), each of R2a, R2b, R2c, and R2d is independently hydrogen, m is 1, n is 3, X is O, p is 0, and Z is heterocyclyl (e.g., an oxygen-containing heterocyclyl, e.g., tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, or oxiranyl). In some embodiments, the compound of Formula (I-d) is Compound 110 or Compound 114.
In some embodiments, the compound is a compound of Formula (I-f). In some embodiments of Formula (I-f), each of R2a and R2b is independently hydrogen, n is 1, M is -CH2-, P is a nitrogen-containing heteroaryl (e.g., imidazolyl), L3 is -C(O)OCH2-, and Z is CH3. In some embodiments, the compound of Formula (I-f) is Compound 115.
In some embodiments, the compound is a compound of Formula (Il-a). In some embodiments of Formula (Il-a), each of R2a and R2b is independently hydrogen, n is 1, q is 0, L3 is -CH2(OCH2CH2)2, and Z is -OCH3. In some embodiments, the compound of Formula (Il-a) is Compound 112.
In some embodiments of Formula (Il-a), each of R2a and R2b is independently hydrogen, n is 1, L3 is a bond or -CH2, and Z is hydrogen or -OH In some embodiments, the compound of Formula (Il-a) is Compound 103 or Compound 104.
In some embodiments, the compound is a compound of Formula (III). In some embodiments of Formula (III), each of R2a, R2b, R2c, and R2d is independently hydrogen, m is 1, n is 2, q is 3, p is 0, Rc is hydrogen, and Z1 is heteroalkyl optionally substituted with R5 (e.g., - N(CH3)(CH2CH2)S(O)2CH3). In some embodiments, the compound of Formula (III) is Compound 120.
In some embodiments, the compound is a compound of Formula (Ill-b). In some embodiments of Formula (Ill-b), each of R2a, R2b, R2c, and R2d is independently hydrogen, m is 0, n is 2, q is 3, p is 0, and Z2 is aryl (e.g., phenyl) substituted with 1 R5 (e.g., -NH2). In some embodiments, the compound of Formula (Ill-b) is Compound 102.
In some embodiments, the compound is a compound of Formula (Ill-b). In some embodiments of Formula (Ill-b), each of R2a, R2b, R2c, and R2d is independently hydrogen, m is 1, n is 2, q is 3, p is 0, Rc is hydrogen, and Z2 is heterocyclyl (e.g., a nitrogen-containing
heterocyclyl, e g., a nitrogen-containing spiro heterocyclyl, e.g., 2-oxa-7-azaspiro[3.5]nonanyl). In some embodiments, the compound of Formula (Ill-b) is Compound 121.
In some embodiments, the compound is a compound of Formula (Ill-d). In some embodiments of Formula (Ill-d), each of R2a, R2b, R2c, and R2d is independently hydrogen, m is 1, n is 2, q is 1, 2, 3, or 4, p is 0, and X is S(O)2. In some embodiments of Formula (Ill-d), each of R2a and R2b is independently hydrogen, m is 1, n is 2, q is 1, 2, 3, or 4, p is 0, and X is S(O)2. In some embodiments, the compound of Formula (Ill-d) is Compound 101, Compound 117, Compound 118, or Compound 119.
In some embodiments, the compound is a compound of Formula (I-b), (I-d), or (I-e). In some embodiments, the compound is a compound of Formula (I-b), (I-d), or (II). In some embodiments, the compound is a compound of Formula (I-b), (I-d), or (I-f). In some embodiments, the compound is a compound of Formula (I-b), (I-d), or (III).
In some embodiments, the compound of Formula (I) is not a compound disclosed in WO2012/112982, WO2012/167223, WO2014/153126, W02016/019391, WO 2017/075630, US2012-0213708, US 2016-0030359 or US 2016-0030360.
In some embodiments, the compound of Formula (I) comprises a compound shown in Table 4, or a pharmaceutically acceptable salt thereof. In some embodiments, the exterior surface and / or one or more compartments within a device described herein comprises a small molecule compound shown in Table 4, or a pharmaceutically acceptable salt thereof.
Conjugation of any of the compounds in Table 4 to a polymer (e.g., an alginate) may be performed as described in Example 2 of WO 2019/195055 or any other suitable chemical reaction.
In some embodiments, the compound is a compound of Formula (I) (e.g., Formulas (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (II), (Il-a), (III), (Ill-a), (Ill-b), (III-c), or (III-d)), or a pharmaceutically acceptable salt thereof and is selected from:
In some embodiments, the device described herein comprises the compound of
pharmaceutically acceptable salt of either compound.
In some embodiments, a compound of Formula (I) (e.g., Compound 101 in Table 4) is covalently attached to an alginate (e.g., an alginate with approximate MW < 75 kDa, G:M ratio > 1.5) at a conjugation density of at least 2.0 % and less than 9.0 %, or 3.0 % to 8.0 %, 4.0-7.0, 5.0 to 7.0, or 6.0 to 7.0 or about 6.8 as determined by combustion analysis for percent nitrogen as described in WO 2020/069429. In an embodiment, the conjugation density of Compound 101 in the modified alginate is determined by quantitative free amine analysis, e.g., as described in WO2020198695, wherein the determined conjugation density is 1.0 % w/w to 3.0 % w/w, 1.3 % w/w to 2.8 % w/w, 1.3 % w/w to 2.6 % w/w, 1.5 % w/w to 2.4 % w/w, 1.5 % w/w to 2.2 % w/w, or 1.7 % w/w to 2.2 % w/w.
A device, device preparation or device composition may be configured for implantation, or is implanted or disposed, into or onto any site or part of the body. In some embodiments, the implantable device or device preparation is configured for implantation into the peritoneal cavity (e.g., the lesser sac, also known as the omental bursa or bursalis omentum). A device, device preparation or device composition may be implanted in the peritoneal cavity (e.g., the omentum, e.g., the lesser sac) or disposed on a surface within the peritoneal cavity (e.g., omentum, e.g., lesser sac) via injection or catheter. Additional considerations for implantation or disposition of a device, device preparation or device composition into the omentum (e.g., the lesser sac) are provided in M. Pellicciaro et al. (2017) CellR4 5(3):e2410.
Device Manufacture
Engineered mammalian cell (e.g., an engineered ARPE-19 cell)s for use in manufacturing a device, e.g., an implantable element, described herein may be generated and cultured using methods known in the art. For example, stably-transfected ARPE-19 cells may be cultured in vitro substantially as described in WO2020198695.
Compounds of Formula (I) and alginates modified with such compounds may be obtained using procedures known in the art, e.g., substantially as those described in WO2020198695.
Alginate solutions for making two-compartment hydrogel capsules may be obtained using procedures known in the art, e.g., substantially as described in W02020198695.
Two-compartment hydrogel capsules encapsulating engineered mammalian cells described herein may be generated using procedure known in the art, e.g., substantially as described in W02020198696.
Methods of Treatment
Described herein are methods for preventing or treating a disease, disorder, or condition in a subject by administering to the subject an implantable element comprising an engineered mammalian cell (e.g., an engineered ARPE-19 cell), wherein the engineered mammalian cell comprises (i) a reduction in the level or function of a MHC class I protein complex, and optionally, a MHC class II protein complex and/or CIITA, and (ii) an exogenous nucleic acid encoding a therapeutic agent that, e.g., treats the disease, disorder or condition. In some embodiments, following administration, the engineered mammalian cell comprises a reduction in antigenicity or immunogenicity, e.g., as compared to an to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of a MHC class I protein complex, and optionally, a MHC class II protein complex and/or CIITA. In some embodiments, the reduction in antigenicity or immunogenicity comprises a reduction in the (a) release of particles or components of an engineered mammalian cell described herein into the subject’s bloodstream, and/or (b) antigen presentation on the subject’s cells comprising particles or components of engineered mammalian cells described herein, e.g., as compared to an to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level or function of a MHC class I protein complex, and optionally, a MHC class II protein complex and/or CIITA. Such reductions can be characterized by standard methods known in the art, e.g., by obtaining a blood sample from a subject and quantifying, e.g., protein expression and/or RNA expression.
The cells may be administered by implanting into the subject an implantable element containing the cells as described herein, or a preparation of such devices. In an embodiment, the implantable element or preparation of implantable elements is implanted (e.g., via laparoscopy)
into the intraperitoneal space, e.g., the greater sac of the peritoneal cavity. In an embodiment, the engineered mammalian cells are engineered RPE cells, and the method comprises administering (e.g., implanting) an effective amount of a composition of two-compartment alginate hydrogel capsules which comprise the engineered RPE cells and a cell-binding polymer described herein in the inner compartment and comprise a Compound of Formula (I), e.g., Compound 101, on the outer capsule surface. In some embodiments, the method of treatment directly or indirectly reduces or alleviates at least one symptom of the disease, disorder, or condition and / or the method prevents or slows the onset of the disease, disorder, or condition. In some embodiments, the subject is a human.
In some embodiments, the disease, disorder, or condition affects a system of the body, e.g., the nervous system (e.g., peripheral nervous system (PNS) or central nervous system (CNS)), vascular system, skeletal system, respiratory system, endocrine system, lymph system, reproductive system, or gastrointestinal tract. In some embodiments, the disease, disorder, or condition affects a part of the body, e.g., blood, eye, brain, skin, lung, stomach, mouth, ear, leg, foot, hand, liver, heart, kidney, bone, pancreas, spleen, large intestine, small intestine, spinal cord, muscle, ovary, uterus, vagina, or penis.
In some embodiments, the disease, disorder or condition is a neurodegenerative disease, diabetes, a heart disease, an autoimmune disease, a cancer, a liver disease, a lysosomal storage disease, a blood clotting disorder or a coagulation disorder, an orthopedic condition, an amino acid metabolism disorder.
In some embodiments, the disease, disorder or condition is a neurodegenerative disease. Exemplary neurodegenerative diseases include Alzheimer’s disease, Huntington’s disease, Parkinson’s disease (PD) amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and cerebral palsy (CP), dentatorubro-pallidoluysian atrophy (DRPLA), neuronal intranuclear hyaline inclusion disease (NIHID), dementia with Lewy bodies, Down’s syndrome, Hallervorden-Spatz disease, prion diseases, argyrophilic grain dementia, cortocobasal degeneration, dementia pugilistica, diffuse neurofibrillary tangles, Gerstmann-Straussler- Scheinker disease, Jakob-Creutzfeldt disease, Niemann-Pick disease type 3, progressive supranuclear palsy, subacute sclerosing pan encephalitis, spinocerebellar ataxias, Pick’s disease, and dentatorubral-pallidoluysian atrophy.
In some embodiments, the disease, disorder, or condition is an autoimmune disease, e.g., scleroderma, multiple sclerosis, lupus, or allergies.
In some embodiments, the disease is a liver disease, e.g., hepatitis B, hepatitis C, cirrhosis, NASH.
In some embodiments, the disease, disorder, or condition is cancer. Exemplary cancers include leukemia, lymphoma, melanoma, lung cancer, brain cancer (e.g., glioblastoma), sarcoma, pancreatic cancer, renal cancer, liver cancer, testicular cancer, prostate cancer, or uterine cancer.
In some embodiments, the disease, disorder, or condition is an orthopedic condition. Exemplary orthopedic conditions include osteoporosis, osteonecrosis, Paget’s disease, or a fracture.
In some embodiments, the disease, disorder or condition is a lysosomal storage disease. Exemplary lysosomal storage diseases include Gaucher disease (e.g., Type I, Type II, Type III), Tay-Sachs disease, Fabry disease, Farber disease, Mucopolysaccharidosis type I (MPS I) (also known as Hurler syndrome), Hunter syndrome, lysosomal acid lipase deficiency, Niemann-Pick disease, Salla disease, Sanfilippo syndrome (also known as mucopolysaccharidosis type IIIA (MPS3A)), multiple sulfatase deficiency, Maroteaux-Lamy syndrome, metachromatic leukodystrophy, Krabbe disease, Scheie syndrome, Hurler-Scheie syndrome, Sly syndrome, hyaluronidase deficiency, Pompe disease, Danon disease, gangliosidosis, or Morquio syndrome.
In some embodiments, the disease, disorder, or condition is a blood clotting disorder or a coagulation disorder. Exemplary blood clotting disorders or coagulation disorders include hemophilia (e.g., hemophilia A or hemophilia B), Von Willebrand disease, thrombocytopenia, uremia, Bernard-Soulier syndrome, Factor XII deficiency, vitamin K deficiency, or congenital afibrinogenimia.
In some embodiments, the disease, disorder, or condition is an amino acid metabolism disorder, e.g., phenylketonuria, tyrosinemia (e.g., Type 1 or Type 2), alkaptonuria, homocystinuria, hyperhomocysteinemia, maple syrup urine disease.
In some embodiments, the disease, disorder, or condition is a fatty acid metabolism disorder, e.g., hyperlipidemia, hypercholesterolemia, galactosemia.
In some embodiments, the disease, disorder, or condition is a purine or pyrimidine metabolism disorder, e.g., Lesch-Nyhan syndrome.
In some embodiments, the disease, disorder, or condition is diabetes (e.g., Type I or Type II diabetes). In some embodiments, the disease, disorder or condition is not diabetes. In some embodiments, the disease, disorder or condition is not Type I diabetes. In some embodiments, the disease, disorder or condition is not Type II diabetes.
ENUMERATED EMBODIMENTS
1. An implantable element comprising an engineered mammalian cell, wherein:
(i) the engineered mammalian cell comprises a reduction in the level or function of a major histocompatibility complex (MHC) class I protein complex; and
(ii) the engineered mammalian cell comprises an exogenous nucleic acid encoding a therapeutic agent.
2. The implantable element of embodiment 1, wherein the MHC class I protein complex comprises one or more of:
(i) human leukocyte antigen (HL A) A;
(ii) HLA-B;
(iii) HLA-C; and
(iv) beta-2-microglobulin (beta-2M).
3. The implantable element of embodiment 2, comprising (i).
4. The implantable element of any one of embodiments 2-3, comprising (ii).
5. The implantable element of any one of embodiments 2-4, comprising (iii).
6. The implantable element of any one of embodiments 2-5, comprising (iv).
7. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a mutation resulting in the reduction of expression of a component of the MHC class I complex.
8. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a lower-functioning or non-functioning variant of a component of the MHC class I component.
9. The implantable element of any one of the preceding embodiments, wherein expression of a component of the MHC class I complex is silenced or knocked down.
10. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
11. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of the MHC class I component HLA-A by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of the MHC class I component HLA-A.
12. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of the MHC class I component HLA-B by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of the MHC class I component HLA-B.
13. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of the MHC class I component HLA-C by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of the MHC class I component HLA-C.
14. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of the MHC class I component beta-2M by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of the MHC class I component beta-2M.
15. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, or 50-75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
16. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 1-25%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
17. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 5-25%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to
the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
18. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 10- 25%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
19. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 25- 50%, , e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
20. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 25- 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
21. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 50- 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
22. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component of greater than 50%, greater than 75%, or greater than 90%, e.g., as compared to an engineered mammalian cell
that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
23. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component of greater than 50%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
24. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component of greater than 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
25. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component of greater than 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component.
26. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
27. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of HLA-A by about 0.05%, 0.1%, 0.5%,
0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of HLA-A.
28. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of HLA-B by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of HLA-B.
29. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of HLA-C by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of HLA-C.
30. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of beta-2M by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of beta-2M.
31. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 1- 25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered
mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
32. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 1- 25%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
33. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 5- 25%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
34. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 10- 25%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
35. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 25- 50%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
36. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 25- 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or
identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
37. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 50- 75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
38. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 75- 100%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
39. The engineered mammalian cell of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component of greater than 50%, greater than 75% or greater than 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
40. The engineered mammalian cell of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component of greater than 50%, e g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
41. The engineered mammalian cell of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component of greater than 75%, e.g., as compared to an engineered mammalian cell that is substantially
identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
42. The engineered mammalian cell of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component of greater than 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component.
43. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell further comprises a reduction in the level or function of a MHC class II complex.
44. The implantable element of embodiment 43, wherein the MHC class II complex comprises one or more of:
(v) human leukocyte antigen (HL A) DP;
(vi) HLA-DM;
(vii) HLA-DOA;
(viii) HLA-DOB;
(ix) HLA-DQ; and
(x) HLA-DR.
45. The implantable element of embodiment 44, wherein the MHC class II complex comprises (v).
46. The implantable element of any one of embodiments 44-45, wherein the MHC class II complex comprises (vi).
47. The implantable element of any one of embodiments 44-46, wherein the MHC class II complex comprises (vii).
48. The implantable element of any one of embodiments 44-47, wherein the MHC class TI complex comprises (viii).
49. The implantable element of any one of embodiments 44-48, wherein the MHC class II complex comprises (ix).
50. The implantable element of any one of embodiments 44-49, wherein the MHC class II complex comprises (x).
51. The implantable element of any one of embodiments 44-50, wherein the cell comprises a reduction in the function or expression of a class II major histocompatibility complex transactivator (CIITA).
52. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell is a human cell.
53. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises an embryonic stem cell (ESC) or an induced pluripotent stem cell (iPSC).
54. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises an ESC.
55. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises an iPSC.
56. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a retinal pigment epithelial (RPE) cell, a CCD-33Lu cell, a MRC-5 cell, a MRC-9 cell, a MCFlOa cell, or a cell derived therefrom.
57. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises an engineered RPE cell (e.g., an engineered ARPE-19 cell).
58. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a CCD-33Lu cell
59. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a MRC-5 cell.
60. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a MRC-9 cell.
61. The implantable element of any one of the preceding embodiments, wherein the engineered mammalian cell comprises a MCFlOa cell.
62. The implantable element of any one of the preceding embodiments, wherein the exogenous nucleotide sequence is extrachromosomal.
63. The implantable element of any one of the preceding embodiments, wherein the exogenous nucleotide sequence is inserted into at least one location in the genome of the mammalian cell.
64. The implantable element of any one of the preceding embodiments, comprising at least one cell-containing compartment which comprises the engineered mammalian cell of any one of the preceding embodiments.
65. The implantable element of any one of the preceding embodiments, further comprising at least one means for mitigating the foreign body response (FBR) when the implantable element is implanted into the subject.
66. The implantable element of any one of embodiments 64-65, wherein the engineered mammalian cell(s) in the at least one cell-containing compartment is derived from an ARPE-19 cell and encapsulated by a polymer composition.
67. The implantable element of embodiment 66, wherein the polymer composition comprises a polymer selected from alginate, hyaluronate, and chitosan.
68. The implantable element of any one of embodiments 66-67, wherein the polymer composition comprises alginate.
69. The implantable element of any one of embodiments 66-67, wherein the polymer composition comprises hyaluronate.
70. The implantable element of any one of embodiments 66-67, wherein the polymer composition comprises chitosan.
71. The implantable element of embodiment 68, wherein the alginate is a high guluronic acid (G) alginate or a high mannuronic acid (M) alginate.
72. The implantable element of embodiment 68, wherein the alginate is a high G alginate.
73. The implantable element of embodiment 68, wherein the alginate is a high M alginate.
74. The implantable element of any one of embodiments 66-73, wherein the polymer composition comprises at least one polymer covalently modified with a peptide.
75. The implantable element of embodiment 74, wherein the peptide comprises, consists essentially of, or consists of GRGDSP, GGRGDSP, or GGGRGDSP.
76. The implantable element of embodiment 75, wherein the peptide comprises, consists essentially of, or consists of GRGDSP.
77. The implantable element of embodiment 75, wherein the peptide comprises, consists essentially of, or consists of GGRGDSP.
78. The implantable element of embodiment 75, wherein the peptide comprises, consists essentially of, or consists of GGGRGDSP.
79. The implantable element of any one of embodiments 66-78, wherein the cell-containing compartment is surrounded by a barrier compartment comprising an alginate hydrogel and
optionally a compound of Formula (I) (e.g., a compound of Formula (I) described herein) disposed on the outer surface of the barrier compartment.
80. The implantable element of any one of embodiments 66-79, wherein the polymer composition comprises an alginate covalently modified with a peptide, wherein the peptide consists essentially of or consists of GRGDSP or GGRGDSP, and wherein the barrier compartment comprises an alginate chemically modified with
pharmaceutically acceptable salt thereof.
81. The implantable element of embodiment 80, wherein the polymer composition comprises an alginate covalently modified with a peptide, wherein the peptide consists essentially of or consists of GRGDSP, and wherein the barrier compartment comprises an alginate chemically modified with
pharmaceutically acceptable salt thereof.
82. The implantable element of embodiment 80, wherein the polymer composition comprises an alginate covalently modified with a peptide, wherein the peptide consists essentially of or consists of GGRGDSP, and wherein the barrier compartment comprises an alginate chemically modified with
pharmaceutically acceptable salt thereof.
83. The implantable element of any one of the preceding embodiments, wherein the implantable element is spherical.
84. The implantable element of any one of the preceding embodiments, wherein the implantable element comprises a two-compartment hydrogel capsule.
85. The implantable element of any one of the preceding embodiments, wherein the implantable element is spherical with a diameter of about 0.75 mm to about 2 mm.
86. The implantable element of any one of the preceding embodiments, wherein the therapeutic agent is a protein, e.g., a hormone, a blood clotting factor, an antibody, or an enzyme.
87. The implantable element of any one of the preceding embodiments, wherein the therapeutic agent is a protein.
88. The implantable element of any one of the preceding embodiments, wherein the therapeutic agent is a hormone.
89. The implantable element of any one of the preceding embodiments, wherein the therapeutic agent is a blood clotting factor.
90. The implantable element of any one of the preceding embodiments, wherein the therapeutic agent is an antibody.
91. The implantable element of any one of the preceding embodiments, wherein the therapeutic agent is an enzyme.
92. The implantable element of any one of the preceding embodiments, comprising:
(i) an engineered ARPE cell capable of reducing the expression of beta- 2M; and
(ii) a polymer composition comprising an alginate covalently modified with one or more of:
(a) a compound of Formula (I) (e.g., as described herein); and
(b) a peptide.
93. The implantable element of any one of the preceding embodiments, comprising:
(i) an engineered ARPE cell capable of reducing the expression of beta-2M; and
(ii) a polymer composition comprising an alginate covalently modified with a compound of Formula (I) (e.g., as described herein).
94. The implantable element of any one of the preceding embodiments, comprising:
(i) an engineered ARPE cell capable of reducing the expression of beta-2M; and
(ii) a polymer composition comprising an alginate covalently modified with a peptide.
95. The implantable element of embodiment 92, wherein the engineered ARPE cell is further capable of reducing the expression of CIITA.
96. The implantable element of any one of the preceding embodiments, comprising:
(i) an engineered ARPE cell capable of reducing the expression of beta-2M;
(ii) a polymer composition comprising an alginate covalently modified with one or more of:
pharmaceutically acceptable salt thereof; and
(b) a peptide comprising or consisting of GRGDSP or GGRGDSP.
97. The implantable element of any one of the preceding embodiments, comprising:
(i) an engineered ARPE cell capable of reducing the expression of beta-2M;
(ii) a polymer composition comprising an alginate covalently modified with one or more of:
pharmaceutically acceptable salt thereof; and
(b) a peptide comprising or consisting of GRGDSP.
98. The implantable element of any one of the preceding embodiments, comprising:
(i) an engineered ARPE cell capable of reducing the expression of beta-2M;
(ii) a polymer composition comprising an alginate covalently modified with one or more of:
pharmaceutically acceptable salt thereof; and
(b) a peptide comprising or consisting of GGRGDSP.
99. The implantable element of embodiment 96, wherein the engineered ARPE cell is further capable of reducing the expression of CIITA.
100. The implantable element of any one of the preceding embodiments, formulated for implantation into a subject (e.g., into the intraperitoneal (IP) space, the peritoneal cavity, the omentum, the lesser sac, the subcutaneous fat).
101. The implantable element of any one of the preceding embodiments, formulated for implantation into a subject (e.g., into the intraperitoneal (IP) space).
102. The implantable element of any one of the preceding embodiments, formulated for implantation into a subject (e.g., into the peritoneal cavity).
103. The implantable element of any one of the preceding embodiments, formulated for implantation into a subject (e.g., into the omentum).
104. The implantable element of any one of the preceding embodiments, formulated for implantation into a subject (e.g., into the lesser sac).
105. The implantable element of any one of the preceding embodiments, formulated for implantation into a subject (e.g., into the subcutaneous fat).
106. The implantable element of any one of the preceding embodiments, formulated for implantation into the IP space of a subject.
107. A preparation of implantable elements, wherein each implantable element in the preparation is an implantable element of any one of embodiments 1-106.
108. A method of treating a disease or disorder in a subject, the method comprising administering to the subject an implantable element of any one of embodiments 1-106 or the preparation of embodiment 107, thereby treating the disease or disorder in the subject.
109. The method of embodiment 108, wherein the disease or disorder is a lysosomal storage disease or a metabolic disorder.
110. The method of embodiment 109, wherein the disease or disorder is a lysosomal storage disease.
111. The method of embodiment 109, wherein the disease or disorder is a metabolic disorder.
112. The method any one of embodiments 108-111, wherein the subject is a human.
EXAMPLES
In order that the disclosure described herein may be more fully understood, the following examples are set forth. The examples described in this application are offered to illustrate the engineered cells, implantable devices, and compositions and methods provided herein and are not to be construed in any way as limiting their scope.
Example 1: Culturing Exemplary Engineered ARPE-19 Cells for Encapsulation
Exemplary engineered ARPE-19 cells comprising one or more genetic modifications as a stably integrated exogenous transcription unit as described herein may be cultured to produce a composition of cells suitable for encapsulation in two compartment hydrogel capsules. Cells are grown in complete growth medium (DMEM:F12 with 10% FBS) in 150 cm2 cell culture flasks or CellSTACK® Culture Chambers (Corning Inc., Corning, NY). To passage cells, the medium in the culture flask is aspirated, and the cell layer is briefly rinsed with phosphate buffered saline (pH 7.4, 137 mM NaCl, 2.7 mM KC1, 8 mM Na2HPO4, and 2 mM KH2PO4, Gibco). 5-10 mL of 0.05% (w/v) trypsin/ 0.53 mM EDTA solution (“TrypsinEDTA”) is added to the flask, and the cells are observed under an inverted microscope until the cell layer is dispersed, usually between 3-5 minutes. To avoid clumping, cells are handled with care and hitting or shaking the flask during the dispersion period is minimized. If the cells do not detach, the flasks are placed at 37°C to facilitate dispersal. Once the cells disperse, 10 mL complete growth medium is added and the cells are aspirated by gentle pipetting. The cell suspension is transferred to a centrifuge tube and spun down at approximately 125 x g for 5-10 minutes to remove TrypsinEDTA. The supernatant is discarded, and the cells are resuspended in fresh growth medium. Appropriate aliquots of cell suspension are added to new culture vessels, which are incubated at 37 °C. The medium is renewed weekly.
Example 2. Reduced Beta-2M protein expression by a Beta-2M-targeting shRNA in IDUA- expressing ARPE-19 cells
ARPE-19 cells that had been genetically modified to stably express human IDUA were transduced with shRNA-containing lentiviral particles at a MOI of 100. The shRNA contained either a beta-2M targeting sequence or a scrambled sequence as a negative control. The beta-2M shRNA sequence consisted of AAGTGGAGCATTCAGACTTGTCTTTCAGC.
Following transductions, the cells underwent selection with puromycin (lug/mL). After selection, the modified cell lines were expanded and characterized using protein specific ELISAs and the results are shown in FIG. 1. Beta-2M protein expression in the IDUA-expressing ARPE- 19 cells containing the beta-2M shRNA was 89% lower than in the IDUA-expressing ARPE-19 cells containing the scrambled control shRNA.
Example 3. Reduced Beta-2M protein expression by CRISPR and a Beta-2M-targeting guide RNA in ARPE-19 cells.
Unmodified ARPE-19 cells were transduced with lentiviral particles containing a beta- 2M-targeting gRNA or a control gRNA with a scrambled sequence and a mCherry fluorescent marker. Following selection with hygromycin, the cells were expanded, and underwent a further transfection with a Cas9/GFP expressing plasmid. Cas9-GFP expressing cells were sorted using flow cytometry to remove the untransfected population. The resulting cells were expanded and characterized by protein-specific ELISA. As shown in FIG. 2, beta-2M expression levels were decreased 99% in the ARPE-19 cells modified with the beta-2M-targeting gRNA compared to ARPE-19 cells modified using the scrambled gRNA.
Example 4. Reduction of Beta-2M protein expression results in decreased HLA Class I expression.
Wild-type ARPE-19 cells and the ARPE19 cells with reduced beta-2M protein expression from previous examples were characterized using flow cytometry. Cells were stained with a fluorescently labelled antibody that recognizes HLA Class 1 ABC. mCherry fluorescence (representative of beta-2M gRNA) and HLA- ABC antibody fluorescence were recorded. 97% of the cells transduced with the B2M-targeting gRNA expressed mCherry (FIG. 3B) compared to 1.4% of the wild type (WT) ARPE-19 cells (FIG. 3A). 99% of the WT cells were stained with the HLA-ABC antibody (FIG. 3C) compared to 7.4% of the cells targeted with beta-2M- targeting gRNA (FIG. 3D). These data confirm targeting beta-2M leads to a corresponding decrease in HLA Class 1 expression on the cell surface.
Example 5: Preparation of exemplary modified polymers
Chemically-modified Polymer. A polymeric material may be chemically modified with a compound of Formula (I) (or pharmaceutically acceptable salt thereof) prior to formation of a device described herein (e.g., a hydrogel capsule). For example, in the case of alginate, the alginate carboxylic acid is activated for coupling to one or more amine-functionalized compounds to achieve an alginate modified with an afibrotic compound, e.g., a compound of Formula (I). The alginate polymer is dissolved in water (30 mL/gram polymer) and treated with 2-chloro-4,6-dimethoxy-l,3,5-triazine (0.5 eq) and N-methylmorpholine (1 eq). To this mixture
is added a solution of the compound of interest (e.g., Compound 101 shown in Table 4) in acetonitrile (0.3M).
The amounts of the compound and coupling reagent added depends on the desired concentration of the compound bound to the alginate, e.g., conjugation density. A medium conjugation density of Compound 101 typically ranges from 2% to 5% N, while a high conjugation density of Compound 101 typically ranges from 5.1% to 8% N. To prepare a solution of low molecular weight alginate, chemically modified with a medium conjugation density of Compound 101 (CM-LMW-Alg-101-Medium polymer), the dissolved unmodified low molecular weight alginate (approximate MW < 75 kDa, G:M ratio > 1.5) is treated with 2- chloro-4,6-dimethoxy-l,3,5-triazine (5.1 mmol/g alginate) and N-methylmorpholine (10.2 mmol/ g alginate) and Compound 101 (5.4 mmol/ g alginate). To prepare a solution of low molecular weight alginate, chemically modified with a high conjugation density of Compound 101 (CM- LMW-Alg-101-High polymer), the dissolved unmodified low-molecular weight alginate (approximate MW < 75 kDa, G:M ratio > 1 5) is treated with 2-chloro-4,6-dimethoxy-l,3,5- triazine (5.1 mmol/g alginate) and N-methylmorpholine (10.2 mmol/ g alginate) and Compound 101 (10.5 mmol/ g alginate).
The reaction is warmed to 55°C for 16h, then cooled to room temperature and gently concentrated via rotary evaporation, then the residue is dissolved in water. The mixture is filtered through a bed of cyano-modified silica gel (Silicycle) and the filter cake is washed with water. The resulting solution is then extensively dialyzed (10,000 MWCO membrane) and the alginate solution is concentrated via lyophilization to provide the desired chemically-modified alginate as a solid or is concentrated using any technique suitable to produce a chemically modified alginate solution with a viscosity of 25 cP to 35 cP.
The conjugation density of a chemically modified alginate is measured by combustion analysis for percent nitrogen. The sample is prepared by dialyzing a solution of the chemically modified alginate against water (10,000 MWCO membrane) for 24 hours, replacing the water twice followed by lyophilization to a constant weight.
CBP -Alginates. A polymeric material may be covalently modified with a cell-binding peptide prior to formation of a device described herein (e.g., a hydrogel capsule described herein) using methods known in the art, see, e.g., Jeon O, et al ., Tissue Eng Part A . 16:2915- 2925 (2010) and Rowley, J.A. et al., Biomaterials 20:45-53 (1999).
For example, in the case of alginate, an alginate solution (1%, w/v) is prepared with 50mM of 2-(N-morpholino)-ethanesulfonic acid hydrate buffer solution containing 0.5M NaCl at pH 6.5, and sequentially mixed with N-hydroxysuccinimide and l-ethyl-3 -[3- (dimethylamino)propyl] carbodiimide (EDC). The molar ratio of N-hydroxysuccinimide to EDC is 0.5 : EO. The peptide of interest is added to the alginate solution. The amounts of peptide and coupling reagent added depends on the desired concentration of the peptide bound to the alginate, e.g., peptide conjugation density. By increasing the amount of peptide and coupling reagent, higher conjugation density can be obtained. After reacting for 24 h, the reaction is purified by dialysis against ultrapure deionized water (diH2O) (MWCO 3500) for 3 days, treated with activated charcoal for 30 min, filtered (0.22 mm filter), and concentrated to the desired viscosity.
The conjugation density of a peptide-modified alginate is measured by combustion analysis for percent nitrogen. The sample is prepared by dialyzing a solution of the chemically modified alginate against water (10,000 MWCO membrane) for 24 hours, replacing the water twice followed by lyophilization to a constant weight.
Example 5: Preparation of exemplary alginate solutions for making hydrogel capsules
70:30 mixture of chemically-modified and unmodified alginate. A low molecular weight alginate (PRONOVA™ VLVG alginate, NovaMatrix, Sandvika, Norway, cat. #4200506, approximate molecular weight < 75 kDa; G:M ratio > 1.5) is chemically modified with Compound 101 to produce chemically modified low molecular weight alginate (CM-LMW-Alg- 101) solution with a viscosity of 25 cp to 35 cP and a conjugation density of 5.1% to 8% N, as determined by combustion analysis for percent nitrogen. A solution of high molecular weight unmodified alginate (U-HMW-Alg) is prepared by dissolving unmodified alginate (PRONOVA™ SLG100, NovaMatrix, Sandvika, Norway, cat. #4202106, approximate molecular weight of 150 kDa - 250 kDa) at 3% weight to volume in 0.9% saline. The CM- LMW-Alg solution is blended with the U-HMW-Alg solution at a volume ratio of 70% CM- LMW-Alg to 30% U-HMW-Alg (referred to herein as a 70:30 CM-Alg:UM-Alg solution).
Unmodified alginate solution. An unmodified medium molecular weight alginate (SLG20, NovaMatrix, Sandvika, Norway, cat. #4202006, approximate molecular weight of 75- 150 kDa), is dissolved at 1.4% weight to volume in 0.9% saline to prepare a U-MMW-Alg solution.
Unmodi fied alginate solution. An unmodified medium molecular weight alginate (SLG20, NovaMatrix, Sandvika, Norway, cat. #4202006, approximate molecular weight of 75- 150 kDa), is dissolved at 1.4% weight to volume in 0.9% saline to prepare a U-MMW-Alg solution.
Alginate Solution Comprising Cell Binding Sites. A solution of SLG20 alginate is modified with a peptide consisting of GRGDSP as described above and concentrated to a viscosity of about lOOcP. The amount of the peptide and coupling reagent used are selected to achieve a target peptide conjugation density of about 0.2 to 0.3, as measured by combustion analysis.
Example 6: Formation of exemplary two-compartment hydrogel capsules
Suspensions of engineered mammalian cells as single cells are encapsulated in two- compartment hydrogel capsules according to the protocols described below.
Immediately before encapsulation, a desired volume of a composition comprising the cells (e.g., from a culture of the cells as described in Example 1) are centrifuged at 1,400 r.p.m. for 1 min and washed with calcium-free Krebs-Henseleit (KH) Buffer (4.7 mM KC1, 25 mM HEPES, 1.2 mM KH2PO4, 1.2 mM MgSO4 x 7H2O, 135 mM NaCl, pH « 7.4, -290 mOsm). After washing, the cells are centrifuged again and all of the supernatant is aspirated. The cell pellet is resuspended in the GRGDSP-modified alginate solution described in Example 3 at a desired cell density (e.g., about 50 to 150 million suspended single cells per ml alginate solution).
Prior to fabricating hydrogel capsules, buffers and alginate solutions are sterilized by filtration through a 0.2-pm filter using aseptic processes.
To prepare two-compartment hydrogel millicapsules of about 1.5 mm diameter, an electrostatic droplet generator is set up as follows: an ES series 0-100-kV, 20-watt high-voltage power generator (EQ series, Matsusada, NC, USA) is connected to the top and bottom of a coaxial needle (inner lumen of 22G, outer lumen of 18G, Rame-Hart Instrument Co., Succasunna, NJ, USA). The inner lumen is attached to a first 5-ml Luer-lock syringe (BD, NJ, USA), which is connected to a syringe pump (Pump 11 Pico Plus, Harvard Apparatus, Holliston, MA, USA) that is oriented vertically. The outer lumen is connected via a luer coupling to a second 5-ml Luer-lock syringe which is connected to a second syringe pump (Pump 11 Pico Plus) that is oriented horizontally. A first alginate solution containing the genetically modified
cells (as single cells) suspended in a GRGDSP -modified alginate solution is placed in the first syringe and a cell-free alginate solution comprising a mixture of a chemically-modified alginate and unmodified alginate is placed in the second syringe. The two syringe pumps move the first and second alginate solutions from the syringes through both lumens of the coaxial needle and single droplets containing both alginate solutions are extruded from the needle into a glass dish containing a cross-linking solution. The settings of each Pico Plus syringe pump are 12.06 mm diameter and the flow rates of each pump are adjusted to achieve a flow rate ratio of 1: 1 for the two alginate solutions. Thus, with the total flow rate set at lOml/h, the flow rate for each alginate solution is about 5 mL/h. Control (empty) capsules are prepared in the same manner except that the alginate solution used for the inner compartment is a cell-free solution.
After extrusion of the desired volumes of alginate solutions, the alginate droplets are crosslinked for five minutes in a cross-linking solution which contain 25mM HEPES buffer, 20 mM BaCb, 0.2M mannitol and 0.01% of poloxamer 188. Capsules that fall to the bottom of the crosslinking vessel are collected by pipetting into a conical tube. After the capsules settle in the tube, the crosslinking buffer is removed, and capsules are washed four times in HEPES buffer, two times in 0.9% saline, and two times in culture media and stored in an incubator at 37°C.
EQUIVALENTS AND SCOPE
This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the disclosure can be excluded from any claim, for any reason, whether or not related to the existence of prior art.
Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, Figures, or Examples but rather is as set forth in the appended claims. Those of ordinary skill in
the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present disclosure, as defined in the following claims.
Claims
1. An implantable element comprising an engineered mammalian cell, wherein:
(i) the engineered mammalian cell comprises a reduction in the level or function of a major histocompatibility complex (MHC) class I protein complex; and
(ii) the engineered mammalian cell comprises an exogenous nucleic acid encoding a therapeutic agent; wherein the implantable element comprises a polymer and a compound of Formula (1):
or a pharmaceutically acceptable salt thereof, wherein:
A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, - C(O)O-, -C(O)-, -OC(O)-, -N(RC)-, -N(Rc)C(O)-, -C(O)N(Rc)-, -N(RC)C(O)(CI-C6- alkylene)-, -N(Rc)C(O)(Ci-C6-alkenylene)-, -N(RC)N(RD)-, -NCN-, -C(=N(Rc)(RD))O-, -S-, -S(O)x-, -OS(O)x-, -N(Rc)S(O)x-, -S(O)xN(Rc)-, -P(RF)y-, -Si(ORA)2 -, -Si(RG)(ORA)-, - B(ORA)-, or a metal, each of which is optionally linked to an attachment group (e.g., an attachment group described herein) and is optionally substituted by one or more R1; each of L1 and L3 is independently a bond, alkyl, or heteroalkyl, wherein each alkyl and heteroalkyl is optionally substituted by one or more R2;
L2 is a bond;
M is absent, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted by one or more R3;
P is absent, cycloalkyl, heterocyclyl, or heteroaryl, each of which is optionally substituted by one or more R4;
Z is hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, -ORA, -C(O)RA, -C(O)ORA, - C(O)N(RC)(RD), -N(RC)CFVA, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted by one or more R5; each RA, RB, RC, RD, RE, RF, and RG is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, azido, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl,
alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more R6; or Rc and RD, taken together with the nitrogen atom to which they are attached, form a ring (e.g., a 5-7 membered ring), optionally substituted with one or more R6; each R1, R2, R3, R4, R5, and R6 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -ORA1, -C(O)ORA1, -C(O)RB1,-OC(O)RB1, -N(RC1)(RD1), -N(RC1)C(O)RB1, -C(O)N(RC1), SRE1, S(O)XRE1, -OS(O)XRE1, -N(RC1)S(O)XRE1, - S(O)XN(RC1)(RD1), -P(RF1)y, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted by one or more R7; each RA1, RB1, RC1, RD1, RE1, and RF1 is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted by one or more R7; each R7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl; x is 1 or 2; and y is 2, 3, or 4.
2. The implantable element of claim 1, wherein the MHC class I protein complex comprises one or more of:
(i) human leukocyte antigen (HLA) A;
(ii) HLA-B;
(iii) HLA-C; and
(iv) beta-2 -microglobulin (beta-2M).
3. The implantable element of claim 2, comprising (i).
4. The implantable element of any one of claims 2-3, comprising (ii).
5. The implantable element of any one of claims 2-4, comprising (iii).
6. The implantable element of any one of claims 2-5, comprising (iv).
7. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises a mutation resulting in the reduction of expression of a component of the MHC class I complex, e.g., as compared to a reference standard.
8. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises a lower-functioning or non-functioning variant of a component of the MHC class I component, e.g., as compared to a reference standard.
9. The implantable element of any one of the preceding claims, wherein expression of a component of the MHC class I complex is silenced or knocked down, e.g., as compared to a reference standard.
10. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component, e.g., as compared to a reference standard.
11. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component between 1-25%, 5-25%, 10-25%, 25-50%, 25-75%, or 50-75%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component, e.g., as compared to a reference standard.
12. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises a reduction in the level of a MHC class I component of greater than 50%, greater than 75% or greater than 90%, e.g., as compared to an engineered mammalian cell
that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the level of an MHC class I component, e.g., as compared to a reference standard.
13. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component by about 0.05%, 0.1%, 0.5%, 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component, e.g., as compared to a reference standard.
14. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component between 1- 25%, 5-25%, 10-25%, 25-50%, 25-75%, 50-75%, or 75-100%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component, e.g., as compared to a reference standard.
15. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises a reduction in the function of a MHC class I component of greater than 50%, greater than 75% or greater than 90%, e.g., as compared to an engineered mammalian cell that is substantially identical to or identical to the engineered mammalian cell except that it does not comprise a reduction in the function of an MHC class I component, e.g., as compared to a reference standard.
16. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell further comprises a reduction in the level or function of a MHC class II complex.
17. The implantable element of claim 16, wherein the MHC class II complex comprises one or more of:
(v) human leukocyte antigen (HLA) DP;
(vi) HLA-DM;
(vii) HLA-DOA;
(viii) HLA-DOB;
(ix) HLA-DQ; and
(x) HLA-DR.
18. The implantable element of claim 17, wherein the MHC class II complex comprises (v).
19. The implantable element of any one of claims 17-18, wherein the MHC class II complex comprises (vi).
20. The implantable element of any one of claims 17-19, wherein the MHC class II complex comprises (vii).
21. The implantable element of any one of claims 17-20, wherein the MHC class II complex comprises (viii).
22. The implantable element of any one of claims 17-21, wherein the MHC class II complex comprises (ix).
23. The implantable element of any one of claims 17-22, wherein the MHC class II complex comprises (x).
24. The implantable element of any one of claims 17-23, wherein the cell comprises a reduction in the function or expression of a class II major histocompatibility complex transactivator (CIITA).
25. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell is a human cell.
26. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises an embryonic stem cell (ESC) or an induced pluripotent stem cell (iPSC).
27. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises a retinal pigment epithelial (RPE) cell, a CCD-33Lu cell, a MRC-5 cell, a MRC-9 cell, a MCFlOa cell, or a cell derived therefrom.
28. The implantable element of any one of the preceding claims, wherein the engineered mammalian cell comprises an engineered retinal pigment epithelial (RPE) cell (e.g., an engineered ARPE-19 cell).
29. The implantable element of any one of the preceding claims, wherein the exogenous nucleotide sequence is extrachromosomal.
30. The implantable element of any one of the preceding claims, wherein the exogenous nucleotide sequence is inserted into at least one location in the genome of the mammalian cell.
31. The implantable element of any one of the preceding claims, comprising at least one cellcontaining compartment which comprises the engineered mammalian cell of any one of claims 1- 30.
32. The implantable element of any one of the preceding claims, wherein the polymer is selected from alginate, hyaluronate, and chitosan.
33. The implantable element of claim 32, wherein the polymer comprises alginate.
34. The implantable element of any one of claims 32-33, wherein the alginate is a high guluronic acid (G) alginate or a high mannuronic acid (M) alginate.
35. The implantable element of any one of the preceding claims, wherein the polymer comprises at least one polymer covalently modified with a peptide.
36. The implantable element of claim 35, wherein the peptide comprises, consists essentially of or consists of GRGDSP, GGRGDSP or GGGRGDSP.
37. The implantable element of any one of claims 31-36, wherein the cell -containing compartment is surrounded by a barrier compartment comprising an alginate hydrogel and optionally a compound of Formula (I) (e.g., a compound of Formula (I) described herein) disposed on the outer surface of the barrier compartment.
38. The implantable element of any one of claims 31-37, wherein the polymer comprises an alginate covalently modified with a peptide, wherein the peptide consists essentially of or consists of GRGDSP or GGRGDSP, and wherein the barrier compartment comprises an alginate chemically modified with
pharmaceutically acceptable salt thereof.
39. The implantable element of any one of the preceding claims, wherein the implantable element is spherical.
40. The implantable element of any one of the preceding claims, wherein the implantable element comprises a two-compartment hydrogel capsule.
41. The implantable element of any one of the preceding claims, wherein the implantable element is spherical with a diameter of about 0.75 mm to about 2 mm.
42. The implantable element of any one of the preceding claims, wherein the therapeutic agent is a protein, e.g., a hormone, a blood clotting factor, an antibody, or an enzyme.
43. The implantable element of any one of the preceding claims, comprising:
(i) an engineered ARPE cell capable of reducing the expression of beta-2M;
(ii) a polymer composition comprising an alginate covalently modified with one or more of:
(a) a compound of Formula (I) (e.g., as described herein); and
(b) a peptide.
44. The implantable element of claim 43, wherein the engineered ARPE cell is further capable of reducing the expression of CIITA.
45. The implantable element of any one of the preceding claims, comprising:
(i) an engineered ARPE cell capable of reducing the expression of beta-2M;
(ii) a polymer composition comprising an alginate covalently modified with one or more of:
pharmaceutically acceptable salt thereof; and
(b) a peptide comprising or consisting of GRGDSP or GGRGDSP.
46. The implantable element of claim 47, wherein the engineered ARPE cell is further capable of reducing the expression of CIITA.
47. The implantable element of any one of the preceding claims, formulated for implantation into a subject (e.g., into the intraperitoneal (IP) space, the peritoneal cavity, the omentum, the lesser sac, the subcutaneous fat).
48. The implantable element of any one of the preceding claims, formulated for implantation into the IP space of a subject.
49. A preparation of implantable elements, wherein each implantable element in the preparation is an implantable element of any one of claims 1-48.
50. A composition for use in treating a disease or disorder in a subject comprising an implantable element of any one of claims 1-48 or the preparation of claim 49.
51. The composition for use of claim 50, wherein the disease or disorder is a lysosomal storage disease or a metabolic disorder.
52. The composition for use of any one of claims 50-51, wherein the subject is a human.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263415271P | 2022-10-11 | 2022-10-11 | |
US63/415,271 | 2022-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024081309A1 true WO2024081309A1 (en) | 2024-04-18 |
Family
ID=88969550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/034936 WO2024081309A1 (en) | 2022-10-11 | 2023-10-11 | Engineered cells and implantable elements for treatment of disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024081309A1 (en) |
Citations (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004187A1 (en) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS |
WO1988000831A1 (en) | 1986-08-01 | 1988-02-11 | Biogen N.V. | Dna sequences coding for modified factor viii:c and modified factor viii:c-like polypeptides and processes for producing these polypeptides in high yields |
EP0295597A2 (en) | 1987-06-19 | 1988-12-21 | BEHRINGWERKE Aktiengesellschaft | Factor VIII:C-like molecule with a coagulant activity |
US4868112A (en) | 1985-04-12 | 1989-09-19 | Genetics Institute, Inc. | Novel procoagulant proteins |
WO1991009122A1 (en) | 1989-12-15 | 1991-06-27 | Kabivitrum Ab | A recombinant human factor viii derivative |
US5112950A (en) | 1987-08-11 | 1992-05-12 | Transgene S.A. | Factor viii analog, preparation process, and pharmaceutical composition containing it |
US5171844A (en) | 1987-06-12 | 1992-12-15 | Gist-Brocades N.W. | Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5972885A (en) | 1993-07-05 | 1999-10-26 | Pharmacia & Upjohn Aktiebolag | Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives |
US6048720A (en) | 1995-09-29 | 2000-04-11 | Pharmacia & Upjohn Ab | Conjugates of a polypeptide and a biocompatible polymer |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
WO2002040544A2 (en) | 2000-11-14 | 2002-05-23 | Board Of Regents, University Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
WO2003020764A2 (en) | 2001-09-04 | 2003-03-13 | Merck Patent Gmbh | Modified factor ix |
EP1373493A1 (en) | 2001-03-22 | 2004-01-02 | Novo Nordisk Health Care AG | Coagulation factor vii derivatives |
EP0742818B1 (en) | 1994-01-13 | 2004-09-01 | The Rogosin Institute | Macroencapsulated secretory cells |
WO2004101740A2 (en) | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
WO2007149406A2 (en) | 2006-06-19 | 2007-12-27 | Nautilus Technology Llc | Modified coagulation factor ix polypeptides and use thereof for treatment |
US20080058255A1 (en) | 2004-06-21 | 2008-03-06 | Novo Nordisk Healthcare A/G | Glycosylation-Disrupted Factor VII Variants |
WO2008118507A2 (en) | 2007-01-09 | 2008-10-02 | Wu, Karl | Recombinant human factor ix and use thereof |
EP2032607A1 (en) | 2006-06-14 | 2009-03-11 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
WO2009051717A2 (en) | 2007-10-15 | 2009-04-23 | The University Of North Carolina At Chapel Hill | Human factor ix variants with an extended half life |
WO2009130198A2 (en) | 2008-04-21 | 2009-10-29 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
WO2009137254A2 (en) | 2008-04-16 | 2009-11-12 | Bayer Healthcare Llc | Modified factor ix polypeptides and uses thereof |
WO2009140015A2 (en) | 2008-04-16 | 2009-11-19 | Bayer Healthcare Llc | Site-directed modification of factor ix |
US7771996B2 (en) | 2003-03-20 | 2010-08-10 | Bayer Healthcare Llc | FVII or FVIIa variants |
WO2011020866A2 (en) | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
WO2012006624A2 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Factor ix polypeptides and methods of use thereof |
WO2012112982A2 (en) | 2011-02-18 | 2012-08-23 | Massachusetts Institute Of Technology | Hydrogel encapsulated cells and anti-inflammatory drugs |
US8278106B2 (en) | 2008-11-14 | 2012-10-02 | Viacyte, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
WO2012167223A1 (en) | 2011-06-02 | 2012-12-06 | Massachusetts Institute Of Technology | Modified alginates for cell encapsulation and cell therapy |
WO2014153126A1 (en) | 2013-03-14 | 2014-09-25 | Massachusetts Institute Of Technology | Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates |
US20160030359A1 (en) | 2013-03-14 | 2016-02-04 | Massachusetts Institute Of Technology | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates |
US20160030360A1 (en) | 2014-08-01 | 2016-02-04 | Massachusetts Institute Of Technology | Modified alginates for anti-fibrotic materials and applications |
US9394353B2 (en) | 2011-10-18 | 2016-07-19 | Csl Limited | Method for improving the stability of purified factor VIII after reconstitution |
US9476037B2 (en) | 2008-04-11 | 2016-10-25 | Catalyst Biosciences, Inc. | Factor VII polypeptides that are modified and uses thereof |
US9526880B2 (en) | 2013-03-07 | 2016-12-27 | Viacyte, Inc. | 3-dimensional large capacity cell encapsulation device assembly |
WO2017075631A1 (en) | 2015-11-01 | 2017-05-04 | Massachusetts Institute Of Technology | Modified alginates for anti-fibrotic materials and applications |
WO2017075630A1 (en) | 2015-11-01 | 2017-05-04 | Massachusetts Institute Of Technology | Materials with improved properties |
US9670267B2 (en) | 2009-10-02 | 2017-06-06 | The Children's Hospital Of Philadelphia | Compositions and methods for enhancing coagulation factor VIII function |
US9724430B2 (en) | 2007-09-28 | 2017-08-08 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
US20170234455A1 (en) | 2011-05-10 | 2017-08-17 | Fujikin Incorporated | Pressure type flow control system with flow monitoring, and method for detecting anomaly in fluid supply system and handling method at abnormal monitoring flow rate using the same |
US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
WO2018232027A1 (en) | 2017-06-13 | 2018-12-20 | Massachusetts Institute Of Technology | Biocompatible microfabricated devices for transplanting cells |
WO2019068059A1 (en) | 2017-09-29 | 2019-04-04 | Semma Therapeutics, Inc. | Cell housing device |
WO2019169089A1 (en) | 2018-03-01 | 2019-09-06 | Seraxis, Inc. | Macro-encapsulated therapeutic cells, devices, and methods of using the same |
WO2019195055A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Implantable particles and related methods |
US10493107B2 (en) | 2014-06-09 | 2019-12-03 | Cornell University | Implantable therapeutic delivery system and methods thereof |
WO2020069429A1 (en) | 2018-09-27 | 2020-04-02 | Sigilon Therapeutics, Inc. | Implantable devices for cell therapy and related methods |
WO2020198696A1 (en) | 2019-03-28 | 2020-10-01 | Agex Therapeutics, Inc. | Induced tissue regeneration using extracellular vesicles |
WO2020198695A1 (en) | 2019-03-27 | 2020-10-01 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for factor vii therapy |
WO2022026606A2 (en) * | 2020-07-28 | 2022-02-03 | Sigilon Therapeutics, Inc. | Genetically modified cell lines expressing an exogenous substance and uses thereof |
-
2023
- 2023-10-11 WO PCT/US2023/034936 patent/WO2024081309A1/en unknown
Patent Citations (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4868112A (en) | 1985-04-12 | 1989-09-19 | Genetics Institute, Inc. | Novel procoagulant proteins |
WO1987004187A1 (en) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS |
US6228620B1 (en) | 1986-01-27 | 2001-05-08 | Chiron Corporation | Protein complexes having factor VIII:C activity and production thereof |
US5789203A (en) | 1986-01-27 | 1998-08-04 | Chiron Corporation | Protein complexes having factor VIII:C activity and production thereof |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
WO1988000831A1 (en) | 1986-08-01 | 1988-02-11 | Biogen N.V. | Dna sequences coding for modified factor viii:c and modified factor viii:c-like polypeptides and processes for producing these polypeptides in high yields |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US5171844A (en) | 1987-06-12 | 1992-12-15 | Gist-Brocades N.W. | Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US6316226B1 (en) | 1987-06-12 | 2001-11-13 | Baxter Trading Gmbh | Proteins with Factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
EP0295597A2 (en) | 1987-06-19 | 1988-12-21 | BEHRINGWERKE Aktiengesellschaft | Factor VIII:C-like molecule with a coagulant activity |
US5112950A (en) | 1987-08-11 | 1992-05-12 | Transgene S.A. | Factor viii analog, preparation process, and pharmaceutical composition containing it |
WO1991009122A1 (en) | 1989-12-15 | 1991-06-27 | Kabivitrum Ab | A recombinant human factor viii derivative |
US5972885A (en) | 1993-07-05 | 1999-10-26 | Pharmacia & Upjohn Aktiebolag | Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives |
EP0742818B1 (en) | 1994-01-13 | 2004-09-01 | The Rogosin Institute | Macroencapsulated secretory cells |
US6048720A (en) | 1995-09-29 | 2000-04-11 | Pharmacia & Upjohn Ab | Conjugates of a polypeptide and a biocompatible polymer |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
WO2002040544A2 (en) | 2000-11-14 | 2002-05-23 | Board Of Regents, University Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
EP1373493A1 (en) | 2001-03-22 | 2004-01-02 | Novo Nordisk Health Care AG | Coagulation factor vii derivatives |
WO2003020764A2 (en) | 2001-09-04 | 2003-03-13 | Merck Patent Gmbh | Modified factor ix |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
US7771996B2 (en) | 2003-03-20 | 2010-08-10 | Bayer Healthcare Llc | FVII or FVIIa variants |
WO2004101740A2 (en) | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
US20080058255A1 (en) | 2004-06-21 | 2008-03-06 | Novo Nordisk Healthcare A/G | Glycosylation-Disrupted Factor VII Variants |
EP2032607A1 (en) | 2006-06-14 | 2009-03-11 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
WO2007149406A2 (en) | 2006-06-19 | 2007-12-27 | Nautilus Technology Llc | Modified coagulation factor ix polypeptides and use thereof for treatment |
WO2008118507A2 (en) | 2007-01-09 | 2008-10-02 | Wu, Karl | Recombinant human factor ix and use thereof |
US9724430B2 (en) | 2007-09-28 | 2017-08-08 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
WO2009051717A2 (en) | 2007-10-15 | 2009-04-23 | The University Of North Carolina At Chapel Hill | Human factor ix variants with an extended half life |
US9476037B2 (en) | 2008-04-11 | 2016-10-25 | Catalyst Biosciences, Inc. | Factor VII polypeptides that are modified and uses thereof |
WO2009140015A2 (en) | 2008-04-16 | 2009-11-19 | Bayer Healthcare Llc | Site-directed modification of factor ix |
WO2009137254A2 (en) | 2008-04-16 | 2009-11-12 | Bayer Healthcare Llc | Modified factor ix polypeptides and uses thereof |
WO2009130198A2 (en) | 2008-04-21 | 2009-10-29 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
US8278106B2 (en) | 2008-11-14 | 2012-10-02 | Viacyte, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
WO2011020866A2 (en) | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
US9670267B2 (en) | 2009-10-02 | 2017-06-06 | The Children's Hospital Of Philadelphia | Compositions and methods for enhancing coagulation factor VIII function |
WO2012006624A2 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Factor ix polypeptides and methods of use thereof |
US20120213708A1 (en) | 2011-02-18 | 2012-08-23 | Massachusetts Institute Of Technology | Hydrogel encapsulated cells and anti-inflammatory drugs |
WO2012112982A2 (en) | 2011-02-18 | 2012-08-23 | Massachusetts Institute Of Technology | Hydrogel encapsulated cells and anti-inflammatory drugs |
US20170234455A1 (en) | 2011-05-10 | 2017-08-17 | Fujikin Incorporated | Pressure type flow control system with flow monitoring, and method for detecting anomaly in fluid supply system and handling method at abnormal monitoring flow rate using the same |
WO2012167223A1 (en) | 2011-06-02 | 2012-12-06 | Massachusetts Institute Of Technology | Modified alginates for cell encapsulation and cell therapy |
US9956269B2 (en) | 2011-10-18 | 2018-05-01 | Csl Limited | Method for improving the stability of purified factor VIII after reconstitution |
US9394353B2 (en) | 2011-10-18 | 2016-07-19 | Csl Limited | Method for improving the stability of purified factor VIII after reconstitution |
US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
US9526880B2 (en) | 2013-03-07 | 2016-12-27 | Viacyte, Inc. | 3-dimensional large capacity cell encapsulation device assembly |
US20160030359A1 (en) | 2013-03-14 | 2016-02-04 | Massachusetts Institute Of Technology | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates |
WO2014153126A1 (en) | 2013-03-14 | 2014-09-25 | Massachusetts Institute Of Technology | Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates |
US10493107B2 (en) | 2014-06-09 | 2019-12-03 | Cornell University | Implantable therapeutic delivery system and methods thereof |
WO2016019391A1 (en) | 2014-08-01 | 2016-02-04 | Massachusetts Institute Of Technology | Modified alginates for anti-fibrotic materials and applications |
US20160030360A1 (en) | 2014-08-01 | 2016-02-04 | Massachusetts Institute Of Technology | Modified alginates for anti-fibrotic materials and applications |
WO2017075630A1 (en) | 2015-11-01 | 2017-05-04 | Massachusetts Institute Of Technology | Materials with improved properties |
WO2017075631A1 (en) | 2015-11-01 | 2017-05-04 | Massachusetts Institute Of Technology | Modified alginates for anti-fibrotic materials and applications |
WO2018232027A1 (en) | 2017-06-13 | 2018-12-20 | Massachusetts Institute Of Technology | Biocompatible microfabricated devices for transplanting cells |
WO2019068059A1 (en) | 2017-09-29 | 2019-04-04 | Semma Therapeutics, Inc. | Cell housing device |
WO2019169089A1 (en) | 2018-03-01 | 2019-09-06 | Seraxis, Inc. | Macro-encapsulated therapeutic cells, devices, and methods of using the same |
WO2019195055A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Implantable particles and related methods |
WO2020069429A1 (en) | 2018-09-27 | 2020-04-02 | Sigilon Therapeutics, Inc. | Implantable devices for cell therapy and related methods |
WO2020198695A1 (en) | 2019-03-27 | 2020-10-01 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for factor vii therapy |
WO2020198696A1 (en) | 2019-03-28 | 2020-10-01 | Agex Therapeutics, Inc. | Induced tissue regeneration using extracellular vesicles |
WO2022026606A2 (en) * | 2020-07-28 | 2022-02-03 | Sigilon Therapeutics, Inc. | Genetically modified cell lines expressing an exogenous substance and uses thereof |
Non-Patent Citations (45)
Title |
---|
ARNDT ET AL.: "Functional HLA-DM on the surface of B cells and immature dendritic cells", THE EMBO JOURNAL., vol. 19, no. 6, 2000, pages 1241 - 51 |
BASHOR CALEB J. ET AL: "Engineering the next generation of cell-based therapeutics", vol. 21, no. 9, 30 May 2022 (2022-05-30), GB, pages 655 - 675, XP093120164, ISSN: 1474-1776, Retrieved from the Internet <URL:https://www.nature.com/articles/s41573-022-00476-6.pdf> DOI: 10.1038/s41573-022-00476-6 * |
BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19 |
CHANG ET AL., J. BIOL. CHEM., vol. 273, 1998, pages 12089 - 94 |
DEFAZIO A ET AL., JHISTOCHEM CYTOCHEM, vol. 35, 1987, pages 571 - 577 |
DOLBEARE F ET AL., PROC NATL ACAD SCI USA, vol. 80, 1983, pages 5573 - 5577 |
EATON ET AL., BIOCHEMISTRY, vol. 25, 1986, pages 8343 - 8347 |
ELIEL: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL |
FIX ET AL.: "Kidney Transplantation: Past, Present, and Future", 1998, UNIVERSITY OF MICHIGAN MEDICAL CENTER/STANFORD UNIVERSITY, article "HLA Matching, Antibodies, and You" |
GILHAM D E ET AL: "Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells", JOURNAL OF CLINICAL ONCOLOGY (2020 ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM); 2020 ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, ASCO 2020 20200529 TO 20200602 CHICAGO, IL, LIPPINCOTT WILLIAMS & WILKINS, USA, vol. 38, no. 15, 1 January 2020 (2020-01-01), XP009541172, ISSN: 1527-7755 * |
GROTE, A. ET AL., NUCLEIC ACIDS RESEARCH, vol. 33, 2005, pages W526 - W531 |
HARTON: "Class II transactivator: mastering the art of major histocompatibility complex expression", MOLECULAR AND CELLULAR BIOLOGY., vol. 20, no. 17, 2000, pages 6185 - 94 |
HEUBERGER ET AL.: "Why do intestinal epithelial cells express MHC class II?", IMMUNOLOGY, vol. 162, no. 4, 2021, pages 357 - 367 |
HOEBEN R. C. ET AL., J. BIOL. CHEM., vol. 265, no. 13, 1990, pages 7318 - 7323 |
JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE |
JEON O ET AL., TISSUE ENG PART A., vol. 16, 2010, pages 2915 - 2925 |
KASUDA, A. ET AL., J. THROMB. HAEMOST., vol. 6, 2008, pages 1352 - 1359 |
KELLEY E. ET AL: "SIG-009: Novel Encapsulated Non-viral Cell-based Therapy for FVII Deficiency - ISTH Congress Abstracts", 1 January 2021 (2021-01-01), XP093120112, Retrieved from the Internet <URL:https://abstracts.isth.org/abstract/sig-009-novel-encapsulated-non-viral-cell-based-therapy-for-fvii-deficiency/> * |
LAGNER, BEHRING INST. MITT., vol. 82, 1988, pages 16 - 25 |
LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS, INC. |
LEIBUNDGUT-LANDMANN ET AL.: "Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes", EUROPEAN JOURNAL OF IMMUNOLOGY., vol. 34, no. 6, 2004, pages 1513 - 25, XP055004616, DOI: 10.1002/eji.200424964 |
M. PELLICCIARO ET AL., CELLR4, vol. 5, no. 3, 2017, pages e2410 |
MA, M ET AL., ADV. HEALTHC MATER., vol. 2, no. 5, 2012, pages 667 - 672 |
MARSH: "2010", TISSUE ANTIGENS, vol. 75, no. 4, 2010, pages 291 - 455 |
MCKEEN: "3- Plastics Used in Medical Devices", HANDBOOK OF POLYMER APPLICATIONS IN MEDICINE AND MEDICAL DEVICES, 2014, pages 21 - 53, XP055214424, DOI: 10.1016/B978-0-323-22805-3.00003-7 |
MEULIEN P. ET AL., PROTEIN ENG., vol. 2, no. 4, 1988, pages 301 - 6 |
MIAO, H. Z. ET AL., BLOOD, vol. 103, 2004, pages 3412 - 3419 |
PASHINE ET AL.: "Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides", IMMUNITY., vol. 19, no. 2, 2003, pages 183 - 92 |
PERSSON, BIOL. CHEM., vol. 272, 1997, pages 19919 - 19924 |
PERSSON, FEBS LETTS, vol. 413, 1997, pages 359 - 363 |
PIPE, S. W. ET AL., J. THROMB. HAEMOST., vol. 9, 2011, pages 2235 - 2242 |
RISS, T. ET AL.: "Bioconjugate Techniques", 2013, ELSEVIER, INC, article "Cell Viability Assays" |
ROSEN, S., SCAND JHAEMATOL, vol. 33, 1984, pages 139 - 145 |
ROWLEY, J.A. ET AL., BIOMATERIALS, vol. 20, 1999, pages 45 - 53 |
RUBIO ET AL.: "HLA class II mediates type 1 diabetes risk by anti-insulin repertoire selection", BIORXIV: 2021.09.06.458974. DOI: 10. 1101/2021.09.06.458974, 2021 |
SANG, S.ROY, S., BIOTECHLIOL BIOENG, vol. 113, no. 7, 2016, pages 1381 - 1402 |
SARVER ET AL., DNA, vol. 6, 1987, pages 553 - 564 |
SHAPIRO AMY D ET AL: "First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia [Alpha]", vol. 136, no. Supplement 1, 5 November 2020 (2020-11-05), US, pages 8 - 8, XP093120106, ISSN: 0006-4971, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/136/Supplement%201/8/470587/First-in-Human-Phase-1-2-Clinical-Trial-of-SIG-001> DOI: 10.1182/blood-2020-141381 * |
SMITH , MARCH: "March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS, INC. |
TOOLE ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 83, 1986, pages 5939 - 5942 |
VEGAS, A. ET AL., NATURE BIOTECHNOL |
WILEN ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725 |
WILEN: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268 |
WOOLDRIDGE ET AL.: "MHC Class I Molecules with Superenhanced CD8 Binding Properties Bypass the Requirement .for Cognate TCR Recognition and Nonspecifically Activate CTLs", J. IMMUNOL., vol. 184, 2010, pages 3357 - 3366, XP055392280, DOI: 10.4049/jimmunol.0902398 |
YIN ET AL.: "Evaluating the Role of HLA-DM in MHC Class II-Peptide Association Reactions", JOURNAL OF IMMUNOLOGY, vol. 195, no. 2, 2015, pages 706 - 16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200263196A1 (en) | Methods, compositions, and implantable elements comprising active cells | |
JP2022514144A (en) | Transplantable devices for cell therapy and related methods | |
US20210145759A1 (en) | Implantable particles and related methods | |
US20230287341A1 (en) | Genetically modified cell lines expressing an exogenous substance and uses thereof | |
US20210145889A1 (en) | Methods, compositions, and implantable elements comprising stem cells | |
US20230038379A1 (en) | Monoclonal cell lines expressing an exogenous substance and uses thereof | |
WO2024081309A1 (en) | Engineered cells and implantable elements for treatment of disease | |
AU2022333903A1 (en) | Fusion protein of interleukin 2 and application thereof in ibd | |
WO2024081310A1 (en) | Engineered cells and implantable elements for treatment of disease | |
WO2022212720A1 (en) | Genetically modified human cell lines and uses thereof | |
WO2023076620A1 (en) | Compositions for cell-based therapies and related methods | |
EP4284298A2 (en) | Compositions, devices and methods for inducing antigen-specific immune tolerance | |
WO2024006551A2 (en) | Covalently crosslinked polysaccharides and methods of use thereof | |
EP4284414A2 (en) | Compositions, devices and methods for treating immune-mediated inflammatory diseases | |
Olalekan | Mechanism of B Cell Suppression of Regulatory T cells in Proteoglycan-Induced Arthritis |